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	Abstract 
Increased osteoclast (OC) bone resorption and/or decreased osteoblast (OB) bone 
formation contribute to bone loss in osteoporosis and rheumatoid arthritis (RA). Findings 
of the basic and translational research presented in this thesis demonstrate a number of 
mechanisms by which cytokine-induced NF-κB activation controls bone resorption and 
formation: 1) Tumour necrosis factor-α (TNF) expands pool of OC precursors (OCPs) 
by promoting their proliferation through stimulation of the expression of macrophage 
colony stimulating factor (M-CSF) receptor, c-Fms, and switching M-CSF-induced 
resident (M2) to inflammatory (M1) macrophages with enhanced OC forming potential 
and increased production of inflammatory factors through induction of NF-κB RelB; 2) 
Similar to RANKL, TNF sequentially activates transcriptional factors NF-κB p50 and p52 
followed by c-Fos and then NFATc1 to induce OC differentiation. However, TNF alone 
induces very limited OC differentiation. In contrast, it pre-activates OCPs to express 
cFos which cooperates with interleukin-1 (IL-1) produced by these OCPs in an autocrine 
mechanism by interacting with bone matrix to mediate the OC terminal differentiation 
and bone resorption from these pre-activated OCPs. 3) TNF-induced OC formation is 
independent of RANKL but it also induces NF-κB2 p100 to limit OC formation and bone 
resorption, and thus p100 deletion accelerates joint destruction and systemic bone loss 
in TNF-induced RA; 4) TNF receptor associated factor-3 (TRAF3) limits OC 
differentiation by negatively regulating non-canonical NF-κB activation and RANKL 
induces TRAF3 ubiquitination and lysosomal degradation to promote OC differentiation. 
Importantly, a lysosomal inhibitor that inhibits TRAF3 degradation prevents 
ovariectomy-induced bone loss; 5) RelB and Notch NICD bind RUNX2 to inhibit OB 
differentiation and RelB:p52 dimer association with NICD inhibit OB differentiation by 
enhancing the binding of RBPjκ to Hes1. These findings suggest that non-canonical NF-
κB signaling could be targets to develop new therapies for RA or osteoporosis. For 
example 1) Agents that degrade TNF-induced RelB could block M1 macrophage 
differentiation to inhibit inflammation and joint destruction for the therapy of RA; 2) 
Agents that prevent p100 processing or TRAF3 degradation could inhibit bone 




ALP, alkaline phosphatase; 
BM, bone marrow; 
BSP, bone sialoprotein; 
CFSE, Carboxyfluorescein Diacetate Succinimidyl Ester; 
Chip, chromatin immunoprecipitation; 
cKO, conditional knockout; 
CQ, chloroquine; 
µCT, micro–computed tomography; 
dKO, double knockout; 
DMARDs, disease modifying anti-rheumatic drugs;  
DPP, dentin phosphoprotein; 
DSP, dentin sialoprotein; 
ELISA, enzyme-linked immunosorbent assay; 
FACS, Fluorescence-activated cell sorting; 
FBS, fetal bovine serum; 
β-GP, β-glycerophosphate; 
HRP, horseradish peroxidase; 
IAP, inhibitor of apoptosis proteins; 
IgG, immunoglobulin G; 
IκB, inhibitory NF-κB protein; 
IKK, IκB kinase; 
IL-1, interleukin-1; 
IL-1Ra, IL-1 receptor antagonist; 
iNOS, inducible nitric oxide synthase; 
KO, knockout; 
M-CSF, macrophage colony stimulating factor; 
MEM, modified essential medium; 
MPC, mesenchymal progenitor cells; 
NEMO, NF-κB essential modulator; 
NFATc1, Nuclear factor of activated T-cells, cytoplasmic 1; 
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells;  
NICD, Notch receptor intracellular domain; 
4




OCPs, osteoclast precursors; 
OPG, osteoprotegerin; 
OPN, osteopontin;  
PBS, Phosphate-buffered saline; 
PCR, polymerase chain reaction;  
PPAR-γ, peroxisome proliferator-activated receptor gamma;  
PTH, parathyroid hormone; 
RA, rheumatoid arthritis; 
RANKL, receptor activator of nuclear factor-kappa B ligand; 
RBPjκ, recombination signal–binding protein jκ; 
RUNX2, runt-related transcription factor 2; 
SIBLING, small integrin-binding ligand, N-linked glycoprotein; 
Smurf, Smad ubiquitin regulatory factor; 
TGF-β1, transforming growth factor β1; 
TNF, Tumour necrosis factor-α; 
TNFR, TNF receptor; 
TNF-Tg, transgenic mice with over-expression of human TNF-alpha; 
TRAF, TNF receptor-associated factor; 
TRAP, tartrate resistant acid phosphatase; 
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	Chapter 1: Introduction  
Bone is a dynamic structure that undergoes constant remodeling throughout life, in 
which mature bone tissue is removed from the skeleton by osteoclasts (OCs), a process 
called bone resorption, and new bone tissue is formed by osteoblasts (OBs), a process 
called bone formation. An OC, a multinucleated cell with 3 or more nuclei on the 
trabecular surface (Fig.1A), is originated from hematopoietic cell (Udagawa et al., 1990). 
The cytoplasm of an OC has a high concentration of vesicles and vacuoles including 
lysosomes filled with acid phosphatase, permitting the cell to be stained for high activity 
of tartrate resistant acid phosphatase (TRAP) (Fig.1 A-C) and Cathepin K. An activated 
OC is characterized by cytoskeletal reorganization, formation of sealing zones and 
specialized cell membrane called ruffled border that opposes the surface of the bone 
tissue, allowing it secretion of acids and lysosomal enzymes onto the resorbing surface 
(Boyce et al., 1992, Stenbeck, 2002). In contrast, an OB with single nuclei is specialized, 
terminally differentiated from a mesenchymal stem/progenitor cell (MSC/MPC) (Clarke, 
2008) and it expresses activity of alkaline phosphatase (ALP) and thus is different from 
a MSC/MPC (Clarke, 2008). A number of connected OBs are organized as a group on 
the bone surface (Fig.1D), particularly OC resorbed lacunae, and this is essential for 
OBs to synthesize and secret bone matrix proteins called osteoid (Fig.1D lower panel), 
mainly composed of very dense, cross-linked collagen and several small amount of 
specialized proteins including osteocalcin and osteopontin (Clarke, 2008). The 
organized OBs then produce and deposit calcium-phosphate-hydroxide salt called 
hydroxyapatite on osteoid to finally form a very strong and dense mineralized bone 
tissue. Imbalance of bone remodeling, increased OC bone resorption and/or decreased 
6
	OB bone formation, results in bone loss contributing to common adult bone diseases 
including osteoporosis, rheumatoid arthritis (RA), bone metastatic cancer, aseptic 
loosening of arthroplasty and periodontitis (Boyle et al., 2003).  
 
Osteoporosis is one of the leading diseases of aging, characterized by decreased 
bone mass and strength, resulting in increased fracture risk. It is estimated that 44 
million people in the U.S. have low bone mineral density (BMD) and 10 million are 
 
Fig.1. Features of OCs and OBs. (A) OCs locate on the surface of trabecular bone (T.B.) 
shown on H&E (upper panel)- and TARP (lower panel)-stained sections and are the TRAP+ 
(pink color) multinuclear cells (red arrow in the lower panel); (B) OCs do not exist in the joint 
surface normally (upper panel) while they are formed in the inflamed tissues adjacent to the 
articular surface to erode cartilage and bone (blue arrow) in a mouse RA model; (C) In vitro 
cultured OCs from mouse bone marrow cells by RANKL plus M-CSF stained with TRAP (pink 
color in the upper panel) and Toluidine blue to show resorption pits (red arrow, in the lower 
panel) on bone slices; (D) OBs are an organized groups of rectangle cells (green arrow) along 
with the trabecular surface (upper panel) and they produce osteoid (purple arrow in the lower 
panel,  toluidine blue stained un-decalcified plastic section) between the organized OBs (red 
arrow) and T.B. along with the trabecular surfaces. 
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	osteoporotic with low BMD. 1 in 2 Caucasian women and 25% of men over the age of 
60 are likely to have osteoporotic fracture in their lifetime (Khosla, 2010, Keyak et al., 
2011).  Elderly patients with osteoporotic fractures develop complications, including 
pneumonia and deep vein thrombosis due to prolonged bed rest and up to 27% of them 
die within the first year after hip fracture (Panula et al., 2011). Currently, there are two 
classes of drugs for the treatment of osteoporosis: anti-resorptive and anabolic. The 
commonly used anti-resorptive drugs include a various bisphosphonates and the 
RANKL inhibitor Denosumab. Although anti-resorptive drugs effectively increase bone 
mass, they only reduce the rate of osteoporotic fracture by 50% (Wasnich and Miller, 
2000). In addition, poor patient compliance and more recent fears about side-effects for 
anti-resorptive drugs such as bone necrosis have limited their use, and thus many 
patients go untreated (Rasmusson and Abtahi, 2014, Kennel and Drake, 2009). 
Teriparatide, a truncated form (amino acids 1-34) of PTH, is the first, and to date only, 
FDA approved agent for the treatment of osteoporosis by stimulating new bone 
formation however its use is limited to 2 years (Ponnapakkam et al., 2014) due to the 
potential to induce osteosarcoma (Cipriani et al., 2012). Developing new anti-resorptive 
and/or anabolic drugs is therefore an urgent need, particularly, there is no single drug 
with dual role that can simultaneously inhibit bone resorption and stimulate bone 
formation. Combined therapy with Teriparatide and a bisphosphonate does not appear 
to offer advantages over the use of the single agent alone (Black et al., 2003, 
Finkelstein et al., 2003) and therefore developing a drug with dual anti-resorptive and 
anabolic effect offers great promise for the prevention and treatment of osteoporosis.   
8
	RA is a chronic inflammatory disease characterized by synovial inflammation and 
joint destruction, leading to severe disability and premature mortality (Storheim and 
Zwart, 2014). About 1% of the world's population is afflicted by RA, women three times 
more often than men. Commonly there are three general classes of drugs used in the 
treatment of RA: non-steroidal anti-inflammatory agents (NSAIDs), corticosteroids, and 
disease modifying anti-rheumatic drugs (DMARDs). None of the treatments however 
can cure RA. Anti-TNF reagents such as Etanercept, Infliximab, Adalimumab, belong to 
the DMARDs and have significantly reduced the morbidity and joint destruction in RA, 
but they are expensive, and only ~50% of RA patients respond well to these agents 
(Hyrich et al., 2006, Symmons and Silman, 2006). In non-responding patients, TNF 
inhibitors are typically administered for several months before a decision is made to 
change to an alternative treatment, which is often another TNF inhibitor that may also 
be ineffective. Thus, there is an unmet need to develop new approaches to treat RA.  
Generally, excessive differentiation and function of OCs, the unique cells that 
degrade bone, plays a central role in bone loss and destruction in RA and osteoporosis 
(Boyle et al., 2003) although the reduced bone formation is also considered to 
contribute these diseases. Normally, OCs don’t present in joint space, articular surface 
and the adjacent synovial tissue (Fig.1B upper panel). In RA, OCs are ectopically 
differentiated and activated on articular cartilage adjacent to the inflamed synovial 
tissue and thus erode the cartilage and subchondral bone (Fig.1B lower panel). In 
postmenopausal osteoporosis, both bone resorption and bone formation are increased 
(Garnero et al., 1994, Garnero et al., 1996, Eriksen et al., 1990) although some 
reported that bone formation was unchanged (Eriksen et al., 1990), resulting in the 
accelerated bone turnover and leading to bone loss finally. An unmet need therefore is 
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	to perform extensive studies to shed light on the mechanism by which the 
differentiation and function of OCs may be controlled to suggest approaches to 
prevent/treat these diseases. 
1.1  OC precursors and factors that control OC differentiation and activation 
OCs are derived from the differentiation and fusion of myeloid lineage monocyte-
macrophages (Udagawa et al., 1990) which are called OC precursors (OCPs). 
Macrophage colony stimulating factor (M-CSF) drives the myeloid progenitor cells to 
become monocyte OCPs and receptor activator of nuclear factor-kappa B (NF-κB) 
ligand (RANKL), a member of TNF superfamily of proteins, mediates the terminal 
differentiation and fusion of OCPs (Lacey et al., 1998, Dougall et al., 1999). 
Osteoprotegerin (OPG), a decoy receptor of RANKL, blocks RANKL-RANK interaction 
to inhibit OC formation and bone resorption (Boyce and Xing, 2007). However, OC 
lifespan and cell cycle of quiescent OCPs are less than a few weeks (Marks and Seifert, 
1985, Mizoguchi et al., 2009), therefore patients with osteoporosis and RA must have 
an increased OCP pool to supplement the successive death of OCs. Indeed, it has been 
reported that the frequency of CD14+CD16+ blood monocytes in patients with active RA 
is increased (Kawanaka et al., 2002), and importantly that these macrophages present 
in RA joints actively produce inflammatory factors (Bingham, 2002).  
Macrophages are classified as classically activated (inflammatory, M1) 
macrophages and alternatively activated (resident, M2) macrophages (Gordon, 2007, 
Gordon and Taylor, 2005, Wynn et al., 2013), which are linked to T helper 1 (TH1)- and 
TH2-type immune responses, respectively (Mosser and Edwards, 2008). M1 
macrophages mediate inflammatory responses to a variety of bacterial, protozoal and 
10
	viral infections and produce many inflammatory cytokines, including TNF, IL-12, IL-18 
and IL-23, which mediate immune reactions in several chronic inflammatory and 
autoimmune diseases, including RA, Crohn’s disease, multiple sclerosis and 
autoimmune hepatitis (Murphy et al., 2003, Smith et al., 2009). M2 macrophages, in 
contrast, inhibit the production of a wide variety of pro-inflammatory mediators, through 
the production of cytokines such as IL-10, TGF-β and low levels of IL-12 and thus 
regulate wound healing (Murai et al., 2009). Thus, targeted depletion of M1 and 
boosting the activities of M2 macrophages are emerging as an attractive combined 
therapeutic strategy for autoimmune diseases (Leuschner et al., 2011, Li et al., 2012a, 
Li et al., 2012b). Better understanding of the mechanisms that regulate OCP pool 
expansion and M1/M2 differentiation is necessary to improve these therapeutic 
approaches and could lead to new strategies to reduce joint destruction in inflammatory 
arthritides.  
Although RANKL generally activates OC formation to increase bone resorption in 
osteoporosis, published data also indicate that serum levels of RANKL are reduced 
(Kerschan-Schindl et al., 2008, Uemura et al., 2008) while OPG are increased with 
aging and in osteoporotic humans and other animals (Fichna et al., 2012, Abrahamsen 
et al., 2005). RANKL expression is also required for normal B cell development and 
lymph node formation (Franzoso et al., 1997), suggesting that it might have a role to 
promote joint inflammation in RA. However, transgenic mice that over-express human 
TNF-alpha, TNF-Tg mice, generated to have a deficiency of RANKL, still develop 
synovial inflammation although joint destruction is blocked due to OCs defect in these 
mice (Redlich et al., 2002a, Redlich et al., 2002b). In addition, preclinical and clinical 
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	studies indicate that RANKL inhibitors do not significantly alter inflammatory processes 
and joint space narrowing in RA (Ferrari-Lacraz and Ferrari, 2011, Cohen et al., 2008). 
These findings suggest that factors other than RANKL/OPG may play a major role in 
inducing OC differentiation in osteoporosis and RA.  
TNF can promote RANKL production and synergizes with it to induce OC formation 
(Lam et al., 2000, Zhang et al., 2001b). TNF also induce osteoclastogenesis in the 
presence of OPG from WT mouse OCPs (Kobayashi et al., 2000) and combined 
treatment of TNF and TGF-β1 also induce OC formation from Rank–/– OCPs in vitro 
(Kim et al., 2005). These suggest TNF induction of OC differentiation independent of 
RANKL so it was therefore puzzling that TNF did not induce OC formation when 
administered in vivo to Rank–/– mice (Li et al., 2000). Our findings indicated that TNF 
induced much smaller number of OCs than RANKL from WT mice OCPs (Yamashita et 
al., 2007), suggesting that TNF may mediate the inhibitory factors to limit OC 
differentiation. The precise conditions in which TNF limits or promotes OC formation 
and the factors that are critical for TNF induction or inhibition of OC formation therefore 
remain unclear.  
Interleukin-1 (IL-1) has long been known to stimulate bone resorption (Boyce et al., 
1989). It is produced by a variety of cell types at sites of inflammation in and around 
bones, including monocytes/macrophages, OCPs, and mature OC themselves (Xing et 
al., 2005, Teitelbaum, 2006). In general, IL-1 alone cannot directly mediate OC 
formation from OCPs in vitro (Kobayashi et al., 2000). Like TNF, it promotes RANKL 
expression by marrow osteoblastic stromal cells to induce osteoclastogenesis indirectly 
(Hofbauer et al., 1999) and also synergize with TNF to promote OC formation (Wei et al., 
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	2005), however the mechanism is unclear. Since only ~50% of RA patients respond well 
to anti-TNF treatment (Hyrich et al., 2006, Symmons and Silman, 2006), it is important to 
demonstrate if IL-1 synergizes with TNF to stimulate OC formation so as to design 
better approach to treat RA.  
1.2  NF-κB signaling pathways in OC differentiation 
Typically, for RANKL and other cytokines such as TNF and IL-1 signaling through 
their receptors is mediated by the recruitment of TNF receptor-associated factors 
(TRAFs) leading to activation of NF-κB, a family of transcription factors including RelA 
(also known as p65), p50, p52, RelB and c-Rel (Karin and Greten, 2005). P50 and p52 
are formed from larger precursor proteins, p105, and p100, which are encoded by NF-
κB1 and NF-κB2 gene, respectively (Karin and Greten, 2005). They were first identified 
binding to the κB site of the kappa light chain gene in B cells to regulate B lymphocyte 
differentiation (Karin and Greten, 2005, Courtois and Gilmore, 2006) but are actually 
involved in both innate and adaptive immune responses to pathogens and autoimmune 
stimuli and play critical roles in the initiation and maintenance of inflammatory 
responses. Each NF-κB subunit has a Rel homology domain in their N-terminus, 
allowing them to form homo- and heterodimers with one another and to bind to specific 
DNA sequences on gene promoters. Their binding to DNA requires a C-terminal 
transcription activation domain (TAD). RelA, RelB, and c-Rel possess TAD but p50 and 
p52 do not, and thus they rely on interactions with these three other family members to 
regulate gene transcription (Vallabhapurapu and Karin, 2009). RelA preferentially form 
heterodimers with p50 to activate cellular response, which is known as canonical NF-κB 
signaling (Fig.2). In many publications, NF-κB or NF-κB activity refers to RelA/p50-
13
	mediated canonical NF-κB signaling. A non-canonical NF-κB pathway is activated 
several hours after canonical signaling has begun by translocation of RelB/52 
heterodimers to the nucleus (Fig.2) and is sustained, lasting for many hours. This 
activation occurs efficiently in response to RANKL, but not to TNF (Novack et al., 2003).  
Fig.2. Canonical and Non-canonical NF-κB signaling. (1) Canonical NF-κB activation. 
Cytokines such as RANKL and TNF induce canonical signaling by recruiting TRAF6 and 
TRAF2/5, respectively, to their receptors to activate a complex consisting of IKK-α, IKK-β and 
IKK-γ (NEMO), which induces phosphorylation and degradation of IκB-α and the release of 
p65/p50 heterodimers, which translocate to the nucleus to activate the target gene expression. 
2) Non-canonical NF-κB activation. In un-stimulated cells, TRAF3-TRA2 complex results in 
constitutive NIK degradation and thus p100 binds RelB to be remained trapped in cytoplasm. 
Cytokines such as CD40L and RANKL recruit cIAP to TRAF2-TRA3 complex, resulting in 
TRAF3 ubiquitin degradation and allowing newly synthesized NIK accumulation. NIK then 
phosphorylates IKK-α, which leads to proteasomal processing of p100 to p52, releasing 
RelB:p52 heterodimers for translocation to nucleus. TNF does not degrade TRAF3, and thus 
NIK is degraded, leading to the accumulation of p100 in the cytoplasm of osteoclast precursors 
to limit their differentiation.  This figure was modified from Fig. 1 in our recent review (Boyce et 
al., 2015). 
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	NF-κB activation comprises a number of steps that require ubiquitination and 
proteasomal degradation or processing of proteins that function as inhibitors that retain 
NF-κB dimers in the cytoplasm of un-stimulated cells. These inhibitory NF-κB proteins 
are known as IκB (Hayden and Ghosh, 2008). The IκB proteins have multiple ankyrin 
repeats that allow them to bind to NF-κB dimers to prevent their nuclear translocation. 
RelA/p50 heterodimers are held in an inactivate state in the cytoplasm mainly by their 
interaction with IκBα. The C-terminal portions of p105 and p100 also contain multiple 
ankyrin repeats, which endow them with IκB-like functions (Dobrzanski et al., 1995, Liou 
et al., 1992). The IκB portion of p105 binds to RelA and c-Rel retaining them in the 
cytoplasm, but it can also bind to p50 molecules in RelA/p50 heterodimers 
(Vallabhapurapu and Karin, 2009). 
1.2.1  Canonical NF-κB signaling 
Canonical NF-κB signaling is activated by a trimeric IκB kinase (IKK) complex, which 
is consists of two catalytic subunits (IKKα and IKKβ) and a regulatory subunit, IKKγ, 
also called NF-κB essential modulator (NEMO) (Vallabhapurapu and Karin, 2009, 
Shibata et al., 2007). This IKK complex phosphorylates IκBα, leading to its 
polyubiquitination and degradation by the 26S proteasome followed by the releasing of 
p50. As a result, RelA:p50 dimers are translocated to the nucleus to activate the target 
genes (Vallabhapurapu and Karin, 2009) (Fig.2).  
1.2.2 Non-canonical NF-κB signaling 
Non-canonical NF-κB signaling is activated by IKKα following its phosphorylation by 
NF-κB-inducing kinase (NIK). In un-stimulated cells, NIK undergoes constitutively 
ubiquitin degradation by TNF receptor-associated factor 3 (TRAF3)-TRAF2 complex. 
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	Cytokine such as CD40L recruits the inhibitor of apoptosis proteins (IAP), cIAP1 and 2 
through its receptor to TRAF3-TRAF2 complex, allowing TRAF3 ubiquitination and 
degradation to release NIK from this complex (Zarnegar et al., 2008). NIK then 
phosphorylates IKKα resulting in processing of p100 in the proteasome to p52, 
releasing RelB:p52 heterodimers (Bonizzi and Karin, 2004, Senftleben et al., 2001) 
Similarly, RANKL also induce TRAF3 ubiquitination followed by lysosomal degradation 
(Xiu et al., 2014, Yao et al., 2009), allowing newly synthesized NIK accumulation, and 
as a result, p100 is processed to p52 which forms heterodimers with RelB to translocate 
to nuclei (Fig.2). The IκB portion of p100 binds preferentially to RelB to retain it in the 
cytoplasm, but interestingly it also binds to and regulates RelA homodimers (Fusco et 
al., 2008).  
A role for NF-κB in bone cells was first discovered unexpectedly 20 years ago by 
two groups generating NF-κB1/2 double knockout (dKO) mice to further investigate their 
role in immunity. In addition to the severe B cell and T cell defects, these dKO mice 
develop severe osteopetrosis due to an OC defect (Franzoso et al., 1997, Iotsova et al., 
1997), all of which were reversed by transplantation of hematopoietic cells from WT 
mice, indicating that the defects were of hematopoietic cell origin (Franzoso et al., 1997). 
The similar defect of OC and immune cells occur in RANKL and RANK knockout mice 
generated by other groups later (Boyce and Xing, 2007). Cytokines, including TNF, IL-1, 
IL-6 and RANKL did not induce OC differentiation from hematopoietic progenitor cells of 
NF-κB p50/p52 dKO mice, indicating that NF-κB plays a central role in this cytokine-
induced OC formation (Xing et al., 2003). However, murine single knockouts of either 
NF-κB1 p50 or NF-κB2 p52 have normal OC numbers and function in vivo (Xing et al., 
16
	2003). This raises the question as to what is the role of NF-κB1 p50 or NF-κB2 p52 in 
OC differentiation in physiological and pathological conditions. RelA-/- mice die early 
during embryogenesis due to TNF-mediated massive hepatocyte apoptosis (Beg et al., 
1995).  A lack of RelA results in the apoptosis of the hematopoietic progenitor cells, 
resulting in reduced OC formation in response to RANKL (Vaira et al., 2008a), but was 
not involved in terminal OC formation (Vaira et al., 2008a). RelB-/- mice have normal 
OCs on their bone in vivo, but it is not fully understood why myeloid progenitor cells 
from RelB-/- mice have an impaired OC formation in response to RANKL in vitro (Vaira 
et al., 2008b). In summary, although it is known that NF-κB in general plays a critical 
role in OC differentiation, how each NF-κB member regulates OC differentiation in 
physiological and pathological conditions remain to be understood.  
1.3  c-Fos and NFATc1 are master genes controlling OC differentiation 
c-Fos is a member of Fos family of transcription factors including c-Fos, FosB, Fra-
1 and Fra-2 as well as smaller FosB splice variants, FosB2 and ΔFosB (Milde-Langosch, 
2005). c-Fos forms a heterodimer with c-jun, a member of Jun family of transcription 
factors, resulting in the formation of Activator Protein-1 (AP-1) complex which binds 
DNA at AP-1 specific sites at the promoter and enhancer regions of target genes and 
converts extracellular signals into changes of gene expression (Milde-Langosch, 2005). 
Mice lacking c-Fos develop osteopetrosis due to blockade of OC differentiation 
(Grigoriadis et al., 1994).  
Nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), one of the five 
members of NFAT transcription factor family, was identified as a master gene 
controlling terminal OC differentiation since OCPs with over-expression of activated 
17
	form of NFATc1 automatically differentiate into mature OCs without addition of RANKL. 
Interestingly, over-expression of NFATc1 can rescue RANKL-induced OC defect from 
OCPs lacking c-Fos, suggesting that NFATc1 is a gene downstream from c-Fos 
(Matsuo et al., 2004). The relationship of NF-κB to c-Fos and NFATc1 for RANKL-
induced osteoclastogenesis and how TNF mediate OC formation was however 
unknown. 
1.4  TNF receptor-associated factors (TRAFs) in the control of OC differentiation. 
RANKL and TNF signaling is mediated by recruitment of TRAFs (Darnay et al., 
2007, Dempsey et al., 2003, Kim et al., 1999), leading to the activation of transcription 
factors including NF-κB, c-Fos, and NFATc1 (Takayanagi, 2007, Yamashita et al., 
2007). The TRAF family of proteins includes 7 members, of which TRAF6 is thought to 
be essential for RANKL-induced OC differentiation (Lomaga et al., 1999, Naito et al., 
1999). However, the OC number on the bone surface of TRAF6-/- mice is normal 
(Lomaga et al., 1999) and combination of TNF with TGFβ1 can induce OC formation 
from TRAF6-/- OCPs (Kim et al., 2005). It was also reported that TRAF5 is involved in 
both RANKL- and TNF-induced OC formation (Kanazawa et al., 2003) and TRAF2 was 
required for TNF-induced OC formation (Kanazawa and Kudo, 2005). Others however 
have found that combined treatment of TNF and TGFβ1 also induced OC formation 
from OCPs lacking TRAF5 or TRAF2 (Kim et al., 2005). Thus much remain unknown 
concerning the mechanism by which TRAF transduce cytokine signaling to induce OC 
formation. TRAF3 has been identified as the key factor in the control of non-canonical 
NF-κB signaling (He et al., 2007, He et al., 2006). It forms a complex with TRAF2 to 
constitutively degrade NIK and thus prevents the processing of p100 into p52 while 
18
	cIAP1/2 induces TRAF3 ubiquitin degradation and thus activates NIK to process p100 
to p52 (Gyrd-Hansen and Meier, 2010). Global deletion of TRAF3 resulted in death of 
mice within a week after birth due to aberrant p100 accumulation and interestingly, 
deletion of p100 partly rescued the phenotype of TRAF3-/- mice (He et al., 2006). It was 
not known if TRAF3 regulate OC formation and bone formation. 
1.5  NF-κB in the control of bone formation 
The role of NF-κB in OC formation and function has been studied in some depth 
(Franzoso et al., 1997, Iotsova et al., 1997, Yamashita et al., 2007, Yao et al., 2009, 
Vaira et al., 2008a, Vaira et al., 2008b). But the role of NF-κB signaling in bone 
formation is less well understood and published data are conflicting. Several groups 
have shown that activation of canonical NF-κB signaling inhibits bone formation based 
on an inhibitory effect of TNF induction of p65 on OB differentiation (Li et al., 2007, 
Gilbert et al., 2005, Gilbert et al., 2002, Yamazaki et al., 2009). Recently it was reported 
that inhibition of canonical NF-κB signaling specifically in mature OBs by genetic 
manipulation results in a transient increase in bone mass in young mice (Chang et al., 
2009). Furthermore, the NF-κB inhibitor, S1627, promotes murine calvarial defect repair 
and increased bone mineral density in ovariectomized mice (Alles et al., 2010), 
providing additional evidences that canonical NF-κB signaling negatively regulates bone 
formation. Other groups however have reported that TNF-induced activation of 
canonical NF-κB signaling in mesenchymal progenitor cells (MPCs) promotes their 
differentiation into OBs (Cho et al., 2010, Hess et al., 2009, Lencel et al., 2011) through 
BMP-2-mediated up-regulation of runt-related transcription factor 2 (Runx2) and Osterix 
(Osx) expression (Hess et al., 2009). These findings indicate that there are complex 
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	interactions involving cytokines and canonical NF-κB signaling that can have positive or 
negative regulatory effects on OBs to influence bone mass, depending upon the form of 
stimulation and the state of osteoblastic cell differentiation. 
A role for non-canonical NF-κB signaling in bone formation has also been reported. 
For example, mice generated to have an accumulation of a non-processed form of NF-
κB2 p100 have enhanced osteoblastic differentiation (Seo et al., 2012), and mice with 
deletion of p100, but retaining a functional p52, have osteopenia due to increased OC 
activity and impaired OB parameters (Soysa et al., 2010). Interestingly, deletion of both 
RelB and p100 in these latter mice prevented the osteopenia seen in the p100−/− mice 
and actually increased bone mass, accompanied by increased OB surfaces (Soysa et 
al., 2010), suggesting an important role of RelB to inhibit OB differentiation. These 
studies did not however include reports of the OB phenotype of single RelB−/− mice and 
did not examine the molecular mechanisms whereby RelB regulates OB differentiation 
or function. It was also unclear how NF-κB works with other signaling to control bone 
formation. 
To address the above questions, the author and colleagues have performed 
extensive basic and translational studies and demonstrated a number of novel 
mechanisms by which cytokine-induced NF-κB activation controls osteoclastic bone 
resorption and osteoblastic bone formation in past ten years: 1) TNF expands OCP pool 
through promoting their proliferation (Yao et al., 2006) and switching M-CSF-induced 
resident to inflammatory macrophages via induction of NF-κB RelB (Zhao et al., 2015); 
2) IL-1 produced in an autocrine mechanism by OCPs by interacting with bone matrix 
relays TNF that pre-activates NF-κB followed by c-Fos and NFATc1 to promote terminal 
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	OC differentiation and bone resorption (Yamashita et al., 2007, Yao et al., 2008); 3) We 
provided first confirmed in vivo evidence that TNF induction of OC formation is 
independent of RANKL signaling but its capacity to make OCs is limited by its induction 
of  NF-κB p100 (Yao et al., 2009); 4) We were the first to report that TRAF3 functions to 
inhibit OC differentiation by negatively regulating non-canonical NF-κB activation and 
RANKL induces TRAF3 ubiquitination and lysosomal degradation to promote OC 
differentiation (Yao et al., 2009). Importantly, a lysosomal inhibitor, chloroquine, that 
inhibits TRAF3 degradation prevents ovariectomy-induced bone loss (Xiu et al., 2014); 
5) RelB and Notch NICD bind RUNX2 to inhibit OB differentiation and RelB:p52 dimer 
association with NICD inhibit OB differentiation by enhancing the binding of RBPjκ to 
Hes1 (Yao et al., 2014, Zhang et al., 2014).  
Our findings also provide direction to develop new therapies for RA or osteoporosis. 
Currently, we are working with chemist to screen for agents that are able to degrade 
TNF-induced RelB and thus block M1 macrophage differentiation to inhibit inflammation 
and joint destruction for the therapy of RA. We are also working on small molecular 
chemicals to prevent p100 processing to inhibit bone resorption and also stimulate bone 
formation simultaneously for the therapy of osteoporosis.  
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	Chapter 2  Method development 
The research in the series of publications relating to this thesis was carried out both 
in vitro and in vivo. The methods used are briefly described below. 
2.1  Reagents. 




2.1.2 Cytokine inhibitors 
a. TGFβ antibody, Cat# AB-100-NA, R&D systems, Minneapolis, MN, USA; 
b.  IL-1Ra, R&D Systems, Minneapolis, MN, USA; 
c. TNF receptor fusion protein (ENBREL), gift from Amgen, Thousand Oaks, CA. 
2.1.3 Antibodies (Abs) for Western blot and immunohistochemestry: 
a. Table-2. Abs purchased from Santa Cruz Biotechnology, CA, USA:  
Ab name         Clone           Cat. No.                  Ab name         Clone           Cat. No. 
P100/p52        C-5               sc-7386;                   RelB               C19            sc-226;  
P65                 C20              sc-372;                     P50                NLS            sc-114;  
NFATc1         7A6               sc-7294;                   c-Fos               4                 sc-52;  
NIK                 H-248           sc-7211;                   BECN1          H-300          sc-11427;  
TRAF3           M20              sc-947;                     TRAF2           H-249           sc-7187 
TRAF5,          H-257           sc-7220;                   TRAF6            D-10            sc-8409  
HDAC2,         H-54             sc-7899                     HES1             H-140           sc-25392 
GAPDH          6C5             sc-32233                    Runx2            M70              sc-10758          
RBP-jk           D-20             sc-8213;                    CyclinD1        H-295           sc-753;                         
Ubiquitin        P4D1            sc-8017;                    VEGF-C         H-190           sc-9047;  
Cytokine      Cat #             Cytokine      Cat #           Cytokine      Cat #          
TNF           410-MT;          M-CSF       416-ML;        RANKL,    462-Tec;         
IL-1            401-ML;          TGF-β1      240-B;  
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Name                         Cat. No.                         Name                                Cat. No.                   
Ascorbic acid,          A4544;                       β-glycerophosphate,      9422;  
MG132,                   2211;                          bafilomycin A1,              B1793;   
 3-Methyladenine,   M9281;                       chloroquine (CQ),          C6628;  
puromycin,              p9620;                        ammonium chloride,      254134; 
Calcein,                  C0875.                        CFSE                             21888 
Hoechst 33342,      B2261 
 
	
Ab name        Clone         Cat. No.               Ab name       Clone        Cat. No. 
HA,                                   H6908;                  β-actin          AC-40,      A4700;  
γ-tubulin        GTU-88      T6557;                   FLAG            M2,           F3165.   
	
Ab name       Clone           Cat. No.                  Ab name         Clone         Cat. No. 
LAMP2          GL2A7          ab13524;               Cyclin E1,                          ab-7959;  
LYVE-1                              ab10278.  
	
Ab name                                  Cat. No.             Company               Address 
Anti-rabbit IgG-HRP                1706515            Bio-Rad,     Hercules, CA, USA 
Anti-mouse IgG-HRP              1721011            Bio-Rad,   Hercules, CA, USA 
Anti-rabbit IgG/biotinylated      E0432               Dako,             Carpinteria, CA, USA 
Anti-Runx2 ,                            D130-3              MBL international,      Woburn, MA.  
Anti-Smurf1,                            AP2104B          Abgent, San Diego, CA 
CD3 (Mec13.3)                                                 Biocare Medical,   Concord, CA, USA 
Anti-hamster IgG/Fluor 488     A-21110,         ThermoFisher,    
Anti-rabbit IgG/Fluor 546 F      A-11018,         ThermoFisher. 











2.1.6 Reagents from other sources 
Reagents purchased from Thermo Scientific, Rockford, IL, USA:    
M-Per mammalian protein extraction reagent, cat# 78501; 
The BCIP/NBT alkaline phosphatase substrate, cat# 34042.  
Fugene 6 transfection reagent, cat# E2691, Promega, Madison, WI, USA. 
Dual-Luciferase Reporter Assay system, cat# E1910, Promega, Madison, WI, USA. 
FBS, Atlanta Biologicals, Lawrenceville, GA, USA. 
NH4Cl solution, Cat# 07850, Stem Cell Technologies, Vancouver, BC, Canada. 
TRIzol reagent, Cat# 15596028, Life Technologies, Carlsbad, CA, USA. 
iQ SYBR Green Supermix, Cat# 170-8882, Bio-Rad, Hercules, CA, USA. 
iQ SYBR cDNA Synthesis Kit, Cat# 170-8891, Bio-Rad, Hercules, CA, USA. 
hPTH(1–34 aa), cat# RP01001, GenScript, Piscataway, NJ, USA. 
BrdU labeling reagent (Zymed),  
Bone matrix proteins including OPN, DSP and BSP were gifts from Dr. Chunlin Qin, 
Department of Biomedical Science, Baylor College of Dentistry, Dallas, Texas. 
2.1.7 ELISA kits 
1. Mouse TNF-a ELISA Ready-Set-Go, Cat# 88-7324, eBioscience, San Diego, CA; 
2. Human TNF-a ELISA Ready-Set-Go, Cat# 88-7346, eBioscience, San Diego, CA; 
3. Mouse IL-1 β ELISA Ready-Set-Go, Cat# 88-7013, eBioscience, San Diego, CA; 
4. Mouse TRaCP5b, Cat# SB-TR103, Immunodiagnostic Systems, NE35 PD, UK; 
5. Mouse osteocalcin ELISA kit, Cat# MBS2020904, MyBioSource, San Diego, CA.  
 
Gene             Cat No.          Gene         Cat No.          Gene        Cat No.        
TRAF3,          sc-36712;      RelA,         sc-29411;      RelB,         sc-36403;  
ATG5,            sc-41445;      BECN1,     sc-29798;      ATG7,       sc-41447,  




	2.2  Animals. 
Animals used in the publications documented here include: (1) C57Bl6 WT mice; (2) 
TNF-transgenic (TNF-Tg) mouse line 3647 (Keffer et al., 1991); (3) RelB-/- mice (Burkly 
et al., 1995, Elewaut et al., 2003); (4)  Nfkb2 (p52)–/– mice C57BL/6 × 129 background 
(Franzoso et al., 1997); (5) Nfkb1 (p50)-/- mice (Franzoso et al., 1997);  (6) Rankl–/– 
(C57BL/6) mice (Kim et al., 2000) ; (7) Rank–/– mice C57BL/6 background (Li et al., 
2000); (8) Traf3-floxed (TRAF3f/f) mice (B6 background); (9) Lysozyme M (LyM)Cre mice 
(B6 background); (10) CathepsinKCre mice (B6 background). TNF-Tg mice were crossed 
with Nfkb2-/- mice to generate TNF-Tg/nfkb2-/-, single TNF-Tg (TNF-Tg/nfkb2+/-) mice 
and their littermate mice. TRAF3f/f mice were crossed with LyMCre mice to generate 
TRAF3 conditional knockout mice in myeloid cells (TRAF3f/fLyMcre mice) and their WT 
literate mice (TRAF3f/f). University of Rochester Medical Center Institutional Animal 
Care and Use Committee approved all protocols for animal studies (see appendix 3). 
2.3  In vitro studies: 
2.3.1  Osteoclast related research methodology 
2.3.1.1  Osteoclast culture and functional tests in vitro (Yao et al., 2006, Yao et al., 
2009, Yao et al., 2008, Xiu et al., 2014, Yamashita et al., 2007): 
Bone marrow (BM), spleen and peripheral blood cells were used to culture OCPs 
and OCs. BM was flushed from the long bones of mice using α-MEM containing 10% 
fetal bovine serum (FBS), passed through a 21-G and then through a 25-G needle to 
make single cell suspensions. The spleen was meshed on a cell strainer and, similarly, 
passed through a 21-G and then through a 25-G needle to make single cell 
suspensions. The cells were incubated in NH4Cl solution for 10 min at room 
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	temperature to lyse red blood cells. 5x104 BM cells or 0.5-2x105 spleen cells were 
seeded in a well of 96-well plates and cultured with 5 ng/ml M-CSF for 2 days, and then 
RANKL (10 ng/ml) or TNF (20 ng/ml) or both were added to the cultures for 48-56 hr at 
which time mature OCs could be observed using an inverted microscope. The cells 
were then fixed with 10% neutral formalin for 10 min and TRAP staining was performed. 
TRAP+ cells with three or more nuclei were considered as mature OCs. To test 
resorption function, the cells were seeded in wells containing a bovine cortical bone 
slice in each well followed by the regular culture procedure for 9 days (Yao et al., 2009, 
Yao et al., 2008). The bone slice was stained with TRAP to evaluate OC formation 
followed by toluidine blue staining to evaluate resorption pit formation.  
2.3.1.2  OC differentiation in Trans-well assays (Yao et al., 2008): 
GFP or c-Fos retrovirus-infected WT mouse OCPs were grown on bovine cortical 
bone slices in the presence of 5 ng/ml of M-CSF for 2 days. The bone slices were then 
transferred to the upper chamber of the Transwell culture plates and cross co-cultured 
with the GFP- or c-Fos-infected OCPs in the lower chamber of the Transwell for an 
additional 8 days in the presence of 5 ng/ml of M-CSF (Yao et al., 2008). When 
multinucleated cell formation was identified under an inverted microscope, the cells 
were fixed with 10% formalin and stained for TRAP activity to evaluate OC number. 
2.3.1.3  TRAP staining (Yamashita et al., 2007, Yao et al., 2006, Yao et al., 2009, Yao 
et al., 2008): 
Tartarate/Acetate Buffer (pH 5.0): dissolve 6.8 g of NaOAc 3H2O (100mM) and 5.8 g of 
Na Tartrate 2H2O (50mM) in 450 ml distilled water, add 1 ml of acetic acid, adjust pH 
to 5.0; add water to 500 ml. 
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	TRAP solution 50 ml 
1. Dissolve 5mg Naphthol AS-MX phosphate (Sigma N-4875) in 250 ul Ethylene 
Glycol Monoethyl Ether (Sigma E-2632) 
2. Dissolve 30 mg Fast Red Violet LB salt (Sigma F-3381) in 50 ml 
Tartarate/Acetate Buffer; 
3. Add 1 to 2 and mix well. 
TRAP staining for cell culture 
1. Fix the cells with 10% neutral Formalin; 
2. Wash the cells three times with PBS; 
3. TRAP staining solution 70 µl/well (96-well plate) 10 -30 min at room temp or 37°C. 
4. After washing, counter stain with Mayer’s Hematoxylin 30 sec followed by 0.5% 
Ammonia Water 30 sec. 
5. Wash with H2O and air dry. 
Evaluation of OCs: TRAP+ cell is pink color. A TRAP+ cell with three or more nuclei is 
considered as a mature OC.  
2.3.1.4  Resorption pit staining (Yao et al., 2009, Yamashita et al., 2007): 
Dipped a bone slice in the water and transferred it to the flat plate, brushed the bone 
slice each side for 10 times with a tooth-brush; Dipped the bone slice in 0.2% toluidine 
blue solution and wiped the remaining staining solution with a piece of soft paper. 
Observed the bone slice under a microscope and the pits were stained with light blue.  
2.3.1.5  Retro-viral constructs and transfection (Yamashita et al., 2007, Yao et al., 
2009, Yao et al., 2008): 
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	The coding regions of genes were amplified by PCR from cDNAs including murine 
origin of c-Fos, human origin of NFATc1, p52/p100, p50/p105, p65, RelB, and cloned 
into the pMX-puro retroviral vector (Matsuo et al., 2004, Kitamura et al., 1995). Each 5′ 
primer contains a Kozak sequence following the start codon. The retrovirus vectors 
were transiently transfected into the Plat-E retroviral packaging cell line (Morita et al., 
2000), and viral supernatant was collected 48 h later. BM or spleen cells prepared as 
above were cultured with 5 ng/ml of M-CSF for 2 days to enrich for OCPs. The culture 
medium was then replaced with fresh medium containing M-CSF, 2 µg/ml polybrene 
and ¼ volume of retro-viral supernatant of target gene prepared from Plat-E packaging 
cells. After 24 hr of infection, RANKL or TNF was added to the cultures for an additional 
48-56 hr to generate OCs.  
2.3.2  Osteoblast studies 
2.3.2.1  Generation of bone-derived MPCs (Yao et al., 2014, Zhang et al., 2014): 
The mouse tibiae and femora were cut into small pieces after BM had been flushed 
out and the cavities had been washed extensively with PBS. The bone fragments were 
cultured for 4 days with α modified essential medium (α-MEM) containing 20% FBS at 
37°C. Bone pieces were transferred into a new dish and cultured for an additional 4 to 5 
days with α-MEM containing 10% FBS. The cells grown on the dish were passaged 
twice when they were 90% confluent, each time excluding cells tightly attached to the 
dishes. Third-passage cells contained over 99% MPCs, sufficient for our experiments. 
We named these cells “bone-derived MPCs” (bMPCs) (Yao et al., 2014) and they were 
frozen for use later in OB differentiation and mineralization experiments. 	
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	2.3.2.2  OB differentiation (Yao et al., 2014, Zhang et al., 2014): 
BM was flushed from long bones of mice with α-MEM containing 20% FBS using a 
25G needle. The cells were filtered with a 40-µm cell strainer, and 4 × 104 cells were 
cultured in 35-mm dishes at 37°C in 5% CO2 for 4 days. Unattached cells were removed 
and replaced with 10% FBS in α-MEM containing 25 µg/mL L-ascorbic acid and 5 mM β-
glycerophosphate (β-GP) to induce OB differentiation. After 5 to 7 days in inducing 
medium, the cells were stained for ALP activity using the ALP substrate, BCIP/NBT. 
Mineralization typically occurs after 10 to 14 days in culture, and the cells were stained 
with the von Kossa method for measurement of mineralized nodule formation. Calvariae 
from new born mice were cut into pieces and digested six times with a mixture of 0.5% 
collagenase I and 0.125% trypsin (both from Sigma) for 20 minutes at 37°C. Cells from 
the second to sixth digestions were collected for pre-OB cultures and OB differentiation 
experiments.	
2.3.2.3  ALP staining (Yao et al., 2014, Zhang et al., 2014). 
Cultured OBs or BM colonies induced for differentiation were fixed with 10% neutral 
Formalin for 10 min followed by washing three times with PBS; added BCIP/NBT 
alkaline phosphatase substrate to cover the dish and incubated the cells for 20-30 min 
at 37°C. Discarded the staining substrate, washed the dish with water followed by air 
dry. ALP+ cells will be stained with blue-black color. An alternative step is to count stain 
the cells with Eosin for 1 min and the cytoplasm of the cells are stained with red so that 
the percentage of ALP+ cells can be calculated. 
2.3.2.4  Von Kossa staining (Yao et al., 2014, Zhang et al., 2014). 
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	Cultured OBs or BM colonies induction for mineralization was fixed with 10% neutral 
formalin for 10 min followed by washing three times with PBS; added 1% silver nitrate to 
cover the dish and exposed the cells with bright light for 30 min. Washed the cells with 
water followed by air dry. Mineralized cells or colonies were stained with block.  
2.4  In vivo studies:  
2.4.1 TNF-induced osteoclastogenesis in vivo (Yao et al., 2009): 
TNF (0.5 µg) or PBS was injected over the calvariae of 3- to 4-week-old mice twice 
daily for 5 days. Mice were sacrificed on day 6, and calvariae and hind limbs were fixed 
in 10% formalin and decalcified with 10% EDTA. TRAP activity was assessed in 
paraffin-embedded sections, as described previously. OC numbers and surfaces as well 
as eroded surfaces were measured using an Osteometrics system (Yao et al., 2009). 
2.4.2. Evaluation of arthritis and osteoporosis (Yao et al., 2009): 
Whilst the features of arthritis in the commonly used 197 line of TNF-Tg mice 
include paw swelling, deformation and reduced strength (Keffer et al., 1991), it was 
found that the only easily identifiable, reproducible parameter in 3647 line of TNF-Tg 
mice, was paw and finger deformation, including atrophy (Yao et al., 2009). We 
generated a deformation score (0, no deformation; 1, mild deformation; 2, moderate 
deformation; 3, severe deformation; 4, very severe deformation), which was blindly 
evaluated once each week to determine the clinical progress of arthritis. Each fore- and 
hind-paw was evaluated separately, and the deformation score was calculated as the 
sum of the 4 paws (Yao et al., 2009). Mice were euthanized to collect right tibiae for 
µCT scanning to evaluate cortical and trabecular bone volume, and left tibiae and 
forepaws were processed as paraffin slices for histologic evaluation of OCs and arthritis, 
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	including inflammatory tissue area and carpal bone eroded cartilage surface (Yao et al., 
2009). 
2.4.3  Repairing of tibial bone defects (Yao et al., 2014, Zhang et al., 2014): 
A 2-mm × 5-mm full-thickness cortical defect was made on the anterior surface of the 
left and right tibiae of SCID mice. Briefly, a hole was pierced through the cortex 1 mm 
below the growth plate using a 25G needle. Scissors were then inserted into the hole 
and a 2-mm × 5-mm defect was created by repeatedly cutting distally through the cortex 
(Yao et al., 2014). The defects were then almost completely filled with decalcified 
trabecular bone matrix, which had been extracted from bovine femoral necks using the 
following serial processing: 20% H2O2 for 2 days, 5 mmol Sodium Azide (NaN3) 
overnight, 1 mol NaOH containing 1% Triton X-100 overnight, methanol/chloroform (1:1) 
for 24 hours, ether overnight, and 10% EDTA for 2 weeks (Yao et al., 2014). bMPCs 
(5 × 105) in 5 µL of Hank's solution were then injected into the bone matrix in the defects. 
The muscle fascia and skin overlying the defects were then sutured closed. Mice were 
euthanized 2, 4, and 8 weeks post-surgery, and the tibiae were fixed in 10% neutral 
buffered formalin for 2 days. The volume of new bone formed in the defects was 
measured using a VivaCT 40 µCT scanner. The bones were then processed through 
alcohols, decalcified, and embedded in paraffin. The volume of newly formed bone and 
fibrous tissue was quantified in H&E-stained sections using OsteoMeasure software.	
2.5  Common methods used throughout this research 
2.5.1  FACS analysis and cell sorting (Yao et al., 2006, Yao et al., 2014, Zhao et al., 
2015): 
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	2x106 BM, spleen, peripheral blood mono-nuclear cells or cultured cells were stained 
with the fluorescent-conjugated antibodies listed in Table-8 for 30 min. Data were 
acquired using a FACScanto flow cytometer and analyzed using FlowJo software.	 
 
2.5.2  Western blot analysis:  
Cultured cells were lysed with M-Per mammalian protein extraction reagent 
(Thermo Scientific, Rockford, IL, USA) containing a protease inhibitor cocktail (Sigma, 
Saint Louis, MI, USA). Lysate proteins (10–20 µg) were loaded in 10% SDS-PAGE gels 
and transferred onto polyvinylidene difluoride membranes. Following blocking in 5% 
milk, membranes were incubated with a specific primary antibody or antibody to mouse 
β-actin (Table-3, 4 and 5) over-night at 4°C. After washing, the membranes were 
incubated with anti-rabbit (or mouse) IgG-HRP conjugate secondary antibody (Bio-Rad, 
Hercules, CA, USA) and exposed to ECL substrate. Signals were analyzed using a Bio-
Rad (Hercules, CA, USA) imaging system. 
2.5.3  Quantitative Real-Time PCR:  
Table-8: Antibodies for FACS analysis 
                                                Antibody name           Fluorescent label     Company 
Monocye-Macrophages          CD11b                        PE-cy7                  eBioscience 
                                                F4/80                          PE-cy5                 eBioscience 
                                                Gr1 (Ly6G)                 PE                        eBioscience 
                                                Ly6C                           APC                     eBioscience 
                                                CD11c                        FITC                     eBioscience 
                                                c-Fms                         FITC                     eBioscience 
Lymphatic cells                       CD8a                          PE-cy7                 eBioscience 
                                                CD4                            PE                       eBioscience 
                                                B220                           PE-cy5                eBioscience 
Mesenchymal Progenitor        CD105                        PE                        eBioscience 
                                                CD45                          APC                     eBioscience 
                                                Scal-1                         FITC                    eBioscience 
Mesenchymal progenitors are CD45- cells. 
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	Total RNA was extracted from cultured cells using 1 ml TRIzol reagent, and 1 µg 
was used for synthesis of cDNA using a GeneAmp RNA PCR core kit. Quantitative PCR 
amplification was performed using an iCycler real-time PCR machine and iQ SYBR 
Green (Bio-Rad, Hercules, CA, USA). Relative mRNA expression levels of target genes 
were analyzed using the CT value of the gene, normalized to β-actin. The primer 
sequences used for real-time PCR are listed in Table-9. 
Table-9: Primer sequence used for real-time PCR. 
 
2.5.4  Luciferase reporter assay:  
The Luc reporter plasmids (NFATc1, Runx2, BECN1) were co-transfected with GFP 
or NF-κB subunit plasmid into plat-E cells or C2C12 cells using a FuGene6 reagent 
(Roche, Indianapolis, IN, USA). A 0.1µg aliquot of the SV40-Renilla Luc construct 
(Addgene, Cambridge, MA, USA) was also co-transfected with the above firefly 
Gene            Forward primer                                         Reverse primer                    
c-Fms:     5′-GTCAGAGGCCCCGTTTGTT-3′;       5′-AGTAAATATAGAGGCTAGCACTGTG-  
NFATc1:  5′-CACATTCTGGTCCATACGA-3′;        5′-CGTGTAGCTGCACAATGG-3′;  
c-Fos:      5′-CTGTCAACACACAGGACTTTT-3′;    5′-AGGAGATAGCTGCTCTACTTTG-;  
β-actin:    5′-ACCCAGATCATGTTTGAGAC-3′;      5′ GTCAGGATCTTCATGAGGTAGT- 
TNFα:      5′-CACACTCAGATCATCTTCTCAA-3′;  5′-AGTAGACAAGGTACAACCCATC-3′  
IL-1β:      5′-ATTAGACAGCTGCACTACAGG-3′;    5′-GGAGAATATCACTTGTTGGTTG-3′  
Smurf1:   5′-AGTTCGTGGCCAAATAGTGG–3′,     5′-GTTCCTTCGTTCTCCAGCAG–3′ 
Smurf2:   5′-GTGAAGAGCTCGGTCCTTTG–3′;     5′-AGAGCCGGGGATCTGTAAAT–3′ 
ALP:        5′-CGGGACTGGTACTCGGATAA–3′;    5′-ATTCCACGTCGGTTCTGTTC–3′ 
OCIN:      5′-CTTGGTGCACACCTAGCAGA–3′;     5′-CTCCCTCATGTGTTGTCCCT–3′ 
VEGF-a:  5'-TTTACTGCTGTACCTCCACCA-3';     5'-ATCTCTCCTATGTGCTGGCTTT-3' 
VEGF-b:  5'-CCTGGAAGAACACAGCCAAT-3';      5'-GGAGTGGGATGGATGATGTC-3' 
VEGF-c:  5'-GGGAAGAAGTTCCACCATCA-3';      5'-ATGTGGCCTTTTCCAATACG-3' 
VEGF-d:  5'-GCTGTCACTGTTGCCCACTA-3';      5'-CCCTTCCTTTCTGAGTGCTG-3'	
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	reporters to standardize results for transfection efficiency (Yao et al., 2014). Cell lysates 
were prepared using a reporter lysis buffer (Promega, Madison, WI, USA). Luciferase 
activity was measured using a Microplate Luminometer (PerkinElmer, Waltham, MA, 
USA) (Yao et al., 2014).  
2.5.5  Chromatin immunoprecipitation (ChiP):  
ChiP was performed using a MAGnify ChIP kit (Invitrogen, Carlsbad, CA, USA) 
following the instruction manual. Briefly, sheared chromatin from cultured cells that had 
been fixed with 1% formaldehyde was immunoprecipitated with 5 µg of antibody, 
negative control rabbit immunoglobulin G (IgG), or positive control H3 histone. 
Immunoprecipitated DNA was then used as a template for quantitative PCR using 
primers (Table-10) specific for the NF-κB binding sites of a gene promoter as well as a 
pair of unrelated primers designed in the region that was 3 kb apart from the specific 
binding sites (Yao et al., 2014).  
Table-10: Primers specific for the NF-κB binding sites of a gene promoter. 
 
Gene Promoter        Forward primer                                         Reverse primer                             
Runx2  
κB site- 1:          5′-TCAACTACACAGCCATGAT           5′-TAAGCTTGGGGATCTGTAAC 
κB site- 2:          5′-CTTCTGAATGCCAGGAAGGC;      5′-TGGGACTGCCTACCACTGT 
Unrelated site   5′-CACTGCTGACTGAAACAAGTC;     5′-AGTCTGAGTGAGCTTCCTGAT 
BECN1 promoter:  
κB site:             5′-AAGAAGCCTAGAGTCCCTGG-3′;   5′-CCTGCGACAGCGGAGAAAAG-3′. 
Unrelated site:  5′-GGGCAAGGCATCATAAAACAGG-3′; 5′-AGGAGATGAAGTTGACCTCC-3′. 
Hes1 promoter 
RBPjκ site: 5′-CTCAGGCGCGCGCCATTGGCC-3′;   5′-GCTTACGTCCTTTTACTTGAC-3′;  
Unrelated site:5′-CCTAGGGAGAAGGAGCTGGCT-3′; 5′-TGGCCGTCAGGAGCCGGCACC-3′	
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	2.5.6  Immunohistochemistry:  
Bones were fixed in 10% phosphate-buffered formalin, decalcified in 10% EDTA, 
and embedded in paraffin wax. Deparaffinized sections were quenched with 3% 
hydrogen peroxide, treated for antigen retrieval for 30 min, and stained with a specific 
primary antibody and a biotinylated secondary antibody. The biotin was detected using 
standard avidin-biotin peroxidase technology and diaminobenzidine (Sigma, Saint Louis, 
MI, USA) as the chromogen.  
2.5.7  Micro–computed tomography and bone histomorphometric analysis: 
Mice were given injections of calcein (10 mg/kg) at 5 days and 1 day before 
euthanasia in a standard bone formation double-labeling protocol. Right tibiae were 
fixed in 10% neutral buffered formalin and subjected to micro–computed tomography 
(µCT) scanning using a VivaCT 40 mCT scanner for assessment of bone microstructure.  
Subsequently, un-decalcified plastic sections were processed to assess the dynamic 
and static parameters of bone formation using OsteoMeasure software. Left tibiae were 
fixed in 10% neutral buffered formalin for 2 days, decalcified and processed to paraffin 
sections to analyze bone volume, OB surface and OC surface on H&E and TRAP  
stained sections (Yao et al., 2014, Yao et al., 2009).  
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	Chapter 3  Summary of research 
The submitted publications forming the basis of this thesis cover five distinct, but 
related, areas of research: 
1. TNF expands the pool of OCPs with enhanced OC forming potential (Yao et al., 
2006, Zhao et al., 2015). 
2. IL-1 produced in an autocrine mechanism by OCPs by interacting with bone 
matrix relays TNF that pre-activates NF-κB followed by c-Fos and NFATc1 to 
promote terminal OC differentiation (Yamashita et al., 2007, Yao et al., 2008). 
3. NF-κB2 p100 limits OC formation and bone resorption (Yao et al., 2009). 
4. TRAF3 negatively regulating OC differentiation (Yao et al., 2009, Xiu et al., 2014).  
5. NF-κB inhibits bone formation by interacting with Notch signaling (Engin et al., 
2008, Kaneki et al., 2006, Yao et al., 2014, Zhang et al., 2014). 
The findings of each topic are briefly described respectively below. 
3.1  TNF expansion of OCPs with enhanced OC forming potential by stimulating 
their proliferation and switching M-CSF-induced M2 to M1 macrophages via 
induction of NF-κB RelB. 
These findings were reported in two publications. 
a. Yao Z; Li P; Zhang Q; Schwarz EM; Keng P; Arbini A; Boyce BF; Xing L. "Tumor 
necrosis factor-alpha increases circulating osteoclast precursor numbers by 
promoting their proliferation and differentiation in the bone marrow through up-
regulation of c-Fms expression." J. Biol. Chem. 2006; 281(17):11846-55.  
b. Zhao Z, Hou X, Yin X, Li Y, Duan R, Boyce BF, Yao Z. TNF Induction of NF-κB 
RelB Enhances RANKL-Induced Osteoclastogenesis by Promoting Inflammatory 
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	Macrophage Differentiation but also Limits It through Suppression of NFATc1 
Expression. PLoS One. 2015;10(8):e0135728. 
The main findings of these publications are outlined in Fig.3 and described below 
 
3.1.1  TNF increase myeloid OCP pool by stimulating their proliferation via up-
regulation of the M-CSF receptor, cFms (Yao et al., 2006). 
 
Fig.3. Mechanism by which TNF expand OCP pool to enhance OC formation (Yao et al., 
2006, Zhao et al., 2015). (1) M-CSF drives myeloid progenitors differentiating into monocytes in 
which the newly synthesized RelB is constutitively degraded and these monocytes mainly 
differentiate into M2 macrophage with lesser  OC formating potential (Zhao et al., 2015); (2) TNF 
stimulates the expression of c-Fms by the CD11b+Gr1-/lo monocyte OCPs to promote their 
proliferation and thus expand OCP pool (Yao et al., 2006);  (3) TNF inhibits the ubiquitin 
degradation of RelB and the accumulated RelB switches M-CSF-induced M2 to Ly6C+/-CD11c+ 
M1 macrophages with enhanced OC forming potenial (Zhao et al., 2015); (4) RelB itself inhibites 
NFATc1 expression and thus TNF alone has limited role to induce OC differentiation (Zhao et al., 
2015); (5) RANKL induces RelB proteasomal degradation in M1 to release the inhibition of RelB 
and thus enhance OC differentiation (Zhao et al., 2015). 
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	Previous findings indicated that peripheral blood CD11b+ myeloid cell number was 
significantly increased in TNF-Tg mice (Li et al., 2004), but CD11b is also expressed on 
the granulocytes in addition to monocyte/ macrophages. To further identify the biological 
feature of OCPs, we stained mouse blood cells with fluorescent conjugated antibodies 
of CD11b and Gr-1 to sort different cell populations by flow cytometry for OC culture. 
We found that CD11b+/Gr-1-/lo cells, but not CD11b+/Gr-1hi and CD11b+/Gr-1-/-cells, 
gave rise to mature OCs in response to M-CSF and RANKL stimulation. Thus, 
CD11b+/Gr-1-/lo cells are OCPs. Importantly, TNF promotes OCP proliferation by up-
regulating the expression of M-CSF receptor, c-Fms. TNF-Tg mice had significantly 
increased CD11b+/Gr-1-/lo cells in both blood and bone marrow, and administration of 
TNF to wild type mice also significantly increased the circulating and bone marrow 
CD11b+/Gr-1-/lo cell population. Interestingly, dividing CD11b+/Gr-1-/lo cells in the bone 
marrow from TNF-Tg mice and TNF treated mice were significantly increased when 
compared to their respective control mice, and in vitro culture indicated that TNF alone 
did not stimulate cell division but significantly enhanced M-CSF induced CD11b+/Gr-1-/lo 
cell division. TNF stimulated conversion of CD11b+/Gr-1-/lo/c-Fms- to CD11b+/Gr-1-/lo/c-
Fms+ cells was not blocked by an M-CSF neutralizing antibody, suggesting that TNF 
directly stimulates the expression of the M-CSF receptor c-Fms to promote OCP 
proliferation.  
3.1.2 CD11b+F4/80+Gr1-Ly6C+ macrophages are authentic OCPs (Zhao et al., 2015). 
As described above, our early results show that CD11b+/Gr-1-/lo cells are OCPs in 
TNF-Tg mouse studies (Yao et al., 2006). Recently, we cultured BM cells with M-CSF 
alone or in combination with TNF to enrich OCPs, which are called M-OCPs and T-
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	OCPs, respectively. Only Gr1-Ly6C+ cells but not Gr1-Ly6C- cells of CD11b+F4/80+ M-
OCPs form OCs in response to RANKL. Thus, CD11b+F4/80+ Gr1-Ly6C+ macrophages 
are authentic OCPs. However, both Gr1-Ly6C+ and Gr1-Ly6C- cells from T-OCPs form 
OCs and their potential to form OCs are largely enhanced compared to that of M-OCPs. 
Interestingly, Gr1+Ly6C+ cells in CD11b+F4/80+ of T-OCPs also form OCPs and this 
population is corresponding to our early reported CD11b+/Gr1lo OCPs. 
3.1.3 TNF switches M-CSF-induced Ly6C-Gr1- M2 to Ly6C+Gr1-CD11c+ and Ly6C-
Gr1-CD11c+ inflammatory M1 macrophages with increased production of 
inflammatory factors and enhanced OC forming potential (Zhao et al., 2015). 
CD11b and F4/80 are common macrophage surface markers; M1 cells are 
CCR2+Gr1+CD62L+CD11c+, while M2 cells are CCR2-Gr1-CD62L-CD11c- in mice 
(Gordon, 2007, Gordon and Taylor, 2005). Ly6C is also widely used to differentiate M1 
and M2 cells. Ly6C+/hi subsets are classified as M1 cells, while Ly6C-/lo subsets are 
classified as M2 cells (Yona and Jung, 2010, Mosser and Edwards, 2008). Gr1-Ly6C+ 
cells comprise 1/4 of CD11b+F4/80+ macrophages of M-OCPs while Gr1-Ly6C- cells 
account for about 2/3 of CD11b+F4/80+ M-OCPs. In contrast, the frequency of Gr1-
Ly6C+ and Gr1-Ly6C- cells are respectively switched to 2/3 and 1/4 of CD11b+F4/80+ 
macrophages in T-OCPs. Interestingly, both Gr1-Ly6C+ and Gr1-Ly6C- cells bear 2-fold 
more CD11c, a typical M1 surface marker (Gordon and Taylor, 2005). Importantly, Gr1-
Ly6C+ cells from M-OCPs express higher M1 effector, iNOS, TNF, TGFβ1 and IL-1β, 
than that from Ly6C-Gr1- cells, confirming that Ly6C+Gr1- cells generally have a M1 
profile. Consistently, Ly6C+Gr1- cells from T-OCPs expressed higher iNOS, IL-1β and 
TGFβ1, but significantly lower M2 markers, IL-10 and PPAR-γ, than those from M-OCPs. 
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	Of note, expression levels of iNOS and TGFβ1 were also increased, while IL-10 and 
PPAR-γ levels were decreased in Ly6C-Gr1- cells from T-OCPs compared to M-OCPs 
cells, providing further support that Ly6C-Gr1- cells from T-OCPs have a M1 phenotype. 
We sorted each of these OCPs into four populations, Ly6C+Gr1-, Ly6C+Gr1+, 
Ly6C-Gr1- and Ly6C-Gr1+ cells, to induce OC formation with RANKL or TNF in the 
presence of M-CSF. In M-OCPs, the OC forming potential of Ly6C+Gr1- cells was much 
higher than Ly6C-Gr1- cells: RANKL induced 125±16 OCs from Ly6C+Gr1- cells, but only 
a few TRAP+ mononuclear cells were formed from Ly6C-Gr1- cells. In contrast, both 
Ly6C+Gr1- and Ly6C-Gr1- cells from T- OCPs formed OCs in response to RANKL, the 
number being 398±26 and 413±17 respectively, and almost matching those from Ly6C-
Gr1- cells of R-OCPs (463±15).  
3.1.4 RelB is required for TNF switching M-CSF-induced M2 to M1 macrophages 
(Zhao et al., 2015). 
RelB is a member of the NF-κB family of transcription factors (Sun, 2011, Sun, 
2012). RelB is required for dendritic cell development (Platzer et al., 2004) but the role 
of RelB in OC differentiation is not fully understood. OC numbers are normal in the 
bones of RelB-/- mice, but BM OCPs from RelB-/- mice form fewer OCs than WT OCPs 
in vitro in response to RANKL (Vaira et al., 2008b). We found that although both RANKL 
and TNF increased RelB mRNA level, TNF also significantly increased RelB protein 
level, whereas RANKL does not due to the fact that it also induces RelB proteasome 
degradation. It was also not known if RelB regulates M1 or M2 but we found that TNF 
induction of Ly6C+CD11c+ and Ly6C-CD11c+ M1 did not occur from RelB-/- BMCs, 
suggesting that RelB is required for TNF induction of M1.   
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	3.1.5 TNF negatively regulates RANKL-induced OC formation via inhibition of 
NFATc1 but stimulates via an NFATc1 independent mechanism (Zhao et al., 2015). 
TNF alone induces terminal differentiation of OCPs primed by M-CSF (Kobayashi 
et al., 2000, Yao et al., 2009), which is independent of RANKL. TNF also promotes 
RANKL expression by osteoblastic and other cells to enhance OC formation (Lam et al., 
2000, Zhang et al., 2001b). However, TNF does not induce degradation of NIK and thus 
increases the level of the inhibitory NF-κB protein, p100, which reduces RANKL- and 
TNF-induced OCP differentiation (Yao et al., 2009). To further investigate the conditions 
in which TNF stimulates or inhibits RANKL-induced OC formation, M- and T-OCPs 
generated from WT mouse BM cells were then treated with TNF, RANKL or 
RANKL+TNF for an additional 48-60 hr to generate mature OCs. TNF alone induced 
relatively small numbers of OCs and significantly inhibited RANKL-induced OC 
formation from M-OCPs. Although the numbers of RANKL-induced OCs from T-OCPs 
were similar to those from M-OCPs, the total area of RANKL-induced OCs from T-OCPs 
was larger than that from M-OCPs (p<0.05), consistent with enhanced fusion, but we 
did not study the regulation of fusion. In addition, TNF did not inhibit RANKL-induced 
OC formation from T-OCPs, the number and area of RANKL+TNF-induced OCs being 
similar to those induced by RANKL alone. Similarly, the NFATc1 mRNA expression 
level matched the number of OCs.  In OCs formed from M-OCPs, RANKL, but not TNF, 
increased NFATc1 mRNA expression, and TNF inhibited RANKL induction of NFATc1 
expression within 24 hr of treatment, showing a 6-fold induction of NFATc1 mRNA for 
RANKL alone and a 2.1-fold induction for RANKL+TNF treated cells. In contrast, TNF 
did not inhibit RANKL-induced NFATc1 expression in T-OCPs. We next infected M-
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	OCPs with GFP or RelB retrovirus to over-express RelB followed by treatment of either 
TNF for 3 days or RANKL for 2 days to generate OCs. We found that over-expression of 
RelB significantly decreased RANKL-induced OC formation and NFATc1 mRNA 
expression. In contrast, over-expression of RelB increased TNF-induced OC formation 
but did not affect TNF-induced low level of NFATc1 mRNA. These findings suggest that 
TNF induction of RelB inhibits RANKL-induced osteoclastogenesis by directly inhibiting 
NFATc1 expression and in contrast, TNF alone induction of OC differentiation is through 
an NFATc1 independent mechanism. 
3.2 IL-1 produced in an autocrine mechanism by OCPs by interacting with 
bone matrix relays TNF that pre-activates NF-κB followed by c-Fos and NFATc1 to 
promote terminal OC differentiation (Yamashita et al., 2007, Yao et al., 2008). 
Two publications deal with the relationship of NF-κB to c-Fos and NFATc1 in 
cytokine-induced OC formation. 
a. Yamashita T; Yao Z (co-first author); Li F; Zhang Q; Badell IR; Schwarz EM; 
Takeshita S; Wagner EF; Noda M; Matsuo K; Xing L; Boyce BF. "NF-kappaB p50 
and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor 
necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and 
NFATc1." J. Biol. Chem. 2007; 282(25):18245-53.  
b. Yao Z; Xing L; Qin C; Schwarz EM; Boyce BF. "Osteoclast precursor interaction 
with bone matrix induces osteoclast formation directly by an interleukin-1-mediated 
autocrine mechanism." J. Biol. Chem. 2008; 283(15):9917-24. 




Fig.4. Cytokines sequentially activate NF-κB, c-Fos followed by NFATc1 to induce OC 
differentiation (Yamashita et al., 2007, Yao et al., 2008). (1) Similar to RANKL, TNF also 
sequentially activate NF-κB, c-Fos followed by NFATc1 to induce OC differentiation 
(Yamashita et al., 2007); (2) TNF induces monocyte OCPs to express c-Fos (Yamashita et 
al., 2007, Yao et al., 2008); (3) The pre-activated OCPs expressing c-Fos attach to bone 
and are stimulated by bone matrix proteins such as dentin sialoprotein (DSP) to produce IL-
1 which mediates the terminal differentiation of OCPs into mature OCs to degrade bone 
(Yao et al., 2008). 
 
3.2.1 c-Fos expression and activation to induce OC formation is NF-κB 
dependent (Yamashita et al., 2007). 
RANKL does not induce OC formation from NF-κB p50/p52 dKO OCPs. RANKL- 
and TNF-induced c-Fos mRNA expression and activation were also impaired in the dKO 
OCPs. Importantly, c-Fos over-expression rescued RANKL- and TNF-induced OC 
formation from dKO OCPs, to a similar extent to p50+p52 over-expression, and these 
OCs functionally resorbed bone on bone slices in vitro. In addition, an NF-κB inhibitor 
prevented RANKL- or TNF-induced c-Fos expression and activation. Finally, NF-κB 
p50+p52 over-expression could not rescue OC defect from c-Fos-deficient cells. These 
findings indicate that RANKL- and TNF-induced c-Fos expression and activation is NF-
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	κB dependent and activated c-Fos by RANKL can efficiently substitute for the lack of 
p50 and p52 in dKO cells to induce OC formation and bone resorption. 
3.2.2 c-Fos activates NFATc1 to induce OC formation in the absence of NF-κB 
p50 and p52 (Yamashita et al., 2007). 
NFATc1 functions downstream of c-Fos during osteoclastogenesis in WT cells 
(Matsuo et al., 2004) but it is not known if this is the case in dKO cells. We found that 
RANKL increased NFATc1 mRNA and nuclear translocation in WT but not p50/ p52 
dKO OCPs. However, c-Fos over-expression rescued RANKL- increased NFATc1 
expression and activation in dKO cells. Interestingly, overexpression of a constitutively 
active form of NFATc1 in NF-κB dKO OCPs induced small number of OCs without 
addition of RANKL, and treatment of these NFATc1 over-expressing dKO cells with 
RANKL induced OC formation, the number being similar to that when NF-κB p50+p52 
or c-Fos were overexpressed in dKO OCPs. Similarly, TNF also induced NFATc1 
mRNA expression in dKO OCPs expressing c-Fos and induced OC formation from dKO 
OCPs with overexpression of NFATc1. Over-expression of c-Fos rescued RANKL- and 
TNF- induced NFATc1 expression and OC formation from NF-κB dKO OCPs, 
suggesting that c-Fos relays NF-κB signaling to mediate OC formation via NFATc1. 
3.2.3 TNF induces the expression of c-Fos by OCPs with limited potential of 
mature OC formation (Yamashita et al., 2007). 
TNF and RANKL induced a similar pattern of NF-κB, c-Fos and NFATc1 
expression, increased c-Fos mRNA levels to similar extent as RANKL as early as 4 hr 
while increased NFATc1 expression much later, peaked at 48 hr for RANKL-treated 
cells and 1 day later for TNF-treated cells. Consistent with this, TNF induction of 
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	osteoclastogenesis peaked one day later (3 days) than that of RANKL (2 days). 
Interestingly, OCs on the eroding inflamed joints of TNF-Tg mice had higher c-Fos 
expression compared with OCs at non-eroding site, suggesting that TNF may stimulate 
OCPs to express c-Fos to promote OC formation in the inflammatory joints. However, 
TNF alone-induced OC formation and bone resorption is very limited, suggesting that 
other factors may involve OC formation and bone resorption in TNF-Tg mice. Our later 
findings indicate that IL-1 produced in an autocrine mechanism from these OCPs and 
TNF induction of NF-κB2 p100 positively and negatively regulate TNF-induced OC 
differentiation, respectively, which will be discussed below. 
3.2.4 c-Fos expressing OCPs automatically differentiate into mature OCs via IL-1 
autocrine mechanism by interacting with bone matrix (Yao et al., 2008). 
It has long been known that IL-1 is a potent stimulator of bone resorption in vitro 
and in vivo (Boyce et al., 1989). It enhances OCP fusion and OC survival in vitro (Lee et 
al., 2002, Jimi et al., 1999, Jimi et al., 1995) and promotes RANKL production by 
stromal cells (Hofbauer et al., 1999) and thus indirectly induces OC formation. It was 
however unknown if it has a direct action on OC formation. We found that c-Fos-
expressing OCPs of WT mice formed mature OCs in response to IL-1 treatment directly, 
which is independent of NF-κB p50/p52 since the dKO OCPs expressing c-Fos also 
formed OCs in response to IL-1. Surprisingly, c-Fos-expressing OCPs from WT and 
dKO mice formed OCs spontaneously on bone slices without addition of cytokine. 
Interestingly, OCPs grown on bone slices produce IL-1β and OC formed from c-Fos 
expressing OCPs was blocked by inhibitor of IL-1β but not by inhibitor of TNF or TGFβ1. 
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	Thus, TNF may pre-activate OCPs to express c-Fos and they will produce IL-1 by 
contacting bone matrix to further mediate their own differentiation and bone erosion.  
3.2.5 The bone matrix proteins osteopontin (OPN) and dentin sialoprotein (DSP) 
stimulated OCP expression of IL-1 (Yao et al., 2008). 
Bone matrix contains at least 20 non-collagenous proteins, including TGF-β1 and 
members of the SIBLING (small integrin-binding ligand, N-linked glycoprotein) family of 
proteins such as osteopontin (OPN), dentin sialoprotein (DSP), bone sialoprotein (BSP) 
and dentin phosphoprotein (DPP) (Qin et al., 2004, Fisher et al., 2001) which are 
released from the matrix during bone resorption. TGFβ1 has multiple effects on bone 
cells and has been proposed to be involved in coupling osteoblasts to sites of bone 
resorption (Chang et al., 2009). OPN appears to anchor OCs to bone matrix through 
interaction with the vitronectin receptor on the OC basolateral membrane (Reinholt et al., 
1990) and is required for the activation of OC bone resorption in hindlimb unloading 
mouse model with disuse atrophy (Ishijima et al., 2001). Bone sialoprotein deficiency 
impairs osteoclastogenesis and mineral resorption in vitro (Boudiffa et al., 2010). 
Several of the bone matrix proteins have also been reported to stimulate macrophages 
to produce cytokines such as IL-1 (Silva et al., 2005).  We found that DSP in particular, 
but also OPN, significantly increased IL-1 and to a lesser extent TNF mRNA expression 
in WT mouse OCPs, whereas DPP and TGF-β1 had no effect. Interestingly, none of 
these proteins induced OC formation from GFP retrovirus control-infected WT mouse 
OCPs. However, DSP or OPN induced OC formation from c-Fos retrovirus-infected WT 
mouse OCPs, which was partially blocked by IL-1Ra to the same extent as observed in 
cultures on bone slices (Yao et al., 2008). It could be concluded from these 
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	observations that when TNF pre-activated OCPs expressing c-Fos adhere to bone 
matrix, interaction with bone matrix proteins including DSP and OPN leads to the 
production of IL-1 and as a result, the pre-activated OCPs expressing c-Fos further 
differentiate into mature OCs to degrade bone (Yao et al., 2008). 
3.3 TNF induces OC differentiation independent of RANKL, but its induction of 
NF-κB2 p100 limits OC formation and bone resorption (Yao et al., 2009) 
One publication in The Journal of Clinical Investigation reports the important 
progress in bone cell biology and rheumatology and provided the first confirmed in vivo 
evidence that TNF-induced OC formation is RANKL independent but its role is limited 
by NF-κB2 p100. Thus, increasing or stabilizing p100 could be a novel strategy to treat 
osteoporosis and RA. These findings made a breakthrough in bone cell biology as the 
JCI editor’s comments (Tanaka and Nakano, 2009).  
a. Yao Z; Xing L; Boyce BF. "NF-kappaB p100 limits TNF-induced bone resorption 
in mice by a TRAF3-dependent mechanism." J. Clin. Invest. 2009; 119(10):3024-34.   
The major findings in this publication are outlined in Fig.5 and described below: 
3.3.1 NF-κB2 p100 deficiency enhances TNF-induced OC formation (Yao et al., 
2009). 
TNF directly induces OC formation from WT mouse OCPs in the presence of OPG 
(Kobayashi et al., 2000) and combined treatment of TNF and TGF-β1 also induces OC 
differentiation from Rank–/– mice OCPs in vitro (Kim et al., 2005). However, TNF-
induced OC number is much smaller than RANKL with less resorption function 
(Yamashita et al., 2007) and it was puzzling that TNF did not induce OC formation when 
it was administered in mice lacking RANK signaling (Li et al., 2000). In comparison with 
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	RANKL that efficiently processes NF-κB2 p100 into p52, TNF does not activate the 
alternative NF-κB pathway and induces p100 accumulation (Novack et al., 2003). It was 
unknown if the limited OC formation induced by TNF was related to p100.  
 
Fig.5. TNF-induced NF-kB2 p100 limits OC differentiation (Yao et al., 2009). (1) 
RANKL activates NIK to process p100 into p52, resulting in OC differentiation and 
activation from OCPs; (2) TNF does not activate NIK and thus newly synthesized p100 
accumulates in the cells to limit OC formation; (3) P100 deficiency promotes TNF-induced 
OC formation and thus enhances joint erosion and systemic bone loss in RA. 
 
We performed OC culture using NFKB2 (p100/p52)–/– mice and found that TNF 
induced significantly more OCs from NFKB2–/– than from WT cells, the OC numbers and 
resorption pit being similar to those in RANKL-treated WT or NFKB2–/– cells. Consistent 
with this, TNF induced a greater c-Fos and NFATc1 expression in NFKB2–/– cells than 
WT cells, with their expression level in NFKB2–/– cells being similar to that induced by 
RANKL when mature OCs were forming. NFKB2–/– OCPs lack both p100 and p52 and 
our findings that over-expression of p100, but not p52, inhibited TNF- and RANKL-
induced osteoclastogenesis significantly in both NFKB2–/– and WT OCPs, confirmed 
that p100 is responsible for TNF inhibition of OC differentiation. Next we injected TNF or 
PBS into the subcutaneous tissues of NFKB2–/– and NFKB2+/– control mice and found 
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	that the parameters of bone resorption were significantly greater in NFKB2–/– mice than 
NFKB2+/– mice. Serum levels of TRAP5b, a specific marker of bone resorption released 
by OCs, were significantly higher in NFKB2–/– mice than in control mice treated with 
TNF, further confirming that NFKB2 deficiency enhances TNF-induced bone resorption. 
3.3.2 TNF induces robust OC formation in vivo in mice lacking RANKL or RANK 
when the mice also lack NF-κB2 p100 (Yao et al., 2009).  
Similar to its effects in WT cells, TNF induced accumulation of p100 but not p52 
protein in RANK–/– and RANKL–/– OCPs. We generated RANK–/–/NFKB2–/– and RANKL–
/–/NFKB2–/– mice to culture OCs and found that spleen cells from RANK–/–/NFKB2–/– and 
RANKL–/–/NFKB2–/– mice treated with TNF formed significantly more OCs than did cells 
from RANK–/–/NFKB2+/– and RANKL–/–/NFKB2+/– mice. Next, we injected TNF to these 
mice to investigate if p100 also limits OC formation in vivo in the absence of RANK 
signaling. Although absence of NFKB2 itself did not induce any OCs in RANK–/– or 
RANKL–/– mice (PBS injection), TNF induced many OCs and resorption lacunae in the 
calvarial bones of the RANK–/–/NFKB2–/– and RANKL–/–/NFKB2–/– mice following local 
injection, associated with increased OCs and eroded surfaces. Only occasional OCs 
were observed in the sections of TNF-injected RANKL–/– or RANK–/–mice, as reported 
previously (Li et al., 2000). Of note, serum resorption marker, TRAP5b, was 
undetectable in RANK–/–/NFKB2+/–and RANK–/–/NFKB2–/– mice and was slightly but 
significantly increased by TNF injection in RANK–/–/NFKB2+/– mice. These values were 
increased further in RANK–/–/NFKB2–/– mice after TNF injection, confirming that OCs 
induced by TNF in RANK–/– mice are functional and that NF-κB2 deficiency enhances 
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	TNF-induced osteoclastogenesis and bone resorption in the mice lacking RANK 
signaling.  
3.3.3 TNF attenuates RANKL-induced osteoclastogenesis in vitro through NF-
κB2 p100 (Yao et al., 2009).  
RANKL and TNF independently support the final stages of OCP differentiation to 
mature OCs and it is therefore important to study how TNF and RANKL work together to 
control osteoclastogenesis. A previous study reported that TNF synergized with RANKL 
to stimulate osteoclastogenesis in vitro (Lam et al., 2000). However, others reported 
that the synergistic effect occurred only in RANKL pretreated cells (Ochi et al., 2007). 
We found that TNF inhibited RANKL-induced osteoclastogenesis from M-CSF- enriched 
OCPs in a dose-dependent manner, and this inhibitory effect was abolished when 
NFKB2 p100 was deleted, suggesting that TNF induction of p100 inhibits RANKL-
induced OC formation. Thus, elevation of p100 or inhibition of p100 degradation could 
be a novel strategy to treat RA. 
3.3.4 TNF-Tg mice lacking NF-κB2 p100 develop more severe systemic bone loss, 
joint erosion and inflammation than do TNF-Tg littermates (Yao et al., 2009).  
To determine the possible pathological role of NF-κB2 absence in joint erosion in 
RA, we generated TNF-Tg/NFKB2–/– mice and found that they developed joint deformity 
earlier, with more severe joint inflammation and erosion than their TNF-Tg littermates. 
TNF-Tg/NFKB2–/– mice also had reduced trabecular bone volume and cortical thickness, 
associated with increased OC numbers and surfaces on the trabeculae compared with 
TNF-Tg/NFKB2+/– mice as evaluated by histomorphometry and 3-dimensional µCT 
imaging. However, serum TNF concentration in TNF-Tg/NFKB2–/– mice did not increase 
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	compared with the TNF-Tg/NFKB2+/– littermate mice. Thus, the increased joint 
inflammation and bone erosion in TNF-Tg mice with NFKB2 deficiency indicates an 
increased susceptibility to RA. 
3.4 TRAF3 prevents bone loss by negatively regulating non-canonical NF-κB- 
mediated OC differentiation (Xiu et al., 2014, Yao et al., 2009).  
These studies include two publications. 
a. Yao Z; Xing L; Boyce BF. "NF-kappaB p100 limits TNF-induced bone resorption in 
mice by a TRAF3-dependent mechanism." J. Clin. Invest. 2009; 119(10):3024-34.   
b. Xiu Y, Xu H, Zhao C, Li J, Morita Y, Yao Z, Xing L, Boyce BF. Chloroquine 
reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 
degradation. J. Clin. Invest. 2014; 124(1):297–310.  
 
 
Fig.6. TRAF3 controls non-canonical NF-κB activation to limit OC formation (Xiu et al., 
2014, Yao et al., 2009). (1) RANKL induces TRAF3 ubiquitination; (2) The ubiquitinated 
TRAF3 is moved to lysomome to be degraded, thus the newly synthesized NIK fails to be 
phosphorytion degraded, resulting in NIK accumulation in the cells; (3) The accumulated NIK 
process p100 into p52 and thus promote OC formation; (4) TRAF3 deficiency enhances 
RANKL-induced OC formation and bone resorption since NIK can continuely process p100. 
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	The findings demonstrated a novel mechanism of TRAF3 controlled NF-κB 
activation during OC differentiation, in which RANKL induces TRAF3 
autophagy/lysosome degradation to activate NF-κB and promote OC formation. These 
findings also indicate that pharmacological inhibition of TRAF3 degradation with 
compounds such as chloroquine may limit bone loss in common bone diseases. The 
main findings are outlined in Fig.6. 
3.4.1 TRAF3 prevents OC differentiation by inhibiting p100 processing (Xiu et al., 
2014, Yao et al., 2009). 
The hallmark of non-canonical NF-κB activation is p100 processing into p52 by NIK 
and it has been reported that TRAF3 negatively regulates NIK to control non-canonical 
NF-κB signaling (He et al., 2007, He et al., 2006). We found that TRAF3 paralleled the 
change of p100 during RANKL- and TNF- induced OC formation, and importantly, 
treatment with TRAF3 siRNA prevented TNF-induced NF-κB2 p100 accumulation and 
inhibition of osteoclastogenesis. Importantly, over-expression of TRAF3 inhibited 
RANKL-induced OC formation directly. These findings confirmed that TRAF3 negatively 
regulates OC differentiation by preventing p100 processing. We then generated mice 
with conditional OC-specific deletion of TRAF3 (cKO mice) and found that the cKO mice 
had mild osteoporosis associated with increased OC formation, further confirming that 
TRAF3 maintains bone homeostasis by inhibiting OC formation.  
3.4.2 RANKL induces TRAF3 autophagy/lysosome degradation to mediate OC 
formation (Xiu et al., 2014).  
CD40 or BAFF-R engagement in B cells induces rapid, proteasome-dependent 
TRAF3 degradation (Vallabhapurapu et al., 2008). Using a high-binding affinity ubiquitin 
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	matrix to capture ubiquitinated proteins of OCPs followed by Western blotting analysis 
using an anti-TRAF3 Ab, we found that RANKL markedly increased TRAF3 
ubiquitination allowing the ubiquitinated protein to be degraded in proteasomes or 
lysosomes  (autophagosomes) (Clague and Urbe, 2010). In an earlier report, we found 
that RANKL-induced TRAF3 degradation was not blocked by proteasome inhibitor, 
MG132 (Yao et al., 2009), but was inhibited by the autophagy/lysosome inhibitor, 
chloroquine (CQ) (Xiu et al., 2014). Autophagy inhibitor Bafilomycin A1 (which blocks 
fusion of the autophagosome and the lysosome (Yamamoto et al., 1998)) increased 
TRAF3 accumulation, consistent with the finding that RANKL significantly increased co-
localization of TRAF3 with LAMP2 (a lysosome marker), which was reduced by CQ. 
Importantly, CQ also inhibited RANKL induced OC formation from WT mouse OCPs but 
not from TRAF3-/- OCPs. These findings confirm that RANKL degrade TRAF3 through 
the lysosome to promote OC differentiation. 
3.4.3 CQ inhibits pathological bone resorption in vivo via TRAF3 (Xiu et al., 2014). 
Hyperparathyroidism is a disease with an excess of parathyroid hormone (PTH) due 
to overactivity of one or more of the body’s four parathyroid glands, resulting in the 
increased serum calcium level, increased bone resorption and bone loss. High level of 
PTH can also induce bone marrow fibrosis, a hallmark of PTH-induced resorption. We 
found that CQ can prevent PTH-induced marrow fibrosis and OC activity in WT mice but 
not TRAF3 conditional knockout mice in myeloid cells. In addition, CQ also prevented 
OVX-induced bone loss and increased OC numbers and surfaces in WT mice, but not in 
c-cKO mice. These suggest that PTH-induced marrow fibrosis and OVX-induced bone 
loss is through TRAF3.  
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	3.4.4 RelB is required for RANKL-induced TRAF3 lysosomal degradation by 
regulating BECN1 expression (Xiu et al., 2014).		
TRAF3 negatively regulates NIK to control non-canonical NF-κB signaling (Sun, 
2011, Sun, 2012), a hallmark being the processing of p100 to p52. It is not known if NF-
κB in turn regulates TRAF3. We found that basal TRAF3 protein levels in RelB-/- BM 
cells were 5-fold higher than in WT cells, and TRAF3 protein was also significantly 
accumulated in RANKL-treated RelB-/- OCPs in comparison with the time-dependent 
decreasing of TRAF3 in RANKL-treated WT OCPs. Consistent with these, RelB over-
expression restored RANKL-induced TRAF3 degradation in RelB-/- OCPs. These 
findings suggest that RelB promotes RANKL-induced TRAF3 degradation. 
As RANKL-induced TRAF3 degradation is lysosome/autophagosome-mediated, we 
examined the key molecules for autophagosome formation including ATG5, ATG7, 
ATG8 and beclin 1 (BECN1) in OCPs (Copetti et al., 2009). We found that RANKL 
upregulated BECN1 protein level approximately 3-fold while other autophagic proteins 
were not changed. Consistent with this, shRNA knockdown of BECN1 impaired RANKL-
induced TRAF3 degradation and autolysosome formation. To determine if TRAF3 
degradation and autolysosome formation induced by RANKL is through RelB-mediated 
BECN1, we investigated if RelB regulates the BECN1 promoter activity since the 
proximal 1.1 kb of the BECN1 promoter has 4 κB binding sites (Copetti et al., 2009).  As 
expected, RelB significantly up-regulated BECN1 transcriptional activity in comparison 
with the minimal induction of its activity by RelA. ChIP assays confirmed that RelB 
directly binds to a conserved κB binding site of the BECN1 promoter. In summary, our 
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	findings indicate that RANKL-induced TRAF3 lysosomal degradation is through RelB 
induction of BECN1-mediated lysosome/autophagosome formation. 
3.5 TNF induction of non-canonical NF-κB inhibits bone formation by 
interacting with Notch signaling.  
Bone remodeling is a coupled process, the old bone being removed by OCs 
followed by new bone formation to repair resorbed lacunae. OB cells produce RANKL to 
stimulate OC differentiation and OCs also produce factors to control bone formation 
(Boyce, 2013). This series of publications report the regulation of bone formation, in 
particular TNF induction of non-canonical NF-κB which inhibits bone formation by 
interacting with Notch signaling. 
a. Kaneki H; Guo R; Chen D; Yao Z; Schwarz EM; Zhang YE; Boyce BF; Xing L. 
Tumor necrosis factor promotes Runx2 degradation through up-regulation of 
Smurf1 and Smurf2 in osteoblasts." J. Biol. Chem. 2006; 281(7):4326-33.   
b. Engin F; Yao Z; Yang T; Zhou G; Bertin T; Jiang MM; Chen Y; Wang L; Zheng H; 
Sutton RE; Boyce BF; Lee B. "Dimorphic effects of Notch signaling in bone 
homeostasis." Nat. Med. 2008; 14(3):299-305.   
c. Yao Z, Li Y, Yin X, Dong Y, Xing L, Boyce BF. NF-κB RelB negatively regulates 
osteoblast differentiation and bone formation. J Bone Miner Res. 2014; 
29(4):866-77.  
d. Zhang H, Hilton MJ, Anolik J, Welle S, Zhao C, Yao Z, Li X, Wang Z, Boyce B, 
Xing L. NOTCH inhibits osteoblast formation in inflammatory arthritis via 
noncanonical NF-κB. J. Clin. Invest. 2014 Jul 1;124(7):3200-14. 
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	In addition to activating OC formation, TNF also inhibits OB differentiation (Li et al., 
2007, Chang et al., 2009, Gilbert et al., 2002, Gilbert et al., 2005, Yamazaki et al., 2009). 
However, the mechanisms by which TNF inhibits OBs have not been fully determined. 
The findings that TNF induction of non-canonical NF-κB inhibits bone formation by 
interacting with Notch signaling are outlined in Fig.7 and discussed below. 
 
 
Fig.7. TNF-induced non-canonical NF-κB interacts with Notch to control bone fromation 
(Engin et al., 2008, Kaneki et al., 2006, Yao et al., 2014, Zhang et al., 2014). (1) TNF 
increases Smurf1 resulting in ubiquitination and degradation of Runx2 and thus inhibit OB 
differentiation; (2) TNF increase RelB which directly binds RUNX2 to inhibit MSC proliferation 
and OB differentiation (Yao et al., 2014); (3) Upon ligand binding, NICD is cleaved to 
translocate to the nucleus where it binds to RUNX2 promoter to promote MSC proliferation but 
inhibit OB differentiation (Engin et al., 2008); (4) RelB:p52 dimer association with NICD 
enhances RBPjκ binding to Hes1 to inhibit OB differentiation (Zhang et al., 2014). 
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	3.5.1 TNF inhibits OB differentiation through Smurf-mediated RUNX2 
Degradation 
Runx2 is a critical transcription factor for OB differentiation and maturation. It is 
required for commitment of mesenchymal osteochondroprogenitors to the osteoblastic 
lineage and OB differentiation during both endochondral and intramembranous 
ossification (Komori, 2011). TNF inhibits osteoblast differentiation through TNFR1-
mediated suppression of Runx2 gene transcription and destabilization of Runx2 mRNA 
(Gilbert et al., 2002, Abbas et al., 2003, Gilbert et al., 2005). It was predicted that TNF 
also post-transcriptionally regulates Runx2 since TNF reduction of nuclear Runx2 
protein (more than 90%) was greater than the reduction of total Runx2 mRNA (50%) 
(Gilbert et al., 2002). Ubiquitin-mediated proteasomal degradation has been implicated 
in the regulation of BMP-2 and TGF-β signaling pathways in various cell types (Datto 
and Wang, 2005, Izzi and Attisano, 2004). The E3 ubiquitin ligase, Smad ubiquitin 
regulatory factor 1 (Smurf1), regulates OB differentiation by promoting proteasomal 
degradation of the BMP signaling proteins, Smad1, Smad5, and Runx2 (Zhu et al., 1999, 
Ying et al., 2003, Zhao et al., 2004). Smurf2, a closely related homolog of Smurf1, was 
shown to reduce the steady-state protein levels of Smad1 and 2, but not Smad3 and 4, 
in Smurf2-transfected cells (Lin et al., 2000, Zhang et al., 2001a).  
Smurf1−/− mice exhibit an age-dependent increase in bone mass (Yamashita et al., 
2005) and Col1a1-Smurf1 transgenic mice have decreased bone formation rates and 
decreased Runx2 protein expression in osteoblasts (Zhao et al., 2004), suggesting that 
Smurf1 negatively regulates OB differentiation and bone formation. We proposed a 
novel molecular mechanism of TNF inhibition of osteoblasts involving Smurf-mediated 
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	ubiquitination and degradation of Runx2 through several lines of evidences (Kaneki et 
al., 2006): (i) TNF promoted ubiquitination and degradation of transfected and 
endogenous Runx2; (ii) TNF increased the expression of Smurf1 and Smurf2; (iii) TNF-
induced ubiquitination and degradation of Runx2 were attenuated in cells 
overexpressing Smurf1 and Smurf2 siRNA; (iv) expression of Smurf1 and Smurf2 
siRNA rescued the inhibitory effect of TNF on Runx2 reporter; (v) bones of mice that 
have elevated TNF levels have increased Smurf1 and decreased Runx2 protein 
expression.  
3.5.2 Non-canonical NF-κB RelB negatively regulate OB differentiation 
Several groups have shown that TNF induction of canonical NF-κB RelA inhibits OB 
differentiation (Gilbert et al., 2002, Gilbert et al., 2005, Li et al., 2007, Yamazaki et al., 
2009, Chang et al., 2009), specifically in mature OBs (Chang et al., 2009). However, it 
was also reported that TNF-induced RelA in mesenchymal progenitor cells (MPCs) 
promotes their differentiation into OBs (Cho et al., 2010, Hess et al., 2009, Lencel et al., 
2011).  A role for non-canonical NF-κB signaling in bone formation has also been 
reported. Mice with accumulation of p100 have enhanced OB differentiation (Seo et al., 
2012) and, consistently, mice with deletion of p100 but retention of a functional p52 
have osteopenia due to increased OC activity and impaired OB parameters (Soysa et 
al., 2010). Interestingly, deletion of both RelB and p100 in these latter mice prevented 
the osteopenia in the p100-/- mice (Soysa et al., 2010), suggesting an important role of 
RelB to inhibit OB differentiation. The molecular mechanism whereby RelB regulates 
OB differentiation or function is however unclear. We found that RelB-/- mice had age- 
related increased bone mass due to increased OB precursor proliferation associated 
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	with enhanced capacity of their MPCs to differentiate into OBs in vitro and to repair 
cortical bone defects in mice in vivo (Yao et al., 2014). Further analysis indicated that 
RelB directly targeted Runx2 promoter to inhibit its activation (Yao et al., 2014). But, it 
was still unclear how RelB determines the fate of MPCs. 
3.5.3 TNF activates Notch signaling though the non-canonical NF-κB pathway 
Notch is a family of evolutionarily conserved receptors that regulate cell fate. Upon 
ligand binding, the Notch receptor intracellular domain (NICD) is cleaved by γ-secretase 
and translocates to the nucleus, where it associates with the recombination signal–
binding protein jκ (RBPjκ), leading to transcriptional activation of target genes such as 
Hes1 and Hey1 (Zanotti and Canalis, 2010). In collaboration with Dr. Lee’s group 
(Baylor College of Medicine, Houston, USA), we found that OB-specific gain of Notch 
function increased proliferation of immature OBs by up-regulating the genes encoding 
cyclin D, cyclin E and osterix. NICD also regulated terminal OB differentiation by directly 
binding Runx2 and repressing its transactivation function (Engin et al., 2008).  
We also investigated if NF-κB interacts with Notch signaling to regulate bone 
formation and MPC fate by performing RNA sequencing and pathway analyses in MPCs 
in a TNF- transgenic murine RA model, to identify pathways responsible for decreased 
OB differentiation. Among the 53 pathways dysregulated in MPCs, genes encoding 
Notch and non-canonical NF-κB pathway members were markedly elevated (Zhang et 
al., 2014). Interestingly, overexpression of p52 and RelB in murine MPCs increased 
NICD-dependent activation of RBPjκ reporter and level of Hes1. We also found that 
TNF promoted p52/RelB binding to NICD, which enhanced binding at the RBPjκ site 
within the Hes1 promoter (Zhang et al., 2014). These data suggest that TNF induction 
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	of non-canonical NF-κB members activates Notch signaling to inhibit OB differentiation. 
Importantly, administration of Notch inhibitors to RA mice prevented bone loss by 
promoting OB differentiation, and CFU-fibroblasts treated with Notch inhibitors formed 
more new bone in recipient mice with tibial defects (Zhang et al., 2014). Together, these 
data indicate that persistent Notch activation in MPCs contributes to decreased OB 
differentiation associated with RA and suggest that Notch inhibitors could prevent 
inflammation-mediated bone loss. 
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	Chapter 4 Discussion  
RA and osteoporosis represent two common bone-related diseases that pose a 
major threat to public health. Although both conditions share some cellular and 
molecular mechanisms, for example, the excessive osteoclast differentiation and 
activation as well as the decreased bone formation during pathological process, their 
etiology, pathological features and treatment are very different. Thus, they will be 
discussed separately.  
4.1 NF-κB control of joint destruction in RA 
Macrophage/monocytes play central role in the pathological process of RA. They not 
only produce abundant inflammatory factors to mediate inflammation, but also 
differentiate into OCs involved in the destruction of cartilage and bone within the joint. A 
number of OC inhibitors such as bisphosphonates and Denosumab have been 
developed to treat osteoporosis. Bisphosphonates also have been used to treat bone 
loss in RA because of the high risk of osteoporosis in RA patients (Kim et al., 2010). 
RANKL inhibitors have also been tested in preclinical and clinical trials in RA but they 
did not alter the inflammatory processes (Ferrari-Lacraz and Ferrari, 2011), which is 
consistent with animal studies data showing that complete deletion of RANK signaling 
did not prevent synovial inflammation, despite blocking joint erosion due to an OC 
defect in TNF-induced RA (Redlich et al., 2002a, Redlich et al., 2002b). RANK deletion 
can result in increased number of macrophages since they do not further differentiate to 
form mature OCs (Dougall et al., 1999) but it is not known if failure of RANKL inhibitor 
for the treatment of joint inflammation in RA is related to the secondary increase in 
macrophages. 
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	Macrophages are classified as inflammatory (M1) and anti-inflammatory (M2) 
(Mosser and Edwards, 2008). M1 macrophages produce many inflammatory cytokines, 
including TNF, IL-18, IL-12 and IL-23, to mediate inflammatory responses in a variety of 
autoimmune diseases (Murphy et al., 2003, Smith et al., 2009, Kaneki et al., 2006). M2 
macrophages, in contrast, inhibit the production of a wide variety of pro-inflammatory 
factors, by inducing anti-inflammatory, pro-resolving mediators such as IL-10, and 
regulate wound healing (Murai et al., 2009). Thus, targeted depletion of M1 and 
boosting the activities of M2 macrophages is emerging as an attractive combined 
therapeutic strategy for autoimmune disease (Leuschner et al., 2011, Li et al., 2012a, Li 
et al., 2012b). Generally, M-CSF drives myeloid progenitor cell differentiation into 
monocyte-macrophages with M2-like phenotypes and an anti-inflammatory response 
(Sierra-Filardi et al., 2010). Indeed, we found that only small portion of M-CSF-induced 
OCPs have M1 phenotype which differentiate to OCs in response to RANKL but most of 
them have M2 phenotype which do not form OCs. Thus, targeting M-CSF or its receptor 
c-Fms to deplete macrophage populations would not be appropriate for the treatment of 
RA although TNF expands OCP pool via stimulating c-Fms expression (Yao et al., 
2006). Our recent findings indicate that TNF switches M-CSF-induced M2 to M1 
macrophages with enhanced OC forming potential in response to RANKL and increased 
production of inflammatory factors through induction of RelB (Zhao et al., 2015). TNF 
induction of RelB also however inhibits terminal OC differentiation by directly inhibiting 
NFATc1 expression and activation (Zhao et al., 2015). This could explain why TNF 
alone can significantly increase OCPs numbers through M2 to M1 switching, while 
having very limited ability to induce terminal OCP differentiation into OCs (Zhao et al., 
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	2015). In contrast, RANKL strikingly increases OC formation from TNF-primed OCPs 
compared to OCPs induced by M-CSF alone since it can efficiently degrade RelB 
protein, resulting in sustained activation of NFATc1 to promote OC formation (Zhao et 
al., 2015). Although over-expression of RelB can enhances TNF-induced OC formation, 
this effect is still lower than that of RANKL since it peaks one day later than that of 
RANKL (Zhao et al., 2015). Thus, TNF induction of RelB to induce terminal OC 
differentiation in physiological and pathologic conditions is limited, and the dominant 
role of TNF induction of RelB is to expand the pool of OCPs by switching the 
differentiation of M-CSF-induced M2 resident to M1 inflammatory macrophages. Thus, 
degrading TNF-induced RelB could be a novel strategy to specifically deplete TNF-
induced M1 macrophages to decrease OC-induced joint destruction and inflammation in 
RA patients without affecting normal bone remodeling. Further study is needed to 
elucidate the detailed mechanism of TNF inhibition of RelB degradation in order to 
design a specific approach to degrade RelB as a therapeutic approach for RA. 
TNF is one of the major pro-inflammatory cytokines that mediate pathological 
processes including joint inflammation and destruction (Boyce et al., 2005) and TNF-Tg 
mice develop arthritis that is very similar to human RA (Boyce et al., 2005, Keffer et al., 
1991). Anti-TNF reagents have been developed to treat RA clinically, which have 
significantly improved RA treatment, but they are expensive and only ~50% RA patients 
respond well to these agents (Hyrich et al., 2006, Symmons and Silman, 2006). This 
suggests that other factors are involved in the TNF-induced pathological processes of 
RA, for example, IL-1 mediates TNF-induced osteoclastogenesis (Wei et al., 2005). We 
found that TNF shares the common critical transcriptional factors, NF-κB, c-Fos and 
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	NFATc1 with RANKL to induce OC formation independent of RANKL signaling 
(Yamashita et al., 2007, Yao et al., 2009), but its potential to make OCs is limited 
(Yamashita et al., 2007, Yao et al., 2009). However, an auto-regulation of OC 
differentiation exists, in which OCPs interact with bone matrix to produce IL-1β which 
stimulates TNF pre-activated OCPs expressing c-Fos to further differentiate into mature 
OCs to erode bone (Yao et al., 2008). This may explain why a combined therapy of anti-
TNF and anti-IL-1β seems to produce better results in RA patients (Williams et al., 
2000).  
The key step in non-canonical NF-κB activation is the processing of p100 to p52 
(Bonizzi and Karin, 2004, Senftleben et al., 2001). RANKL efficiently processes p100 to 
p52 to induce full OC differentiation, but in contrast, TNF does not process p100 to p52 
and thus induces a limited OC formation (Yao et al., 2009). Importantly, p100 deletion 
significantly enhances joint destruction and inflammation in the RA model of TNF-Tg 
mice but it does not however increase serum TNF concentrations in these mice (Yao et 
al., 2009). This suggests that p100 deficiency could increase the susceptibility to, or 
pathological progress of, rheumatoid arthritis. Mice with a mutation in NFKB2 gene that 
prevents the processing of p100 into the active subunit, p52, express a complex 
phenotype with abnormalities in a variety of tissues including disorganized splenic 
architecture and disrupted B cell development due to activation of RelA (Tucker et al., 
2007). It was recently reported that a common variable immunodeficiency (CVID) 
results from an 8bp deletion in the C-terminal part of NFKB2 gene, resulting in a peptide 
that is 19 amino acids shorter due to a frameshift altering 17 C-terminal amino acids 
(Liu et al., 2014). It is currently unknown if an NFKB2 genetic mutation results in p100 
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	deficiency or enhanced processing to influence the susceptibility, disease severity and 
progress of human RA. Further study is also needed to determine if there are NFKB2 
genetic variations that limit the therapeutic response of RA patients to anti-TNF 
treatment. Similarly, since p100 deficiency also enhances RANKL-mediated bone 
destruction (Yao et al., 2009), further study is also needed to explore if agents that 
prevent p100 degradation, for example NIK inhibitors, can inhibit joint destruction to 
treat RA. 
4.2 Targeting non-canonical NF-κB signaling to develop novel therapies for 
osteoporosis 
A various bisphosphonates are the widely used anti-resorptive drugs for the 
treatment of osteoporosis and are prescribed at 73 percent of physician visits for 
osteoporosis (Stafford et al., 2004). About 4 percent of patients (Sedghizadeh et al., 
2009) develop osteonecrosis of the jaw after taking oral bisphosphonates for 4.6 years 
(and a minimum of three years) (Zavras, 2011). The prevalence of bone necrosis is 
considerably higher in patients who are taking high-dose intravenous bisphosphonates 
(Ruggiero et al., 2004). Recently FDA approved anti-resorptive drug Denosumab can 
also results in bone necrosis (Aghaloo et al., 2010). PTH (teriparatide) is the only 
anabolic drug but its use is limited to 2 years (Ponnapakkam et al., 2014). PTH also has 
the risk to result in osteosarcoma (Cipriani et al., 2012) although this possibility is low in 
human. Thus, PTH is contraindicated in anyone: (1) with a history of osteosarcoma or 
any bone cancer (primary or metastatic); (2) at risk for osteosarcoma (Paget's disease 
of bone, previous radiation therapy to the skeleton or to other organs if skeletal tissue is 
exposed); or (3) children and young adults with open epiphyses (Cipriani et al., 2012). 
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	Therefore, there is an unmet need to develop new anti-resorptive and/or anabolic drugs, 
particularly, the agents with dual anti-resorptive and anabolic effect simultaneously, for 
the treatment of osteoporosis since currently there is no single drug with dual role that 
can simultaneously inhibit bone resorption and stimulate bone formation, and combined 
therapy with teriparatide and a bisphosphonate does not appear to offer advantages 
over the use of the single agent alone (Black et al., 2003, Finkelstein et al., 2003). Our 
findings have demonstrated several new molecular targets for the development of new 
therapeutic approach of osteoporosis.  
Numerous factors including hormones, cytokines and chemokines regulate multiple 
intracellular signaling pathways to act on bone formation and resorption, both positively 
and negatively, with aging (McLean, 2009, Ginaldi et al., 2005). It is unclear how these 
factors interact to result in osteoporotic bone loss through the stimulation of OC bone 
resorption and inhibition of OB bone formation. It is therefore crucial to identify the key 
molecules that control bone resorption and formation and to understand how other 
factors regulate them in order to develop agents with dual anti-resorptive and anabolic 
effects. Our findings and publications have indicated that non-canonical NF-κB 
activation plays a dual role in the stimulation of bone resorption and also inhibition of 
bone formation. Mice lacking functional NIK have impaired RANKL–stimulated 
osteoclastogenesis due to p100 accumulation (Aya et al., 2005). This is consistent with 
our findings that TNF induction of p100 accumulation inhibits TNF- and RANKL- 
induced OC formation, and that p100 deletion enhances TNF-induced systemic bone 
loss and joint destruction (Yao et al., 2009). More recently, it was reported that TNF also 
limits OC formation through RBP-jκ (Zhao et al., 2012) and IRF-8 (Zhao et al., 2009), 
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	indicating that there are several potential mechanisms to restrict the destructive effects 
of TNF on bone. Interestingly, accumulation of p100 due to a loss-of-function of NIK 
also increased bone mass, associated with increased bone formation in mice (Soysa et 
al., 2010, Seo et al., 2012). Mice with a deletion of p100, but retaining a functional p52 
protein however develop osteopenia with reduced osteoblast numbers (Soysa et al., 
2010). These data suggest that increasing p100 protein levels not only inhibit bone 
resorption but also stimulate or maintain bone formation and thus, inhibiting non-
canonical NF-κB activation could be a novel strategy to develop agents with both anti-
resorptive and anabolic effect. Since the key step of non-canonical NF-κB activation is 
that NIK is activated to process p100 into p52, NIK could be an important target 
molecule to develop new therapeutic agents that inhibit non-canonical NF-κB activation. 
A number of NIK inhibitors have been reported (Mortier et al., 2010). No any reagent 
has reported to inhibit OC and/or stimulate OB differentiation but we are currently 
screening for if the reported NIK inhibitors can do so. The discovery of NIK crystal 
structure (Liu et al., 2012) enables us to design new class of NIK inhibitors for the 
purpose of development of dual anti-resorptive and anabolic agents for the treatment of 
osteoporosis.  
TRAF3 is the key molecule that controls non-canonical NF-κB activation (He et al., 
2007, He et al., 2006). It forms a complex with TRAF2 and cIAP1/2 to constitutively 
degrade NIK and thus prevent the processing of p100 into p52 (Gyrd-Hansen and Meier, 
2010). We were the first to identify the role of TRAF3 in OC differentiation and function 
(Yao et al., 2009) and specific deletion of TRAF3 in myeloid cells results in the age-
associated bone loss (Xiu et al., 2014). Interestingly, we recently found that a specific 
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	deletion of TRAF3 in MPCs in mice also results in age-associated bone loss by 
decreasing OB differentiation and bone formation (un-published). These suggest that 
TRAF3 also play dual role to inhibit bone resorption and stimulate bone formation. 
Targeting TRAF3 could therefore be another strategy to develop new agents with dual 
anti-resorptive and anabolic effect. One of such approaches is to inhibit degradation of 
TRAF3.  We also importantly showed that inhibition of TRAF3 degradation by lysosomal 
inhibitor chloroquine (CQ) that has long been used to treat malaria and RA prevents 
ovariectomy-induced osteoporosis and PTH-induced bone loss (Xiu et al., 2014). 
However, like many other anti-RA drugs, CQ also has severe side effects, for example, 
renal toxic and blindness in up to 0.5-1% of patients (Costedoat-Chalumeau et al., 2015, 
Taylor and White, 2004). An attractive strategy to minimize side effects of drugs used to 
treat bone diseases is to administer them in a form that specifically targets them to bone. 
This could allow drugs to be given to patients at doses with reduced risk of side effects, 
while also delivering effective concentrations specifically to bone.  Based on the high 
bone affinity of bisphosphonates (BPs) that are currently used to osteoporosis, we have 
generated a Bone-Targeted CQ (BTCQ) analog using a BP that binds avidly to bone, 
but does not inhibit bone resorption. The preliminary results in vitro and in vivo are 
excited. Further in vivo testing for the treatment of osteoporosis is being undertaken. In 
addition, we will need to perform profound research to elucidate how TRAF3 
ubiquitintion and degradation is controlled in order to design specific agents to prevent 
TRAF3 degradation for the therapy of osteoporosis. 
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	4.3 Summary 
Our studies have revealed a number of mechanisms by which cytokine-induced 
non-canonical NF-κB signaling controls both bone resorption and formation including: 
1) TNF expands the pool of OCPs with enhanced OC forming potential (Yao et al., 
2006, Zhao et al., 2015); 
2) NF-κB p50 and p52 sequentially activate c-Fos and NFATc1 to induce OC 
differentiation (Yamashita et al., 2007, Yao et al., 2008); 
3) NF-κB2 p100 limits OC formation and bone resorption (Yao et al., 2009); 
4) TRAF3 negatively regulates OC differentiation (Xiu et al., 2014, Yao et al., 2009); 
5) NF-κB inhibits bone formation by interacting with Notch signaling (Engin et al., 
2008, Kaneki et al., 2006, Yao et al., 2014, Zhang et al., 2014).  
Importantly, targeting non-canonical NF-κB signaling could be used to develop new 
agents for the therapy of RA or osteoporosis. For example, agents that degrade TNF-
induced RelB could block M1 macrophage differentiation to inhibit inflammation and 
joint destruction for the therapy of RA. In addition, NIK inhibitors that prevent p100 
processing or agents that prevent TRAF3 degradation could inhibit bone resorption and 
simultaneously stimulate bone formation for the therapy of osteoporosis. We are 
currently working with chemists to develop agents for the therapy of RA and/or 
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Osteoclasts are essential cells for bone erosion in inflammatory
arthritis and are derived fromcells in themyeloid lineage. Recently,we
reported that tumor necrosis factor- (TNF) increases the blood
osteoclast precursor (OCP) numbers in arthritic patients and animals,
which are reduced by anti-TNF therapy, implying that circulating
OCPs may have an important role in the pathogenesis of erosive
arthritis. The aim of this study is to investigate the mechanism by
whichTNF induces this increase inOCP frequency.We found that
TNF stimulated cell division and conversion of CD11b/Gr-1/lo/
c-Fms to CD11b/Gr-1/lo/c-Fms cells, which was not blocked
by neutralizing macrophage colony-stimulating factor (M-CSF)
antibody. Ex vivo analysis of monocytes demonstrated the follow-
ing: (i) blood CD11b/Gr-1/lo but not CD11b/Gr-1 cells give
rise to osteoclasts when they were cultured with receptor activator
NF-B ligand andM-CSF; and (ii) TNF-transgenic mice have a sig-
nificant increase in blood CD11b/Gr-1/lo cells and bone marrow
proliferating CD11b/Gr-1/lo cells. Administration of TNF to
wild type mice induced bone marrow CD11b/Gr-1/lo cell prolif-
eration, which was associated with an increase in CD11b/Gr-1/lo
OCPs in the circulation. Thus, TNF directly stimulates bonemar-
row OCP genesis by enhancing c-Fms expression. This results in
progenitor cell proliferation and differentiation in response to
M-CSF, leading to an enlargement of the marrow OCP pool.
Increased marrow OCPs subsequently egress to the circulation,
forming a basis for elevatedOCP frequency.Therefore, the first step
of TNF-induced osteoclastogenesis is at the level of OCP genesis in
the bone marrow, which represents another layer of regulation to
control erosive disease.
Mature osteoclasts are essential effector cells for normal bone remod-
eling and pathologic bone loss seen in many forms of erosive diseases,
such as rheumatoid arthritis (RA).3 The importance of osteoclastic
resorption in this process has been proven in studies with various
knock-out mice deficient in genes essential for osteoclastogenesis,
which develop osteopetrosis because of the accumulation of
un-resorbed bone matrix within the bone marrow cavity (1, 2). Simi-
larly, thesemice are completely resistant to bone destruction of affected
joints when they are induced to develop erosive arthritis (3–5). Oste-
oclasts are derived from common osteoclast/monocyte precursors that
are generated in bone marrow and travel to peripheral tissues through
the bloodstream (6). In patients or animals with RA, these precursor
cells constantly migrate to inflamed joints perhaps from the following
two directions: “outside in,” from blood to the pannus-bone interface,
and “inside out,” from epiphysial bonemarrow to the subchondral bone.
They then differentiate to mature osteoclasts in response to high levels
of osteoclastogenic cytokines, including receptor activator NF-B
ligand (RANKL), macrophage-colony-stimulating factor (M-CSF), and
tumor necrosis factor- (TNF), produced by inflammatory cells in the
synovium (7, 8). Although the teams ofmature osteoclastsmediate focal
erosions via resorption of the periarticular and subchondral bone over
long periods of time (months to years), the life span of individual oste-
oclasts is only a fewweeks. Thus, mature osteoclasts must be constantly
replaced by a perpetual supply of osteoclast precursors (OCPs). Cur-
rently, the molecular mechanism by which joint inflammation sustains
the perpetual supply of OCPs is poorly understood.
OCPs are derived from c-Kit multipotent hematopoietic stem
cells in the bone marrow through a series of differentiation processes
(9). The first step of OCP ontogeny is the commitment of hemato-
poietic stem cells to the myeloid lineage under the control of the Ets
transcription factor PU.1 (10). Then the myeloid progenitors sur-
vive, proliferate, and differentiate into various “downstream” lineages,
including OCPs. These events have been characterized by changes in
the surface expression of distinct markers. For instance, early myeloid
progenitors do not express detectable levels of c-Fms, the receptor for
M-CSF, an essential survival factor for OCPs. As such, they exhibit
lower proliferation and differentiation potency. However, under the
influence of hematopoietic factors such as stem cell factor and perhaps
M-CSF itself, c-Fms cells differentiate to c-Fms cells (11). The con-
version of c-Fms cells to c-Fms cells is an important landmark for the
progression of myelopoiesis because the M-CSF signal at this stage is
critical for cell survival (anti-apoptosis), proliferation, and differentia-
tion. However, the regulation of this conversion in chronic inflamma-
tory bone diseases has not been well studied.
TNF is one of themost potent pro-inflammatory cytokines, and its role
in RA has been formally established by the development of anti-TNF ther-
apy. Additional proof comes from studies of TNF transgenic (TNF-Tg)
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mice that develop erosive arthritis featuredwith intense synovial inflamma-
tion and destruction of cartilage and bone (12). These mice have increased
numbers of OCPs in spleen and blood and increased numbers of mature
osteoclasts in the affected joints (13). The role of TNF in osteoclastogen-
esis has been studied extensively in the last decade. Administration of
TNF into wild-type (WT) mice greatly increases the number of tartrate-
resistant acid phosphatase (TRAP)-positive osteoclasts locally and system-
ically (13, 14). In vitro, TNF directly stimulates mature osteoclast forma-
tion from OCPs in the absence of osteoblasts/stromal cells through
activation ofNF-B and nuclear factor of activated T cells pathways (15). It
also promotes the production ofM-CSF by T lymphocytes and RANKL by
osteoblasts, thereby indirectly stimulating osteoclast formation (16, 17).
However, whether TNF promotes OCP generation from early myeloid
precursors and the mechanisms involved in this process have not been
investigated.
In this study, we test the hypothesis that TNF increases OCP num-
bers through regulation of c-Fms expression. We demonstrate that
TNF increases the proliferation of OCPs in vivo and in vitro and pro-
motes the differentiation of c-Fms cells to c-Fms cells. TNF-in-
duced OCP genesis is directly related to increased blood OCP fre-
quency. Thus, our results reveal a new mechanism for TNF in the
control of peripheral osteoclast numbers and provide an additional reg-
ulatory step to control osteoclast formation and bone resorption in
inflammatory erosive diseases.
EXPERIMENTAL PROCEDURES
Reagents—Recombinantmurine RANKL, TNF, and humanM-CSF
were purchased from R & D Systems (Minneapolis, MN). Anti-murine
CD11b (M1/70), c-Fms (AFS98), CD3 (145–2C11), B220 (RA3–6B2),
and isotype controls were from eBioscience Inc. (San Diego, CA); anti-
murine CD16/32 (FcIII/II), c-Kit (2B8), Gr-1 (1A8), and isotype con-
trols were from Pharmingen.
Animals—TNF-Tg mice in a CBA  C57Bl/6 background (3647
TNF-Tg line) were obtained from Dr. G. Kollias (12). Four-month-old
TNF-Tg mice were used because this is the age when they typically
develop severe joint disease with elevated serum human TNF concen-
trations (13). Acute TNF in vivo treatment was performed as we
described previously (13). In brief, 2-month-oldC57/B6malemicewere
randomly divided into TNF and PBS groups. Murine TNF (0.5 g in
25l of PBS) or the same volume of PBS was injected four times/day for
3 days into the subcutaneous layer overlying the calvariae of WT mice.
Bone marrow and PBMCs were collected for cell cycle analysis, as
described below. The Institutional Animal Care and Use Committee
approved all animal studies.
Generation of Osteoclasts—Cells from several sources were used to
generate osteoclasts: 1) freshly isolated bonemarrow cells; 2) M-CSF or
TNF pretreated nonadherent bone marrow cells; and 3) flow-sorted
bonemarrow or blood cells. Cells were cultured in -modified essential
medium (Invitrogen) with 10% fetal calf serum (Hyclone Laboratories,
Logan, UT), RANKL (5 ng/ml), and M-CSF (10 ng/ml) for 3–5 days
when multinucleated cells typically were observed under an inverted
microscope. Cells were then fixed and stained for TRAP activity, and
TRAP cells containing3 nuclei were counted as mature osteoclasts
as we described previously (13).
Fluorescence-activated Cell Sorting (FACS) Analysis and Cell Sorting—
For FACS analysis, freshly isolated bone marrow, PBMCs or cultured
OCPs were incubated with anti-murine CD16/32 to block Fc receptor-
mediated antibody binding. Cells were then stained with various fluo-
rescent-labeled antibodies. Data were acquired using a FACSCalibur
flow cytometer (BD Biosciences) and analyzed using the Cellquest soft-
ware (version 3.1), as described previously (13). For cell sorting, pooled
bonemarrow cells or peripheral blood cells from either TNF-Tg orWT
mice were double-stained with FITC-anti-CD11b and PE-anti-Gr-1
antibodies, and then sorted by a FACSVantage SE Turbo sorter.
CD11b/Gr-1/lo, CD11b/Gr-1, and CD11b/Gr-1hi cells were col-
lected separately, reanalyzed to ensure their purity (98%), and used for
osteoclastogenesis assays, as described above.
Cell Cycle Analysis of Blood and Bone Marrow OCPs—PBMCs or
bone marrow cells were stained with FITC anti-CD11b and PE anti-
Gr-1 antibodies first, and the labeled cells were then incubated with
Hoechst 33342 (5 g/ml) for 45 min at 37 °C in a reaction buffer (19)
prior to FACS analysis. Cell cycle distributions of CD11b /Gr-1/lo,
CD11b /Gr-1hi , andCD11b /Gr-1 cells were analyzed using a FACS-
Vantage flow cytometer (BD Biosciences) equipped with UV light and
488-nm laser excitations. The percentage of the cells in G1, S, andG2/M
phases of the cell cycle was determined using the ModFit program
(Verity Software, Topsham, ME).
In Vitro Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE)
Labeling—Fresh bone marrow cells were isolated from femur and tibia
of WT mice. Red blood cells were removed using ACK lysis buffer
(0.15 M NH4Cl, 1.0 mM KHCO3, 0.1 mM Na2 EDTA). The cells were
then resuspended in PBS at a density of 5  107/ml, and an equal
volume of CFSE (10 M) was added by drop while vortexing. The
reaction was incubated at 37 °C for 10 min and mixed once during
the incubation. The labeled cells were washed with -minimum
Eagle’s medium plus 10% fetal bovine serum three times and seeded
in a 6-well plate at a density of 4–5  106/well.
Quantitative Real Time RT-PCR—RNA from TNF-treated and
nontreated bone marrow cells or sorted CD11b/Gr-1/lo cells was
extracted using the RNeasy kit and the QiaShredder from Qiagen
(Valencia, CA). cDNA was synthesized with the use of 20 l of RT
reaction solution containing 1 g of total RNA, 10 mM Tris-HCl buffer
(pH 8.3), 50 mM KCl, 5 mM MgCl2, 1 mM deoxynucleoside triphos-
phates, 2.5 M random hexamers, 20 units of RNase inhibitor, and 50
units of Moloney murine leukemia virus reverse transcriptase (all from
Roche Applied Science). Quantitative PCR amplification was per-
formed with gene-specific primers using a Rotor-Gene 2000 real time
amplification operator (Corbett Research, Mortlake, Australia). The
primer sequences included the following: 1) c-Fms primers, 5-GTCA-
GAGGCCCCGTTTGTT-3 and 5-AGTAAATATAGAGGCTAG-
CACTGTGAGAAC-3; and 2) actin primers, 5-AGATGTGGATCAG-
CAAGCAG-3 and 5-GCGCAAGTTAGGTTTTGTCA-3. The relative
standard curve method was used to calculate the amplification differ-
ence for each primer set (20). The standard curve was made from four
points corresponding to 10-fold cDNAdilution series for each gene. For
each sample, the relative amount was calculated from their respective
relative standard curves. The relative c-Fms expression value was then
obtained by dividing each value by the actin value. Standardswere run in
triplicate, and samples were run three times in triplicate.
Statistics—All results are given as means  S.E. Comparisons were
made by analysis of variance and Student’s t test for unpaired data. p
values less than 0.05 were considered statistically significant.
RESULTS
CD11b and Gr-1 Are Cell Surface Markers for Blood and Bone Mar-
row OCPs—Previously, we have used CD11b as a single cell surface
marker for OCPs in the spleen and demonstrated that TNF-Tg arthritic
mice have increased CD11b OCP frequency (13). However, CD11b
protein is broadly expressed on the surface of various myeloid lineage
cells, especially on granulocytes that consist of more than 70% of the
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total blood (72.4 3.4%) or bone marrow (77.4 2%) CD11b cells in
adult C57/B6 mice. Because of this, OCP numbers may be overesti-
mated if the frequency of CD11b cells is used to assess the number of
OCPs in these compartments. In this study, we first characterized the
osteoclastogenic potential of blood and bonemarrow cells using CD11b
and Gr-1 to eliminate CD11b/Gr-1hi granulocytes (Fig. 1). Peripheral
blood mononuclear cells (PBMC) and bone marrow cells from WT
adult mice were stained with anti-CD11b and Gr-1 antibodies, and
FIGURE 1. Identificationof cell populationswith
osteoclastogenic potential from peripheral
blood and bonemarrow cells. A, PBMCs or bone
marrow cells (B) from a pool of five WT mice were
stained with FITC anti-CD11b and PE anti-Gr-1
antibodies and subjected to FACS analysis. The liv-
ing cellswere gatedusing forward and side scatter
(R1). The CD11b/Gr-1/lo (R2), CD11b/Gr-1hi
(R3), and CD11b/Gr-1 (R4) populations were
sorted and cultured with M-CSF and RANKL to
generate osteoclasts. Photography (4) of the
TRAP osteoclasts formed from purified PBMCs
and frombonemarroware shown in theupper and
lower panels, respectively.C, the number of TRAP
osteoclasts formed fromabove cultureswasquan-
tified and presented as means plus S.E. of three
wells. Experiments were repeated once with simi-
lar results.
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three populations were fractionated by FACS on the basis of their sur-
face expression: CD11b/Gr-1/lo (R2), CD11b/Gr-1hi (R3), and
CD11b/Gr-1 (R4). The sorted cells were cultured with M-CSF and
RANKL to generate osteoclasts that were assessed by TRAP staining. In
blood, only CD11b/Gr-1/lo cells (R2) formed osteoclasts. Although
both CD11b/Gr-1/lo (R2) and CD11b/Gr-1 (R4) marrow cells
gave rise to osteoclasts (Fig. 1), the number of TRAP osteoclasts was
much higher in the CD11b/Gr-1/lo (R2) fraction than that in the
CD11b/Gr-1 (R4) fraction (Fig. 1,B andC). TheCD11b/Gr-1hi cells
did not form TRAP osteoclasts and died off under our culture condi-
tions. Because it is likely that marrow CD11b cells differentiate to
TRAP osteoclasts through theCD11b stage and only bloodCD11b/
Gr-1/lo cells give rise to osteoclasts, we reasoned that CD11b/Gr-
1/lo cells include themajority of OCPs and can be used as OCP surface
markers.
TNF-Tg Mice Have Increased Blood and Bone Marrow OCPs—By
using CD11b/Gr-1/lo as OCP markers, we found that in TNF-Tg
mice, the percentage of blood CD11b/Gr-1/lo OCPs increased 5-fold
(Fig. 2A), and their absolute number increased 14-fold, compared with
WT littermates. TNF-Tg mice also had a 1-fold increase in bone mar-
row CD11b/Gr-1/lo but not in CD11b/Gr-1 cells (Fig. 2B). Con-
sistent with this change, the percentage of CD11b/Gr-1hi granulocyte
numbers was reduced in these mice. However, the absolute number of
granulocytes was unchanged both in blood (cell number (106/ml),
1.48 0.21 inTNF-Tgmice versus 1.36 0.16 inWTmice) and in bone
marrow (cell number (106/femur), 3.53 1.34 in TNF-Tg versus 3.32
1.14 in WT mice, respectively). The osteoclast-forming potential of
purified marrow CD11b/Gr-1/lo cells from TNF-Tg mice and WT
littermates was determined by cell culture in the presence of different
amounts ofM-CSF andRANKL. In all cases, TNF-TgCD11b/Gr-1/lo
cells formed significantly more TRAP osteoclasts (Fig. 2C), indicating
that TNF-Tg mice have more OCPs within the CD11b/Gr-1/lo
population.
TNF Promotes the Proliferation of Bone Marrow OCPs—To exam-
ine whether increased bone marrow CD11b/Gr-1/lo OCPs in
TNF-Tg mice results from an alteration in proliferation, cell cycle anal-
ysis was performed using a combination of anti-CD11b and Gr-1 anti-
bodies and Hoechst 33342 DNA dye staining. This approach allows us
to assess cell cycle status in different fractions of CD11b- and Gr-1-
stained cells simultaneously and avoid cell sorting and in vitro labeling.
Compared with CD11b/Gr-1 and CD11b/Gr-1hi cells, the CD11b /
Gr-1/lo population contained cells in the S/G2/M phase of the cell cycle
in both TNF-Tg and WT mice (Fig. 3A). Furthermore, more TNF-Tg
CD11b/Gr-1/lo cells were in the S/G2/M phase than those of WT
littermates, and there was no difference in the frequency of apoptosis
(Fig. 3B, upper panel). In contrast to marrow cells, PBMCs were not in
FIGURE 2. Increased blood and bone marrow OCP frequency in TNF-Tg mice. A, PBMCs from 4-month-old TNF-Tg mice and WT littermates were stained with anti-CD11b and
anti-Gr-1 antibodies and subjected to FACS analysis. Representative histograms show the gated population of CD11b/Gr-1/lo OCPs. The percentage of blood OCPs is shown as
means plus S.E. from three pairs of TNF-Tg mice and WT littermates. B, bone marrow cells were stained with anti-CD11b and anti-Gr-1 antibodies and analyzed by FACS. The
percentage of individual cell population is shown asmeans S.E. from three pairs of TNF-Tgmice andWT littermates. C,purified CD11b/Gr-1/lo cells frombonemarrowof TNF-Tg
mice and WT littermates were cultured with M-CSF and RANKL to generate osteoclasts. The number of TRAP osteoclasts was counted and shown as means S.E. of three wells.
Similar results were obtained from two independent experiments. *, p 0.05 versusWTmice.
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FIGURE 3. Increased cycling OCPs in bone marrow, but not in blood, of TNF-Tg and TNF-treated WT mice. A, bone marrow cells from TNF-Tg mice and WT littermates were
stained with anti-CD11b, anti-Gr-1 antibodies, and Hoechst 33342 DNA dye and subjected to FACS analysis. Representative histograms show cell cycle profiles of various gated cell
populations. B, cell cycle analysis was performed for blood and bonemarrowCD11b/Gr-1/lo OCPs. The percentage of cells in various phases of cell cycles is shown asmeans S.E.
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the cell cycle, and themajority of themwere at the G0/G1 phase (Fig. 3B,
lower panel).
To investigate whether increased cycling of marrow OCPs leads to
increased total numbers of OCPs in the bonemarrow and subsequently
in the peripheral blood, we injected TNF (0.5g/injection, four times/
day for 3 days) into WT mice and examined the cell cycle status of
marrow OCPs, as well as the number of OCPs in blood and bone mar-
row by FACS analysis. A 3-day regimen was used because our prelimi-
nary experiments showed that it took 3 days for TNF to increase blood
OCPs (data not shown). TNF significantly increased the percentage of
cycling marrowOCPs, which started after the 2nd day and peaked after
the 3rd day of injection. Correspondingly, total OCP numbers in bone
marrow increased at 3 days. Blood OCPs were slightly elevated after 2
days and increased significantly after 3 days of TNF treatment, in
parallel with bone marrow cells (Fig. 3, C and D). Together, these find-
ings suggest that TNF may increase bone marrow OCP numbers by
promoting their proliferation.
To determine the direct effects of TNF andM-CSF on OCP prolifer-
ation in vitro, we labeled WT bone marrow cells with 5-(and 6-)-car-
boxyfluorescein diacetate succinimidyl ester (CFSE) to monitor cell
division. The labeled cells were then treated with PBS, M-CSF (10
ng/ml), TNF (10 ng/ml), orM-CSF/TNF for 24, 48, and 72 h, stained
with anti-CD11b, and subjected to FACS analysis. The percentage
of dividing cells in the CD11b population was measured as an indica-
tor of OCP division. Because our initial results demonstrated that 100%
of CD11b/Gr-1hi cells die off, leaving only CD11bGr-1/lo cells 24 h
after culture (data not shown),Gr-1 stainingwas omitted in these exper-
iments. TNF alone had no effect on cell division at any time point, and
M-CSF stimulated OCP division after treatment for 48 h (Fig. 4). In
contrast, TNF synergizedwithM-CSF to stimulateOCP division from
33% in M-CSF-treated cells alone up to 70% in TNF plus M-CSF-
treated cells (Fig. 4, A and B).
TNF Induces c-Fms Expression of Bone Marrow OCPs—Increased
M-CSF-dependent proliferation after TNF treatment suggests that
FIGURE 4. TNF enhances the proliferation of bonemarrowOCPs that is dependent onM-CSF. A,WT bonemarrow cells were isolated, labeled with CFSE, and cultured in vitro.
The cultures were treatedwith PBS, M-CSF (10 ng/ml), TNF (10 ng/ml), and a combination of TNF andM-CSF. Nonadherent cells were collected after 3 days and subjected to FACS
analysis for CD11b and CFSE. The histograms are representative of three independent experiments. The percentage of fast-dividing cells (upper left panels) and non- or slow-dividing
cells (upper right panels) in the CD11b population is shown. B, the CD11b cells were then gated, and the dividing cells with decrease CFSE labeling in this population were
quantified. The results are presented as means S.E. of three independent experiments. *, p 0.05 versus PBS-treated cultures; **, p 0.05 versusM-CSF treated cultures.
from three pairs of TNF-Tgmice andWT littermates. *, p 0.05 versusWTmice. C, TNFwas injected intoWTmice (0.5g/mouse/injection, intraperitoneally, four times/day) for 1–3
days, or PBSwas injected intoWTmice for 3 days. The cell cycle analysis was performed for the CD11b/Gr-1/lo OCP population. The percentage of cells in the G2/M/S phase of cell
cycles is shown asmeans S.E. of threemice. *, p 0.05 versus 3-day PBS-treatedmice.D, the total number of CD11b/Gr-1/lo OCPs in bonemarrow and in bloodwas determined
by FACS and cell counting. Values are themeans S.E. from three pairs of mice. *, p 0.05 versus blood cells; #, p 0.05 versus bonemarrow cells of PBS-treatedmice, respectively.
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FIGURE5.TNF increasesc-Fmsexpression inOCPs.A,bonemarrowcells andPBMCs fromTNF-Tgmice andWT littermateswere stainedwithanti-CD11b,Gr-1, andc-Fms antibodies and
subjected to FACS analysis. The percentage of c-Fms cells within the CD11b /Gr-1/lo population was determined. Values are the means S.E. from four pairs of TNF-Tg mice and WT
littermates.B,WTbonemarrowcellswere culturedwith PBSorTNF (10ng/ml) for 3 days, andnonadherent cellswere collected. The expression levels of c-Fmsweredeterminedby real time
RT-PCR using c-Fms- and -actin-specific primers and are shown as mean fold changes of TNF-treated cells over PBS-treated cells (upper panels). The osteoclast forming potential was
examined by culturing cells withM-CSF and RANKL and is shown asmeans S.E. of number of TRAP osteoclasts from three wells (lower panel). C, purified CD11b /Gr-1/lo cells fromWT
bonemarrowwere treated with TNF (10 ng/ml) for 24 h, and c-Fms expression levels were determined by real time RT-PCR. D,WT bonemarrow cells were incubated with PBS, M-CSF (10
ng/ml), or TNF (10 ng/ml) in the presence of various doses ofM-CSF neutralizing antibody for 3 days, and the percentage of CD11b /c-Fms cells was determined by FACS analysis. *, p
0.05 versus PBS-treated group. All experiments were repeated once with similar results.
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TNF may affect the factors essential for M-CSF signaling. Because the
M-CSF receptor, c-Fms, is expressed on the surface of late stage ofmyeloid
precursors, including OCPs (21), we hypothesized that TNF-Tg CD11b /
Gr-1/lo OCPs may contain more c-Fms cells to account for the TNF-
induced M-CSF-dependent proliferation. To test this, we compared the
percentage of c-Fms cells in the gated CD11b /Gr-1/lo population of
TNF-Tg with that of WT mice, and we found that the TNF-Tg mice had
significantly more c-Fms cells in CD11b/Gr-1/lo OCPs in both blood
and bone marrow (Fig. 5A).
To determine whether TNF promotes the differentiation of c-Fms
cells to c-Fms cells, we examined the induction of CD11b /c-Fms cells
in vitro in response to TNF. WT marrow cells were treated with PBS,
M-CSF (10 ng/ml), TNF (10 ng/ml), or M-CSF/TNF, and the percent-
age of CD11b/c-Fms cells was examined after 24, 48, and 72 h in non-
adherent and adherent fractions (Fig. 5). TNF increased the percentage of
CD11b/c-Fms cells at 24 h, and this peaked at 72 h. M-CSF decreased
c-Fms expression over the first 12–24 h, which may reflect ligand-induced
receptor internalization (22). However, after 48 h, M-CSF significantly
stimulated c-Fms expression. TNF alone increased the percentage of
CD11b/c-Fms cells in nonadherent cells by 9–10-fold and synergized
with M-CSF to stimulate c-Fms expression in those cells (Fig. 5B). TNF
also stimulated the percentage of CD11b/c-Fms cells in adherent cells,
but to a lesser extent (by 3–4-fold, data not shown).
To confirm the functional consequence of increased c-Fms expres-
sion by TNF in osteoclastogenesis, nonadherent TNF- or PBS-
treated cells were cultured to assess their osteoclast-forming potency.
Cells primed by TNF formed significantly more osteoclasts when they
were subsequently cultured with M-CSF and RANKL (Fig. 5B). To
examine if TNF stimulates c-Fms gene transcription, mRNA expres-
sion levels of c-Fms were determined in TNF-treated nonadherent
cells or purified CD11b/Gr-1/lo OCPs. TNF significantly increased
the c-Fms expression levels in both cell preparations (Fig. 5C). Finally,
we treated cells with TNF in the presence ofM-CSF neutralizing anti-
body todeterminewhetherTNF-inducedc-Fmsexpression ismediat-
ed by M-CSF. This treatment completely prevented M-CSF-induced
c-Fms expression in a dose-dependent manner but had little effect on
TNF-induced c-Fms up-regulation (Fig. 5D). These findings indicate
that TNF can directly stimulate c-Fms expression by OCPs.
DISCUSSION
TNF is a pleiotropic cytokine that induces focal erosions in inflamed
arthritic joints by several mechanisms. Recently, we have demonstrated
that one of these mechanisms involves an increase in the frequency of
peripheral blood CD11b OCP in arthritic patients and in TNF-Tg
arthritic mice. We also found that this increased OCP frequency is
reduced by and associated with a successful outcome of anti-TNF ther-
apy (4, 13), implying that circulating OCP numbers may have an impor-
tant role in the pathogenesis of inflammatory erosive arthritis. However,
the mechanism by which systemic TNF induces this increase in OCP
frequency remains unknown.
Although it has been well established that osteoclasts are derived from
myeloid precursors (23, 24), the identity, function, and regulation of OCPs
in vivo remain poorly understood, partly because of the absence of unique
cell surface markers to identify them. We and other have previously used
CD11b as a single surface marker for spleen OCPs (13, 25). Recently, we
established that many of these cells are blood granulocytes that express
CD11b, and the number ofOCPmay be significantly overestimated by this
method. Apart from CD11b, c-Fms and RANK expression also has been
used to estimate OCPs, based on the essential role of M-CSF and RANKL
for osteoclastogenesis (11). However, CD11b/c-Fms and CD11b /c-
Fms cells as well as CD11b/RANK and CD11b /RANK cells all can
give rise to osteoclasts. Thus, they also are suboptimal OCP markers (13,
26). To try to improve on this, here we assessed CD11b /Gr-1/lo cells,
excluding CD11b/Gr-1hi granulocytes, which include both early (c-Fms
or/and RANK) and late OCPs (c-Fms or/and RANK ). We found that
60–70% of CD11b/Gr-1/lo cells can differentiate to TRAP mononu-
clear osteoclasts when cultured with M-CSF and RANKL, indicating that
most of these cells have osteoclast-forming potential. However, it is impor-
tant to realize that CD11b/Gr-1/lo cells are not composed of only OCPs
because they can differentiate into macrophages and dendritic cells under
the appropriate conditions. At present, it is not known if there are commit-
tedmono-potentialOCPs that can be separated from other precursor cells.
Recently, Geissmann et al. (27) proposed that blood monocytes can be
divided into two functional subsets according to expression patterns of an
array of surface proteins: CD11b/Gr-1/CX3CR1lo /CCR2 /CD62L
cells are the cells that are actively recruited to inflamed tissues, and
CD11b/Gr-1/CX3CR1/CCR2/CD62L cells are residentmonocytes
that give rise to specialized cell types, including osteoclasts. According to
this classification, our CD11b/Gr-1/lo cells appear to belong to resident
monocytes. Although the significance of this kind of classification in vivo is
controversial (28), it may be possible to define further OCPs by using mul-
tiple surface markers.
Using CD11b/Gr-1/lo as broad OCP markers, we demonstrated
that TNF promotes the differentiation of bone marrow CD11b/
Gr-1/lo/c-Fms cells to CD11b/Gr-1/lo/c-Fms cells. Thus, the
first step of TNF-induced osteoclastogenesis is the conversion of
c-Fms OCPs to c-Fms OCPs. This results in enhanced sensitiza-
tion of precursor cells to M-CSF and provides more M-CSF-re-
sponding cells. TNF-induced c-Fms mRNA expression has been
reported in murine tissue macrophages (29). However, tissue macro-
phages are terminally differentiated cells that do not have osteoclast-
forming potential (30), and the findings from macrophages may dif-
fer from those of osteoclasts or their precursors. Our findings
provide the first experimental evidence of TNF increasing c-Fms
expression by OCPs, and the functional consequence of this
increased c-Fms expression on osteoclastogenesis (Fig. 5). In addi-
FIGURE 6. TNF-mediated osteoclast precursor genesis in chronic erosive arthritis.
During the early stages of osteoclastogenesis, TNF increases the pool size of marrow
osteoclast precursors by promoting their proliferation and differentiation in response to
M-CSF and by stimulating c-Fms expression (TNF in boldface) (this study). These oste-
oclast precursors then are released to the peripheral blood and differentiate to mature
osteoclasts at the inflamed joints in the presence of M-CSF and RANKL, which are accel-
erated by TNF.
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tion, the failure of neutralizing M-CSF antibodies to block TNF-
induced c-Fms expression indicates that this is a direct effect and is
not secondary to M-CSF autoregulation (Fig. 5). Recently, Kitaura et
al. (31) used chimerical WT and TNF receptor knock-out mice to
dissect the contribution of cells in the osteoclast lineage from that of
stromal cells in the response to TNF-mediated osteoclastogenesis
in vivo. From the findings of this elegant study, they conclude that in
conditions where TNF concentrations are high, TNF can fully
exert its bone erosive effects by directly promoting the differentia-
tion of osteoclast precursors independent of cytokine-responsive
stromal cells and T lymphocytes (31). Our results are consistent with
their findings and further point out that one of the mechanisms by
which TNF promotes OCP differentiation is though up-regulation of
c-Fms expression.
We found that M-CSF alone increases c-Fms cell numbers (Fig. 5),
indicating that M-CSF can induce its own receptor expression and
thereby forms an autocrine loop to amplify M-CSF-mediated signals.
This is not a surprising because c-Fms expression is controlled by PU.1,
one of the Ets transcription factors that is stimulated by M-CSF treat-
ment (32). Because M-CSF is constitutively expressed in the bone
microenvironment in vivo, andTNF stimulates osteoblasts andT lym-
phocytes to up-regulate their expression of M-CSF (16, 17), TNF-
induced c-Fms expression must work through both M-CSF-dependent
and -independent mechanisms. We have reported previously that
TNF promotes mature osteoclast survival (33). However, we did not
observe clear changes in OCP apoptosis. Thus, TNF likely has a dif-
ferent effect on OCPs versusmature osteoclasts; it stimulates prolifera-
tion and differentiation of the former to provide more OCPs and
increases survival of the latter to prolong the duration of bone resorp-
tion (Fig. 6).
TNF administration stimulates bone marrow OCP proliferation
1 day before the increase in total OCPs numbers are observed in both
bone marrow and blood (Fig. 3). This finding, along with similar
findings in TNF-Tg mice, suggests that TNF-induced OCP prolif-
eration and the subsequent increase in the bone marrow OCP pool
may lead to the increased OCPs numbers in the peripheral blood.
Based on these observations, we propose that in chronic inflamma-
tory arthritis, where TNF levels are elevated, TNF increases mar-
row OCP numbers, which may directly result in a “push” of cells out
of the bone marrow (marrow cell release) into the bloodstream
because of the limited space available in the bone marrow cavity.
Thus, chronic exposure to TNF could increase the total turnover
rate of OCPs. Unfortunately, we do not yet have experimental evi-
dence to prove that the increase in blood OCP numbers in TNF-Tg
mice is a direct consequence of an enlarged bone marrow pool. How-
ever, it is known that proliferation is not a pre-requisite for cell
release from the bone marrow. In fact, the majority of common
mobilizing factors stimulates marrow cell release without influenc-
ing their proliferation (18). Thus, TNF-induced elevation in blood
OCPs might result from different mechanisms than common mobi-
lization and represent a unique response to chronic inflammation.
One important question regarding circulating OCPs is the role of
these cells in normal bone remodeling, because this process occurs
exclusively within the bone marrow cavity. Do OCPs need to travel
in the blood to initiate physiological bone remodeling or do they
simply receive signals from osteoblast/lining cells adjacent to them
on or near bone surface identified for remodeling? We do not know
the answers to these questions at this time. However, given that focal
erosions develop from chronic inflammation over a number of years
and the active osteoclasts that mediate these erosions have a half-life
of only a few weeks, these cells must be replaced continuously.
Because these osteoclasts are known to enter the joint through syno-
vium as OCPs, our conclusion is that circulating OCPs serve as the
pre-osteoclast reservoir. Identification of the mechanisms whereby
OCP generation and trafficking are regulated should help answer
these important questions.
In summary, our studies reveal a new mechanism by which TNF
stimulates osteoclast-mediated bone resorption in chronic inflam-
matory arthritis. We propose that the first influence of TNF on
osteoclastogenesis is to increase bone marrow OCP genesis through
the following two mechanisms (Fig. 6): 1) TNF directly stimulates
the conversion of CD11b/Gr-1/lo/c-Fms cells to c-Fms cells;
and 2) it stimulates osteoblasts/stromal cells to produce M-CSF,
which subsequently increases c-Fms cell proliferation. These
CD11b/Gr-1/lo/c-Fms cells are then released to the blood-
stream, through a yet to be defined mechanism, and then home to
inflamed joints where they differentiate in response to RANKL and
other osteoclastogenic signals.
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Abstract
TNF induces bone loss in common bone diseases by promoting osteoclast formation directly
and indirectly, but it also limits osteoclast formation by inducing expression of NF-κB p100.
Osteoclast precursors (OCPs) are derived fromM1 (inflammatory) and M2 (resident) macro-
phages. However, it is not known if TNF stimulates or limits osteoclast formation through reg-
ulation of M1 or M2 differentiation or if RelB, a partner of p100, is involved. To investigate
these questions, we treated bonemarrow cells (BMCs) with M-CSF alone or in combination
with TNF to enrich for OCPs, which we called M-OCPs and T-OCPs, respectively. We found
that TNF switched CD11b+F4/80+ M-OCPs from Ly6C-Gr1- M2 to Ly6C+Gr1-CD11c+ and
Ly6C-Gr1-CD11c+ M1 cells. RANKL induced osteoclast formation from both Ly6C+Gr1- and
Ly6C-Gr1- T-OCPs, but only from Ly6C+Gr1- M-OCPs, which formed significantly fewer oste-
oclasts than T-OCPs. Importantly, Ly6C+Gr1- cells from both M- and T-OCPs have
increased expression of the M1marker genes, iNOS, TNF, IL-1β and TGFβ1, compared to
Ly6C-Gr1- cells, and Ly6C-Gr1- cells from T-OCPs also have increased expression of iNOS
and TGFβ1 compared to cells fromM-OCPs. Both RANKL and TNF increased RelBmRNA
expression. TNF significantly increased RelB protein levels, but RANKL did not because it
also induced RelB proteasomal degradation. TNF inhibited RANKL-induced NFATc1 mRNA
expression and osteoclast formation fromM-OCPs, but not from T-OCPs, and it did not
induce Ly6C+Gr1-CD11c+ or Ly6C-Gr1-CD11c+ M1macrophages from RelB-/- BMCs. Fur-
thermore, overexpression of RelB in M-OCPs reduced RANKL-induced osteoclast formation
and NFATc1mRNA expression, but it increased TNF-induced OC formation without affect-
ing NFATc1 levels. Thus, TNF induction of RelB directly mediates terminal osteoclast differ-
entiation independent of NFATc1 and limits RANKL-induced osteoclastogenesis by
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inhibiting NFATc1 activation. However, the dominant role of TNF is to expand the OCP pool
by switching the differentiation of M-CSF-induced M2 to M1macrophages with enhanced
osteoclast forming potential. Strategies to degrade RelB could prevent TNF-induced M2/M1
switching and reduce osteoclast formation.
Introduction
TNF is the major cytokine driving inflammation in rheumatoid arthritis (RA), a chronic
inflammatory disease affecting about 1% of the world's population and characterized by syno-
vial inflammation and joint destruction, leading to severe morbidity and premature mortality
[1]. Transgenic mice over-expressing TNF (TNF-Tg mice) develop a form of arthritis that is
very similar to human RA [2]. Although anti-TNF therapies have significantly reduced the
morbidity and joint destruction in RA, they are expensive, and only about 60% of patients have
a good response to these agents [3, 4]. In non-responding patients, TNF inhibitors typically are
administered for several months before a decision is made to switch to an alternative treatment,
which is often another TNF inhibitor that also may be ineffective. Thus, there is a need to better
understand how TNF induces joint inflammation and destruction.
Inflammatory cells, such as lymphocytes, macrophages and mast cells, drive chronic inflam-
matory processes, including synovial inflammation, by producing cytokines and autoantibodies
at involved sites. Joint destruction in RA is mediated by ectopic differentiation of osteoclasts
(OCs) from their monocyte-macrophage lineage precursors in affected joints. Receptor activator
of nuclear factor-κB ligand (RANKL), a member of the TNF superfamily, mainly controls later
phases of OC differentiation and activation [5], and its expression by synoviocytes and inflam-
matory cells in affected joints is promoted by TNF and other cytokines [6, 7]. RANKL expres-
sion is also required for normal B cell development and lymph node formation [8], suggesting
that it might have a role to promote joint inflammation in RA. However, TNF-Tg mice gener-
ated to have deficiency of RANKL also develop synovial inflammation, but not joint destruction
because OCs do not form in these mice [9, 10]. Preclinical and clinical studies indicate that
RANKL inhibitors do not significantly alter inflammatory processes in RA [11]. These findings
suggest that RANKL does not contribute significantly to TNF-induced inflammation in RA.
TNF can induce osteoclastogenesis directly from Rank–/–OC precursors (OCPs) in vitro
when the cells are co-cultured with [12] or without [13] TGF-β1, which is released from bone
matrix during bone resorption and activated by the acidic microenvironment in resorption lacu-
nae as a result of acid release from OCs [14, 15]. However, the numbers of OCs induced by TNF
fromWTOCPs are much lower than those induced by RANKL [16]. Despite these findings, it
was puzzling that TNF did not induce OC formation when administered in vivo to Rank–/–mice
[17]. We have reported that TNF induces expression of NF-κB p100 and that p100 limits TNF-
and RANKL-mediated OC formation [13]. Consistent with this inhibitory effect of p100, we
also found that TNF efficiently induced OC formation in vivo when it was administered to
RANKL-/- or RANK-/- mice also deficient in p100 [13]. TNF-Tg mice that we generated to be
deficient in p100 have significantly accelerated development of arthritis and systemic bone loss,
suggesting that p100 not only limits OC formation, but also joint inflammation induced by TNF
[13]. More recently, it was reported that TNF also limits OC formation through RBP-j [18] and
IRF-8 [19], indicating that there are several mechanisms to restrict the destructive effects of
TNF on bone. In contrast, TNF can also synergize with RANKL to induce OC formation [20,
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21]. However, the precise conditions in which TNF limits or promotes OC formation and the
factors that are critical for TNF induction or inhibition of OC formation remain unclear.
OCPs comprise both classically activated (inflammatory, M1) macrophages and alterna-
tively activated (resident, M2) macrophages [22–24]. LPS, which induces TNF production
[25], promotes the differentiation of M1 macrophages [22, 24], and TNF increases the numbers
of circulating OCPs by promoting their proliferation through up-regulation of expression of
the receptor for M-CSF [26]. Expression of M-CSF, like RANKL, is essential for OC formation
[27]. However, it is not known if TNF induction or inhibition of OC formation involves modu-
lation of M1/M2 macrophage differentiation into OCs. We report here that TNF switches the
differentiation of M-CSF-primed M2 into M1 macrophages to enhance osteoclastogenesis by
inducing the expression of NF-κB RelB, the partner of p100/p52, and that RelB also directly
targets NFATc1 to limit OC formation.
Materials and Methods
Reagents
Recombinant murine M-CSF, RANKL, TNF were purchased from R&D Systems (Minneapolis,
MN). Antibodies of RelB for Western blot were purchased from Santa Cruz and anti-actin anti-
body was from Sigma. Goat anti-rabbit (or mouse) IgG-HRP conjugate secondary antibody
was purchased from Bio-Rad. Fluorescent-labeled rat anti-mouse antibodies APC-Ly6C,
PEcy7-CD11b, PE-Gr1 (also called Ly6G) and PECy5-F4/80 were purchased from eBioscience.
Ammonium Chloride (NH4Cl) solution was purchased from STEMCELL technologies.
Animals
Cells from 6–8 week-old C57Bl6 mice as well as RelB-/- and WT littermate mice on an inbred
C57BL/6 background [28–30] were used for in vitro studies. This study was carried out in strict
accordance with the administrative regulations of Laboratory Animals of the National Science
and Technology Commission of People’s Republic of China and the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The
protocols were approved by the Committee on the Ethics of Animal Experiments of Henan
University and the University of Rochester Medical Center Institutional Animal Care and Use
Committee. Mice were euthanized by CO2 followed by neck dislocation according to AVMA
guidelines.
Osteoclastogenesis
The culture procedure was modified from our previous reports [13, 16, 26, 31]. Briefly, bone
marrow (BM) was flushed from the long bones of mice using α-MEM containing 10% FBS,
passed through a 21-G and then through a 25-G needle to make single cell suspensions. The
cells were incubated in NH4Cl solution for 10 min at room temperature to lyse red blood cells.
6x104 BM cells were seeded in 96-well plates and cultured with 5 ng/ml M-CSF for 2 days, and
then RANKL (10 ng/ml) or TNF (20 ng/ml) or both were added to the cultures for 48–56 hr at
which time mature OCs could be observed using an inverted microscope. The cells were then
fixed with 10% neutral phosphate-buffered formalin for 10 min and TRAP staining was per-
formed. TRAP+ cells with three or more nuclei were considered as mature OCs.
Over-expression of RelB
BM cells prepared as above were seeded in 96-well plates (4x104/well) for the evaluation of OC
formation or in 60-mm dishes (1.2x106 cells per dish) for Western blot or FACS analysis
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followed by culture with M-CSF for 2 days to enrich for OCPs. For over-expression of RelB,
the culture medium was replaced with fresh medium containing M-CSF, 2 μg/ml polybrene
and ¼ volume of retro-viral supernatant of pMX-GFP or pMX-GFP-RelB prepared from Plat-
E packaging cells, as we described previously [13, 16, 31]. After 24 hr of infection, RANKL or
TNF was added to the cultures for an additional 48–96 hr to generate OCs.
FACS analysis and cell sorting
2×106 BM or cultured cells were stained with APC-Ly6C, PEcy7-CD11b, PE-Gr1 and
PECy5-F4/80 antibodies for 30 min. Data were acquired using a FACScanto flow cytometer
and analyzed using FlowJo software, as described previously [26, 30]. For cell sorting, cultured
OCPs fromWTmice were stained with the above fluorescent-conjugated antibodies to confirm
that each cell population was similar to those generated in our regular culture procedure, and
the cells were then sorted by a Statler sorter to collect Ly6C+Gr1-, Ly6C+Gr1+, Ly6C-Gr1- and
Ly6C-Gr1+ cells separately. The sorted cells were reanalyzed to ensure their purity (98%) and
used for osteoclastogenesis assays, as we described previously [26].
Western blot analysis
Cultured cells were lysed with M-Per mammalian protein extraction reagent (Thermo Scien-
tific) containing a protease inhibitor cocktail (Sigma). Lysate proteins (10–20 μg) were loaded
in 10% SDS-PAGE gels and transferred onto polyvinylidene difluoride membranes. Following
blocking in 5% milk, membranes were incubated with a specific primary antibody to RelB or
mouse β-actin over-night at 4°C. After washing, the membranes were incubated with anti-rab-
bit (or mouse) IgG-HRP conjugate secondary antibody (Bio-Rad) and exposed to ECL sub-
strate. Signals were analyzed using a Bio-Rad imaging system.
Quantitative Real-Time PCR
Total RNA was extracted from cultured cells using 1 ml TRIzol reagent, and 1 μg of RNA was
used for synthesis of cDNA using a GeneAmp RNA PCR core kit. Quantitative PCR amplifica-
tion was performed using an iCycler real-time PCR machine and iQ SYBR Green (Bio-Rad).
Relative mRNA expression levels of target genes were analyzed using the CT value of the gene,
normalized to β-actin.
Statistics
All results are given as the mean ± S.D. Comparisons between two groups were analyzed using
Student's two-tailed unpaired t test. One-way analysis of variance and Dunnett's post hoc multiple
comparisons were used for comparisons among three or more groups. p values<0.05 were con-
sidered statistically significant. Each experiment was repeated at least twice with similar results.
Results
TNF switches the differentiation of M-CSF-induced Ly6C-Gr1- M2 to
Ly6C+Gr1-CD11c+ and Ly6C-Gr1-CD11c+ inflammatory M1
macrophages
OCPs belong to the monocyte/macrophage lineage. Mouse CD11b+Gr1-/lo cells are precursors
that efficiently form OCs [26]. Since macrophages have been classified as M1 and M2 cells and
TNF generally stimulates M1 differentiation [23], we investigated if TNF regulates M1/M2
cells and if this affects their OC formation potential. More than 30 cell surface markers are
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used to classify M1 and M2 macrophages [22, 23]. CD11b and F4/80 are common macrophage
surface markers; M1 cells are CCR2+Gr1+CD62L+CD11c+, while M2 cells are
CCR2-Gr1-CD62L-CD11c- in mice [22, 23]. Ly6C is also widely used to differentiate M1 and
M2 cells. Ly6C+/hi subsets are classified as M1 cells, while Ly6C-/lo subsets are classified as M2
cells [32, 33].
To characterize TNF-induced OCPs, we examined expression of the cell surface markers:
CD11b, F4/80, Ly6C, CD11c and Gr1. About 40% of primary BM cells were CD11b+F4/80+
cells and of these ~80% were Ly6C+Gr1hi+ granulocytes and ~15% were Ly6C+Gr1-/lo+ cells
(Fig 1A), corresponding to our previously reported CD11b+Gr1-/lo+ OCPs [26]. We cultured
BM cells with M-CSF alone or in combination with TNF or RANKL for 3 days to generate
OCPs, which we called M-CSF-induced OCPs (M-OCPs), TNF-induced OCPs (T-OCPs) and
RANKL-induced OCPs (R-OCPs), respectively. We found that the two common macrophage
surface markers, CD11b+F4/80+, comprised ~75% and ~79% of T- and R-OCPs respectively,
compared to ~87% of M-OCPs (p<0.05, Fig 1B upper panel and S1 Fig). We also found that in
these CD11b+F4/80+ populations, Ly6C+Gr1- cells comprised 23.9%, 50.8% and 15.9% of
M-OCPs, T-OCPs and R-OCPs, respectively, while Ly6C-Gr1- cells comprised 73%, 47% and
82.8% of these cells, respectively (Fig 1B middle panel), suggesting that TNF switched M-CSF-
induced Ly6C-Gr1- M2 to Ly6C+Gr1- M1 macrophages, an effect similar to that induced by
IFN-γ, which is a standard stimulator of M1 macrophage differentiation [22, 23]. In contrast,
RANKL did not change the phenotype of M-CSF-induced macrophages. We also analyzed
another M1 marker, CD11c, in Ly6C+Gr1- and Ly6C-Gr1- cells, and found that in the Ly6C+-
Gr1- cells from the CD11b+F4/80+ populations, the frequency of CD11c+ cells in T-OCPs
(5.96%) was double that in M-OCPs (3.18%), while it remained low in R-OCPs (1.83%, Fig 1B
lowest panel). Similarly, in the Ly6C-Gr1- cells from the CD11b+F4/80+ populations, CD11c+
cells in T-OCPs (11.2%) were almost twice as frequent as those that in M-OCPs (6.67%) (Fig
1B lowest panel). We used IFN-γ as a positive control and found that it also increased CD11c+
cells in both Ly6C+Gr1- and Ly6C-Gr1- cells from CD11b+F4/80+ populations, about four-fold
more than those that in M-OCPs (Fig 1B lowest panel). These data suggest that Ly6C-Gr1- cells
from T-OCPs had also shifted to M1 macrophages.
TNF-induced CD11b+F4/80+Ly6C+Gr1- and CD11b+F4/
80+Ly6C-Gr1-CD11c+ macrophages have higher OC forming potential
than M-CSF-induced macrophages
M-, T-, and R-OCPs generated fromWTmouse BM cells were stained with PEcy7-CD11b,
PEcy5-F4/80, APC-Ly6C and PE-Gr1 antibodies to analyze their macrophage surface markers.
We confirmed that the expression levels of cell surface markers in each OCP type (Fig 2A
upper panel) were similar to those in OCPs in Fig 1B. We sorted each of these OCPs into four
populations: Ly6C+Gr1-, Ly6C+Gr1+, Ly6C-Gr1- and Ly6C-Gr1+ cells. 4x104 of the sorted cells
were seeded into 96-well plates and treated with RANKL or TNF in the presence of M-CSF to
induce OC formation. In M-OCPs, the OC forming potential of Ly6C+Gr1- cells was much
higher than Ly6C-Gr1- cells: RANKL induced 125±16 OCs from Ly6C+Gr1- cells, but only a
few TRAP+ mononuclear cells were formed from Ly6C-Gr1- cells at this time point (Fig 2B).
In contrast, both Ly6C+Gr1- and Ly6C-Gr1- cells from T- and R-OCPs formed many OCs, and
both Ly6C+Gr1- and Ly6C-Gr1- cells from T-OCPs formed similar numbers of OCs, but Ly6C-
+Gr1- cells from R-OCPs formed more OCs than Ly6C-Gr1- cells in response to RANKL
(p<0.01). In addition, OC numbers from Ly6C-Gr1- T-OCPs almost matched those from
R-OCPs. TNF also induced large numbers of OCs from Ly6C+Gr1- and Ly6C-Gr1- cells from
R-OCPs (Fig 2B) probably because R-OCPs had already undergone some further
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differentiation. There were fewer Gr1+ cells (Ly6C+Gr1+and Ly6C-Gr1+) in these cultured
OCPs (Fig 2A) and the Gr1+ cells fromM-OCPs did not form OCs in response to TNF or
RANKL (not shown). RANKL also induced OC formation from Ly6C+Gr1+ cells from T- and
R-OCPs (not shown), but the total numbers of these cells were small.
Fig 1. TNF promotes the differentiation of Ly6C+Gr1-CD11c+ M1macrophages. (A) Freshly isolated bone marrow cells (BMCs) from 3-month-old
C57Bl6 mice were stained with anti-mouse APC-Ly6C, PEcy7-CD11b, PE-Gr1, FITC-CD11c and PEcy5-F4/80 antibodies and expression levels of these cell
surface markers were analyzed by flow cytometry. (B) BMCs (2x106) from the mice in (A) were cultured with M-CSF, M-CSF+TNF (20ng/ml) or M-CSF
+RANKL (10ng/ml) in 60 mm-dishes for 3 days to recruit OCPs, which we called M-CSF-induced OCPs (M-OCPs), TNF-induced OCPs (T-OCPs), and
RANKL-induced OCPs (R-OCPs), respectively. IFN-γ (1ng/ml) was also added to M-CSF-treated cells as a positive control for M1 macrophage recruitment.
Cells attached to the dishes were collected and stained with the above antibodies to analyze expression of cell surface markers by flow cytometry:
CD11b+F4/80+ cells in the total cultured OCPs (upper panel), Ly6C+Gr1- and Ly6C-Gr1- cells in the CD11b+F4/80+ population (middle panel) and CD11c+
cells in the Ly6C+Gr1- and Ly6C-Gr1- populations (lower panel). The experiment was repeated three times with similar results.
doi:10.1371/journal.pone.0135728.g001
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Ly6C+Gr1- cells express M1 macrophage markers and Ly6C-Gr1- cells
from T-OCPs are also polarized to M1 macrophages
We next sorted Ly6C+Gr1- and Ly6C-Gr1- cells fromM-, T- and R-OCPs (Fig 3A) to extract
total RNA. We used 1 μg RNA from each sample to reverse transcribe cDNA to test levels of
the M1 marker genes, iNOS, TNF, TGFβ1 and IL-1β as well as the M2 markers, IL-10 and
PPAR-γ, by real-time PCR. We found that the expression levels of iNOS, TNF, TGFβ1 and IL-
1β were increased by 2.5, 1.95, 1.62 and 1.87 fold (p<0.05), respectively, in Ly6C+Gr1- cells
fromM-OCPs compared to Ly6C-Gr1- cells, while the levels of IL-10 and PPAR-γ were not
Fig 2. TNF-inducedmacrophages have higher OC forming potential than M-CSF-inducedmacrophages. (A) M-, T-, and R-OCPs cultured from BMCs
from a 4-month-old C57Bl6 mouse were stained with the fluorescent-labeled antibodies as in Fig 1. Ly6C+Gr1- and Ly6C-Gr1- populations from CD11b+F4/
80+ cells were sorted by flow cytometry. (B) The sorted cell populations were seeded in 96-well plates (4x104 cells/well) and treated with RANKL or TNF in
the presence of M-CSF for 2 additional days to generate mature OCs, which were stained for TRAP activity. (C) Quantitation of numbers of OCs formed from
each sorted population in (B), 4 wells per group, *p < 0.05, **p < 0.01. The experiment was repeated twice with similar results. M = M-CSF, P = PBS,
R = RANKL, T = TNF, R+T = RANKL+TNF.
doi:10.1371/journal.pone.0135728.g002
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significantly different (Fig 3B), confirming that Ly6C+Gr1- cells generally have a M1 profile.
Ly6C+Gr1- cells from T-OCPs expressed higher iNOS, IL-1β and TGFβ1, but significantly
lower IL-10 and PPAR-γ levels than those fromM-OCPs (p<0.05). Of note, expression levels
of iNOS and TGFβ1 were also increased, while IL-10 and PPAR-γ levels were decreased in
Ly6C-Gr1- cells from T-OCPs compared to M-OCPs cells (Fig 3B), providing further support
Fig 3. TNF-inducedmacrophages express M1markers. Ly6C+Gr1- and Ly6C-Gr1- cells were sorted from
cultured M-, T- and R-OCPs from 3-month-old C57Bl6 mice, as in Fig 2A (A). Total RNA was extracted from
these sorted cells and mRNA expression levels of the M1 macrophage genes, TNF-α, iNOS, IL-1β and
TGFβ1 as well as the M2 macrophage marker genes, PPAR-γ and IL-10, were tested by real-time PCR,
normalized to β-actin (B). The data are representative of two independent experiments. *p < 0.05, **p < 0.01.
doi:10.1371/journal.pone.0135728.g003
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that Ly6C-Gr1- cells from T-OCPs have a M1 phenotype. The expression level of iNOS in
Ly6C+Gr1- cells from T-OCPs was 2-fold higher than in Ly6C+Gr1- cells fromM-OCPs
(p<0.05), but it was 6-fold higher in Ly6C-Gr1- cells from T-OCPs than in Ly6C-Gr1- cells
fromM-OCPs probably because the Ly6C-Gr1- cells from T-OCPs had also switched to
CD11c+ M1 cells.
TNF induction of RelB promotes the differentiation of Ly6C+Gr1- and
Ly6C-Gr1-CD11c+ macrophages
RelB is a member of the NF-κB family of transcription factors [34, 35]. OC numbers are nor-
mal in the bones of RelB-/- mice, but bone marrow OCPs from RelB-/- mice form fewer OCs
than WT OCPs in vitro in response to RANKL [36]. To investigate the role of RelB in TNF-
induced OC formation, we first tested RelB protein expression levels in M-, T- and R-OCPs
fromWTmouse BM cells, generated as in Fig 1B. We then used regular OC-inducing culture
medium containing M-CSF and treated the cells with PBS, TNF, RANKL or a combination of
TNF and RANKL for an additional 8 or 48 hr (mature OCs being formed at 48 hr). In M- and
R-OCPs, RelB protein levels in RANKL-treated cells were similar to or lower than PBS-treated
cells, while in contrast, TNF- and TNF+RANKL-treated cells had significantly higher RelB pro-
tein levels at both time-points (Fig 4A). After 8 hr treatment, the basal (PBS-treated cells) RelB
protein level in T-OCPs was significantly higher than in M- and R-OCPs, while RANKL
reduced and TNF increased it slightly (Fig 4A). At 48 hr, RelB protein levels remained low in
PBS- and RANKL-treated M- and R-OCPs, while in T-OCPs they dropped to those of M- and
R-OCPs and remained high in both TNF- and RANKL+TNF-treated OCPs (Fig 4A).
Increased protein levels can result from increased synthesis and/or decreased degradation.
In general, both TNF and RANKL increased RelB mRNA expression (Fig 4B). Compared to
PBS, RANKL and TNF increased RelB mRNA expression in M-OCPs by 4.5- and 7.5-fold,
respectively, after 4 hr of treatment, and these remained high at 24 hr (Fig 4B). At 48 hr when
mature OCs have begun to form, TNF or TNF+RANKL induced 3-fold higher RelB mRNA
levels than PBS-treated M-OCPs, but RANKL did not change RelB levels at this time-point.
Furthermore, in T- and R-OCPs treated with TNF or RANKL or both in combination RelB
mRNA levels were still significantly increased when OCs had formed.
In contrast to the generally increased RelB mRNA, RelB protein levels in RANKL-treated
OCPs or mature OCs was lower than or similar to PBS-treated cells (Fig 4A). In many cases,
RelB protein levels in RANKL+TNF-treated M-OCPs were slightly lower than in cells treated
with TNF alone, suggesting that RANKL may also induce RelB degradation. To test this
hypothesis, M-OCPs generated fromWTmouse BM cells were serum-starved for 2 hr followed
by treatment of vehicle or the proteasome inhibitor, MG-132, for 3 hr. We found that RelB pro-
tein levels increased by 7.5- and 9-fold in PBS- and RANKL-treated cells, respectively, in the
presence of MG-132, but by only 2-fold in TNF-treated cells (Fig 4C), suggesting that RelB
undergoes strong constitutive degradation and that the additional RelB induced by RANKL is
also efficiently degraded.
To determine if TNF induction of Ly6C+Gr1- and Ly6C-Gr1-CD11c+ macrophages requires
RelB expression, we used RelB-/- mouse BM cells to examine expression of macrophage mark-
ers in cytokine-induced OCPs. RelB-/- mice develop multiorgan inflammation [28], and con-
sistent with this, the % CD11b+ myeloid cells in freshly isolated RelB-/- BM was higher than in
WT cells. For example, CD11b+F4/80+ cells comprised ~76% of RelB-/- BM cells compared to
45% in WTmice (not shown), and Ly6C+ cells were also increased in the CD11b+F4/80+ popu-
lation from the RelB-/- mice (not shown). After 3 days of culture, the total percentage of
CD11b+F4/80+ cells from RelB-/- mice was ~93–94% in M-, T- and R-OCPs (Fig 5A).
TNF Induced Osteoclast Formation
PLOS ONE | DOI:10.1371/journal.pone.0135728 August 19, 2015 9 / 20
108
However, TNF did not induce Ly6C+Gr1- cells from the RelB-/- CD11b+F4/80+ population
(Fig 5B). Similarly, although the percentage of CD11c+ cells in the Ly6C+Gr1- and Ly6C-Gr1-
population of M-OCPs was higher (18% and 8.84%) in RelB-/- cells than in WT cells (2.98%
and 4.55%) (Fig 5C), the frequency of CD11c+ cells did not change (~12%) in Ly6C+Gr1-, but
was reduced to 7.84% in Ly6C-Gr1- cells from RelB-/- T-OCPs compared to their respective
WT T-OCPs (12.4% and 20.6%). These data suggest that RelB is required for TNF induction of
Ly6C+Gr1- and Ly6C-Gr1-CD11c+ cells and that the increase in CD11c+ cells seen in RelB-/-
mice in vivo is independent of TNF.
Fig 4. TNF increases expression of RelBmRNA and prevents RelB protein degradation. (A) M-, R-, and T- OCPs generated as in Fig 1B were treated
with PBS (P), R, T or R+T for 8 hr or for 48 hr by which time mature OCs had formed. Cell lysates were subjected to Western blot analysis of RelB and β-actin.
(B) M-OCPs were treated with P, R, T or R+T for 4 and 24 hr (left panel), or M-, R- and T-OCPs were treated with P, R, T or R+T for 48 hr by which time
mature OCs had formed (right panel). Total RNA was extracted to test mRNA expression of NFATc1 normalized to β-actin. **p < 0.01 vs. the respective
PBS-treated cells. (C) M-OCPs were serum-starved for 2 hr followed by treatment of P, R or T in the presence of 10 μMMG-132 for 3 hr. Protein levels of
RelB and β-actin were tested byWestern blot. The data are the band levels measured densitometrically, normalized to β-actin.
doi:10.1371/journal.pone.0135728.g004
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Fig 5. RelB deficiency prevents TNF-induced M1macrophage differentiation. BMCs from 4-month-old
RelB-/- andWT littermate mice were cultured to produce M-, R- and T-OCPs, as in Fig 1B. Cells were
subjected to flow cytometry to analyze expression of CD11b and F4/80 (A), Ly6C and Gr1 cells in the
CD11b+F4/80+ population (B), and CD11c+ cells in the Ly6C+Gr1- and Ly6C-Gr1- populations (C), as in Fig
1B. The experiment was repeated twice with similar results.
doi:10.1371/journal.pone.0135728.g005
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TNF inhibits RANKL-induced osteoclastogenesis from OCPs primed by
M-CSF alone, but not by RANKL and TNF
TNF or RANKL alone induces terminal differentiation of OCPs primed by M-CSF [13, 37].
However, TNF induces significantly fewer osteoclasts than RANKL [16]. TNF increases levels of
TNF receptor-associated factor 3 (TRAF3) in OCPs and this induces degradation of NF-κB-
inducing kinase (NIK) leading to increased cytoplasmic levels of the inhibitory NF-κB protein,
p100, and reduced RANKL- and TNF-induced OCP differentiation [13]. However, TNF also
promotes RANKL expression by osteoblastic and other cells to enhance OC formation [20, 21].
To further investigate the conditions in which TNF stimulates or inhibits RANKL-induced OC
formation, we cultured BM cells with M-CSF alone or in combination with RANKL or TNF for
2 days to generate M-, R- and T-OCPs, as in Fig 1B. The culture medium was replaced with
freshly made medium containing M-CSF and the cells were then treated with TNF, RANKL or
RANKL+TNF for an additional 48–60 hr to generate mature OCs. We found that TNF alone
induced relatively small numbers of OCs and significantly inhibited RANKL-induced OC for-
mation fromM-OCPs (Fig 6A). TNF induced fewer OCs here than in our earlier reports [13,
16] because we stopped these experiments one day earlier to examine early events in OC forma-
tion (Fig 6B). In contrast, the numbers and area of OCs induced by TNF from R-OCPs almost
matched those induced by RANKL (Fig 6B). The area of OCs induced by TNF+RANKL from
R-OCPs was larger than that induced by RANKL alone (p< 0.01, but there was no difference in
OC numbers (Fig 6B). Furthermore, RANKL induced more OCs (number and area) from
R-OCPs than fromM-OCPs (Fig 6B). Although the numbers of RANKL-induced OCs from
T-OCPs were similar to those fromM-OCPs, the total area of RANKL-induced OCs from
T-OCPs was larger than that fromM-OCPs (p<0.01), consistent with enhanced fusion. In addi-
tion, TNF did not inhibit RANKL-induced OC formation from T-OCPs, the number and area
of RANKL+TNF-induced OCs being similar to those induced by RANKL alone (Fig 6B).
To further investigate the conditions in which TNF stimulates or inhibits RANKL-induced
OC formation, we next tested mRNA expression levels of NFATc1, the master gene controlling
terminal OC differentiation and maturation [38, 39], by real-time PCR. In general, the
NFATc1 mRNA expression level matched the number of OCs (Fig 6C). After 4 hr of treatment,
neither RANKL nor TNF changed NFATc1 mRNA expression levels (S2 Fig) in M-OCPs, but
after 24 hr, RANKL increased NFATc1 mRNA expression by 13-fold. In contrast TNF
increased NFATc1 expression by only 2-fold and significantly inhibited RANKL induction of
its expression (S2 Fig). After 48 hr, the expression patterns of NFATc1 in mature OCs from
M-OCPs in response to RANKL, TNF or RANKL+TNF (Fig 6C) were very similar to those at
24hr (S2 Fig). In contrast, TNF and RANKL+TNF induced similar levels of NFATc1 mRNA
expression as RANKL alone in mature OCs from R-OCPs after 48 hr (Fig 6C). In addition,
RANKL increased NFATc1 mRNA levels in OCs from T-OCPs significantly more than TNF
(Fig 6C). However, the expression level of NFATc1 in OCs induced by RANKL from T-OCPs
was only about half of that fromM- or R-OCPs (Fig 6C). This may be due to the low basal
expression level of NFATc1 in T-OCPs (PBS-treated cells). Of note, TNF did not inhibit
RANKL-induced NFATc1 expression in T-OCPs (Fig 6C).
Biphasic effect of RelB on OC formation
The precise role of RelB in OC differentiation remains incompletely understood. For example,
RANKL-induced OC formation from RelB-/- precursors is impaired in vitro, but the basal OC
numbers in RelB-/- mice in vivo are normal [36]. To further investigate the role of RelB in
OCP differentiation and OC formation, we over-expressed RelB in WT BM cells using a RelB
retrovirus. GFP protein expression in pMX-GFP- and pMX-GFP-RelB retrovirus-infected cells
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analyzed by flow cytometry andWestern blot confirmed RelB over-expression (Fig 7A). We
treated the infected cells with RANKL or TNF for 3 or 4 days and found that over-expression
of RelB significantly decreased RANKL- but increased TNF-induced OC formation (number
and area) after 3 days (Fig 7B). In contrast, after 4 days, the number and area of RANKL-
Fig 6. TNF inhibits RANKL-induced osteoclastogenesis fromM-OCPs, but not from T-OCPs. (A) BMCs (1x105 per well) from 2-month-old C57Bl6 mice
were cultured for M-OCPs in 96-well plates for 2 days, as in Fig 1B. R, T or both were added to the cultures for an additional 2.5 days to generate mature
OCs. TRAP staining was performed to evaluate OC numbers, 4 wells per group (*p<0.05, **p<0.01). (B)&(C) BMCs (1x105 per well) from 3-month-old
C57Bl6 mice were cultured for M-, R- and T-OCPs in 96-well plates for 2 days. RANKL, TNF or both were added for an additional 2 days in the presence of
M-CSF to generate mature OCs. (B) The cells were fixed with 10% neutral buffered formalin for 10 min and TRAP staining was performed to evaluate OC
numbers (N) and area (A), 4 wells per group (*p<0.05, **p<0.01). (C) Total RNA was extracted frommature OCs generated fromM-, R- and T-OCPs treated
with the above cytokines for 48 hr. NFATc1 mRNA expression was tested by real-time PCR normalized to β-actin, **p<0.01. The experiment was repeated
twice with similar results.
doi:10.1371/journal.pone.0135728.g006
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Fig 7. Over-expression of RelB inhibits RANKL-, but enhances TNF-induced OC differentiation. (A) BMCs from 3-month-old C57Bl6 mice were
cultured with M-CSF for 2 days followed by treatment of¼ volume of pMX-GFP or pMX-GFP-RelB retroviral supernatant in the presence of 2 ng/ml of
polybrene for 3 days. GFP+F4/80+ cells were analyzed by flow cytometry (left panel) and RelB protein levels in GFP or RelB expressing cells that had been
treated with P, R or T for 8 hr were tested byWestern blot (right panel). (B) M-OCPs were infected with pMX-GFP or pMX-GFP-RelB retrovirus as above.
After 24 hr of infection, the cells were treated with RANKL or TNF for 3 days or 4 days in the presence of M-CSF when mature OCs were observed under
inverted microscopy. TRAP staining was performed to evaluate OC numbers and area, 4 wells per group, *p< 0.05, **p< 0.01. (C) M-OCPs were infected
with GFP or GFP-RelB retrovirus and cultured with P, R or T for 3 or 4 days as above (B). Total RNA was extracted from these cells using Trizol reagent, and
mRNA expression of NFATc1 normalized to β-actin was tested by real-time PCR. *p< 0.05, **p< 0.01 vs. GFP. The in vitro experiment was repeated twice
with similar results.
doi:10.1371/journal.pone.0135728.g007
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induced OCs were similar in GFP- and RelB-overexpressing cells, reflecting a plateau in OC
formation, while OC area induced by TNF from RelB-overexpressing cells was still significantly
larger than that from GFP-overexpressing cells, although OC numbers were similar (Fig 7B).
We also tested NFATc1 mRNA expression in control and RelB retrovirus-infected M-OCPs
treated with TNF or RANKL for 3 or 4 days. We found that TNF did not affect NFATc1
mRNA expression levels in either GFP- or RelB-infected cells. However, RANKL-induced
NFATc1 mRNA levels in RelB overexpressing cells were significantly reduced compared to
GFP-infected cells after 3 days, but not after 4 days, probably because mature OCs begin to die
after 3–4 days (Fig 7C).
Discussion
M1 and M2 macrophages are linked to T helper 1 (TH1)- and TH2-type immune responses,
respectively [33]. M1 macrophages mediate inflammatory responses to a variety of bacterial,
protozoal and viral infections and produce many inflammatory cytokines, including TNF, IL-
18, IL-12 and IL-23, which mediate immune reactions in several chronic inflammatory and
autoimmune diseases, including rheumatoid arthritis, Crohn’s disease, multiple sclerosis and
autoimmune hepatitis [40–42]. M2 macrophages, in contrast, inhibit the production of a wide
variety of pro-inflammatory mediators, such as IL-10, and regulate wound healing [43]. Thus,
targeted depletion of M1 and boosting the activities of M2 macrophages are emerging as an
attractive combined therapeutic strategy for autoimmune diseases [44–46]. Better understand-
ing of the mechanisms that regulate M1/M2 differentiation should improve these therapeutic
approaches and could lead to reduced joint destruction in inflammatory arthritides.
Granulocyte macrophage-colony stimulating factor (GM-CSF) drives myeloid progenitor
differentiation into granulocytes and M1 monocyte/macrophages with a pro-inflammatory
cytokine profile (e.g. TNF and IL-23 expression) and also into cells with dendritic cell (DC)
properties, and thus it is often employed in studies of DC development and function [47, 48].
However, GM-CSF is not critical for macrophage development since mice lacking GM-CSF do
not have notable defects in tissue macrophages [49]. In contrast, targeted ablation of M-CSF or
its receptor causes severe depletion of macrophages in many tissues associated with failure of
osteoclast formation and osteopetrosis, indicating that M-CSF plays a major role in the genera-
tion of macrophages [24].
Macrophages induced in response to M-CSF alone have an anti-inflammatory cytokine pro-
file (e.g. IL-10 expression) and are similar to M2 macrophages [50]. In general, M2 macro-
phages switch to a M1 phenotype in response to IFN-γ and LPS and secrete large amounts of
cytokines involved in autoimmune responses [22, 24, 33, 51]. We previously reported that TNF
increases CD11b+Gr-1-/lo OCP numbers by stimulating expression of the M-CSF receptor, c-
fms [26], which has important roles in OCP proliferation [52], OC formation and survival
[53]. However, it was not known if these are M1 or M2 macrophages or if the positive or nega-
tive regulatory effects of TNF on OC formation involve modulation of M1/M2 differentiation.
Here, we have shown that TNF promotes a switch of M-CSF-induced F4/80+CD11b+-
Ly6C-Gr1- M2 to F4/80+CD11b+Ly6C+Gr1- and F4/80+CD11b+Ly6C-Gr1-CD11c+ M1 macro-
phages based on our findings that: 1) the Ly6C+ Gr1- cells comprise 50–63% of CD11b+F4/80+
from T-OCPs and only 17–25% fromM-OCPs; and in contrast, Ly6C-Gr1- cells comprise 34–
47% of the CD11b+F4/80+ T-OCPs compared to 67–78% of these cells fromM-OCPs (Figs 1B,
2A, 3A and 5B); 2) CD11c+ cells in both Ly6C+Gr1- and Ly6C-Gr1- populations from T-OCPs
are also increased compared to the respective populations fromM-OCPs (Figs 1B and 5B); and
3) importantly, Ly6C+Gr1- cells from both M- and T-OCPs have increased expression of the
M1 marker genes, iNOS, TNF, IL-1β and TGFβ1, compared to Ly6C- Gr1- cells. Ly6C-Gr1-
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cells from T-OCPs also have increased expression of iNOS and TGFβ1 compared to those
fromM-OCPs, and both Ly6C+Gr1- and Ly6C-Gr1- cells from T-OCPs have decreased expres-
sion of the M2 genes, IL-10 and PPAR-γ (Fig 3B).
A switch from a M2 to a M1 phenotype can also change the OC forming potential of these
cells. For example, Raw264.7 cells, a murine macrophage cell line that can differentiate into
OCs in response to RANKL without the need to add M-CSF, have enhanced OC forming
potential when they are induced to a M1 phenotype by IFN-γ and LPS [54]. We found that
only Ly6C+Gr1- M1 cells, but not Ly6C-Gr1- M2 cells in the CD11b+F4/80+ population from
M-OCPs formed OCs in response to RANKL. Thus, CD11b+F4/80+Ly6C+Gr1- M1 macro-
phages are authentic OCPs. However, both Ly6C+Gr1- and Ly6C-Gr1- cells primed by TNF
have significantly enhanced OC forming potential, and both cell populations have increased
expression of the M1 surface marker, CD11c, and express the M1 effector molecules, iNOS,
TGFβ1 and IL-1β, suggesting that these cells have been switched to a M1 phenotype. In addi-
tion, TNF-primed Ly6C+/-Gr1+CD11b+F4/80+ cells form OCs in response to RANKL,
although the numbers are small. This population could be similar to our previously identified
CD11b+Gr1+/- OCPs in TNF-Tg mice [26]. With all of these features, it is not surprising that
TNF did not inhibit RANKL-induced OC formation from TNF-primed OCPs. Robust induc-
tion of OC formation by TNF from RANKL-primed OCPs probably reflects the fact that these
cells are already well along the OC differentiation process since NFATc1 expression was signifi-
cantly increased within 24 hours of RANKL treatment [16].
In general, the transcription factor, PU.1, controls the global macrophage-specific enhancer
repertoire, irrespective of polarization [55]. In response to M1-inducing stimuli, transcription
factors, signal transducer and activator of transcription 1 (STAT1) and interferon-regulatory
factor 5 (IRF5) are activated to polarize M1 macrophages [55], while factors that activate
STAT6, IRF4 and peroxisome proliferator activated receptor-γ (PPAR-γ) control the polariza-
tion of M2 macrophages [55]. NF-κB p50 and p65 have been identified as regulators of macro-
phage polarization and cytokine production [56, 57]. p50 is considered as a key component in
the orchestration of M2-driven inflammatory reactions. It inhibits M1-polarization and IFN-β
production, and p50-deficient mice show exacerbated M1-driven inflammation and defective
capacity to mount allergy-driven M2-polarized inflammatory reactions [57]. Similarly, trans-
fection of p50 siRNA into M2-like macrophages resulted in a significant decrease in expression
of the M2 marker, IL-10, and increased production of the M1 markers, IL-12, TNF-α and IL-6
[58]. Hyperacetylated p65 and increased NF-κB binding activity in bone marrow cells with tar-
geted deletion of mammalian sirtuin member 1 (SIRT1) in myeloid cells resulted in increased
M1 polarization, migration, and pro-inflammatory cytokine production, suggesting that p65
also plays an important role in M1 activation [56]. Here, we report a novel mechanism by
which TNF induction of M1 macrophages is through NF-κB RelB, based on our findings that
TNF significantly increased RelB protein levels associated with switching of M-CSF-induced
Ly6C-Gr1-CD11c- M2 to Ly6C+Gr1- and Ly6C-Gr1-CD11c+ M1 F4/80+CD11b+ macrophages,
while TNF induction of Ly6C+Gr1- and Ly6C-Gr1-CD11c+ M1 macrophages does not occur in
RelB-/- bone marrow cells (Fig 5).
The role of RelB in OC differentiation is also poorly understood. OC numbers in the bones
of RelB-/- mice are normal in vivo, while RANKL-induced OC formation from RelB-/- myeloid
progenitors is impaired in vitro, and cancer-induced osteolysis is reduced in RelB-/- mice in
vivo [26]. These findings suggest that RelB is not required for basal OC formation, but appears
to play a positive role in the enhanced osteoclastogenesis in pathologic conditions. Contrary to
the reported positive role for RelB in OC differentiation [26], we found that RelB itself func-
tions as a transcriptional repressor of NFATc1 to inhibit terminal OC differentiation based on
our findings that: 1) TNF inhibits RANKL-induced OC formation and NFATc1 mRNA
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expression in M-CSF-primed OCPs; and 2) over-expression of RelB significantly inhibits
RANKL-induced OC formation and NFATc1 mRNA expression. These are consistent with the
reports that RelB acts as a transcriptional repressor of inflammatory mediators by forming an
inactive complex with RelA [59–62]. TNF induction of RelB to inhibit NFATc1 activation
could explain why TNF alone can significantly increase OCPs numbers through M2 to M1
switching, while having very limited ability to induce terminal OCP differentiation into OCs.
In contrast, RANKL strikingly increases OC formation from TNF-primed OCPs compared to
OCPs induced by M-CSF alone since it can efficiently degrade RelB protein, resulting in sus-
tained activation of NFATc1 to promote OC formation. Although over-expression of RelB can
significantly enhance TNF-induced OC formation, this effect is still lower than that of RANKL
since it peaks one day later than that of RANKL. Thus, the ability of TNF alone to induce ter-
minal OC differentiation in physiological and pathologic conditions is limited.
In summary, our findings provide further evidence of positive and negative effects of TNF on
OC formation through its induction of RelB. TNF induction of RelB in OCPs limits OC differ-
entiation in the absence of other stimulators and it also directly limits RANKL-induced OC for-
mation by inhibiting NFATc1 activation. However, TNF-induced RelB also directly mediates
terminal OC differentiation independently of NFATc1. Our findings show that the dominant
role of TNF is to expand the pool of OCPs with enhanced OC forming potential by switching
the differentiation of M-CSF-induced M2 resident to M1 inflammatory macrophages. Thus,
strategies to degrade RelB could reverse the differentiation of TNF-induced M1 to M2 macro-
phages and would represent a novel therapeutic approach for inflammatory arthritides.
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Postmenopausal osteoporosis and rheumatoid joint destruc-
tion result from increased osteoclast formation and bone
resorption induced by receptor activator of NF-B ligand
(RANKL) and tumor necrosis factor (TNF). Osteoclast forma-
tion induced by these cytokines requires NF-B p50 and p52,
c-Fos, and NFATc1 expression in osteoclast precursors. c-Fos
inducesNFATc1, but the relationship betweenNF-Band these
other transcription factors in osteoclastogenesis remains poorly
understood. We report that RANKL and TNF can induce oste-
oclast formation directly from NF-B p50/p52 double knock-
out (dKO) osteoclast precursorswhen either c-Fos orNFATc1 is
expressed. RANKL- or TNF-induced c-Fos up-regulation and
activation are abolished in dKO cells and in wild-type cells
treated with anNF-B inhibitor. c-Fos expression requires con-
comitant RANKL or TNF treatment to induce NFATc1 activa-
tion in the dKO cells. Furthermore, c-Fos expression increases
the number and resorptive capacity of wild-type osteoclasts
induced byTNF in vitro.We conclude thatNF-B controls early
osteoclast differentiation from precursors induced directly by
RANKL and TNF, leading to activation of c-Fos followed by
NFATc1. Inhibition of NF-B should prevent RANKL- and
TNF-induced bone resorption.
Osteoclasts are specialized bone-resorbing cells derived
from multipotent myeloid progenitor cells. They play a crucial
homeostatic role in skeletal modeling and remodeling and
destroy bone inmany pathologic conditions (1, 2). Understand-
ing of the regulation of osteoclast formation, activation, and
survival has increased dramatically in recent years following the
identification of osteoprotegerin and of receptor activator of
NF-B (RANK)3 and its ligand, RANKL (3–5). RANKL is a
member of the TNF superfamily (6, 7). It is expressed by a
variety of cell types, particularly osteoblast/stromal cells, and its
expression by these cells increases in response to a variety of
factors, including cytokines, growth factors, and hormones, to
induce osteoclast formation, activation, and survival in normal
and disease states (2, 8, 9). Osteoprotegerin is a decoy receptor
for RANKL that negatively regulates bone resorption by bind-
ing to RANKL, and thus, preventing it binding to RANK on
osteoclasts or their precursors. Thus, in many circumstances,
osteoclast formation is regulated indirectly by accessory cells.
In addition to passively responding to RANKL, osteoclasts
also actively regulate their own formation, activation, and sur-
vival, both positively and negatively. For example, they produce
both ligands (10, 11) and receptors (12–14) for positive regula-
tory cytokines, such as TNF and interleukin-1, as well as for
interferon-, which negatively regulates their formation (15,
16). TNF has been implicated in postmenopausal and inflam-
mation-associated bone loss mainly by inducing expression of
RANKL (8, 17) and macrophage colony-stimulating factor
(M-CSF) (18, 19) by accessory cells. By this mechanism, these
cytokines indirectly increase osteoclastogenesis. In addition,
TNF increases expression of RANKand c-Fms on the surface of
osteoclast precursors to amplify RANKL and M-CSF signaling
(20, 21). TNFalso induces activation of the transcription factors
NF-B, AP-1, and nuclear factor of activated T cells c1
(NFATc1, also known as NFAT2) in osteoclast precursors
(reviewed in Refs. 1 and 22, 23), thereby directly controlling the
differentiation of these precursors to osteoclasts (24–27).
NF-B, AP-1 and NFATc1 are essential for RANKL-induced
osteoclastogenesis (28–31) and are activated downstream in
the RANKL/RANK signaling pathway to induce a variety of
responses in osteoclast precursors (29, 32). c-Fos, a component
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and Wagner (23)), mediates RANKL stimulation of osteoclast
formation by transcriptionally inducing NFATc1 (29, 33).
NFATc1 is a member of the NFAT transcription factor family
of five proteins that regulate the expression of cytokines and
immunoregulatory genes in several cell types (34–36). NFATc1
rescues osteoclastogenesis in cells lacking c-Fos (29, 33, 37–39),
indicating that c-Fos is upstream of NFATc1.
NF-B comprises a family of five transcription factors, and
expression of both p50 and p52 is required for osteoclast for-
mation (30, 31). NF-B p50/p52 double knock-out (dKO) mice
do not form osteoclasts, whereas osteoclast formation in p50 or
p52 single knock-out mice is normal. The dKO mice have
increased numbers of CD11b/RANK osteoclast precursors
in their spleens (40), indicating that p50/p52 expression is
required for progression of these cells along the osteoclast dif-
ferentiation pathway. The defect cannot be rescued by treat-
ment of dKO splenocytes with RANKL or TNF (40), each of
which activates NF-B in wild-type (WT) osteoclasts (25, 26).
This is important becauseTNF can induce osteoclast formation
in vitro fromWT, RANKL/, or RANK/ osteoclast precur-
sors (41–43), indicating that p50 andp52 expression is required
for this in vitro effect of TNF. Despite these observations, the
mechanismwhereby TNF induces osteoclast formation in vitro
in the absence of RANKL/RANK signaling remains unknown.
Although it is established that RANKL activates c-Fos and
NFATc1 in osteoclasts or their precursors (29, 33), there are
conflicting data on its effects on NF-B activation (44). Recent
studies have indicated thatNF-Bp65 and to a lesser extent p50
proteins are recruited along with NFATc2 to the NFATc1 pro-
moter within 1 h of treatment of osteoclast precursors with
RANKL (45). c-Fos is not recruited to the NFATc1 promoter
until much later (at 24 h), by which time NFATc2 and NF-B
p65 andp50 are no longer detectable. Interestingly, by this time,
NFATc1 has been recruited to its own promoter. These inves-
tigators suggested that RANKL induces cooperation of
NFATc2 pre-existing in precursors with other transcription
factors, such as NF-B to activate initial induction of
NFATc1, followed by a later auto-amplification phase of
NFATc1 to induce osteoclast formation. Despite these dem-
onstrations of transient NF-B p65 and p50 association with
NFATc2, but not NFATc1, on the NFATc1 promoter, it is
still not clear what the relationship is among NF-B, c-Fos,
and NFATc1 during the early events that mediate RANKL or
TNF-induced osteoclast formation. This is exemplified by
the pathways illustrated in recent review papers of signaling
downstream from RANK (46, 47). Thus, it is still not clear
whether the essential role of NF-B p50 and p52 in oste-
oclast formation is up- or downstream of c-Fos given that
expression of both is required for osteoclastogenesis in vitro
and in vivo, nor is it clear whether it is necessary for NF-B
p50 and p52 to interact with NFATc1 in osteoclast precur-
sors for their differentiation into osteoclasts.
Here, we report that RANKL or TNF can induce osteoclast
formation from NF-B dKO osteoclast precursors when
c-Fos is expressed, indicating that NF-B is upstream of
c-Fos. RANKL or TNF treatment and c-Fos expression in
dKO cells also induces NFATc1 expression, and retroviral
expression of NFATc1 plus treatment with these cytokines
rescue the defect in osteoclast formation. These findings
indicate that interaction betweenNFATc1 andNF-B p50 or
p52 is not required for NFATc1 to execute its osteoclasto-
genic effect.
MATERIALS ANDMETHODS
Animals—Generation of NF-B p50/p52 dKO mice (C57Bl/
6  129) was described previously (30), and mice were used
when they were 3–6 weeks old. Littermates of dKO mice that
have normal teeth eruption and skeletal development were
used as WT controls. The Institutional Animal Care and Use
Committee approved all animal studies.
Reagents—Recombinant human M-CSF, murine RANKL,
interleukin-1, and TNFwere purchased from R&D Systems,
Inc. (Minneapolis, MN). Polybrene and puromycin were
obtained from Sigma. NF-B activation inhibitor was pur-
chased from Calbiochem.
Constructs and Transfection—The coding regions of genes
were amplified by PCR from cDNAs and cloned into the pMX-
puro retroviral vector (33, 48). Each 5 primer contains a Kozak
sequence following the start codon. c-Fos was murine, and
NF-B p50 and p52 were of human origin. The pMSCV-
caNFATc1 construct was a gift from Dr. N. Clipstone (North-
western University, Chicago, IL) (49). The pMX-GFP-puro
vector was used as a control for infection efficiency. These
retrovirus vectors were transiently transfected into the
Plat-E retroviral packaging cell line (50), and viral superna-
tant was collected 48 h later.
Osteoclastogenesis and Viral Infection—Splenocytes were
extracted from spleens through a fine wire mesh and cultured
with conditioned medium from a M-CSF-producing cell line
(51) (1:20 dilution) for 3 days in -modified essential medium
with 10% fetal calf serum (Hyclone Laboratories, Logan, UT) to
enrich for osteoclast precursors, which we named M-CSF-de-
pendent splenocytes (MDS). Then the cells were infected with
the retroviral supernatants in the presence of M-CSF (10
ng/ml) and Polybrene (8g/ml). On day 2 after infection, puro-
mycin (2 g/ml) was added to the cultures to select for gene-
integrated cells. 50–80% of MDS were GFP-positive under
fluorescence microscopy 2 days after infection, and this
increased to 90% following puromycin treatment. The cells
were culturedwithM-CSF (10 ng/ml) for 3–7 days. RANKL (10
ng/ml) and TNF (20 ng/ml) (these doses for RANKL and TNF
effectively induce osteoclast formation from WT spleen cells)
were added every other day. The experiments were stopped
during this time based on a visual assessment ofmultinucleated
cell formation using an inverted microscope. Optimal oste-
oclast formation occurs inWT cell preparations 1–2 days after
those from the dKOmice. The cells were fixed, stained for tar-
trate-resistant acid phosphatase (TRAP) activity to identify
osteoclasts as TRAP cells containing3 nuclei, and counted,
as described previously (52). For functional studies, infected cells
were culturedonbone slices for 10days under the sameconditions
as described above. Osteoclasts were then removed, resorption
pits were visualized after 0.1% toluidine blue staining, and the
mean pit area was measured, as described previously (53).
Quantitative Real-time RT-PCR—RNA from MDS or
infected cells was extracted using the RNeasy kit and the
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QiaShredder fromQiagen (Valencia, CA). cDNA synthesis was
performed as described previously (40). Quantitative PCR
amplification was performed with gene-specific primers using
an iCycler real-time PCRmachine using iQ SYBRGreen super-
mix (both from Bio-Rad Laboratories) according to the manu-
facturer’s instructions. The primer sequences are as follows:
NFATc1, forward, 5-CACATTCTGGTCCATACGA-3, and
reverse, 5-CGTGTAGCTGCACAATGG-3; c-fos, forward, 5-
CTGTCAACACACAGGACTTTT-3, and reverse, 5-AGGAG-
ATAGCTGCTCTACTTTG-3; -actin, forward, 5-ACCCA-
GATCATGTTTGAGAC-3, and reverse, 5-GTCAGGATCT-
TCATGAGGTAGT-3. The relative standard curve method
was used to calculate the amplification difference for each
primer set (54). The standard curve was made from four points
corresponding to 10-fold cDNA serial dilution for each gene.
For each sample, the relative amount was calculated from its
respective standard curve. The quantity of c-fos or NFATc1
mRNAwas then obtained by division of each value by the actin
value. Standards and samples were run in triplicate.
Western Blot Analysis—Infected cells were lysed with radio-
immunoprecipitation buffer (50 mMHEPES at pH 7, 1% Triton
X-100, 1 mM EDTA, 0.1% sodium dodecyl sulfate, 1% sodium
deoxycholate, 150 mM NaCl with protease inhibitors, and
sodium orthovanadate). The lysates (20 g of protein) were
resolved by 10% SDS-PAGE and immunoblotted with a rabbit
anti-c-Fos, mouse anti-NFATc1 (both from Santa Cruz Bio-
technology, Santa Cruz, CA), or a mouse anti-actin (Sigma)
antibody.
NFATc1 Nuclear Translocation—c-Fos or GFP virus-in-
fected MDS were cultured with M-CSF and RANKL in 96-well
culture plates to generate osteoclasts. After mature osteoclasts
were observed, cells were fixed with 10% neutral buffered for-
malin and permeabilized using 0.1%TritonX-100. Immunoflu-
orescent staining was performed using mouse anti-NFATc1
antibody followed by Cy3-conjugated anti-murine immuno-
globulin (Jackson ImmunoResearch, West Grove, PA). Subcel-
lular localization of Cy3-labeled NFATc1 was observed using
fluorescence microscopy.
Electrophoretic Mobility Shift Assay (EMSA)—To assess
c-Fos activation, EMSAwas performed as described previously
(55). Briefly, 5 g of nuclear extracts prepared from untreated
MDS or RANKL- or TNF-treated MDS were incubated with
32P-end-labeled 21-mer double-stranded oligonucleotide con-
taining the consensus AP-1 site (5-CGCTTGATGACTCAG-
CCGGAA-3) (Santa Cruz Biotechnology) for 30 min at room
temperature. The DNA-protein complex formed was then sep-
arated from free oligonucleotide on 5% native polyacrylamide
gels. Binding specificity was examined by competition with
30-fold excess unlabeled AP-1 oligonucleotide. SP-1 binding
sequence 5-CGAGCCGGCCCCGCCCATC-3 (Invitrogen)
was used as a loading control.
Statistics—All experiments were performed more than once
with similar results. Results are given as mean S.E. Compar-
isonsweremade by analysis of variance andMann-Whitney’sU
test for unpaired data. p values0.05 were considered statisti-
cally significant.
RESULTS
NF-B Is Upstream from c-Fos in RANKL and TNF-induced
Osteoclast Formation—c-Fos, like NF-B, is activated by
RANKL and TNF to induce osteoclast formation (15), but it is
not known whether c-Fos can substitute for NF-B expression
in osteoclast precursors. To examine this question, we overex-
pressed c-Fos in NF-B p50/p52 dKOMDS.MDS were used as
osteoclast precursors in our study because NF-B dKO mice
have severe osteopetrosis, which prevents harvesting of bone
marrow cells. We first examined whether NF-B p50, p52, and
p50p52 retroviral expression would rescue the defect in oste-
oclast formation in dKOMDSwhen the cells were treated with
RANKL. Overexpression of p50p52 in dKO cells rescued
osteoclast formation, inducing 150 osteoclasts/96 wells (Fig.
1A). In comparison, RANKL-treated GFP-infected WT cells
typically formed 300 TRAP osteoclasts (data not shown),
indicating that the maximal rescue efficiency of our system is
50% of that ofWT cells. c-Fos expression alone, like p50, p52,
or p50p52, did not induce osteoclasts in the absence of
RANKL (Fig. 1,A and B). However, when RANKLwas added to
c-Fos-expressing dKO cells, the combination rescued the oste-
oclast formation defect, inducing 150 osteoclasts (Fig. 1, B
and C). The TRAP cells that formed on plastic dishes and
bone slices from dKO cells overexpressing c-Fos appeared sim-
ilar to those ofWTMDS treated withM-CSF and RANKL, and
they formed numerous resorption pits on bone slices, typical of
matureWTosteoclasts (Fig. 1D). These data indicate that c-Fos
activated by RANKL can efficiently substitute for the lack of
p50 and p52 in dKO cells in these culture conditions and that
the resulting c-Fos-overexpressing osteoclasts have a bone
resorptive capacity similar to that of WT cells.
TNF plays important roles in osteoclast formation, activa-
tion, and survival in a number of pathologic conditions (9, 56)
by stimulating RANKL expression in stromal and other cell
types. To determine whether TNF, like RANKL, could induce
osteoclast formation directly when c-Fos was overexpressed in
dKO MDS, we treated c-Fos-expressing dKO MDS with TNF.
We observed numerous TRAP osteoclasts. However, the
number of osteoclasts formed (80/well) was less than in the
c-Fos/RANKL-treated cultures (150/well; Fig. 1B).
To determine whether there is impaired RANKL or TNF-
induced c-Fos up-regulation and AP-1 binding activity in the
absence of NF-B p50 and p52, we compared c-Fos mRNA
expression and activation in dKO and WT MDS. RANKL or
TNF stimulated c-FosmRNA expression inWT cells but not in
dKO cells (Fig. 2A). Accordingly, RANKL or TNF induced
binding of c-Fos protein to anAP-1 oligonucleotide probe in an
EMSA using nuclear extracts from WT MDS but not using
dKO cells. In contrast, binding to the SP-1 control probe was
similar between dKO and WT nuclear extracts, indicating
equal loading in the EMSA (Fig. 2B). To further determine
whether NF-B is upstream from c-Fos induced by RANKL or
TNF, we treatedWTcells with a newly developedNF-B inhib-
itor (57) and demonstrated thatNF-B inhibitor treatment pre-
vented RANKL or TNF-induced c-Fos expression (Fig. 2C) and
activation (data not shown). Finally, we infected c-Fos-deficient
cells with NF-B p50p52 retroviral constructs and treated
NF-B Regulation of RANKL and TNF-induced Bone Resorption
JUNE 22, 2007•VOLUME 282•NUMBER 25 JOURNAL OF BIOLOGICAL CHEMISTRY 18247
 at University of Rochester on August 15, 2013http://www.jbc.org/Downloaded from 123
them with RANKL. As expected, overexpression of NF-B in
these cells did not rescue their defect in osteoclast formation
(data not shown). These findings indicate that c-Fos is down-
stream of NF-B in RANKL and TNF-induced osteoclast
formation.
c-Fos Up-regulates NFATc1 Expression in NF-B dKO Oste-
oclast Precursors, and NFATc1 Overexpression Rescues the
Defect in Osteoclast Formation in NF-B dKO Cells—NFATc1
functions downstream of c-Fos during osteoclastogenesis in
WT cells (29). If this is also the case in dKO cells, we should not
observe increased NFATc1 expression in RANKL-treated dKO
cells, and NFATc1 expression should be rescued by c-Fos over-
expression. We found that RANKL treatment of WT, but not
dKOMDS, increasedNFATc1mRNA5-fold. In contrast, c-Fos
overexpression plus RANKL induced NFATc1 mRNA in both
WT and dKO cells, as assessed by real-time RT-PCR (Fig. 3A).
Consistent with this, c-Fos/RANKL-induced dKO osteoclasts
had increased NFATc1 protein expression (Fig. 3B), but
RANKL alone did not induce endogenous c-Fos or NFATc1
expression in dKOMDS in the absence of c-Fos retroviral infec-
tion (Fig. 3B). NFATc1 activation by RANKL in both WT and
dKO osteoclasts was examined by immunofluorescence stain-
ing using an anti-NFATc1 antibody. In WT or dKO osteoclast
precursors cultured in the absence of RANKL, NFATc1 is
detectable only in the cytoplasm regardless of c-Fos overex-
pression (Fig. 3C, panels a–d). In mature WT osteoclasts,
NFATc1 translocated to nuclei in response to RANKL plus
either GFP or c-Fos infection (Fig. 3C, panels e and f). By con-
trast, in dKO MDS only infected with c-Fos, no mature oste-
oclasts formed, and therefore, no NFATc1 translocation was
observed (Fig. 3C, panel g). However, NFATc1 was observed in
FIGURE 1. c-Fos is downstream of NF-B in RANKL-induced osteoclasto-
genesis.A and B, NF-BdKO splenocyteswere culturedwithM-CSF for 3 days
to generate osteoclast precursors, called MDS (as described above). MDS
were infectedwith retroviral supernatant containingNF-Bp50p52, p50, or
p52 (A) or c-Fos (B) with M-CSF for 2 days, selected in medium containing
puromycin (2 g/ml) plus M-CSF (10 ng/ml) for 2 days, and cultured with
M-CSF and RANKL (10 ng/ml) or TNF (20 ng/ml) for 5 days (n	 4wells/group),
and TRAP osteoclasts were counted. C, c-fos mRNA was assessed by real-
time RT PCR using total RNA from c-Fos- or GFP-infectedMDS after culture for
4 days. Values (means of triplicate loadings plus S.E.) are the -fold changes of
c-fos/actin in c-Fos- over GFP-infected samples. D, TRAP-stained c-Fos- or
GFP-infected dKO cells culturedwith RANKL on plastic dishes (panels a and d)
or bone slices (panels b and e). Resorption pits (panel f, arrows) produced by
these cells (panels c and f) stainedwith toluidine blue; osteoclasts and resorp-
tion pits fromWT cells were induced by c-Fos/RANKL (panels g–i). *, p 0.05
versus GFP-treated groups.
FIGURE 2. ImpairedRANKLor TNF-induced c-Fos activation inNF-BdKO
osteoclast precursors. A, NF-B dKO or WT MDS were treated with RANKL,
TNF, or PBS. Total RNA was extracted, and expression of c-fos mRNA was
measured by real-time RT-PCR at 4 h as in Fig. 1. Values are the -fold changes
of c-fos/actin in cytokine-treatedover PBS-treated samples andare themeans
of triplicate loading plus S.E. B, WT and NF-B dKO MDS were treated with
RANKL, TNF, or PBS control for 8 h. Nuclear protein (5 g) was subjected to
EMSA for AP-1 binding activity. AP-1 bands are indicated by the arrowhead,
and SP-1 probe was used as a loading control. C, WT MDS were treated with
various doses of NF-B inhibitor in the presence of RANKL or TNF for 4 h. The
expressionof c-fosmRNAwasdeterminedby real-timeRT-PCR. Values are the
-fold changes of c-fos/actin in cytokine-treated over vehicle (Veh) (Me2SO)-
treated samples.
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nuclei of c-Fos/RANKL-induced
mature osteoclasts from NF-B
dKOMDS (Fig. 3C, panel h). These
data indicate that NFATc1 nuclear




We next overexpressed a consti-
tutively active form of NFATc1 in
NF-B dKO MDS to determine
whether it could rescue their
defect in osteoclast formation.
Treatment of these NFATc1-ex-
pressing dKO cells with RANKL
induced osteoclast formation (Fig.
4, A and B). Maximal osteoclast
numbers appeared 1 day earlier
than with c-Fos overexpression in
the same experiment (data not
shown). The number of osteoclasts
formed when NFATc1 was overex-
pressed in the dKO cultures (Fig.
4A) was similar to that when NF-B
p50p52 or c-Fos were overex-
pressed in dKO MDS, consistent
with sequential activation ofNF-B,
c-Fos, and then NFATc1 in
RANKL-induced osteoclastogen-
esis. Notably, small numbers of
osteoclasts formed in the dKO cultures expressing NFATc1
alone (Fig. 4B), presumably because unlike the c-Fos or NF-B
constructs, thisNFATconstruct is constitutively active because
it is not phosphorylated.
We next determined whether TNF-induced dKO osteoclast
formation, like RANKL, is mediated through NFATc1. We
observed induction of NFATc1 expression in c-Fos-expressing
dKOMDS treated with TNF (Fig. 4C). TNF also induced oste-
oclast formation from NF-B dKO cells when NFATc1 was
overexpressed in these cells (Fig. 4D).
RANKL and TNF Induce a Similar Pattern of c-Fos or
NFATc1 Expression during Osteoclastogenesis from WT
Splenocytes—Both RANKL and TNF plus c-Fos overexpres-
sion rescued the defect in osteoclastogenesis and increased
NFATc1 expression in osteoclasts formed from NF-B dKO
MDS, suggesting that TNFmay trigger osteoclastogenesis by
up-regulating c-Fos and NFATc1 sequentially, like RANKL,
as described previously in WT cells (15). Wild-type MDS
were treated with RANKL or TNF for various times, and
expression levels of c-Fos and NFATc1 and osteoclast for-
mation were examined. TNF increased c-fosmRNA levels to
the same extent as RANKL as early as 4 h, although c-fos
levels were significantly higher in the RANKL-treated than
in the TNF-treated cultures thereafter (Fig. 5A). NFATc1
expression increased much later than c-Fos (Fig. 5, A and B).
Notably, RANKL-induced NFATc1 expression peaked at
48 h when mature osteoclasts formed (Fig. 5C). In contrast,
TNF-induced NFATc1 expression and osteoclast formation
FIGURE 3. c-Fos expression and RANKL induce NFATc1 expression and activation in NF-B dKO oste-
oclast precursorsduringosteoclast differentiation.A,WTorNF-BdKOMDSweregenerated, infectedwith
c-FosorGFP, and treatedwithM-CSFRANKL, andNFATc1expressionwas assessedasdescribed in the legend
for Fig. 1. *, p 0.05 versusWT cells. B, c-Fos and NFATc1 protein expression levels in c-Fos and GFP-infected
dKO cultures treated with and without RANKL for 5 days were assessed by Western blot analysis. C, mature
osteoclasts were generated fromWT or NF-B dKOMDS that were infected with c-Fos or GFP retroviral super-
natants in thepresenceofM-CSFRANKLor PBS.Whenmultinucleated cellswith themorphologic features of
osteoclasts were observed under an invertedmicroscope, the cells were stainedwith anti-NFATc1 antibody to
identify nuclear translocation (10; insets are40).
FIGURE 4. NFATc1 expression and RANKL or TNF treatment induce oste-
oclast formation from NF-B dKO osteoclast precursors. A, NF-B dKOMDS
were generated, infected with NFATc1, c-Fos or GFP, and treated with M-CSF
RANKL or PBS, and TRAP osteoclast formationwas assessed as described in the
legend for Fig. 1. B, TRAP osteoclasts (Ocls, arrows) formed in the NFATc1-in-
fected cultures treated with PBS, but their numbers were much smaller than in
the cultures treated with RANKL. C, NF-B dKO MDS were generated, infected
withNFATc1orGFP, and treatedwithM-CSFTNForPBS, andTRAP osteoclast
formation was assessed, as described in the legend for Fig. 1. D, NFATc1 mRNA
was assessed by real-time RT PCR using total RNA from c-Fos- or GFP-infected
MDS. *, p 0.05 versusGFP-infected group.
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peaked 1 day later (Fig. 5, A–C), associated with lower levels
of NFATc1 expression and fewer osteoclasts. This suggests
that the weaker osteoclastogenic effect of TNF in compari-
son with RANKL in these cultures may be due to lower
induced NFATc1 expression.
c-Fos Expression Increases the Resorptive Activity of Oste-
oclasts Induced fromWTMDS by TNF—Having demonstrated
that c-Fos can substitute for NF-B in osteoclast formation, we
next examined whether c-Fos could increase the bone-resorb-
ing capacity of mature osteoclasts induced by TNF. The ability
of TNF to induce osteoclast formation and bone resorption in
vitro has been controversial (13). However, we found that TNF-
induced osteoclasts do resorb bone (Fig. 6), although the pits
were smaller and shallower than those formed in response to
RANKL (data not shown). c-Fos also significantly increased the
TNF-induced pit area (Fig. 6).
DISCUSSION
Expression of NF-B, c-Fos, and NFATc1 is required for
osteoclast precursors to differentiate into osteoclasts in
response to RANKL. Here, we show that c-Fos and NFATc1
induction is downstream of NF-B p50 and p52 activation in
RANKL-mediated signaling in osteoclast precursor differenti-
ation because either c-Fos or NFATc1 can efficiently substi-
tute for NF-B p50 and p52 in RANKL-treated NF-B p50/
p52 dKO cells to induce osteoclast formation and bone
resorption. Furthermore unexpectedly, c-Fos or NFATc1
can substitute for NF-B in TNF-stimulated osteoclast for-
mation from NF-B dKO cells in vitro. NFATc1 has been
described as the master switch for regulating terminal differ-
entiation of osteoclasts downstream from RANKL, and its
expression is regulated by c-Fos (29, 33). Our findings indi-
cate that NF-B p50 and p52 play an essential role regulating
the early differentiation of osteoclast precursors upstream
from c-Fos and NFATc1 in response to RANKL and TNF,
both of which can induce osteoclast formation directly from
osteoclast precursors in vitro.
The importance of these findings is that expression of
RANKL and TNF is increased in a variety of common bone
diseases associated with increased bone resorption, including
postmenopausal osteoporosis, rheumatoid arthritis, and peri-
odontal disease (2, 58, 59). These two cytokines can increase the
expression of each other by accessory cells and of TNF by oste-
oclasts and their precursors (60, 61). By this latter mechanism,
TNF could amplify its osteoclastogenic effects in an autocrine
auto-amplifying manner, setting up what we propose is an
auto-amplifying cycle of increasing osteoclastogenesis whereby
TNF inducesmore osteoclasts and their precursors, which pro-
ducemoreTNF to induce formation ofmore osteoclasts, and so
on. Excessive production of TNF in joints of patients with rheu-
matoid arthritis could account in large part for the aggressive
bone resorption seen in affected joints of these patients. The
FIGURE5.RANKLandTNF induce c-Fos followedbyNFATc1expression in
WT osteoclast precursors. A and B, WT MDS were generated and treated
with M-CSF  RANKL (10 ng/ml) or TNF (20 ng/ml), and c-Fos and NFATc1
mRNA (A) and protein (B) expression was assessed by real-time RT-PCR and
Western blot analysis, respectively, at the times indicated. C, TRAP oste-
oclast formationwas assessed, as described in the legend for Fig. 1 in parallel
experiments. P, PBS; R, RANKL; T, TNF.
FIGURE 6. c-Fos expression increases the resorptive activity of WT oste-
oclasts (Ocls) treated with TNF. WT MDS were generated, infected with
c-Fos orGFP, and treatedwith TNF (20 ng/ml) for 8 days. Osteoclast formation
and resorption pit area were assessed. *, p  0.05 versus TNF-treated GFP-
infected group.
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efficacy of anti-TNF therapy in many rheumatic patients sup-
ports this assertion (62).
Overexpression of NF-B p50 and p52 or c-Fos alone in dKO
MDS did not induce osteoclast formation in our cultures.
Although NFATc1 overexpression alone did induce small
numbers of osteoclasts, as with NF-B p50 and p52 or c-Fos,
concomitant treatment with cytokines was required to rescue
the osteoclast formation defect efficiently. Currently, we do not
know why cytokines are required for this efficient rescue of the
osteoclast formation defect. When c-Fos or NFATc1 was over-
expressed alone in c-fos/ cells, this, too, did not rescue the
osteoclastogenesis defect and needed the addition of RANKL
for efficient rescue (33). We therefore speculate that this retro-
viral rescue system has an intrinsic deficiency that prevents full
recovery of osteoclastogenesis or that to initiate the osteoclast
formation program, these virus-encoded transcription factors
need to be activated through RANKL signaling and interact
with a yet to be identified RANKL-inducedmolecule. However,
it is also possible that other mechanisms are involved in
RANKL-induced osteoclast formation. Further studies will be
required to address this particular issue.
To date, there is no evidence that NF-B activates c-Fos
directly, and there are no consensus NF-B binding sites on
the c-Fos promoter. Indirect activation of c-Fos by NF-B
through serum-response factors has been described in
embryonic fibroblasts (63). Recently, we have found that
NF-B binding activity was significantly higher in c-fos/
MDS when compared with WT cells, supporting the argu-
ment that NF-B is upstream rather than downstream of
c-Fos (64). The report that NF-B p65 and p50 transiently
interact with NFATc2, but not with NFATc1, on the
NFAT2c1 promoter is intriguing and warrants further study
to determine exactly what the role of NF-B p50 and p52 and
NFAT2 proteins is in the early stages of osteoclastogenesis.
TNF, like RANKL, can activate a variety of signaling path-
ways in osteoclasts and their precursors (reviewed in Refs. 8, 58,
and 65) that induce osteoclast formation and activation. Our
observation of a sequence of induction by RANKL and TNF
beginning with NF-B followed by c-Fos and NFATc1 suggests
that these cytokines may share a common pathway to induce
osteoclast precursor differentiation in addition to activating
c-Fos. However, RANKL and TNF recruit different adapter
proteins, TNF receptor-associated factor (TRAF) 6 (66) and
TRAF2 (67), respectively, to their receptors to mediate down-
stream signaling, suggesting that they should activate different
pathways. RANKL has been reported to regulate stimulated,
but not basal, osteoclast formation by a pathway involvingNF-B-
inducing kinase and NF-B p100 processing to p52 in the NF-B
alternative pathway (68). However, these authors did not observe
this effect with short term TNF treatment, again suggesting that
RANKL andTNFmay use different pathways. Further studies will
be required to determine what these are.
In the later stages of our cultures after 24–48 h when
osteoclasts begin to form, RANKL and TNF induced expres-
sion of NFATc1 in c-Fos-infected dKO MDS. That NFATc1
is essential for osteoclastogenesis and works downstream of
c-Fos has been established by genetic studies (29, 33). For
example, overexpression of NFATc1 retrovirus plus RANKL
treatment rescued the osteoclastogenesis defect in Fos/
osteoclast precursors (33). The recent studies by Asagiri
et al. (45) reporting that NF-B p65 and p50 bind transiently
to the promoter region of NFATc1 along with NFATc2
within 1 h of treatment with RANKL highlight the complex-
ity of the signaling downstream from RANKL/RANK inter-
action and our limited understanding of how RANKL medi-
ates osteoclast formation.
The current paradigmon osteoclastogenesis posits thatmost
cytokines, hormones, and growth factors induce osteoclast for-
mation and bone resorption predominantly by an indirect
mechanismwhereby they promoteRANKLandM-CSF expres-
sion in osteoblast/stromal cells, rather than by directly acting
on osteoclast precursors to mediate the differentiation of
RANK-expressing precursors into mature osteoclasts. Indeed,
it has been proposed recently that stromal cells expressing
M-CSF make a greater contribution to TNF-mediated oste-
oclast formation than osteoclast precursors (18) and that oste-
oclast formation in vitro requires prior priming of these precur-
sors by RANKL (69). However, the claim in this latter study has
now been disproved (42, 43). Thus, it is now clear that TNF can
induce osteoclast formation both directly and indirectly at least
in vitro, although the relative contributions of these two mech-
anisms in vivo remain uncertain.
Our findings suggest that osteoclastogenesis is controlled by
a hierarchical transcriptional program in which NF-B activa-
tion appears to be the first event and is followed by c-Fos and
NFATc1 activation. NF-B is not essential for the commitment
of hematopoietic stem cells to the osteoclast progenitor cells
because these cells can give rise to functional osteoclasts if the
downstream transcription factors, c-Fos or NFATc1, are over-
expressed in these cells. Thus, inhibitors of NF-B should pre-
vent osteoclast formation induced directly or indirectly by
RANKL or TNF in the early stages of osteoclast precursor dif-
ferentiation, rather than during the later stages where an
NFATc1 inhibitor would be predicted to work, based on pub-
lished data (70, 71) and on our data. Blockade of NF-B signal-
ing using such an approach may be an effective therapeutic
strategy to prevent bone loss in a variety of common bone dis-
eases. This overall beneficial effect of NF-B inhibition in pre-
clinical studies contrastswith the disappointing results with the
calcineurin inhibitor, cyclosporin A, which induces osteoporo-
sis in humans (72), presumably because it inhibits not only
NFATc1 activation in osteoclasts but also in osteoblasts by
down-regulating expression of the NFATc1 target gene,
osterix, in osteoblasts, and thus, reducing bone formation
directly (73).
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Interleukin-1 (IL-1) and tumor necrosis factor (TNF)mediate
bone resorption in a variety of diseases affectingbone. LikeTNF,
IL-1 is secreted by osteoclast precursors (OCPs), but unlike
TNF, it does not induce osteoclast formation directly from
OCPs in vitro. TNF induces IL-1 expression and activates c-Fos,
a transcription factor required in OCPs for osteoclast forma-
tion.Here, we examinedwhether IL-1 can induce osteoclast for-
mation directly from OCPs overexpressing c-Fos and whether
interaction with bone matrix affects OCP cytokine expression.
We infected OCPs with c-Fos or green fluorescent protein ret-
rovirus, cultured them with macrophage colony-stimulating
factor and IL-1 on bone slices or plastic dishes, and assessed
osteoclast and resorption pit formation and expression of IL-1
by OCPs. We used a Transwell assay to determine whether
OCPs secrete IL-1 when they interact with bone matrix. IL-1
induced osteoclast formation directly from c-Fos-expressing
OCPs on plastic. c-Fos-expressing OCPs formed osteoclasts
spontaneously on bone slices without addition of cytokines.
OCPs on bone secreted IL-1, which induced osteoclast forma-
tion from c-Fos-expressingOCPs in the lower Transwell dishes.
The bone matrix proteins dentin sialoprotein and osteopontin,
but not transforming growth factor-, stimulated OCP expres-
sion of IL-1 and induced c-Fos-expressing OCP differentiation
intoosteoclasts.Osteoclasts eroding inflamed joints havehigher
c-Fos expression compared with osteoclasts inside bone. We
conclude thatOCPs expressing c-Fosmay induce their differen-
tiation directly into osteoclasts by an autocrine mechanism in
which they produce IL-1 through interaction with bone matrix.
TNF could induce c-Fos expression in OCPs at sites of inflam-
mation in bone to promote this autocrine mechanism and thus
amplify bone loss.
Increased osteoclast formation and activity are responsible
for bone loss in commonbone diseases such as postmenopausal
osteoporosis, rheumatoid arthritis, periodontal disease, and
orthopedic implant loosening (1). Osteoclast differentiation
and function are controlled primarily by macrophage colony-
stimulating factor (M-CSF)2 and RANKL (receptor activator of
NF-B ligand) expressed by osteoblast/stromal cells and by sig-
naling downstream from their receptors in osteoclast precur-
sors (OCPs) (2–5). M-CSF induces expression of RANK, the
receptor for RANKL, in OCPs (6). Binding of RANKL to RANK
completes the differentiation of OCPs into mature osteoclasts
through sequential activation of the transcription factors
NF-B, c-Fos, and NFATc1 (nuclear factor of activated T cells
c1) (7). Expression of each of these transcription factors is re-
quired in OCPs for osteoclastogenesis (1, 8, 9). c-Fos is a com-
ponent of the dimeric transcription factor AP-1 (10, 11), which
mediates RANKL-stimulated osteoclast formation by tran-
scriptionally activating NFATc1 (12–14). Overexpression of
c-Fos in fos/ OCPs rescues the defect in RANKL-mediated
osteoclast formation from these cells (12), although overex-
pression of c-Fos is not sufficient by itself for induction of OCP
differentiation into osteoclasts on plastic culture plates (12–
14). We have reported recently that c-Fos can substitute for
NF-B p50 and p52 in OCPs frommice lacking NF-B p50 and
p52 and that, under these circumstances, RANKL or tumor
necrosis factor (TNF) can induce osteoclast formation from
these cells, but not when the cells express green fluorescent
protein (GFP) (7).
Interleukin-1 (IL-1) and TNF are pro-inflammatory cyto-
kines that stimulate bone resorption and are expressed in abun-
dance at sites of inflammation in and around bones (15–17).
They are produced by a variety of cell types, including mono-
cytes/macrophages, OCPs, and mature osteoclasts themselves
(18, 19). Like TNF, IL-1 promotes RANKL expression by mar-
row osteoblastic stromal cells (20) and by this mechanism
induces osteoclastogenesis indirectly. However, unlike TNF,
IL-1 alone cannot directly mediate osteoclast formation from
OCPs in vitro (21). OCPs and osteoclasts express IL-1 recep-
tors, and IL-1 appears to enhance osteoclast differentiation by
promoting fusion of OCPs (22) and supporting the survival of
mature osteoclasts (23–25).* This work was supported by National Institutes of Health Grants AR43510
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OCPs are attracted to bone surfaces by signaling, which
appears to involve bone-lining cells (26) and osteocytes (27).
Once they are attached to bone matrix, osteoclasts and OCPs
receive survival-enhancing signals through integrin-mediated
signaling (28), and they secrete cytokines such as IL-1 and TNF
(29) aswell as factors that can affect the differentiation of osteo-
blast precursors (30). Bone matrix contains several non-collag-
enous proteins, including transforming growth factor-
(TGF) (31, 32) and members of the SIBLING (small integrin-
binding ligand, N-linked glycoprotein) family of proteins such
as osteopontin (OPN), dentin sialoprotein (DSP), and bone sia-
loprotein (33, 34). These proteins are released from the matrix
during bone resorption. TGF has multiple effects on bone
cells and has been proposed to be involved in coupling osteo-
blasts to sites of bone resorption (31, 32). OPN appears to
anchor osteoclasts to bonematrix through interaction with the
vitronectin receptor on the osteoclast basolateral membrane
(35) and is required for the activation of osteoclastic bone
resorption in unloaded mice (36). Overexpression of bone sia-
loprotein in osteoblasts leads to bone loss indirectly in mice by
enhancing RANKL expression by osteoblastic cells and thus
inducing osteoclast differentiation (37). However, it is not
known if any of the bonematrix proteins play amore direct role
in osteoclast formation.
Here, we report thatwhenOCPs interactwith bonematrix or
are treated with DSP or OPN, they increase their expression of
IL-1. This induces differentiation of c-Fos-expressing OCPs
directly into osteoclasts in the absence of RANKL by an auto-
crine/paracrine mechanism.
MATERIALS ANDMETHODS
Reagents and Animals—Recombinant human M-CSF,
murine RANKL, IL-1, TNF, IL-1 receptor antagonist (IL-1Ra),
TGF1, and a pan-specific TGF antibody were purchased
from R&D Systems, Inc. (Minneapolis, MN). TNF receptor
fusion protein (ENBREL) was from Amgen (Thousand Oaks,
CA). DSP and dentin phosphoprotein (DPP) were extracted
from rat dentin, andOPNwas extracted from rat long bone cortex
as we reported previously (38). Wild-type (WT) mice (C57Bl/6),
NF-B p50/p52 double knock-out (dKO) mice (C57Bl/6129),
and human TNF transgenic (TNF-Tg) mice (line 3647,
CBAC57Bl/6) were used as we described previously (7, 39).
The Institutional Animal Care and Use Committee approved
all animal studies.
Osteoclastogenesis and Viral Infection—Splenocytes were
extracted from spleens through a fine wire mesh and cultured
with conditioned medium from a M-CSF-producing cell line
(1:20 dilution) (40) for 3 days in -modified essential medium
with 10% fetal calf serum (HyClone Laboratories, Logan, UT) to
enrich for osteoclast precursors, which we named M-CSF-de-
pendent splenocytes (MDS). The cells were then infected with
retroviral supernatants of c-Fos-, NFATc1-, or GFP control-
infected Plat-E packaging cells in the presence of M-CSF (10
ng/ml) and Polybrene (8 g/ml) as we described previously (7).
For Transwell assays, GFP or c-Fos retrovirus-infected WT
MDS were seeded directly on bovine cortical bone slices (4 
4  0.2 mm) in 96-well plates or on plastic in the wells of the
lower chamber of a 24-well Transwell dish and cultured in the
presence of M-CSF for 2 days. The bone slices were then trans-
ferred to the upper chamber of the Transwell culture plates and
co-cultured with the GFP- or c-Fos-infected MDS in the lower
chamber for an additional 8 days in the presence of M-CSF.
When multinucleated cell formation was identified under an
invertedmicroscope, the cells were fixedwith 10% formalin and
stained for tartrate-resistant acid phosphatase (TRAP) activity
to identify osteoclasts as TRAP cells containing three ormore
nuclei, and these cells were counted as described previously (7).
For cytokine blockade experiments using different inhibi-
tors, GFP- or c-Fos-infected MDS were cultured directly on
plastic plates or bone slices for 2 days in the presence ofM-CSF
and then treated with cytokines  inhibitors. When primary
spleen cells were used, they were cultured with M-CSF for 3
days prior to inhibitor treatment.
For functional assays, infected cells were cultured on bone
slices for 10 days under the same conditions as described above.
Osteoclasts were then removed; resorption pits were visualized
after 0.1% toluidine blue staining; and the mean pit area (mm2/
slice) was measured as described previously (7).
Quantitative Real-time Reverse Transcription (RT)-PCR—
RNA from MDS or retrovirus-infected cells cultured on
either plastic dishes or bone slices was extracted using TRIzol
reagent (Invitrogen), and cDNA synthesis was performed using
the GeneAmp RNA PCR core kit (Applied Biosystems, Foster
City, CA). Quantitative PCR amplification was performed with
gene-specific primers using an iCycler real-time PCR machine
and iQ SYBR Green Supermix (both from Bio-Rad) according
to the manufacturer’s instruction. The murine primer
sequences used were as follows: TNF, 5-CACACTCAGAT-
CATCTTCTCAA-3 (forward) and 5-AGTAGACAAGGTA-
CAACCCATC-3 (reverse); IL-1, 5-ATTAGACAGCTGCA-
CTACAGG-3 (forward) and 5-GGAGAATATCACTTGTT-
GGTTG-3 (reverse); c-fos, 5-CTGTCAACACACAGGACT-
TTT-3 (forward) and reverse 5-AGGAGATAGCTGCTCT-
ACTTTG-3 (reverse); and -actin, 5-ACCCAGATCATGT-
TTGAGAC-3 (forward) and 5-GTCAGGATCTTCATGAG-
GTAGT-3 (reverse). The relative standard curve method was
used to calculate the amplification difference for each primer
set (41). A standard curve was made from four points corre-
sponding to 5-fold cDNA serial dilutions for each gene. For
each sample, the relative amount was calculated from its
respective standard curve. The quantity of the target gene
mRNAwas then obtained by division of each value by the actin
value. Standards and samples were run in triplicate.
Immunohistochemistry—Long bones from 4-month-old
TNF-Tg mice and WT littermates (three/group) were fixed in
10% phosphate-buffered formalin, decalcified in 10% EDTA,
and embedded in paraffin wax. Deparaffinized sections were
quenched with 3% hydrogen peroxide, treated for antigen
retrieval for 30 min, and stained with a rabbit anti-c-Fos anti-
body (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and a
biotinylated goat anti-rabbit secondary antibody (Dako,
Carpinteria, CA). The biotin was detected using standard avi-
din-biotin peroxidase technology (Dako) and diaminobenzi-
dine (Sigma) as the chromogen. An adjacent section was used
for TRAP staining to identify mature osteoclasts as described
previously (42). c-Fos-positive and -negative osteoclasts on the
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joint surfaces and in the primary spongiosa of the metaphyses
were counted, and the number of c-Fos-positive osteoclastswas
expressed as a percentage of the total number of osteoclasts at
each site.
IL-1 Protein Measurement—Culture medium from GFP- or
c-Fos-infected cells grown on plastic or bone slices in 96-well
plates or in the Transwell assay systemwas collected at the time
when osteoclasts could be seen on the plastic of the culture
wells or around bone slices using an inverted microscope (gen-
erally after 7–9 days). A mouse IL-1 enzyme-linked immu-
nosorbent assay kit (eBioscience, San Diego, CA) was used to
measure IL-1 concentration according to the manufacturer’s
instructions.
Statistics—All results are given as the mean S.D. Compar-
isons between two groups were analyzed using Student’s two-
tailed unpaired t test. One-way analysis of variance and Dun-
nett’s post hoc multiple comparisons were used for
comparisons among three ormore groups. p values0.05 were
considered statistically significant. Each experiment was
repeated at least twice with similar results.
RESULTS
IL-1 Induces Osteoclast Formation Directly from Osteoclast
Precursors Overexpressing c-Fos or NFATc1 and Synergizes with
RANKL—To determine whether IL-1 can induce osteoclast
formation from WT OCPs overexpressing c-Fos, we infected
WT MDS with c-Fos retrovirus and cultured them on plastic
culture plates in the presence ofM-CSF. c-Fos-expressingMDS
alone did not give rise to osteoclasts on plastic plates, but they
formed numerous TRAP osteoclasts when they were treated
with IL-1 (Fig. 1A). These cells also formed resorption pits
when they were cultured on bone slices with IL-1 (data not
shown). Furthermore, like TNF and RANKL (7), IL-1
induced osteoclast formation directly from NF-B dKO
OCPs overexpressing c-Fos (Fig. 1A). In addition, subopti-
mal doses of IL-1 and RANKL induced osteoclast formation
synergistically (Fig. 1E).
c-Fos induces expression of NFATc1, which is critical for
osteoclastogenesis (12). We found that expression of NFATc1
was up-regulated in cells overexpressing c-Fos when they were
treated with IL-1 for 72–96 h, the time when osteoclasts were
forming in these cultures (data not shown). IL-1 induced oste-
oclast formation frombothWTandNF-B dKOMDS express-
ingNFATc1 (Fig. 1B), and notably, NFATc1 induced osteoclast
formation 1 day earlier than c-Fos, although both ultimately
induced similar numbers of osteoclasts (data not shown).
Overexpression of c-Fos in Osteoclast Precursors on Bone
Slices Promotes Osteoclast Differentiation through Production
of Soluble Factors—Whenwe cultured c-Fos-expressingWTor
NF-B dKOMDS on bone slices without IL-1, we found unex-
pectedly that they gave rise to osteoclasts, and these cells also
formed resorption pits (Fig. 1C, panels a–d, and D). Interest-
ingly, osteoclasts also formed from c-Fos-expressing OCPs on
the plastic around the bone slices (Fig. 1C, panels e and f).
Because there was no other cytokine added to these bone slice
cultures except M-CSF and because c-Fos-overexpressing
OCPs cultured on plastic did not form osteoclasts in the
absence of IL-1, we hypothesized that c-Fos-expressing OCPs
grown on bone produce and release a soluble factor(s) to drive
differentiation of the precursors on the adjacent plastic into
mature osteoclasts or that osteoclasts or OCPs migrate from
the bone onto the plastic.
To examine whether c-Fos-expressing OCPs grown on bone
secrete a soluble factor(s), we used a Transwell assay system.
GFP- or c-Fos-expressingOCPswere cultured on bone slices in
the upper chamber, and either GFP- or c-Fos-infected cells
were cultured on plastic in the lower chamber of the Transwell
culture system (Fig. 2A). These cultures also containedM-CSF.
We found that c-Fos-expressing cells grown on the bone slices
in the upper chamber induced mature osteoclasts from c-Fos-
but not GFP-infected cells in the lower chamber (Fig. 2B). Fur-
thermore, GFP-expressing OCPs cultured on bone slices in the
upper chamber induced more osteoclasts in the lower cham-
bers compared with c-Fos-expressing OCPs (Fig. 2B). Bone
slices placed alone in the upper chamber without cells did not
induce osteoclast formation from c-Fos-expressing OCPs.
FIGURE 1. c-Fos overexpression in osteoclast precursors directly induces
their differentiation into osteoclasts onbone slices.GFP, c-Fos, or NFATc1
retrovirus-infectedWT andNF-Bp50/p52 dKOMDSwere cultured onplastic
culture plates  IL-1 or on bone slices  M-CSF to form osteoclasts. Oste-
oclasts were identified by TRAP staining, and resorption pits were visualized
by toluidine blue staining. The number of osteoclasts (Ocls) that formed on
plastic dishes fromGFP- or c-Fos-infected (A) or NFATc1-infected (B) cells was
assessed. TRAP osteoclasts in c-Fos-overexpressing cells on bone slices
(C, panels a–d) and TRAP cells that formed on the plastic dish around bone
slices (panels e and f) and the number of osteoclasts on bone slices and pit
area (D) were assessed. c-Fos retrovirus-infectedWTMDSwere cultured with
various doses of IL-1 and RANKL on plastic plates to form osteoclasts. The
numbers of osteoclasts were assessed (E). Values are the mean S.D. of four
plastic culture wells or bone slices. *, p 0.05 versus the respective value for
GFP-infected cells or phosphate-buffered saline (PBS)-treated cells.
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IL-1 Is Produced by Osteoclast Precursors Interacting with
Bone and Promotes Osteoclastogenesis from c-Fos-expressing
Precursors—TNF and IL-1 are pro-inflammatory cytokines
known to be secreted by osteoclasts and OCPs (29). Thus, we
considered both as candidate factors that could be produced by
OCPs on bone slices to induce osteoclast formation. BothGFP-
and c-Fos-expressing OCPs grown on bone slices expressed
markedly more IL-1 mRNA (100–150-fold higher) compared
with similar OCPs cultured on plastic dishes after 9 days of
culture (Fig. 3A), the time when osteoclast formation begins. In
contrast, the expression of TNF mRNA by the OCPs was
increased by only 3–5-fold on bone slices. Furthermore, GFP-
expressing OCPs expressed significantly higher levels of IL-1
mRNA on bone slices (Fig. 3A) and secreted more IL-1 protein
into the culture medium compared with c-Fos-expressing
OCPs (Fig. 3B).
To determine whether IL-1 or TNF is responsible for the
differentiation of c-Fos-expressing OCPs on bone slices and
functions as a soluble factor, OCPs were infected with c-Fos
retrovirus and cultured on bone slices in the presence of IL-1Ra
or the TNF inhibitor ENBREL. IL-1Ra reduced c-Fos-induced
osteoclast formation by50% (Fig. 4A), an effect similar to that
reported as the maximal effect of this protein to inhibit IL-1-
induced osteoclast activity (29). In contrast, ENBREL at doses
that completely blocked TNF-induced osteoclast formation on
plastic had no inhibitory effect on c-Fos-induced osteoclast for-
mation on bone slices (Fig. 4B). Furthermore, IL-1Ra reduced
osteoclast formation (Fig. 4C) induced by IL-1 in c-Fos-ex-
pressing OCPs cultured on plastic to a similar extent as in
c-Fos-expressing OCPs without IL-1 on bone slices (Fig. 4A).
BoneMatrix Proteins Stimulate Osteoclast Precursors to Pro-
duce IL-1 and Induce Their Differentiation into Osteoclasts
When c-Fos Is Overexpressed—Bone matrix contains at least 20
non-collagenous proteins, several of which have been reported
to stimulate macrophages to produce cytokines such as IL-1
(43). To examine whether this is also the case for OCPs, we
cultured OCPs on plastic, treated them with the bone matrix
proteins (DSP, DPP, OPN, or TGF), and determined their
effects on the levels of IL-1 and TNFmRNA expression by real-
time RT-PCR. DSP in particular and also OPN significantly
increased IL-1 and to a lesser extent TNF mRNA expression,
whereas DPP and TGF had no effect (Fig. 5A).
To determine whether IL-1 induced by DSP or OPN can
substitute for exogenous IL-1 and stimulate c-Fos-expressing
OCPs to differentiate into osteoclasts, we treated GFP- or
c-Fos-infected cells with DSP or OPN on plastic. As expected,
these proteins did not induce osteoclast formation from GFP-
infected cells. However, they induced osteoclast formation
from c-Fos-expressing precursors, which was partially blocked
by IL-1Ra (Fig. 5B) to the same extent as observed in cultures on
bone slices (Fig. 4A) or in IL-1-induced osteoclast formation
(Fig. 4C).
TNF, but Not IL-1, Increases c-Fos Expression in Osteoclast
Precursors—Our experiments demonstrated that IL-1-induced
osteoclast formation requires forced c-Fos expression inOCPs.
We reasoned that IL-1 would not have this effect by itself, oth-
erwise IL-1 alone should be able to induce osteoclast formation.
TNF has been reported to induce osteoclast differentiation
FIGURE 2. Osteoclast precursors grown on bone slices induce osteoclast
formation from c-Fos-overexpressing precursors on plastic below them.
A, GFP or c-Fos retrovirus-infected WT MDS were cultured on bone slices or
plastic in 24-well plates for 2 days in thepresence of addedM-CSF. Bone slices
with either GFP- or c-Fos-infected cells or control slices with no cells were
moved into the upper chambers of the Transwells and co-cultured with cells
onplastic in the lower chambers as indicated in thepresenceof addedM-CSF.
B, the cells in the lower chambers were stained for TRAP activity, and the
numberof osteoclasts (Ocls)was counted. Values are themeanS.D. of three
wells. *, p  0.05 versus the co-culture of c-Fos-infected cells in the lower
chamber with blank bone.
FIGURE 3. Osteoclast precursors grown on bone slices express markedly
more IL-1 than those cultured on plastic plates. GFP or c-Fos retrovirus-
infected WT MDS were cultured on plastic or bone slices in the presence of
M-CSF for 9 days. A, total RNA was extracted and subjected to real-time RT-
PCR to determine the expression levels of IL-1 and TNF. The -fold changes
were calculated by dividing the value of the target gene by that of the GFP-
infected samples on plastic. Values are themean S.D. of triplicate loadings.
*, p 0.05 versus cells grown on plastic. B, IL-1 protein concentrations were
measured by enzyme-linked immunosorbent assay in the culture medium
collected from the cultures described in A at the end of the culture. Data are
the mean S.D. of five wells from one independent experiment representa-
tive of three. *, p 0.05 between the two groups indicated.
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directly fromOCPs in the absence of RANKL (7, 44). To exam-
ine whether TNF induces high c-Fos expression in OCPs in
vitro, we first treated OCPs with TNF and compared its effects
on the expression of c-Fos by OCPs with that of IL-1 and
RANKL, which was included here as a positive control. TNF
induced sustained c-Fos expression from 8 to 96 h and induced
osteoclast formation. RANKL had a similar but less pro-
nounced effect. In contrast, IL-1 did not have any stimulatory
effect on c-Fos expression or induce osteoclast differentiation
(Fig. 6A).
We then examined the effect of TNF on c-Fos expression by
osteoclasts in vivo using TNF-Tg mice, which develop an
inflammatory erosive arthritis similar to rheumatoid arthritis
(45). In bone sections fromTNF-Tgmice with erosive arthritis,
we found a strong signal for c-Fos in the cytoplasmandnuclei of
many osteoclasts (43  10%) eroding the bone on the outer
surfaces of inflamed joints (Fig. 6B), where local concentrations
of IL-1 and TNF are increased (46, 47). In contrast, fewer oste-
oclasts (21 1%) in the subjacent primary spongiosa away from
the inflammation expressed c-Fos, and the intensity of the
staining in the same sections was much weaker (Fig. 6B). In the
primary spongiosa, c-Fos was expressed strongly in osteoblasts,
cells known to up-regulate their expression of c-Fos in response
to factors such as parathyroid hormone (48, 49), indicating that
the lower intensity of the signal for c-Fos in osteoclasts inside
the bones was not due to suboptimal specimen fixation or
processing.
DISCUSSION
IL-1 is a potent stimulator of bone resorption in vitro and in
vivo (50). It enhances osteoclast precursor fusion and osteoclast
survival in vitro (23–25). However, unlike TNF and RANKL,
IL-1 cannot induce osteoclast formation directly fromOCPs in
vitro. In this study, we have demonstrated that IL-1 can induce
osteoclast formation directly fromOCPswhen they are overex-
pressing c-Fos and that these cells can resorb bone in vitro.
Thus, under conditions in which c-Fos expression is increased
in OCPs, IL-1 could potentially induce osteoclast formation
directly to mediate bone loss in addition to its known effect to
induce osteoclast formation indirectly through up-regulation
of RANKL expression by accessory cells such as osteoblast/
stromal cells or synoviocytes.
c-Fos plays an essential role in osteoclast formation. Its
expression is required in OCPs for RANKL- and TNF-induced
osteoclast formation (7, 12). c-Fos acts downstream from




























c-Fos +IL-1 on plastic dish
c-Fos on bone slice
c-Fos on bone slice
FIGURE 4. IL-1Ra decreases c-Fos expression-induced osteoclast forma-
tiononboneslices. c-Fos retrovirus-infectedWTMDSwere culturedonbone
slices and treated with the indicated doses of IL-1Ra (A) or ENBREL (B) or
cultured on plastic plates and treated with IL-1 (10 ng/ml) plus the indicated
doses of IL-1Ra (C) in the presence of M-CSF. The number of TRAP oste-
oclasts (Ocls) was counted. Values are the mean S.D. of four bone slices or
wells. *, p 0.05 versus the non-blocker control.
FIGURE 5. Bone matrix proteins stimulate osteoclast precursors to
express IL-1, which induces c-Fos-expressing precursors to form oste-
oclasts. A, WT MDS were treated with DSP, DPP, OPN, or TGF for 4 h at the
indicated doses. The expression levels of IL-1 mRNA were evaluated by real-
time RT-PCR. The -fold changes were calculated by dividing the value of the
treated cells by that of the phosphate-buffered saline (PBS)-treated samples.
Values are the mean S.D. of triplicate loadings. B, GFP or c-Fos retrovirus-
infected WT MDS were treated with DSP (3 g/ml) or OPN (3 g/ml) in the
absence or presence of IL-1Ra (0.1 g/ml) for 6 days. The number of TRAP
osteoclasts (Ocls)was counted. Values are themean S.D. of fourwells. *,p
0.05 versus the non-blocker control (Ctrl).
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osteoclasts and can substitute for NF-B p50 and p52 in this
process (7). We found that TNF and RANKL, but not IL-1,
increase c-Fos expression by OCPs in vitro. This failure of IL-1
to induce c-Fos expression inOCPs could explain its inability to
induce osteoclast formation directly from these cells.We found
that c-Fos expression is increased in osteoclasts on the eroded
surfaces of joints and to a lesser extent in themetaphyseal bones
of TNF-Tg mice. TNF and RANKL expression is increased in
the joints of these mice and of patients with rheumatoid arthri-
tis, where IL-1 expression is also increased (46). Thus, TNF and
RANKL could increase the expression of c-Fos in OCPs in
rheumatoid arthritis and other inflammatory bone diseases,
and IL-1 could directly induce differentiation of these OCPs
into osteoclasts. Our finding that IL-1 acts synergistically with
RANKL at very low doses to induce osteoclast formation
directly from c-Fos-expressing WT OCPs suggests that this
osteoclast-inducing effect of IL-1 could be further enhanced by
RANKL. This would represent a new role for IL-1 to increase
osteoclast formation by a direct autocrine mechanism that
would amplify the bone-resorbing effects of TNF and RANKL
and contribute to the vicious cycle we have proposed for cyto-
kine-induced bone loss (7). This effect would be similar to that
reported previously for bone sialoprotein, which contributes to
RANKL-mediated bone resorption by inducing osteoclasto-
genesis and osteoclast survival and decreasing osteoclast apo-
ptosis (51).
NFATc1, the master transcription factor regulating late-
stage osteoclast differentiation, is activated downstream from
c-Fos (7, 12). In NF-B p50/p52 dKO OCPs treated with
RANKL or TNF, NFATc1 rescues the defect in osteoclast for-
mation as effectively as c-Fos (7). We found that NFATc1 also
rescues this defect in dKO OCPs treated with IL-1 and that it
mediates osteoclast formation from WT OCPs treated with
IL-1. These findings indicate that although IL-1 is unable to
induce osteoclast formation on its own, its downstream signal-
ing can lead to osteoclast formation in a pathway that requires
c-Fos and NFATc1.
Surprisingly, we also found that when OCPs overexpressing
c-Fos were cultured on bone slices along with M-CSF, they
released sufficient amounts of IL-1 to promote their differenti-
ation into mature bone-resorbing osteoclasts in the absence of
other cytokines. This induction of osteoclast formation was
inhibited significantly by IL-1Ra, but not by the TNF inhibitor
ENBREL, indicating that IL-1 largely mediated the effect. The
failure of the IL-1Ra to completely prevent osteoclast formation
in any of our assays, including IL-1-treated c-Fos-expressing
OCPs, suggests that osteoclast interaction with bone matrix
may induce the expression by OCPs of another factor(s). How-
ever, a previous study using this reagent (29) and our experi-
ence with it indicate that these reagents do not completely pre-
vent IL-1-induced effects on osteoclasts orOCPs. Thus, further
studies will be required to resolve this issue.
Our Transwell culture assays showed that GFP-expressing
OCPs express more IL-1 and thus support more osteoclast for-
mation from precursors in the lower chamber compared with
c-Fos-expressing OCPs. RANKL induces c-Fos expression in
OCPs, but it also induces expression of interferon-, which
limits osteoclast formation by down-regulating c-Fos expres-
sion (52). However, we found that c-Fos- and GFP-expressing
OCPs express similar levels of interferon- (data not shown).
At this time, we do not have a definitive explanation for this
difference between these culture conditions. It may represent
another autoregulatorymechanismwithinOCPs to limit excess
osteoclast differentiation.
Interaction of osteoclasts with bone matrix is known to
increase osteoclast survival (53) through integrin-mediated sig-
naling (28). Our findings indicate a previously unknown effect
of interaction of osteoclastic cells with bone matrix, viz. release
of IL-1 and differentiation of c-Fos-expressing precursors into
mature bone-resorbing osteoclasts. We found that the bone
matrix proteins DSP and OPN stimulate expression of IL-1 by
OCPs. A previous study has shown that dental matrix proteins
stimulate macrophages to release cytokines, including IL-1,
TNF, and MCP-1 (monocyte chemoattractant protein-1) (43).
Furthermore, we found that DSP and OPN stimulate differen-
tiation of c-Fos-expressing OCPs into osteoclasts and that
FIGURE 6. TNF increases c-Fos expression in osteoclasts and precur-
sors. A, WT MDS were treated with IL-1 (10 ng/ml), TNF (20 ng/ml), RANKL
(10 ng/ml), or phosphate-buffered saline (PBS) for the indicated time
points. Expression of c-Fos mRNA was measured by real-time RT-PCR. The
-fold changes were calculated by dividing the value of the treated cells by
that of the untreated base-line samples. Values are the mean  S.D. of
triplicate loadings. B, long bone sections from a knee joint of a 4-month-
old TNF-Tg mouse showing severe synovial inflammation and adjacent
bone and cartilage erosion were stained for TRAP activity. Adjacent sec-
tions were stainedwith anti-c-Fos antibody. The upper panels show TRAP
osteoclasts actively resorbing subchondral bone and also strongly
expressing c-Fos (arrows). The lower panels show the primary spongiosa of
the same animal below the growth plate, where osteoclasts were actively
resorbing bone as part of normal endochondral ossification, with these
TRAP osteoclasts having low or no c-Fos protein expression. Data are
representative of three TNF-Tg mice.
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IL-1Ra significantly inhibits this effect. It could be concluded
from these observations that when OCPs adhere to bone
matrix, they begin to resorb it and so cause release of these
proteins, which in turn could stimulate the OCPs to produce
IL-1. However, GFP-expressing OCPs also express increased
amounts of IL-1, and they do not form resorption pits even after
they have been on the matrix for 10 days. Thus, resorption
does not seem to be required for OCPs to increase their expres-
sion of IL-1. Furthermore, neither NF-B p50 nor NF-B p52
expression appears to be required for OCPs to produce IL-1
because c-Fos-overexpressing NF-B dKO OCPs also form
osteoclasts on bone slices (Fig. 1C). Nevertheless, release of
DSP and OPN from bone matrix by osteoclasts during resorp-
tion could augment the effect of this interaction.
It is becoming increasingly clear that osteoclasts are involved
in more complex processes than simply resorption of bone.
Their precursors are formed in the marrow cavity, where they
increase their proliferation and expression of c-Fms, the recep-
tor forM-CSF, in response to cytokines such asTNF (54).OCPs
circulate in the blood and are attracted to sites of inflammation,
where pro-inflammatory cytokine concentrations are high (18),
and to sites destined for resorption. OCPs enter resorption
lacunae through blood vessels, where they appear to be sepa-
rated from the adjacent marrow cells by a membrane inside
which osteoclasts, osteoblasts, and other cells interact (55).
OCPs and osteoclasts secrete cytokines to modulate the activi-
ties of cells around them and, in that respect at least, can be
considered to be immune cells at sites of inflammation in bone
(8, 18, 56). Recent studies indicate that OCPs not only respond
to osteoblasts to have their formation regulated either posi-
tively or negatively (1) but also regulate osteoblast formation
both positively and negatively (30, 57). Our studies indicate that
OCPs also react to signals coming from bone matrix by secret-
ing IL-1. It is likely that this interaction between OCPs and
osteoblastic cells is more complicated than these recent studies
suggest and that other proteins released from the matrix will
affect the function of osteoclasts and other cells in the resorp-
tion lacunae. IL-1 has multiple ways of promoting bone resorp-
tion, including mediating the pro-osteoclastogenic effects of
TNF through osteoblast/stromal cells (29). IL-1 is generally a
more powerful stimulator of bone resorption than TNF, and
this direct action mediated through interaction with bone
matrix may be one of the mechanisms that accounts for these
differences.
In conclusion, our findings have defined novel interactions
among OCPs, bone matrix, and cytokines at sites of bone
resorption. These involve an autocrine role for IL-1 to induce
osteoclast formation fromOCPs in which c-Fos expression has
been up-regulated by cytokines such as TNF and RANKL to
amplify their effects at sites in bone where their concentrations
are increased. They also support involvement of a paracrine
loop in which matrix proteins such as DSP and OPN could
induce increased secretion of IL-1 by OCPs to induce the dif-
ferentiation of c-Fos-expressing OCPs into bone-resorbing
osteoclasts. Collectively, these processes could account for the
aggressive resorption observed in common inflammatory bone
diseases.
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Osteoclasts, the cells that degrade bone, play a central role in bone 
destruction in common erosive bone diseases, including postmeno-
pausal osteoporosis, RA, and periodontitis (1). In these conditions 
there is increased production of the proinflammatory cytokines 
TNF (2) and RANKL (3), members of the TNF superfamily (4) that 
stimulate bone resorption by osteoclasts (5, 6). Signaling through 
their receptors is mediated by recruitment of TNF receptor–associ-
ated factors (TRAFs) (7–9) and leads to activation of transcription 
factors including NF-κB, c-Fos, and NFATc1 (10, 11). Among the 
TRAF family of proteins, TRAF6 is essential for RANKL-induced 
osteoclast differentiation in vitro but not in vivo (12, 13), while 
TRAF2 may be required for TNF-induced osteoclast formation 
(14). TRAF5 is involved in both RANKL- and TNF-induced osteo-
clast formation (15). Similar to RANKL, but not many other osteo-
clast-stimulating factors, TNF can induce osteoclast formation 
directly from osteoclast precursors (OCPs) in vitro in the presence 
of M-CSF independent of RANKL/RANK signaling (16–18), by 
activation of NF-κB (10, 11). TNF induces fewer osteoclasts from 
WT OCPs and less bone resorption in vitro than RANKL (11, 17), 
but the molecular basis for this difference is unknown.
The NF-κB family of proteins includes NF-κB p105 (also known 
as NF-κB1), NF-κB p100 (also known as NF-κB2) (precursor pro-
teins, which can act as inhibitory κB proteins by binding to other 
NF-κB proteins), RelA (p65), RelB, and c-Rel (19, 20). In response to 
RANKL and TNF, p105 is processed constitutively to p50 (19–21), 
which forms dimers, typically with RelA (19, 20). RANKL and TNF 
activate these p50/RelA dimers in the canonical NF-κB pathway 
to promote OCP differentiation, but they also induce expression 
of p100 in these cells (22). p100 undergoes efficient proteasomal 
processing to p52 in response to RANKL through activation of 
NF-κB–inducing kinase (NIK) and IKKα in the alternative pathway 
(23), thus releasing p52/RelB complexes to translocate to nuclei. 
In mice lacking NIK, unprocessed p100 can accumulate in OCPs 
and limit pathologic, but not basal, osteoclastogenesis induced by 
RANKL (23). TNF increases p100 protein levels slightly in OCPs 
(24), but it is not known whether TNF limits osteoclastogenesis 
through this mechanism. NIK is also involved in canonical NF-κB 
signaling (25). Its activity is regulated negatively by constitutive 
proteasomal degradation as a result of its association with TRAF3 
(26–28), which limits p100 processing and inhibits noncanonical 
NF-κB signaling. Thus, ablation of TRAF3 protein in B cells in 
which CD40 or BAFF-R activation induces TRAF3 degradation and 
prevents NIK degradation, resulting in progressive accumulation of 
NIK and activation of the noncanonical NF-κB pathway through 
processing of p100 (26–28). Further, early postnatal lethality occurs 
in TRAF3–/– mice because of uncontrolled NIK activity; this is res-
cued by crossing the mice with Nfkb2–/– mice (28). However, it is 
not known whether TNF affects TRAF3 or NIK levels in OCPs as a 
mechanism to control osteoclast numbers or activity.
Basal osteoclast formation requires expression of RANKL (29), 
RANK (30), and NF-κB p105 and p100 (31, 32), but not of TNF, 
TNF receptors (p55 and p75) (33), or TRAF2, -5, or -6 (12, 14, 15, 
18), although the precise roles of TRAF2, -5, and -6 in osteoclasts 
are controversial (12, 14, 15, 18). Despite compelling evidence for 
a strong proresorptive function of TNF, which induces osteoclast 
formation from Rankl–/– and Rank–/– OCPs in vitro when costimu-
lated with TGF-β (17, 18), TNF does not induce osteoclast forma-
tion in vivo when administered to Rank–/– mice (34). These find-
ings have led to the conclusion that RANKL/RANK signaling is 
a prerequisite for osteoclast differentiation in vivo (35). Here we 
report an unexpected role for TNF to limit TNF- and RANKL-
induced osteoclastogenesis by inducing expression of NF-κB p100 
and TRAF3 in OCPs. TNF also induces robust osteoclast forma-
tion in vivo in Rankl–/– and Rank–/– mice when they also lack NF-κB 
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p100. Importantly, deficiency of NF-κB2 accelerates TNF-induced 
bone loss and joint inflammation in a model of RA, pointing to a 
role for NF-κB p100 to limit bone resorption and inflammation in 
diseases in which TNF expression is increased.
Results
TNF induces expression of noncanonical NF-κB proteins differently from 
RANKL in OCPs. To investigate the possibility that TNF induces 
fewer osteoclasts from OCPs than RANKL by promoting accu-
mulation of the inhibitory NF-κB p100 protein, we examined the 
expression pattern of p100 in WT OCPs. Both RANKL and TNF 
increased p100/p52 mRNA levels within 4 hours of treatment by 
11- and 7-fold, respectively, and these remained elevated by 7- and 
5-fold, respectively, at 8 hours (data not shown). We examined 
p100 and p52 protein expression levels during our typical cul-
ture period (1–96 hours). TNF induced sustained accumulation 
of p100 between 4 and 72 hours (Figure 1A). In contrast, RANKL 
more efficiently processed p100 to p52 during this period (Figure 
1A), and this was associated with the formation of larger num-
bers of osteoclasts (Figure 1B). p100 levels in TNF-treated cells 
were not different from those of PBS-treated controls at 96 hours, 
by which time osteoclast formation has peaked in these cultures 
(11). TNF also induced increased p52 levels, but to a lesser extent 
than RANKL between 8 and 48 hours, confirming that p100 is 
processed in response to TNF (24), especially at 72 and 96 hours, 
when TNF induces peak osteoclast formation (11). Both TNF 
and RANKL markedly increased RelB levels, but the effect of TNF 
was greater than that of RANKL from 48 to 96 hours (Figure 1A). 
Deficiency of p100 did not affect either TNF- or RANKL-mediated 
nuclear translocation of RelB (Supplemental Figure 1A; supple-
mental material available online with this article; doi:10.1172/
JCI38716DS1), presumably because RelB also can associate with 
p50 and translocate into nuclei (36). In contrast, TNF and RANKL 
overall had similar stimulatory effects on the expression levels of 
the canonical NF-κB p50 and p65 proteins during osteoclastogen-
esis (24–96 hours), with some variation at each time point (Fig-
ure 1A). Of note, although both TNF and RANKL mediated rapid 
NF-κB p65 nuclear translocation, the effect of TNF was more 
sustained than that of RANKL (Supplemental Figure 1, B and C). 
We had observed this previously in OCPs from NF-κB1/2 double-
knockout mice that do not form osteoclasts (11).
TNF-induced NF-κB p100 limits osteoclastogenesis. To determine 
whether TNF-induced NF-κB p100 limits the number of osteo-
clasts formed in response to TNF, we treated Nfkb2–/– and WT 
OCPs with TNF and found significantly more osteoclasts from 
Nfkb2–/– than from WT cells, the numbers being similar to those 
in RANKL-treated WT or Nfkb2–/– cells (Figure 1B). This effect was 
not associated with induction in vitro or in vivo in OCPs of IFN-β 
(data not shown), which limits RANKL-induced osteoclastogene-
sis by downregulating c-Fos expression in OCPs (37). Importantly, 
osteoclasts induced by TNF from Nfkb2–/– OCPs formed resorption 
pits as effectively as those induced by RANKL (Figure 1B). TNF 
activates c-Fos and NFATc1, the same critical transcriptional fac-
tors activated by RANKL to induce osteoclast differentiation, but 
TNF induces these to a lesser extent than RANKL when mature 
osteoclasts are formed (11). However, we found that TNF induced 
a fold induction of c-Fos and NFATc1 similar to that of RANKL 
when osteoclasts were forming in Nfkb2–/– cells (data not shown). 
Erk and p38 signaling are also involved in osteoclast differentia-
tion and are activated in response to RANKL and TNF (38). We 
found that TNF induced stronger activation of both Erk and p38 
than RANKL, and this was observed in both WT and Nfkb2–/– cells 
(data not shown).
Nfkb2–/– OCPs lack both p100 and p52. To determine whether p100 
or p52 is responsible for the inhibitory effect of TNF, we infected 
Nfkb2–/– and WT OCPs with p100, p52, or GFP control retrovirus 
and treated them with TNF. p100 inhibited TNF- and RANKL-
induced osteoclastogenesis significantly in both Nfkb2–/– and WT 
OCPs (Figure 1C). p52 also caused a small but significant reduction 
in osteoclast numbers (Figure 1C), which may be due to a minor 
inhibitory effect of p52 homodimers, but this effect was much less 
than that of p100. High expression of these retrovirally induced 
proteins was confirmed in infected WT OCPs (Figure 1C).
To determine whether p100 limits TNF-induced osteoclastogen-
esis in vivo, we injected TNF or PBS vehicle into the supra-calvarial 
subcutaneous tissues of Nfkb2–/– and Nfkb2+/– control mice twice 
daily for 5 days and examined its effects on osteoclastogenesis and 
resorption. Basal osteoclast numbers as well as osteoclast surface 
and eroded surface were similar in Nfkb2–/– and Nfkb2+/– mice (Figure 
1D). Mean values for these parameters of bone resorption increased 
significantly in the Nfkb2+/– and Nfkb2–/– mice in response to TNF, 
but the increase was significantly greater in the Nfkb2–/– mice (Fig-
ure 1D). Serum levels of tartrate-resistant acid phosphatase 5b 
(TRAP5b), a specific marker of bone resorption released by osteo-
clasts, were significantly higher in Nfkb2–/– mice than in control mice 
treated with TNF (7.3 ± 0.5 vs. 5.4 ± 0.8 U/l; P < 0.01), confirming 
that Nfkb2 deficiency enhances TNF-induced bone resorption. We 
also found that basal TRAP5b levels were higher in Nfkb2–/– mice 
than in their littermate controls (6.2 ± 0.1 vs 3.6 ± 0.4 U/l; P < 0.01), 
which suggests that osteoclasts in Nfkb2–/– mice are more active than 
WT osteoclasts, as we did not observe any difference in the number 
of osteoclasts at this time point. This effect differs from those we 
reported previously with IL-1, which induced similarly increased 
numbers of osteoclasts in Nfkb2+/– and Nfkb2–/– mice (39). IL-1 does 
not induce osteoclast formation from WT OCPs in the absence of 
RANKL but can do so when the cells overexpress c-Fos, which is acti-
vated by, and downstream of, NF-κB (40).
TNF induces osteoclastogenesis in Rank–/– or Rankl–/– mice in the absence 
of NF-κB2. TNF induces p100 expression through canonical NF-κB 
signaling (41). To test the hypothesis that p100 induced by TNF 
prevents osteoclast formation in vivo in Rank–/– mice, we first 
examined whether TNF increases the expression of NF-κB p100 
protein in Rank–/– or Rankl–/– OCPs. Similar to its effects in WT 
cells, TNF induced p100 accumulation but not p52 protein in 
Rank–/– and Rankl–/– cells (Figure 2A), indicating that TNF-induced 
p100 protein expression is independent of RANK signaling. There 
was some variability in basal levels of p100 expression from one 
experiment to another, which is a recognized feature of currently 
available antibodies to this protein, but basal levels of expression 
overall did not vary significantly among WT, Rank–/–, and Rankl–/– 
OCPs. As expected, RANKL did not have any effect on p100/p52 
protein in Rank–/– cells, while it clearly increased p52 in Rankl–/– 
cells (Figure 2A). Of note, different from WT cells, RANKL did not 
increase p100 levels in Rankl–/– OCPs, possibly because they had 
not encountered RANKL previously and therefore might be more 
sensitive to RANKL and completely process p100 to p52.
We next generated Rank–/–/Nfkb2–/– and Rankl–/–/Nfkb2–/– mice 
to determine whether TNF could induce osteoclastogenesis in the 
absence of NF-κB2 and either RANK or RANKL. First, we treated 
OCPs from Rank–/–/Nfkb2+/– and Rankl–/–/Nfkb2+/– mice with TNF 
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and found that they formed slightly but significantly more osteo-
clasts than did OCPs from Nfkb2+/– littermates (Figure 2B). This 
likely reflects the fact that Rank–/– (42) and Rankl–/– (data not shown) 
mouse spleens contain more OCPs than do spleens of WT mice 
because of extramedullary hematopoiesis that results from their 
lack of an adequate marrow cavity. OCPs from Rank–/–/Nfkb2–/– and 
Rankl–/–/Nfkb2–/– mice treated with TNF formed significantly more 
osteoclasts than did OCPs from Rank–/–/Nfkb2+/– and Rankl–/–/
Figure 1
TNF-induced expression of NF-κB p100 inhibits osteoclastogenesis. (A) WT mouse OCPs, cultured from splenocytes with M-CSF for 3 days, 
were treated with RANKL or TNF for the indicated times. NF-κB proteins in whole-cell lysates were determined by Western blot. Experiments 
were repeated at least twice with similar results. P, PBS; R, RANKL 10 ng/ml; T, TNF 20 ng/ml. (B) WT or Nfkb2–/– OCPs were treated with 
RANKL or TNF directly on plastic or bone slices in 96-well plates in the presence of M-CSF for 2 and 5 days, respectively, to induce osteoclasts 
(OCs) and resorption pits. Top: Representative TRAP-stained osteoclasts (original magnification, ×4) and toluidine blue–stained pits (original 
magnification, ×20). Bottom: Osteoclast number and resorption pit area (n = 4/group; *P < 0.05 vs RANKL). (C) Nfkb2–/– or WT OCPs were 
infected with GFP, p100, or p52 retroviruses for 2 days and treated with TNF for 2 more days. Osteoclast numbers were counted (left panel; 
*P < 0.05 versus GFP), and the infection efficiency was confirmed by Western blot from the infected WT OCPs (right panels). (D) Murine 
TNF (0.5 μg in 10 μl PBS) or 10 μl PBS were injected twice daily over the calvariae of 4-week-old Nfkb2–/– or Nfkb2+/– control mice for 5 days 
(n = 4/group). The number of osteoclasts/mm bone surface, percentage of osteoclast surface/bone surface, and percentage of eroded surface/
bone surface were measured in TRAP-stained calvarial bone sections, and serum TRAP5b was tested with ELISA.
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Nfkb2+/– mice, the numbers being slightly higher than those from 
Nfkb2–/– OCPs (Figure 2B). We also found that TNF induced the 
formation of bone-resorbing osteoclasts from Rank–/–/Nfkb2+/– and 
Rankl–/–/Nfkb2+/– OCPs without the addition of TGF-β, which was 
suggested to be necessary as a pretreatment (18). A neutralizing 
TGF-β antibody did not prevent these effects, nor did the addi-
tion of TGF-β increase TNF-induced osteoclast numbers (data not 
shown). To exclude the possibility that haploinsufficiency of Nfkb2 
affects the status of Rank–/– and Rankl–/– osteoclast differentiation, 
we treated spleen cells from Rank–/– and Rankl–/– mice with TNF in 
the presence of M-CSF and found that similar osteoclast numbers 
were formed as with OCPs from Rank–/– and Rankl–/– mice with Nfkb2 
haploinsufficiency (Figure 2B, right panel). We believe that we were 
able to induce osteoclastogenesis in our cultures because we used 
lower numbers of M-CSF–dependent OCPs from these KO mice 
than we used from WT controls. The KO mice had higher numbers 
of OCPs in their spleens, as described above, and when we used simi-
lar numbers of OCPs from Rankl–/– or Rank–/– mice as from WT mice, 
Figure 2
NF-κB2 deficiency enhances TNF-induced osteoclastogenesis in Rank–/– or Rankl–/– mice in vitro and in vivo. (A) NF-κB p100 and p52 were ana-
lyzed by Western blot in whole-cell lysates of PBS-, RANKL-, or TNF-treated (8 hours) OCPs from Rank–/– or Rankl–/– mice. (B) Left: OCPs from 
Rank–/–/Nfkb2–/– or Rankl–/–/Nfkb2–/– mice and their Nfkb2+/– littermates were treated with TNF for 2 days to evaluate osteoclast formation using 
TRAP staining (*P < 0.05 vs. Nfkb2+/–). Right: OCPs from Rank–/–/Nfkb2+/+ and Rankl–/–/Nfkb2+/+ mice were treated with RANKL or TNF for com-
parison with Rank–/–/Nfkb2+/– and Rankl–/–/Nfkb2+/– mice to determine the effects of haploinsufficiency of Nfkb2. (C) Murine TNF (0.5 μg in 10 μl 
PBS) or 10 μl PBS was injected twice daily over the calvariae of Rank–/–/Nfkb2–/– or Rankl–/–/Nfkb2–/– mice and Rank–/– or Rankl–/– littermates. Top: 
TRAP-stained sections show numerous actively resorbing TRAP+ osteoclasts locally in calvarial sections (original magnification, ×20) from TNF-
injected Rank–/–/Nfkb2–/– or Rankl–/–/Nfkb2–/– mice. Bottom: Numbers and surface extent of osteoclasts (n = 3/genotype). Occasional osteoclasts 
induced by TNF from a Rank–/–/Nfkb2+/+ mouse are illustrated in the left panels. *P < 0.05 vs. single KO mice. (D) Left: Occasional binucleate 
(arrowhead), but mainly mononuclear (arrows), TRAP+ cells (left panel) formed beneath hypertrophic chondrocytes in the growth plate of the 
tibia of a Rank–/–/Nfkb2–/– mouse (original magnification, ×40), but not of Rank–/–/Nfkb2+/– littermates injected with TNF as described in C. Right: 
Osteoclast numbers (expressed per mm of length of growth plate) counted in representative sections. (E) Serum TRAP5b levels were tested 
with ELISA from TNF- or PBS-injected Rank–/–/Nfkb2–/– and Rank–/–/Nfkb2+/– mice (n = 3/group; *P < 0.05).
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TNF did not induce osteoclastogenesis (data not shown), presum-
ably because their increased density inhibits differentiation.
Although absence of Nfkb2 itself did not induce any osteoclasts 
in Rank–/– or Rankl–/– mice (PBS injection; data not shown), TNF 
induced many osteoclasts and resorption lacunae in the calvarial 
bones of the Rank–/–/Nfkb2–/– and Rankl–/–/Nfkb2–/– mice following 
local injection, associated with increased osteoclast and eroded sur-
faces (Figure 2, C and D). Only occasional osteoclasts were observed 
in the sections of TNF-injected Rankl–/– or Rank–/– mice, as reported 
previously (34). We also observed small numbers of TRAP+ osteo-
clasts in the long bones of the TNF-injected Rank–/–/Nfkb2–/– and 
Rankl–/–/Nfkb2–/– mice, although in contrast to those formed in the 
calvariae, these were mainly mononuclear cells located predomi-
nantly along the edge of the growth plates (Figure 2D) or in the 
centers of the physes. These cells had no effect on the increased 
bone volume in these osteopetrotic mice, presumably reflecting the 
short period of 5-day administration and their small size. To assess 
the possible function of these cells further, we measured serum 
TRAP5b levels. TRAP5b was undetectable in Rank–/–/Nfkb2+/–and 
Rank–/–/Nfkb2–/– mice and was slightly but significantly increased 
by TNF injection in Rank–/–/Nfkb2+/–mice (0.61 ± 0.25 U/l). These 
values were increased further in Rank–/–/Nfkb2–/– mice after TNF 
injection (1.77 ± 0.34 U/l; Figure 2E), confirming that osteoclasts 
induced by TNF in Rank–/– mice are functional and that NF-κB2 
deficiency enhances TNF-induced osteoclastogenesis and bone 
resorption in the mice lacking RANK signaling. TRAP5b was not 
observed in serum or osteoclasts in bone sections from vehicle-
treated Rank–/–/Nfkb2–/– or Rankl–/–/Nfkb2–/– mice, presumably 
because the concentration of endogenous TNF in the marrow cavi-
ties of these mice is low and not sufficiently high to induce OCP 
differentiation even in the absence of p100.
TNF-Tg mice lacking NF-κB p100 have more severe joint erosion and 
inflammation and systemic bone loss than TNF-Tg mice. To determine 
whether the absence of NF-κB2 would enhance joint erosion in 
TNF-Tg mice, we generated TNF-Tg/Nfkb2–/– mice and found that 
they developed joint deformity earlier than their TNF-Tg litter-
mates, that is, at 8 weeks versus 12 weeks of age (Figure 3A). At 
12 weeks of age, TNF-Tg/Nfkb2–/– mice had significantly increased 
areas of inflammation and osteoclast numbers in their forepaw 
joints assessed histomorphometrically (Figure 3B). However, we 
observed no significant difference in the types of inflammatory 
cells or in the appearance of the hyperplastic synoviocytes in the 
TNF-Tg/Nfkb2–/– mice compared with control mice upon histo-
logic analysis. FACS analysis showed that Nfkb2–/– mice had sig-
nificantly reduced numbers of B220+ B cells in their spleens and 
peripheral blood compared with Nfkb2+/– control mice. This fea-
ture was also present in TNF-Tg/Nfkb2–/– mice. In contrast, there 
was no difference in numbers of CD3+, CD4+, or CD8+ cells among 
the Nfkb2+/–, Nfkb2–/–, TNF-Tg/Nfkb2+/–, and TNF-Tg/Nfkb2–/– mice 
(data not shown).
Figure 3
Increased joint inflammation and osteoclastogenesis in TNF-Tg/Nfkb2–/– mice. (A) Age-related changes in clinically assessed joint deformation 
scores showed that joint deformation occurred earlier in the TNF-Tg/Nfkb2–/– mice (n = 7) than in their TNF-Tg/Nfkb2+/– littermates (n = 8). (B) 
Representative TRAP-stained sections (original magnification, ×20) from 12-week-old animals showed more severe wrist joint inflammation 
(green arrows) and more osteoclasts (yellow arrowheads) in a TNF-Tg/Nfkb2–/– mouse than in a TNF-Tg/Nfkb2+/– mouse. Histomorphometric 
analysis showed that the area of inflammatory tissue (upper panel) and osteoclast numbers (lower panel) were increased in the wrists of TNF-Tg/ 
Nfkb2–/– mice. *P < 0.05. (C) The percentage of cartilage eroded surface/total joint surface was measured in carpal bones of 6-week-old mice 
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TNF-Tg/Nfkb2–/– mice also had reduced long bone trabecular bone 
volume and cortical thickness compared with TNF-Tg/Nfkb2+/– mice 
(Figure 4A), which we confirmed morphometrically by 3-dimension-
al μCT imaging (Figure 4B). These TNF-Tg/Nfkb2–/– mice had lost 
almost all of their metaphyseal trabecular bone (Figure 4A), making 
it difficult to quantify and normalize osteoclast parameters histo-
morphometrically. However, in 6-week-old TNF-Tg/Nfkb2–/– mice, 
which had slightly but not significantly lower trabecular bone vol-
ume/tissue volume ratios than TNF-Tg mice, metaphyseal osteo-
clast numbers and surfaces were increased significantly (Figure 4C). 
These mice also had enhanced erosion of cartilage on their carpal 
bone joint surfaces compared with TNF-Tg/Nfkb2+/– littermates 
(Figure 3C). Bone formation rates assessed in undecalcified bone sec-
tions following double calcein labeling were similar in the TNF-Tg/ 
Nfkb2–/– and control mice (data not shown).
We next determined whether NF-κB2 deficiency influences human 
(Tg) or mouse serum TNF concentrations in these mice. Murine 
TNF values were similar among the groups in both 6- and 12-week-
old mice. NF-κB2 deficienc0y did not affect human TNF concentra-
tions in 6-week-old TNF-Tg mice, but mean values were significantly 
lower in TNF-Tg/Nfkb2–/– mice than in TNF-Tg/Nfkb2+/– littermates 
aged 12 weeks. We do not have an explanation for the reduction of 
TNF in these mice, but by this age TNF-Tg/Nfkb2–/–mice were much 
smaller than control mice, and some had already died. The cause of 
this early mortality requires further study.
TNF attenuates RANKL-induced osteoclastogenesis in vitro through 
NF-κB p100. Many cytokines, including RANKL, TNF, IL-1, and 
M-CSF, are involved in bone destruction in pathological condi-
tions. Of these, RANKL and TNF can support the final stages of 
OCP differentiation to osteoclasts. Therefore, it is important to 
study how TNF and RANKL work together to control osteoclas-
togenesis. A previous study reported that TNF synergizes with 
RANKL to stimulate osteoclastogenesis in vitro (35) when both 
cytokines are added at the beginning of the culture period. How-
ever, the synergistic effect occurs only in RANKL pretreated cells 
(43), which we confirmed (data not shown). We then used a dif-
Figure 4
More severe systemic bone loss in TNF-Tg/Nfkb2–/– mice. (A) Tibiae from 12-week-old Nfkb+/– (n = 4), Nfkb2–/– (n = 4), TNF-Tg/Nfkb2+/– (n = 7), 
and TNF-Tg/Nfkb2–/– mice (n = 8) were subjected to μCT scanning. Representative images (left) and data analysis (right) showed reduced tra-
becular bone volume and cortical bone thickness in TNF-Tg/Nfkb2–/– mice. (B) H&E-stained sections of tibiae (original magnification, ×2) showed 
decreased trabecular bone in the metaphyseal regions and thinner cortices (green arrow) in TNF-Tg/Nfkb2–/– mice. (C) TRAP-stained sections 
of 6-week-old mice showed increased numbers of osteoclasts in the secondary spongiosa of the proximal tibia of a TNF-Tg/Nfkb2–/– mouse (left 
panels), which was confirmed by histomorphometric analysis (right panels). BV/TV, bone volume/tissue volume. *P < 0.05 vs. TNF-Tg/Nfkb2+/– 
mice. Original magnification, ×2 (top), ×40 (bottom).
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ferent osteoclastogenesis protocol in which spleen cells are first 
cultured with M-CSF for 3 days, to enrich for OCPs, and then 
TNF with or without RANKL was added to these cells for a fur-
ther 2–3 days. TNF inhibited RANKL-induced osteoclastogenesis 
in a dose-dependent (0.8–20 ng/ml) manner (Figure 5A) at both 
optimal (10 ng/ml) and low (1 ng/ml) RANKL concentrations. 
Of note, although the number of osteoclasts induced by 1 ng/ml 
RANKL was just slightly less than the optimal dose, osteoclasts 
formed later and were smaller in these cultures, and this was evi-
dent as a reduced osteoclast area (Figure 5A). TNF alone (4 and 
20 ng/ml) induced small numbers of osteoclasts in the absence of 
RANKL, as expected. In these experiments, NF-κB p100 levels in 
WT OCPs treated with TNF (20 ng/ml) plus RANKL (10 ng/ml) 
were significantly higher than in cells treated with RANKL alone, 
but the levels were less than those in cells treated with TNF alone, 
presumably because RANKL induced some proteasomal degrada-
tion of p100 through NIK, despite the inhibitory effect of TNF 
(Figure 5A). Accordingly, p52 expression was higher in the cultures 
of RANKL plus TNF than in those treated with TNF alone.
We next treated WT and Nfkb2–/– OCPs with low but effective doses 
of TNF with or without RANKL and found that TNF (4 ng/ml) sig-
nificantly reduced osteoclastogenesis induced by RANKL (1 ng/ml) 
in WT cultures but had no inhibitory effect in Nfkb2–/– cultures in 
which both cytokines had nearly maximal osteoclastogenic effects 
either alone or in combination (Figure 5B), confirming that NF-κB 
p100 mediates this TNF-induced inhibition of osteoclastogenesis.
TNF induction of NF-κB p100 and inhibition of osteoclastogenesis is 
mediated by TRAF3. To determine the mechanism whereby TNF-
induced NF-κB p100 accumulation limits osteoclastogenesis, 
we examined the effects of TNF and RANKL on the expression 
of TRAFs in OCPs. TRAFs directly interact with TNF superfam-
ily receptors and trigger intracellular signaling events, including 
NIK-mediated processing of p100 to p52 (7). In addition, TRAF2 
and -3 can also mediate proteasomal degradation of signal-
ing molecules (26, 27). We found that neither RANKL nor TNF 
affected the mRNA expression levels of TRAF3 or -6 (data not 
shown). However, both RANKL and TNF increased the protein 
levels of TRAF6, which activates NIK, and this is consistent with 
our observation that both cytokines slightly elevated NIK pro-
tein levels (Figure 6A). Importantly, TNF induced significantly 
higher levels of TRAF3, paralleling the elevated NF-κB p100 levels 
(Figure 6A). RANKL alone slightly reduced TRAF3, but it signifi-
cantly decreased TNF-induced TRAF3 protein levels, which was 
matched by relatively lower levels of p100 (Figure 6A). Neither 
TNF nor RANKL affected protein levels of TRAF2 or -5 signifi-
cantly in these cultures (data not shown).
To determine how TRAF3 is regulated by TNF, we added cyclo-
heximide to the cultures of WT OCPs treated with PBS, RANKL, 
or TNF to prevent the synthesis of new protein and thus observe 
degradation of TRAF3 by Western blot. RANKL accelerated the 
degradation of TRAF3, starting at 1 hour and continuing through 
4 hours (Figure 6B). In contrast, TNF prevented TRAF3 degrada-
tion, suggesting that TNF induction of TRAF3 results in the accu-
mulation of NF-κB p100 and inhibition of osteoclastogenesis. 
To test this possibility, WT OCPs were transfected with TRAF3 
siRNA to examine its effects on expression of NIK and p100 and 
on osteoclastogenesis. Transfection of TRAF3 siRNA reduced 
TRAF3 protein levels, and this was associated with higher levels 
of NIK and lower p100 levels in the TNF-treated cells compared 
with control siRNA-treated cells (Figure 6C). Surprisingly, we did 
not detect a significant change in p52 levels in either cytoplas-
mic or nuclear extracts using TRAF3 siRNA. This was a consis-
tent finding that will require further study to determine whether 
TRAF3 also regulates p52 expression. TRAF3 siRNA significantly 
increased TNF-induced nuclear and cytoplasmic RelB, the typi-
cal partner of p52, which was reported recently to be involved 
in RANKL-induced osteoclastogenesis in vitro (44). Consistent 
with these results, TRAF3 siRNA significantly increased TNF-
induced osteoclastogenesis (Figure 6D), although it had no effect 
on osteoclast numbers in RANKL-treated cultures, presumably 
because RANKL can degrade TRAF3 and TRAF3 siRNA likely 
would not have an additional effect on TRAF3 degradation. Of 
note, inhibition of TRAF3 attenuated the TNF-induced reduction 
of RANKL-mediated osteoclastogenesis.
Figure 5
TNF-induced NF-κB p100 inhibits RANKL-
induced osteoclastogenesis. (A) WT mouse 
spleen cells were cultured with M-CSF for 3 
days, and RANKL and/or TNF were added at 
the indicated doses for 2 more days to gener-
ate osteoclasts. Top: TNF dose-dependently 
inhibited RANKL-induced osteoclastogenesis, 
assessed by osteoclast number (black bars) and 
area (red bars) per well. Bottom: The protein 
levels of NF-κB p100 and p52 were analyzed 
with Western blot and assessed in whole-cell 
lysates extracted from RANKL-treated (10 ng/
ml) and/or TNF-treated (20 ng/ml) WT mouse 
OCPs at 8 hours. (B) The inhibitory effect of 
TNF on RANKL-induced osteoclastogenesis 
was abolished in Nfkb2–/– OCPs (*P < 0.05 vs. 
RANKL treatment alone; 4 wells/group). The 
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Discussion
There is compelling evidence for a strong proresorptive function 
of TNF, which has long been implicated in the pathogenesis of 
bone loss and inflammation in a variety of common bone diseases 
(1, 4, 10, 45) and, more recently, cherubism (46). TNF induces bone 
loss by indirect and direct mechanisms, including promotion of 
RANKL expression by accessory cells (4, 6) and induction of OCP 
proliferation and differentiation (47). These cells can then secrete 
proinflammatory osteoclastogenic cytokines and thus lead to the 
initiation of autocrine and paracrine self-amplifying cycles that 
increase bone loss (48). A pivotal role of TNF in pathologic bone 
loss is evidenced by the efficacy of anti-TNF therapy to limit dis-
ease progression in approximately 70% of patients with RA (49) 
and to reduce bone erosion soon after menopause (2).
Despite this evidence, TNF does not induce osteoclast forma-
tion when administered in vivo to Rankl–/– or Rank–/– mice (34), 
although it can induce osteoclastogenesis directly from Rank–/– 
OCPs in vitro when costimulated with TGF-β (18), leading some 
to suggest that prior priming of OCPs by RANKL (35) or IL-1 
expression by stromal cells (50) is necessary for TNF-induced 
bone resorption. Here we explain these discrepant findings by 
showing that locally injected TNF fails to induce osteoclasto-
genesis in Rankl–/– and Rank–/– mice because of the inhibitory 
effects NF-κB p100 and provide conclusive evidence that TNF 
can induce osteoclastogenesis in these mice when they are defi-
cient also in NF-κB p100.
The osteoclastogenesis induced locally by TNF in calvariae of 
Rank–/–/Nfkb2–/– or Rankl–/–/Nfkb2–/– mice was associated with 
systemic induction of small numbers of mainly mononuclear 
TRAP+ cells along epiphyseal growth plates. We have reported that 
RANKL induced by BMP2 in hypertrophic chondrocytes at the 
growth plate attracts OCPs to this site to remove bone (51), which 
is formed rapidly and must be removed to prevent development 
of osteopetrosis during development. Our findings suggest that 
the administered TNF directed OCPs to this site independently 
of RANKL. However, further studies are required to determine 
whether this was by a direct or indirect mechanism and whether 
TNF induces expression of chemokines here as it also does to 
attract circulating OCPs to inflamed joints (52).
Our observation that TRAP+ cells do not form in untreated 
Rank–/–/Nfkb2–/– or Rankl–/–/Nfkb2–/– mice is important because it 
suggests that TNF levels at the growth plate during endochondral 
ossification are too low to induce OCP differentiation to osteo-
clasts and that TNF does not have an important positive or nega-
tive regulatory role in this physiologic process. However, TRAP5b 
released from osteoclasts induced by locally injected TNF resulted 
in slightly increased serum TRAP5b levels in Rank–/–/Nfkb2+/– mice 
and significantly increased levels in Rank–/–/Nfkb2–/– mice, sup-
porting our conclusion that TNF-induced resorption in patholog-
ic bone remodeling is attenuated by NF-κB2. The inhibitory role 
for NF-κB p100 in osteoclastogenesis is further supported by the 
development of erosive arthritis and systemic bone loss in TNF-Tg/ 
Nfkb2–/– mice much earlier than TNF-Tg/Nfkb2+/– littermates.
The reports that TNF induces RANKL expression in the joints 
of TNF-Tg mice (53, 54) led us to consider whether NF-κB p100 
also limits RANKL-induced resorption in TNF-Tg mice. Indeed, 
we found that TNF limits RANKL-induced differentiation of WT 
OCPs in vitro through induced NF-κB p100 and that retroviral 
expression of NF-κB2 in OCPs reduced RANKL-induced osteoclas-
togenesis. Interestingly, inhibition of osteoclastogenesis alone does 
not prevent TNF-induced synovial inflammation, since TNF-Tg/ 
c-Fos–/– hybrid mice lack osteoclasts and joint destruction but still 
have synovial inflammation (55). Therefore, inhibition of osteo-
clasts alone is likely to have a limited role in the treatment of RA. 
Unexpectedly and importantly, we found that the TNF-Tg/Nfkb2–/– 
mice also had significantly increased inflammation in their joints, 
indicating that NF-κB p100 limits not only OCP differentiation 
Figure 6
TNF-induced TRAF3 negatively regulates osteoclastogenesis through 
NIK. (A) WT mouse OCPs were treated with RANKL and/or TNF for 
8 hours, and whole-cell lysate protein was extracted and subjected to 
Western blotting for TRAF3, TRAF6, NIK, and NF-κB p100 and p52. 
(B) Cycloheximide (10 μM) was added to WT mouse OCPs treated 
with RANKL (10 ng/ml), TNF (20 ng/ml), or PBS control for the indi-
cated times. Whole-cell lysates were subjected to Western blotting for 
TRAF3. (C) WT mouse OCPs were transfected with TRAF3 siRNA or a 
nonspecific control siRNA for 8 hours. The cells were treated with TNF 
(20 ng/ml) or PBS for an additional 8 hours. Whole-cell lysates were 
subjected to Western blotting to determine the levels of cytoplasmic 
TRAF3, NIK, and NF-κB p100 (left panel) and either nuclear p52 or cyto-
plasmic p100 and RelB (right panels). (D) TRAF3 siRNA–transfected 
cells were treated with TNF and/or RANKL (10 ng/ml) for 3 days in the 
presence of M-CSF to generate osteoclasts. *P < 0.05 vs. control).
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but also the number of inflammatory cells attracted to the joints 
of the mice in response to TNF.
Deficiency of Nfkb2 dramatically accelerated TNF-Tg–induced 
arthritic bone erosion and inflammation, but this was not associat-
ed with an increase in their serum concentrations of either human 
or murine TNF, suggesting that deficiency of NF-κB p100 could 
be associated with more severe joint inflammation in RA patients. 
This might be of great importance in the clinical setting of arthritis, 
but it will require further study to determine whether there are vari-
ations in the transcription, function, or degradation of p100 that 
could increase the susceptibility of RA patients to TNF. Similarly, 
further study is also required to determine the precise mechanism 
whereby p100 limits the inflammatory infiltration, and specifically 
whether NF-κB p100 can be further increased locally, for example 
by using local adenoviral gene delivery, to inhibit inflammation 
and bone resorption in these mice.
TNF stimulates Nfkb2 mRNA expression through the canonical 
NF-κB p65/p50 pathway to increase the total amount of NF-κB 
p100 transcripts and protein (24). At the same time, TNF activates 
the noncanonical pathway leading to some processing of NF-κB 
p100 to NF-κB p52 (24), but the molecular mechanisms have not 
been identified. We found that TNF stabilized TRAF3, resulting in 
its accumulation in OCPs in parallel with p100 levels, a finding that, 
to our knowledge, has not been reported previously in any cell type. 
This could account for limited NF-κB p100 degradation by NIK 
because TRAF3 induces degradation of NIK in B cells (26, 27). These 
effects of TNF differ from those of RANKL, which does not increase 
TRAF3 protein levels and activates NIK to induce efficient process-
ing of p100 to p52 (23). TRAF3 negatively regulates p100 process-
ing to p52 by promoting proteasomal degradation of NIK through 
its physical association with the TRAF3 binding motif in NIK (25, 
26). Loss of TRAF3 results in accumulation of NIK and constitutive 
p100 processing in TRAF3–/– B cells (25, 28). TRAF6, which mediates 
RANKL/RANK-activated canonical NF-κB signaling, cannot associ-
ate with NIK directly and therefore does not inhibit it (56).
TRAF3 siRNA reduced TRAF3 protein levels in WT OCPs associ-
ated with increased NIK levels and p100 processing, which released 
more RelB to go to nuclei in the cells and increased osteoclasto-
genesis. TNF induced only a slight increase NIK levels in the OCPs, 
but this in part may reflect the difficulty in detecting low levels of 
NIK in cells with currently available reagents (57) and the fact that 
most published studies were able to detect changes in NIK levels 
only when NIK was overexpressed (26, 57). Although some inves-
tigators have suggested that TRAF2 is required for TNF-induced 
osteoclastogenesis (14) and TRAF5 is involved in both RANKL- 
and TNF-induced osteoclastogenesis (15), others have found that 
TRAF2- or TRAF5-deficient OCPs can differentiate into mature 
osteoclasts in response to TNF (18). TRAF2 functions along with 
TRAF3 in B cells to degrade NIK (26). However, TRAF2, -5, and -6 
do not appear to play a major role in p100 processing in OCPs, 
based on our observation that their protein levels are similar in 
TNF- and RANKL-treated cells. Currently, we do not know the pre-
cise molecular mechanism by which TNF increases TRAF3 protein 
levels in OCPs. TNF does not affect TRAF3 mRNA, but it clearly 
prevents its degradation. It will be important to work this out in 
further studies, since stabilization of TRAF3 could potentially be 
one mechanism to limit bone resorption and possibly inflamma-
tion in inflammatory arthritis.
Our findings, coupled with the fact that TNF, RANKL, and IL-1 
can all induce TNF expression by OCPs (40), support an impor-
tant direct role for TNF in osteoclastogenesis in conditions such 
as RA and postmenopausal osteoporosis, in which production of 
these cytokines is increased beyond physiologic levels (58), while 
physiologic levels of the cytokines are unable to induce osteoclas-
togenesis in Rankl–/– and Rank–/– mice. However, they also identify 
an important negative regulatory role for TNF to limit its effects 
and those of RANKL. Given the important role that TNF has in 
inducing inflammation and bone destruction in many common 
bone diseases, we propose that this negative regulatory role for 
TNF in limiting bone resorption and inflammation might be har-
nessed to help reduce the high morbidity associated with many 
common diseases in which its expression is increased. These might 
include increasing the stability or expression of p100 or TRAF3 
and inhibiting NIK in OCPs.
Methods
Reagents and animals. Recombinant M-CSF, RANKL, and TNF for cell cul-
tures were from R&D Systems. TNF for in vivo experiments was a gift from 
Amgen. Cycloheximide was from Calbiochem. The sources of Nfkb2–/– 
(C57BL/6 × 129) (11, 31), human TNF-Tg (CBA × C57BL/6, TNF-Tg line 
3647) (40), Rankl–/– (C57BL/6) (59), and Rank–/– (C57BL/6) mice (30) were 
described previously. Nfkb2–/– mice were crossed with Rank+/– or Rankl+/– 
mice to generate Nfkb2+/–/Rankl–/– or Nfkb+/–/Rankl–/– and Nfkb2–/–/Rank–/– 
or Nfkb2–/–/Rank–/– mice. Nfkb2–/– mice were crossed with TNF-Tg mice to 
generate TNF-Tg/Nfkb2+/– and TNF-Tg/Nfkb2–/– mice. The University of 
Rochester Medical Center Institutional Animal Care and Use Committee 
approved all animal studies.
Osteoclast formation and functional assays. Spleen cells (1.75 × 105/well in 
96-well plates) from WT mice were cultured with M-CSF (10 ng/ml) for 
2–3 days in α-MEM with 10% FBS to enrich for OCPs. To generate osteo-
clasts from Rankl–/– and Rank–/– mice in response to TNF, we seeded about 
1/5th the number of splenocytes we used from WT cells. This allowed 
us to obtain comparable numbers of OCPs after 3-day treatment with 
M-CSF and to induce osteoclastogenesis from these splenocytes. OCPs 
were treated with RANKL (10 ng/ml) and/or TNF (20 ng/ml) for 2–3 days 
to generate mature osteoclasts. To test the role of NF-κB p100 on OCP 
differentiation, Nfkb2–/– and WT littermate OCPs were infected with ret-
roviral supernatants of p100, p52, or GFP controls for 2 days and then 
treated with TNF or RANKL for 2–4 days, as described previously (11, 
40). To test the role of TRAF3 in TNF-induced osteoclastogenesis, WT 
OCPs were transfected with a pool of 3 TRAF3-specific siRNAs (Santa 
Cruz Biotechnology Inc.) or nonspecific control siRNA for 8 hours, and 
then treated with TNF and/or RANKL for 3–4 days. For functional assays 
of osteoclasts, spleen cells were seeded in 96-well plates containing bovine 
cortical bone slices and cultured with TNF or RANKL, and resorption pit 
formation was assessed, as reported previously (11, 40). Cells were costim-
ulated with M-CSF in all experiments.
Western blot analysis. Whole-cell lysate protein from OCPs or mature 
osteoclasts and nuclear protein from TRAF3 siRNA–transfected OCPs cul-
tured in 60- or 100-mm dishes were prepared as described previously (11). 
Lysates (10 μg) were loaded in 10% SDS-PAGE gels and immunoblotted 
with antibodies to NF-κB1, NF-κB2, p65, RelB, TRAF2, TRAF3, TRAF5, 
TRAF6, and NIK (Santa Cruz Biotechnology Inc.) or mouse actin (Sigma-
Aldrich). To test for degradation of the TRAF3 protein, 10 μM CHX was 
added to WT OCPs treated with RANKL (10 ng/ml), TNF (20 ng/ml), or 
PBS control to inhibit new protein synthesis, and whole-cell lysates were 
subjected to Western blot for TRAF3.
TNF-induced osteoclastogenesis in vivo. TNF (0.5 μg) or PBS was injected over 
the calvariae of 3- to 4-week-old mice twice daily for 5 days. Mice were sac-
rificed on day 6, and calvariae and hind limbs were fixed in 10% formalin 
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and decalcified with 10% EDTA. TRAP activity was assessed in paraffin-
embedded sections, as described previously (11, 40). Osteoclast numbers 
and surfaces and eroded surfaces were measured using an Osteometrics 
system, as described previously (11, 40).
Evaluation of arthritis and osteoporosis. Although the features of arthritis in 
the commonly used 197 line of TNF-Tg mice include paw swelling, reduced 
strength, and deformation (60), we found that the only easily identifiable, 
reproducible parameter in our 3647 line of TNF-Tg mice, which carry only 
1 copy of the TNF transgene (40), is paw and finger deformation, includ-
ing atrophy. We generated a deformation score (0, no deformation; 1, mild 
deformation; 2, moderate deformation; 3, severe deformation; 4, very 
severe deformation), which was evaluated once each week to determine 
the clinical progress of arthritis. Each forepaw and hindpaw was evaluated 
separately, and the deformation score was calculated as the sum of the 
4 paws. Mice were sacrificed in a CO2 container. Right tibiae were collected 
for μCT scanning to evaluate cortical and trabecular bone volume. Left 
tibiae and forepaws were fixed, decalcified, and processed through paraffin 
for histologic evaluation of osteoclasts and arthritis, including inflamma-
tory tissue area and carpal bone eroded cartilage surface.
ELISA. Mouse TRAP5b (Immunodiagnostic Systems) were assessed in 
serum collected from TNF- or PBS-injected Nfkb2–/– and Rank–/–/Nfkb2–/– 
mice and their littermate controls, and human and mouse TNF (eBiosci-
ence) were determined in serum of TNF-Tg/Nfkb2–/– mice and their litter-
mate controls according to the manufacturer’s instructions
Statistics. All results are given as mean ± SD. Comparisons between 
2 groups were analyzed using the 2-tailed unpaired Student’s t test. One-
way ANOVA and Dunnett’s post-hoc multiple comparisons were used for 
comparisons among 3 or more groups. P values less than 0.05 were consid-
ered statistically significant.
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Chloroquine reduces osteoclastogenesis  
in murine osteoporosis by preventing  
TRAF3 degradation
Yan Xiu,1 Hao Xu,1 Chen Zhao,1 Jinbo Li,1 Yoshikazu Morita,1 Zhenqiang Yao,1,2  
Lianping Xing,1,2 and Brendan F. Boyce1,2
1Department of Pathology and Laboratory Medicine, and 2Center for Musculoskeletal Research,  
University of Rochester Medical Center, Rochester, New York, USA.
The cytokines RANKL and TNF activate NF-κB signaling in osteoclast precursors (OCPs) to induce osteoclast 
(OC) formation. Conversely, TNF can limit OC formation through NF-κB p100, which acts as an inhibitor, 
and TNF receptor–associated receptor 3 (TRAF3); however, a role for TRAF3 in RANKL-mediated OC forma-
tion is unknown. We found that TRAF3 limits RANKL-induced osteoclastogenesis by suppressing canoni-
cal and noncanonical NF-κB signaling. Conditional OC-specific Traf3-KO (cKO) mice had mild osteoporosis 
and increased OC formation. RANKL induced TRAF3 degradation via the lysosome/autophagy system. The 
autophagy/lysosome inhibitor chloroquine reduced RANKL-induced OC formation and function by increas-
ing TRAF3 expression in OCPs in vitro and in vivo. Although chloroquine had no effect on basal bone resorp-
tion, it inhibited parathyroid hormone– and ovariectomy-induced OC activation in WT, but not cKO, mice. 
Deletion of the transcription factor gene Relb resulted in increased TRAF3 expression in OCPs, which was 
associated with decreased RANKL-induced TRAF3 degradation. RelB directly increased expression of BECN1, 
a key autophagy regulator, by binding to its promoter. These data indicate that autophagic/lysosomal degrada-
tion of TRAF3 is an important step in RANKL-induced NF-κB activation in OCPs. Furthermore, treatments 
that increase TRAF3 levels in OCPs, including pharmacological inhibition of its degradation with compounds 
such as chloroquine, may limit bone destruction in common bone diseases.
Introduction
Bone homeostasis is maintained by a delicate balance between 
osteoclastic bone resorption and osteoblastic bone formation. 
Disruption of this balance with a higher rate of bone resorption 
occurs in metabolic and inflammatory bone disorders, such as 
postmenopausal osteoporosis and RA, resulting in increased risk 
of fracture and joint destruction, respectively (1). Osteoclasts 
(OCs) resorb bone in physiologic and pathologic conditions (2), 
and their formation and activity are increased in osteoporosis 
and RA as a result of increased production of proinflammatory 
cytokines, such as TNF and RANKL, which activate NF-κB (3).
NF-κB transcriptional factors regulate immune and numerous 
other cellular responses and play critical roles in skeletal development, 
endochondral ossification, OC and osteoblast functions, and com-
mon bone diseases (4). In mammals, there are 5 NF-κB family mem-
bers: RelA (p65), RelB, and c-Rel, and the precursor proteins NF-κB1 
(p105) and NF-κB2 (p100), which are processed into p50 and p52, 
respectively (5). Canonical NF-κB signals through IKKβ and NF-κB 
essential modulator (NEMO), leading to phosphorylation of IκBα 
and translocation of p65/p50 heterodimers into nuclei in response 
to cytokines; noncanonical NF-κB stimulates IKKα-mediated phos-
phorylation of p100 through activation of NF-κB–inducing kinase 
(NIK) and leads to processing of p100 to p52 and release of RelB/p52 
complexes. Noncanonical signaling is induced by TNF family mem-
bers, including RANKL, CD40 ligand, BAFF, and lymphotoxin-β (5).
A role for NF-κB signaling in bone was first identified in reports 
of defective cytokine-induced osteoclastogenesis in NF-κB1/2 
double-KO mice (6, 7), but NF-κB–induced osteoclastogenesis 
by cytokines remains incompletely understood. NF-κB is a piv-
otal regulator of RANKL- and TNF-induced osteoclast precursor 
(OCP) differentiation and is activated via TNF receptor–associat-
ed factors (TRAFs), which share a common C-terminal structural 
TRAF domain that mediates oligomerization and receptor bind-
ing. RANKL activates both canonical and noncanonical NF-κB sig-
naling in OCPs through TRAF6 and NIK, leading to activation of 
IKKβ and IKKα, respectively (4, 8), and to stimulatory and inhibi-
tory signaling in the cells (5). Similarly, TNF stimulates OC for-
mation directly, but it also limits RANKL-and TNF-mediated OC 
formation by increasing cellular levels of NF-κB p100 (9) and other 
inhibitory proteins (4, 10). TNF typically induces fewer OCs than 
RANKL in vitro when WT OCPs are used, but it induces similar 
numbers of OCs from Nfkb2–/– OCPs as RANKL and also robust 
OC formation in Rankl–/– and Rank–/– mice deficient in p100. 
These findings indicate that p100 inhibits TNF-induced osteo-
clastogenesis by a TNF receptor–associated receptor 3–dependent 
(TRAF3-dependent) mechanism (9), but the mechanism whereby 
TRAF3 inhibits osteoclastogenesis has been unclear, although it 
does involve NIK degradation (11).
Apart from their role as adaptor proteins, TRAFs also act as E3 
ubiquitin ligases, a function crucial for the activation of NF-κB 
signaling (12). Overexpression and genetic studies identified 
positive activation roles for TRAF2, -5, and -6 in canonical NF-κB 
signaling (13–15). However, study of the role of TRAF3 in NF-κB 
signaling has been difficult because most Traf3-KO mice die within 
the first week after birth (16). A report that TRAF3 is constitutively 
bound to NIK and mediates NIK ubiquitination and degradation 
in B cells identified a critical negative regulatory role of TRAF3 
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in noncanonical signaling (17). Furthermore, Traf3–/– mice have 
marked B cell accumulation of NIK, and compound deficiency of 
NF-κB p100 rescued their early postnatal lethality (18). Although 
deficiency of NIK or its downstream signaling molecule, RelB, 
appears to have little effect on basal bone homeostasis, Nik–/– 
and RelB–/– mice have defective osteoclastogenesis in response to 
pathologic osteolysis in vivo (8, 19). Additionally, transgenic mice 
with OC-targeted overexpression of a mutant NIK lacking the 
TRAF3-binding domain have decreased bone mass and increased 
bone erosion in a serum-transfer model of RA (11). Collectively, 
these data indicate that NIK and TRAF3 play important negative 
regulatory roles in noncanonical NF-κB signaling.
Results
Mice with OC-specific deletion of TRAF3 have increased osteoclastogenesis 
and osteoporosis, mediated by increased canonical and noncanonical NF-κB 
signaling. Culture of WT BM cells with M-CSF for 2 days followed by 
RANKL typically results in microscopically recognizable OCs 4 days 
later (data not shown). Expression of NFATc1, the master regula-
tor of osteoclastogenesis (4), increased significantly 4 days after 
RANKL treatment, while TRAF3 protein levels decreased progres-
sively (Figure 1A) and TRAF3 mRNA levels remained unchanged 
(Supplemental Figure 1A; supplemental material available online 
with this article; doi:10.1172/JCI66947DS1). We generated a 
TRAF3 retroviral expression vector by inserting a human TRAF3 
cDNA fragment into a pMX-IRES-GFP retroviral expression vec-
tor. After transfecting pMX-IRES-GFP or pMX-TRAF3-IRES-GFP 
vectors into PlatE packaging cells using Fugene 6, virus superna-
tants were collected and added to WT OCPs generated by cultur-
ing BM cells with M-CSF for 3 days (20). Approximately 60%–70% 
infection efficiency was confirmed in all samples by flow cytometry 
(data not shown). GFP+ cells were sorted and cultured with M-CSF 
plus RANKL. Numerous tartrate-resistant acid phosphatase–posi-
tive (TRAP+) OCs were observed in pMX-GFP–infected cells, but 
OC formation was decreased approximately 3-fold in pMX-TRAF3-
IRES-GFP–infected cells (Figure 1B).
We next generated 2 new lines of mice with TRAF3 expression 
targeted to OC lineage cells: Traf3f/f;cathepsin Kcre (which we call 
C-cKO) and Traf3f/f;lysozyme Mcre (L-cKO) mice, and found that 
C-cKO BM cells cultured with M-CSF plus RANKL for 3 days 
formed TRAP+ multinucleated OCs, but WT cultures did not 
(Supplemental Figure 1B). Although C-cKO and WT cells had 
formed similar numbers of OCs 2 days later, C-cKO OCs were 
larger, resulting in significantly increased OC area (Supplemental 
Figure 1B) and suggesting that TRAF3 negatively regulates osteo-
clastogenesis and perhaps fusion. We observed similar findings in 
cells from L-cKO mice (data not shown). L-cKO and C-cKO mice 
have normal bone phenotypes, similar to WT mice (Supplemen-
tal Figure 1C). Thus, we used Cre littermates as WT controls for 
future experiments. When we used RANKL at low concentrations 
(≤5 μg/ml), WT OCs generally formed later and were smaller (data 
not shown), but C-cKO cells in these conditions had greater OC-
forming ability than WT cells (Figure 1C) and increased resorption 
pit areas when cultured on bone slices with M-CSF plus RANKL 
for 9 days, although OC numbers were similar by this time (Sup-
plemental Figure 2). We also cultured these cells on 6-well plates 
for 6 days, resuspended the cells with 0.25% trypsin/EDTA, and 
replated equal numbers of OCs on bone slices in 96-well plates 
for an additional 4 days. Resorption pit area and numbers were 
similar between C-cKO and WT OCs (data not shown), consistent 
with TRAF3 having its major role in RANKL-induced OC forma-
tion rather than function.
Importantly, we found that 2-month-old C-cKO mice have mild 
osteoporosis, as indicated by significantly reduced tibial trabecular 
bone volume (BV) (Figure 1D), trabecular number, and thickness, 
with mean values for trabecular connectivity and separation being 
numerically lower and higher, respectively, but these did not reach 
statistical significance (Supplemental Figure 1D). These were 
associated with increased OC numbers and surfaces (Figure 1E), 
compared with control mice.
Previous TRAF3 overexpression studies in B cells suggested 
that TRAF3 suppresses canonical NF-κB activation (21). To test 
the mechanism by which TRAF3 inhibits osteoclastogenesis, we 
examined canonical and noncanonical protein levels in OCPs 
overexpressing TRAF3 in response to RANKL and observed mark-
edly increased expression of NFATc1, NIK, p52, RelB, and RelA 
in pMX-GFP–infected OCPs (Figure 1F). In RANKL-treated pMX-
TRAF3-IRES-GFP–infected OCPs, induction of NFATc1, NIK, 
RelA, and RelB was reduced compared with GFP-infected controls, 
accompanied by decreased p100 to p52 processing (Figure 1F). 
Consistent with these findings, we observed increased RelA, RelB, 
and NIK levels and increased p100 to p52 processing in L-cKO 
OCPs, even without RANKL stimulation (Figure 1G). Further 
addition of RANKL did not affect expression levels of these mol-
ecules, presumably reflecting prior exposure of primary cells to 
RANKL in vivo or the effects of constitutively active NIK. Fur-
thermore, RelA nuclear translocation is increased in L-cKO OCPs 
under basal and RANKL-induced conditions (Figure 1H), indicat-
ing enhanced NF-κB signaling. We observed similar findings in 
C-cKO cells (data not shown).
TRAF3 ring finger domain is required for RANKL-induced TRAF3 
degradation through a lysosome/autophagosome-dependent mechanism. 
TRAF3 contains 3 major domains: a ring finger (RF), required for 
suppression of NIK (22); a zinc finger (ZF), required for NF-κB 
activation (23); and a TRAF domain, which binds degradation-
targeted proteins, such as NIK (22). We overexpressed RANK and 
TRAF3 in 293T cells to examine which TRAF3 domain or domains 
are required for its degradation. TRAF3 protein levels decreased 
significantly in these cells with serum starvation, which can induce 
autophagy in many cell types (24), and with RANKL treatment 
(Figure 2A). In contrast, TRAF3 accumulated with serum starva-
tion or RANKL in cells expressing TRAF3 deletion mutants lack-
ing either the RF or the RF and ZF domains. In contrast, with 
serum-starvation or RANKL treatment, TRAF3 levels decreased 
slightly in cells with the TRAF domain deleted. We observed simi-
lar findings in L-cKO OCPs infected with WT and mutant TRAF3 
retroviruses. These findings contrast with a report that a NIK 
mutant lacking the TRAF3-binding domain is constitutively active 
(11). They suggest that the TRAF3-binding domain of NIK is nec-
essary for NIK proteasomal degradation, while the TRAF domain 
of TRAF3 is not essential for TRAF3 degradation.
CD40 or BAFF-R engagement in B cells induces rapid, protea-
some-dependent TRAF3 degradation (25). To determine whether 
RANKL induces TRAF3 ubiquitination and degradation in OCPs, 
we incubated endogenous TRAF3 proteins with a high-binding 
affinity ubiquitin matrix and captured ubiquitinated proteins 
using an anti-TRAF3 Ab. RANKL markedly increased TRAF3 
ubiquitination (Figure 2B), which can occur in proteasomes, lyso-
somes, and autophagosomes in mammalian cells (26). To examine 
the mechanism involved, we pretreated WT OCPs with the lyso-
151
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 124   Number 1   January 2014 299
Figure 1
Mice with OC-specific deletion of TRAF3 have increased osteoclastogenesis and mild osteoporosis mediated by increased canonical and nonca-
nonical NF-κB signaling. (A) WBs of TRAF3 and NFATc1 expression in WT BM cells treated with M-CSF plus RANKL. Lanes were run on the same 
gel, but were noncontiguous. (B) OCs formed from FACSAria-sorted WT OCPs infected with GFP or TRAF3-IRES-GFP (TRAF3-GFP) retroviruses 
treated with RANKL. Original magnification, ×10. *OC centers. TRAP+ OCs were counted. (C) BM-derived C-cKO or WT cells cultured with RANKL. 
*P < 0.05. (D) Representative tibial μCT scans from 2-month-old CatK-Cre or C-cKO mice. *P < 0.05. (E) Representative TRAP-stained tibial sec-
tions and bone histomorphometry from 2-month-old WT or C-cKO mice; boxed areas in lower images. Scale bars: 500 μm (upper panels); 50 μm 
(lower panels). OcS/BS, OC surface/bone surface (%). *P < 0.05. (F) WBs of whole cell lysates of WT OCPs infected with GFP or TRAF3-IRES-
GFP retroviruses and cultured with RANKL for 5 days. (G and H) WBs of WT and L-cKO OCPs treated with RANKL for 48 hours. Cyto, cytoplasmic.
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some inhibitors chloroquine (CQ) for 6 hours or NH4Cl for 1 hour 
or with the proteasome inhibitor MG132 for 4 hours, followed by 
RANKL, and evaluated the extent of TRAF3 degradation by West-
ern blot (WB). Pretreatment with either CQ or NH4Cl, but not 
MG132, markedly increased TRAF3 levels in response to RANKL 
(Figure 2C). To confirm that MG132 functioned effectively as a 
proteasome inhibitor (27), we treated WT OCPs with RANKL plus 
MG132 for 15 and 30 minutes and found that compared with 
DMSO control, MG132 blocked RANKL-induced IκBα degrada-
tion (Figure 2C).
Figure 2
RANKL-induced TRAF3 degradation is lysosome mediated. (A) 293T cells transfected with HA-tagged WT or mutant TRAF3 constructs. L-cKO 
BM-derived OCPs infected with WT or mutant pMX-TRAF3 viruses were serum deprived or treated with RANKL for 8 hours. (B) Ubiquitinated 
(Ub) proteins from whole cell lysates of RANKL-treated (2 hours) WT OCPs using UbiQapture-Q Matrix blotted with anti-TRAF3 Ab. (C) WT OCPs 
pretreated with NH4Cl (50 mM) for 1 hour, CQ (50 mM) for 6 hours, or MG132 (20 mM) for 4 hours were treated with RANKL for 8 hours. For IκBα, 
WT OCPs were treated with DMSO or MG132 with or without RANKL for indicated times. Lanes were run on the same gel, but were noncontigu-
ous in B and C. (D) WT OCPs pretreated with bafilomycin (Bafilo; 50 ng/ml) for 16 hours or 3-MA (3-MA (5 mM) for 2 hours were treated with or 
without RANKL for 8 hours in serum-enriched or -deprived conditions. (E) TRAF3-GFP retrovirus–infected WT OCPs treated with RANKL for 
8 hours were fixed and double-stained with TRAF3 and LAMP2 Abs. Left plot shows background staining with isotype control Abs. (F) TRAF3-
GFP retrovirus–infected WT OCPs stained with anti-LAMP2 Ab. Colocalization assessed using confocal microscopy. Original magnification, ×60. 
(G) TRAF3-GFP retrovirus–infected WT OCPs treated with or without RANKL or CQ (2 mM) were stained with anti-LAMP2 Ab. TRAF3/LAMP2 
double-positive cells were counted. Original magnification, ×20. *P < 0.05.
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Figure 3
CQ inhibits OC formation in vitro. (A) Typical in vitro OC 
formation time-course. BM-derived WT OCPs were 
treated with M-CSF (M) for 2 days and with M-CSF 
plus RANKL (R) for 4 days. CQ was added on day 2 
(B), or day 4 (C). Original magnification, ×4. *P < 0.05. 
(D) WBs of WT OCPs treated with RANKL with or 
without CQ (10 μM) for 3 days. (E) WBs of Traf3f/f 
OCPs infected with MSCV-GFP (GFP) or MSCV-Cre-
GFP (Cre-GFP) retroviruses and GFP-FACS sorted 
or (F) cultured with RANKL with or without CQ (2 μM) 
for 5 days. (G) WBs of whole cell lysates from WT or 
TRAF3 L-cKO mouse tissues. (H) WBs of BM cells 
cultured with RANKL with or without CQ (2 μM) for 
5 days. **P < 0.01 vs. PBS.
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Figure 4
CQ affects OC function in vitro and in vivo. (A) WT OCPs cultured with RANKL with or without CQ (5 μM) for 9 days. TRAP staining (left panels) 
and toluidine blue (right panels, to highlight resorption pits). Values are means + SEM of 4 wells. **P < 0.01 vs PBS. Original magnification, ×20. 
(B–D) Representative TRAP-stained sections and OC numbers in calvarial (B) and tibial (C) sections from 10- to 12-week-old male WT or L-cKO 
mice treated with CQ (50 mg/kg/d i.p. for 10 days) and given supracalvarial injections of hPTH(1-34 aa) (10 μg/mouse) 4×/d for 3 days beginning 
on day 7. (D) Representative H&E-stained tibial sections from the mice in C illustrating marrow fibrosis (arrows) and values for percentage of 
marrow space occupied by marrow fibrosis. Values are means + SEM of 4 mice/group. *P < 0.05. Boxed areas in B–D are illustrated at higher 
magnification in Supplemental Figure 5. Scale bars: 50 μm (B); 500 μm (C and D).
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We next tested autophagy inhibitors on RANKL-induced TRAF3 
degradation. Bafilomycin A1 blocks fusion of the autophago-
some and the lysosome (28); it increased accumulation of TRAF3 
(Figure 2D). 3-Methyladenine (3-MA), which blocks PI3K, had no 
effect on TRAF3 degradation in serum-enriched conditions. How-
ever, TRAF3 accumulated in serum-deprived OCPs treated with 
3-MA (Figure 2D), consistent with 3-MA–inhibiting autophagy 
only in serum-deprived cells (29). We next infected WT OCPs with 
a pMX-TRAF3-GFP retrovirus and found that TRAF3 and LAMP2 
(a lysosome marker) were coexpressed in approximately 23% of 
RANKL-treated cells (Figure 2E). Confocal microscopy showed that 
the TRAF3-GFP fusion protein was localized mostly in the cytosol 
in OCPs (Figure 2F). RANKL significantly increased colocalization 
of TRAF3 and LAMP2, which was reduced by CQ (Figure 2G).
CQ inhibits RANKL-induced OC formation by preventing lysosomal degra-
dation of TRAF3. To determine whether CQ affects OC formation, we 
cultured WT BM cells with M-CSF for 2 days, added RANKL, and 
stained them for TRAP activity on days 2, 4, 5, and 6. Two days after 
RANKL addition, OCPs differentiated into TRAP+ mononuclear cells, 
which we called pre-OCs, that ultimately fused to form OCs over the 
following 2 days (Figure 3A). When we added CQ during the initial 
stages of OC formation, the total number of OCs and large OCs and 
OC area were significantly reduced dose dependently, with the highest 
dose (10 μM) inducing a 3-fold reduction in OC numbers (Figure 3B). 
Addition of CQ during the later stages of OC formation reduced OC 
area, with no effect on total and large OC numbers (Figure 3C). Fur-
thermore, when these OCPs were treated with RANKL plus CQ for 3 
days, the percentage of apoptotic and dead cells was similar to that in 
controls (6.1 vs. 5.3%, data not shown). Thus, CQ inhibits OCP dif-
ferentiation, but not OCP fusion or OC survival.
CQ is an anti-malarial agent, and like its derivative, hydroxychlo-
roquine, has been used early in the treatment of systemic lupus 
Figure 5
CQ prevents OVX-induced bone loss in WT, but not in C-cKO mice. OVX or sham-operated 8- to 9-week-old WT and C-cKO mice treated with 
PBS or CQ (50 mg/kg/d i.p. for 28 days). (A) Representative μCT images of tibiae and trabecular BVs. (B) Representative TRAP-stained tibial 
sections and histomorphometric data for OC surface and numbers. Values are the mean + SEM of 5∼9 mice/group. *P < 0.05. Boxed areas are 
shown at higher magnification in Supplemental Figure 6B. Scale bar: 500 μm.
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erythematosus and RA, but the precise mechanism of action in 
autoimmune diseases is not clear (30). We found that TRAF3 levels 
increased markedly in OCPs after CQ treatment (10 μM for 3 days); 
this was accompanied by decreased NFATc1 expression (Figure 3D). 
We infected OCPs from Traf3f/f mice with MSCV-Cre-GFP (where 
MSCV indicates murine stem cell virus) or MSCV-GFP retrovirus 
and sorted GFP+ cells to verify deletion of TRAF3 (Figure 3E). Sorted 
GFP+ cells then were cultured with or without CQ in OC formation 
assays. TRAF3-deficient and WT OCPs formed similar numbers of 
OCs, and CQ reduced OC numbers from WT cells (∼80%), but had 
no effect on TRAF3-deficient cells (Figure 3F). We next confirmed 
specific deletion of TRAF3 protein in BM cells and OCPs from 
L-cKO mice (Figure 3G) and found that CQ did not inhibit RANKL-
induced OC formation in TRAF3-deficient cells (Figure 3H).
CQ inhibits OC formation in vitro and PTH- and ovariectomy-induced 
bone resorption in vivo via TRAF3. We next cultured WT OCPs on 
bone slices with RANKL for 9 days and found that CQ-treated 
cells formed few TRAP+ OCs (12 ± 3 vs. 656 ± 17 in controls) and 
few resorption pits, which covered very little of the bone slices 
(0.04 ± 0.01 mm2) compared with controls where pits occupied 
most of the surface (6.9 ± 0.7 mm2) (Figure 4A). We then treated 
3-week- or 3-month-old WT and C-cKO mice with CQ (25 mg/kg 
i.p, once daily) for 28 days and found no significant difference in 
BV or other structural parameter values assessed by μCT in tibiae 
compared with those of vehicle-treated mice (Supplemental Fig-
ure 3, A and B), suggesting that this regimen of CQ has no effect 
on basal bone resorption or bone mass. Further time-course and 
dose-response studies will be required to determine whether CQ 
can inhibit basal bone resorption.
To determine whether CQ affects osteoblast formation or func-
tion, we performed CFU-F, CFU–alkaline phosphatase (CFU-ALP), 
and bone nodule formation assays using 2 μM CQ, which inhibits 
OC formation. We found that CQ had no effects on any of these 
indices of osteoblast function in WT BM stromal cells (Supple-
mental Figure 4A), suggesting that the predominant effect of 
CQ is on OCs. Parathyroid hormone (PTH) is a primary regula-
tor of calcium homeostasis and has both anabolic and catabolic 
effects, associated with intermittent or continuous administra-
tion, respectively (31, 32). To test whether CQ affects PTH-induced 
bone formation, we administered PTH (2 μg/kg, 3×/d) intermit-
tently to WT mice for 14 days along with CQ (50 mg/kg, 1×/d). 
PTH treatment significantly increased trabecular BV, trabecular 
thickness, and mineral apposition (MAR) and bone formation 
rates (BFR), but CQ had no effect (Supplemental Figure 4, B–D).
Figure 6
RelB positively regulates RANKL-induced TRAF3 degradation. (A) WBs of WT and RelB–/– BM whole cell lysates and TRAF3 levels quantified 
densitometrically (mean + SEM of 3 blots). (B) WBs of RANKL-treated RelB–/– OCPs. (C) WBs of WT or RelB–/– OCPs infected with pMY-GFP 
or pMY-RelB-GFP retrovirus for 2 days and treated with RANKL for 8 hours. Arrowhead, specific RelB band. Lanes were run on the same gel, 
but were noncontiguous. (D) WT or RelB–/– OCPs infected with control GFP shRNA (Ctl-shRNA) or TRAF3 shRNA lentiviruses for 2 days were 
cultured with MCSF plus RANKL for 4 days. TRAF3 knockdown was confirmed by RT-PCR. Total numbers of OCs and large OCs were counted. 
(E) EM images of WT or RelB–/– OCPs treated with RANKL for 4 days in 2-well culture chambers showing autophagosomes (arrows).
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We next examined the effects of CQ in an in vivo model of patho-
logic bone resorption in which PTH stimulates OC formation by 
inducing RANKL expression (33). We treated L-cKO or Cre-nega-
tive control mice with CQ (50 mg/kg, 1×/d) for 7 days followed by 
CQ plus PTH (10 μg/mouse, 4×/d, s.c. over calvariae) for another 
3 days (34). CQ markedly reduced PTH-induced OC formation in 
calvariae and tibiae in WT mice compared with PBS treatment, but 
not in L-cKO mice (Figure 4, B and C, and Supplemental Figure 
5, A and B). A similar pattern of change was observed in serum 
TRAP5b levels (Supplemental Figure 5D). Furthermore, marrow 
fibrosis (a hallmark of PTH-induced resorption) was observed in all 
groups except the WT mice treated with CQ and PTH (Figure 4D 
and Supplemental Figure 5C). Similar results were obtained in a 
separate experiment using C-cKO mice (data not shown).
To further evaluate the effects of CQ on bone resorption in vivo, 
we used 8- to 9-week-old female C-cKO or Cre-negative control mice 
in an ovariectomy (OVX) model. Two days after surgery, mice were 
treated with PBS or CQ (50 mg/kg, i.p. 1×/d) for 28 days, and tibiae 
were analyzed using μCT and histology. Four weeks after surgery, 
uterine weights and tibial BVs in OVX mice were markedly reduced 
compared with those of sham-operated WT and C-cKO mice, con-
sistent with OVX, and BVs were significantly lower in C-cKO than 
in WT mice (Figure 5A and Supplemental Figure 6A). In addition, 
CQ prevented OVX-induced bone loss and increased OC num-
bers and surfaces in WT mice, but not in C-cKO mice (Figure 5, 
A and B, and Supplemental Figure 6, B and C).
RelB is required for RANKL-induced TRAF3 lysosomal degradation by 
regulating BECN1 expression. We next investigated basal and induc-
ible TRAF3 levels in RelB–/– OCPs, in part because RANKL/NIK/
p100 signaling activates RelB (5) and also to determine whether 
RelB regulates TRAF3 degradation. Basal TRAF3 protein levels 
were 5-fold higher in RelB–/– BM cells than in WT cells (Figure 
6A). In addition, in contrast to the time-dependent decrease in TRAF3 
levels induced by RANKL in WT OCPs (Figure 1A), significant 
accumulation of TRAF3 protein was observed in RANKL-treated 
RelB–/– OCPs (Figure 6B), suggesting that RelB promotes RANKL-
induced TRAF3 degradation. To test this, we infected RelB–/– 
OCPs with pMY-RelB to determine whether adding back RelB 
could restore RANKL-induced TRAF3 degradation. TRAF3 levels 
decreased significantly in GFP control virus–infected OCPs 8 hours 
after RANKL stimulation (similar to Figure 2C). This decrease did 
not occur in GFP control virus–infected RelB–/– OCPs, but was seen 
in RelB–/– OCPs overexpressing pMY-RelB (Figure 6C).
M-CSF plus RANKL–treated RelB−/− BM cells generated signifi-
cantly fewer mature OCs than WT cells (8). To further investigate 
the role of TRAF3 in these conditions, we infected WT and RelB−/− 
OCPs with control GFP (Ctl-GFP) or TRAF3 shRNA lentivirus and 
confirmed TRAF3 knockdown by RT-PCR. TRAF3 mRNA levels were 
35% higher in RelB−/− than in control OCPs (Figure 6D), and RelB−/− 
cells formed fewer OCs than WT cells. TRAF3 knockdown induced 
significantly more OCs from RelB−/− cells (267 ± 18 to 490 ± 54) and 
to a greater extent than WT virus-infected cells (367 ± 6; Figure 6D).
Figure 7
RANKL-induced TRAF3 degradation is absent in BECN1, but not in ATG5/7 knockdown OCPs. (A) WBs of WT OCPs treated with RANKL. (B–E) 
WT OCPs infected with Ctl-GFP, BECN1, or ATG5 and ATG7 shRNA lentiviruses for 2 days. (B) mRNA levels of BECN1, ATG5, and ATG7. (C) 
WB of infected cells treated with RANKL for 8 hours. (D) OCs formed from infected cells cultured with RANKL for 5 days. *P < 0.05 vs. Ctl-GFP 
shRNA. (E) EM images and numbers of autophagosomes (arrows, expressed/cell in at least 50 cells/preparation from 2 independent experi-
ments) in infected cells.
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teins (Figure 7A). Moreover, RANKL-induced TRAF3 degradation 
and autolysosome formation were impaired in cells with shRNA 
knockdown of BECN1, but not of ATG5/7 (Figure 7, B, C, and E), 
associated with a significant reduction in OC numbers (Figure 7D). 
TRAF3 levels in OCPs treated with ATG5/7 shRNA fell in response 
to RANKL, similar to control shRNA, but this was associated with 
reduced osteoclastogenesis and increased autolysosome numbers, 
suggesting that ATG5/7 may regulate the degradation of other 
modulators that contribute to RANKL-induced OC formation.
BECN1 associates with PI3KIII/Vps34 as a platform that modu-
lates autophagosome formation during early steps of autophagy 
(37). The reduction in TRAF3 induced by RANKL was accompa-
nied by increased RelB and BECN1 protein and mRNA levels in 
WT OCPS, but not in RelB–/– OCPs (Figure 8, A and B), suggesting 
an association between RelB and BECN1. There are 4 κB binding 
sites in the BECN1 promoter and in its first intron region, and 
RelA upregulates BECN1 transcriptional activity (37). We there-
To further explore the role of RelB in RANKL-induced TRAF3 
lysosomal degradation, we used transmission EM (widely used to 
monitor autophagy) (35) to evaluate the ability of WT and RelB–/– 
cells to form autophagosomes. Initial steps in autophagy include 
formation and expansion of an isolation membrane, also called a 
phagophore, the edges of which fuse to form an autophagosome, 
a double-membraned vesicle that sequesters cytoplasmic material. 
Autophagosomes then fuse with lysosomes to form autolysosomes 
where the captured material, together with the inner membrane is 
degraded (36). Autophagic vacuoles with their characteristic dou-
ble membranes formed in WT, but not in RelB−/−, cells in response 
to RANKL (Figure 6E).
Having demonstrated that RANKL-induced TRAF3 degrada-
tion is lysosome/autophagy-mediated, we next examined protein 
levels in OCPs of ATG5, ATG7, ATG8, and beclin 1 (BECN1), key 
molecules in autophagosome formation (37). RANKL upregulated 
expression of BECN1 (∼3-fold), but not of the other autophagic pro-
Figure 8
RelB binds to the BECN1 promoter and regulates its expression. Whole cell lysate WBs (A) and RT-PCR–detected BECN1 mRNA levels (B) in WT 
or RelB–/– OCPs treated with RANKL or vehicle for 8 hours. (C) 293T cells transfected with RelA- or RelB-expressing plasmids or cotransfected 
with a human BECN1 promoter pGL3-Luc reporter and a Renilla luciferase plasmid and RelA- and/or RelB-expressing plasmids. RANKL-treated 
samples were cotransfected with a hRANK plasmid. (D) RelA- or RelB siRNAs were transfected into 293T cells 48 hours before cotransfection with 
pGL3-Luc and Renilla plasmids. Protein levels were assessed by WB. Dual-luciferase assays were performed 24 hours after transfection. Values 
in C and D are means + SEM from 3 independent experiments. *P < 0.05; **P < 0.01. (E) WT OCPs treated with RANKL for 8 hours and sheared 
chromatin precipitated with RelA- or RelB-specific Abs, or IgG (negative control [CTL]). Recovered DNA was used as a template for PCR. Primers 
for the A κB site inside the IκBα promoter and a non-κB site in the proximal BECN1 promoter region were positive and negative controls, respec-
tively. RelA or RelB binding to the indicated promoters was quantified by real-time PCR. Data are representative of 2 independent experiments.
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in these NF-κB pathways and also whether it might have positive 
regulatory roles, as reported in other cell types (12).
In normal eukaryotic cells, autophagosomes digest dam-
aged organelles and misfolded and long-lived proteins (47) and 
ultimately fuse with lysosomes, leading to degradation of their 
contents. Human genome-wide association data suggest a link 
between autophagy genes and osteoporosis (48), and the OC ruf-
fled border membrane has been described as an autophagosome 
that fuses with lysosomes to facilitate secretion of matrix-degrad-
ing enzymes, especially cathepsin K. Furthermore, autophagy 
proteins, including Atg5, Atg7, Atg4B, and LC3, are important 
for generating the ruffled border (49). However, a potential role 
for autophagy in OC formation has not been reported. Here, we 
demonstrate for what we believe is the first time that autophagy 
also plays a role in osteoclastogenesis by regulating degradation of 
TRAF3, which we show undergoes ubiquitination and sequential 
autophagic-lysosomal degradation in response to RANKL. Our 
data are supported by a report that proteasome inhibition only 
marginally reduced TRAF3 degradation upon LTβR stimulation 
in 293T cells (50). However, TRAF3 can undergo K48-linked poly-
ubiquitination by Triad3A and subsequent proteasomal degrada-
tion following virus infection in A549 human epithelial cells (51). 
Thus, the fate of TRAF3 may vary in response to different stimuli 
and be cell context dependent. In B cells, CD40 or BAFF recep-
tor activation reduced TRAF3 degradation in a TRAF2/cIAP1/2-
dependent manner, and CD40-induced TRAF3 degradation was 
inhibited by a small-molecule mimetic, which inhibits cIAPs (52). 
We found that knockdown of cIAP1/2 reduced RANKL-induced 
TRAF3 degradation and decreased OC formation (Supplemental 
Figure 8), but the precise function of cIAPs in RANKL-induced 
TRAF3 lysosomal degradation will require further study.
Our finding that RelB is required for RANKL-induced TRAF3 
lysosomal degradation is important because it points to a nega-
tive feedback loop between NF-κB signaling and TRAF3. Many 
factors known to induce autophagy, including TNF (53), also act 
as NF-κB activators. Depletion of essential autophagy modulators, 
including Atg5, Atg7, BECN1, and Vsp34 by RNAi inhibited TNF-
driven NF-κB activation in human cancer cell lines (54). Similarly, 
KO of the genes encoding IKKα, IKKβ, IKKγ, or their upstream 
activator, TAK1, reduced autophagy induced by nutrient depletion 
or by treatment with rapamycin or other autophagy stimulators 
(55). However, the detailed molecular mechanisms are still unclear. 
We found that RANKL-induced TRAF3 degradation is absent in 
RelB–/– OCPs (Figure 8A). Our data suggest that RelB induction of 
TRAF3 lysosomal degradation is through transcriptional modu-
lation of the early autophagic protein BECN1 (Figure 8E), with 
degradation of TRAF3 leading to activation of NF-κB signaling. 
Although the mechanism by which BECN1 might target TRAF3 
for transfer to the lysosome is unclear, our findings have identified 
a RelB-regulated autophagy pathway involving NF-κB activation.
Given the essential functions of NF-κB in inflammation, autoim-
mune disease, and oncogenesis, large numbers of natural or syn-
thetic NF-κB inhibitors have been produced (56). Although many 
of these inhibitors suppress osteoclastogenesis and bone resorption, 
none of them has progressed to clinical trials for the treatment of 
common bone diseases, such as postmenopausal osteoporosis or RA 
(4). Biologic inhibitors directed at pathogenetic cytokines, such as 
TNF, IL-1, and IL-6, have been approved for the treatment of inflam-
matory arthritis (57, 58). However, these treatments fail to achieve 
remission in up to 40% of patients (57). Thus, additional insights 
fore cotransfected a pGL3-BECN1 reporter vector, including 
1.1 kbp upstream of the human BECN1 promoter (37), togeth-
er with RelA or RelB expression vectors into 293T cells and per-
formed dual luciferase assays. We confirmed RelA and RelB overex-
pression in 293T cells by WB (Figure 8C). BECN1 transcriptional 
activity was upregulated significantly by RelB, but only minimally 
by RelA, overexpression (Figure 8C), which may reflect RelA pro-
tein levels being relatively low in our assays compared with pub-
lished levels (37). RANKL markedly increased BECN1 transcrip-
tional activity, consistent with the increased BECN1 protein level 
induced by RANKL (Figure 8C). However, RANKL did not increase 
BECN1 activity further when RelA or RelB was overexpressed. Fur-
thermore, siRNA knockdown of RelA or RelB in 293T cells result-
ed in reduced protein levels and an approximately 50% reduction 
in BECN1 promoter activity (Figure 8D). To further assess interac-
tion of RelB with the BECN1 promoter, we performed ChIP assays. 
An A κB site is conserved in humans and mice (37), and real-time 
PCR and standard PCR analyses of ChIP DNA revealed that RelB 
binds to this A κB site with a lower binding ability than RelA. Nei-
ther nonspecific IgG nor primers covering the proximal BECN1 
promoter region displayed detectable binding (Figure 8E).
Discussion
TRAF3, a relatively understudied TRAF family member, has been 
shown recently to act as an important multifunctional regula-
tor of type I IFN and balanced cytokine production by serving as 
an adaptor molecule that facilitates assembly of a NIK/TRAF2/
activated/cellular inhibitor of apoptosis (cIAP) complex (38). NIK 
plays a key role in noncanonical NF-κB signaling, and its stabil-
ity is regulated by TRAF3 in B cells (17) and in OCPs (11). Here, 
we have shown using gain- and loss-of-function approaches that 
TRAF3 suppresses RANKL-induced OC formation, consistent 
with TRAF3 being a negative regulator of noncanonical signal-
ing (11). Mice that we generated with conditional KO of TRAF3 
in OCPs were osteoporotic with increased OC numbers (Figure 1, 
D and E), indicating that TRAF3 plays an important protective 
role in physiological bone remodeling.
Our finding that TRAF3 also inhibits expression of p65 is con-
sistent with the increased p65-binding activity in Traf3–/– cells (39) 
and increased phospho-p65 level in TRAF3 knockdown cells in 
response to TNF or LTβR (40), but the mechanism whereby TRAF3 
inhibits NF-κB signaling is unclear. TRAF3 deficiency did not alter 
protein levels of RANK or DC-STAMP (Supplemental Figure 7, 
A and B), key regulators of RANKL-induced OCP differentiation 
and fusion (41, 42). TRAF3 could inhibit both NF-κB pathways 
by affecting NIK-IKKα signaling because IKKα is required for 
formation of IKKα/IKKβ/IKKγ and IKKα/IKKα complexes in the 
canonical and noncanonical pathways, respectively (43, 44). In 
addition, TRAF3 overexpression upregulated expression of type I 
IFN (Supplemental Figure 7C), which can act as a negative regula-
tor of osteoclastogenesis (45). Thus, TRAF3 might also suppress 
OC formation through RANKL/IFN-α signaling crosstalk. The 
primary role of canonical signaling appears to be to mediate OCP 
survival (46). However, when we inhibited RANKL-induced OC 
formation with CQ to prevent TRAF3 lysosomal degradation, we 
found no change in OCP proliferation or apoptosis rates (Figure 3, 
C and D), despite seeing a CQ-induced reduction in levels of the 
p65 target gene NFATc1 (Figure 4A) and a reduction in p65 lev-
els in OCPs when TRAF3 was overexpressed (Figure 1F). Further 
studies will be required to determine exactly how TRAF3 functions 
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NIK (clone H-248), RelB (clone C19), p65 (clone C20), p50 (clone NLS), 
and BECN1 (clone H-300). p100/p52 Ab was from Millipore. HA (clone 
H6908) and β-actin (clone AC-40) Abs were from Sigma-Aldrich. Recom-
binant M-CSF and RANKL were from R&D Systems. MG132, bafilo-
mycin A1, 3-MA, NH4Cl, and CQ were from Sigma-Aldrich. LAMP2 Ab, 
clone GL2A7, was from Abcam.
Plasmid construction and retroviral transfer Abs and reagents. The retroviral vector 
pMX-TRAF3-IRES-GFP WT and mutants were generated by inserting a cDNA 
fragment encoding TRAF3 WT and mutants into a pMX-IRES-GFP retroviral 
expression vector from K. Matsuo (Keio University, Minato, Tokyo, Japan). A 
pMX-TRAF3-GFP fusion protein vector was generated by inserting a TRAF3 
PCR fragment into BamHI-NcoI sites of pMX-TRAF3-IRES-GFP. pMY-GFP 
vector, was from A. Hirao (Keio University). We generated pMY-RelB-GFP by 
inserting a RelB cDNA fragment into the pMY-GFP vector. MSCV-Cre and 
MSCV-Cre-GFP were from T. Reya (UCSD, La Jolla, California, USA). Retrovi-
rus packaging was performed by transfecting plasmids into Plat-E cells (pMY 
virus) or 293T cells (MSCV virus) using Fugene 6 (Roche) following the manu-
facturer’s protocol. WT and mutant TRAF3 constructs were from S.C. Sun 
(17) (University of Texas, MD Anderson Cancer Center, Houston, Texas, USA). 
These plasmids were transfected into 293T cells using Fugene 6.
In vitro OC formation and functional assays. BM cells (4 × 104) were cultured in 
96-well plates in α-MEM with 10% FBS and recombinant M-CSF (10 
ng/ml 
in all experiments) for 2 days to enrich for OCPs. OCPs were infected with 
retrovirus for 2 days followed by RANKL (10 ng/ml in all experiments, unless 
otherwise stated; R&D Systems) for 5 to 7 days or treated with 2 to 10 μM CQ and RANKL for 5 days. O te clast genesis was ssessed by c unting
TRAP+ multinucleated cells with 3 or more nuclei. OC area was assessed 
using standard stereologic methods, an ocular eyepiece grid, an Olympus 
TH4-100 microscope, and a ×4 objective lens. WT BM cells were cultured 
with M-CSF for 2 days on bone slices to generate OCPs and then CQ (5 μM) 
and RANKL were added. Cells were fixed and stained for TRAP activity to 
allow counting of OCs, which were then removed; bone slices were stained 
with 0.5% toluidine blue to visualize resorption pits, as described (67).
In vitro CFU-F, CFU-ALP, and bone nodule formation assays. For CFU-F and 
CFU-ALP colony formation assays, BM cells from long bones were cultured 
in 10-cm dishes with 106 cells/dish in 10 ml α-MEM plus 10% FCS with or 
without 50 μg/ml ascorbic acid and 10 mM β-glycerophosphate. Media 
were changed every 3 to 4 days, and cultures were maintained for 24 days 
when cells were stained with H&E or for ALP activity. For bone nodule 
formation, BM cells were cultured in α-MEM plus 10% FCS for 7 to 10 days 
and cultured in osteoblast-inducing medium containing 50 μg/ml ascorbic 
acid and 10 mM β-glycerophosphate for 21 to 28 days; mineralized bone 
nodules were examined after Von Kossa staining.
WB analysis. Whole-cell lysate protein from retrovirus-infected OCPs, 
TRAF3 plasmid-transfected 293T cells, WT, or cKO OCPs were cultured 
in 60-mm dishes and lysed with RIPA Lysis Buffer (Millipore) containing 
a protease inhibitor cocktail (Roche). Lysates (10–40 μg) were loaded in 
10% SDS-PAGE gels and immunoblotted with Abs to TRAF3, NFATc1, 
c-Fos, p65, RelB, p50, GAPDH, NIK, p100, HA, HDAC, BECN1, RANK, 
DC-STAMP, or mouse actin.
In vitro ubiquitination assays. WT BM cells were treated with M-CSF for 2 days 
and RANKL was added for 2 hours. Whole cell lysates were prepared using 
lysis buffer containing 20 mM HEPES, 250 mM NaCl, 20 mM Tris-HCl, 
0.5% NP-40, 2 mM EDTA, 2 μg/ml leupeptin, 2 μg/ml aprotinin, 1 mM 
DTT, 1 mM PMSF, and 1 mM N-ethylmaleimide (Sigma-Aldrich) to limit 
deubiquitination and incubated with UbiQapture-Q matrix (Enzo Life 
Sciences) to pull down all ubiquitinated proteins, following the manufac-
turer’s protocol. Precipitates were subjected to WB using anti-TRAF3 Abs.
Flow cytometry and cell sorting. WT OCPs were infected with pMX-TRAF3-
GFP retrovirus for 3 days, and the cells were stained using an intracellular 
into the pathogenesis of joint destruction in this common disease 
and new drugs are needed. Our identification of TRAF3 as an inhibi-
tor of osteoclastogenesis suggests a new target for treatment of RA.
CQ was used for many years to reduce inflammation in RA until 
it was replaced by hydroxychloroquine because the latter has fewer 
ophthalmic side effects. However, clinical studies indicate that, 
when given alone or in combination with methotrexate, hydroxy-
chloroquine does not prevent joint destruction in 60%–70% of 
affected patients (58), suggesting that it may have limited use as 
an antiresorptive in most RA patients. CQ and hydroxychloro-
quine prevent acidification of the lysosomal compartment, but 
their mechanism of action is unclear, and reports of the effects of 
these drugs on OCs in vitro have been contradictory. For example, 
hydroxychloroquine had no inhibitory effect on human OCP dif-
ferentiation (59), while CQ inhibited the formation of large OCs 
in the later phases of osteoclastogenesis (60). This latter finding 
differs from our in vitro observations and may reflect differences 
in culture conditions, but it does support a role for this class of 
compounds as inhibitors of bone resorption. Our finding that CQ 
inhibits OC formation in vitro and in vivo by preventing TRAF3 
lysosomal degradation suggests that CQ could inhibit bone resorp-
tion in humans by this mechanism. The dose of CQ that we used in 
our in vivo studies (50 mg/kg) is higher than the dose of hydroxy-
chloroquine given to patients (∼5 mg/kg), and this could account 
for the efficacy we observed in our mouse studies coupled with 
the fact that PTH- and OVX-induced resorption is less complex 
than the severe inflammatory milieu in RA. Recent studies indi-
cate that CQ can have therapeutic efficacy in a number of other 
diseases, including cancer and pulmonary hypertension, and there 
are more than 30 clinical trials underway examining combinations 
of hydroxychloroquine with anticancer agents (61, 62). Other CQ 
derivatives could possibly have better anti-OC efficacy and fewer 
side effects, but further studies will be required to examine this.
In addition to this newly identified function of TRAF3 in bone 
homeostasis, TRAF3 has been implicated in the pathogenesis of a 
number of diseases, including multiple myeloma (63) and experi-
mental autoimmune encephalomyelitis/multiple sclerosis (64). 
TRAF3 mutations in humans with multiple myeloma result in the 
accumulation of NIK and constitutive activation of NF-κB, there-
by promoting myeloma cell survival. Strategies to increase TRAF3 
levels in OCPs by CQ or CQ derivatives should inhibit bone resorp-
tion in conditions in which RANKL is increased. Manipulating 
TRAF3 expression levels in other cell types, such as B cells, could 
also have beneficial therapeutic effects in patients with RA.
Methods
Mice. All animals were 6 to 12 weeks old. WT C57BL/6 (B6) mice were from 
the National Cancer Institute (Frederick, Maryland, USA). RelB–/– mice 
have been described previously (65). Traf3-floxed mice (B6 background) 
were from L. Rui (University of Michigan, Ann Arbor, Michigan, USA) (66). 
Lysozyme M-Cre (Lyz2tm1(cre)Ifo/J; B6 background) mice were purchased 
from the Jackson Laboratories. Cathepsin K-Cre mice (B6 background) were 
provided by Y.-P. Li (University of Alabama at Birmingham, Birmingham, 
Alabama, USA). To generate cKO mice, Traf3-floxed mice were bred with 
cathepsin K-Cre or lysozyme M-Cre transgenic mice. Cathepsin K-Cre, lyso-
zyme M-Cre, and Traf3-floxed mice all have normal bone phenotypes (BV/ 
tissue volume [TV], Tb. N, Tb.Th, and Tb. Sp values; data not shown). Cre-
negative littermates were used as WT controls in all in vivo experiments.
Abs and reagents. The following Abs were from Santa Cruz Biotech-
nology Inc.: TRAF3 (clone M20), NFATc1 (clone 7A6), c-Fos (clone 4), 
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an hRANK construct. Cells were treated with RANKL or PBS, and dual-
luciferase assays were performed 24 hours after transfection. siRNA tar-
geting RelA or RelB (Santa Cruz Biotechnology Inc.) was transfected into 
293T cells following the manufacturer’s instructions. CHET4 and a Renilla 
luciferase plasmid were cotransfected by Fugene 6 48 hours later.
ChIP assay. ChIP was performed as described (37). In brief, BM-derived 
OCPs were treated with RANKL for 8 hours and fixed in 1% formaldehyde. 
Chromatin was sheared by sonication (16 rounds of 20 pulses with 2 min-
utes between rounds (Qsonica 125 sonicator). Then samples were incu-
bated overnight at 4°C with Abs to p65, RelB, and IgG (negative control). 
Precipitated DNAs were analyzed by real-time PCR. Primers for the mIkBa 
promoter (–316 to –15) were a positive control: 5′-GGACCCCAAAC-
CAAAATCG-3′ and 5′-TCAGGCGCGGGGAA-TTTCC-3′ as described (71). 
A primer set that covers the BECN1 proximal promoter region (–1897 to 
approximately –1513) was used as a negative control: 5′-GGGCAAGGCAT-
CATAAAACAGG-3′ and 5′-AGGAGATGAAGTTGACCTCC-3′. Specific 
primers for the A κB site in the BECN1 promoter region (–241 to approxi-
mately –1) are: 5′-AAGAAGCCTAGAGTCCCTGG-3′ and 5′-CCTGCGA-
CAGCGGAGAAAAG-3′.
Statistics. Values are shown as means + SEM of 4 samples unless otherwise 
stated. One-way ANOVA and nonparametric comparison (Bonferroni’s 
multiple comparison test) were used with Prism software version 4.0b for 
experiments with more than 2 groups. Two-tailed Student’s t test was used 
for other statistical analyses, and significance was set at P < 0.05.
Study approval. All animal experiments were performed using University 
of Rochester Medical Center ACUAC–approved protocols and conformed 
to the Guide for the Care and Use of Laboratory Animals (NIH. Revised 2011).
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staining kit (BD Bioscience). In brief, the cells were fixed and permea-
bilized by Cytofix/Cytoperm buffer, then stained with PE-Traf3 Ab and 
Rat anti-mouse LAMP2 Ab (Santa Cruz Biotechnology Inc.). The second-
ary Ab (biotinylated anti-rat IgG; Vector Laboratories) was visualized by 
APC-streptavidin (BD Biosciences). WT OCPs were treated with RANKL 
and 10 μM CQ for 3 days and stained with FITC–annexin V and prop-
idium iodide (BD Biosciences) for 15 minutes. Cytometric analyses were 
performed using a flow cytometer (FACS LSR II; BD Biosciences) and 
FlowJo software. GFP-positive retrovirus-infected OCPs were sorted 
using FACSAria (BD Biosciences).
Immunocytochemistry and confocal microscopy. pMX-TRAF3-GFP–infected 
OCPs were seeded into 8-well chamber slides (Lab-Tek, NUNC), fixed with 
4% paraformaldehyde, and permeabilized with 0.1% Triton X-100. After 
blocking with 5% goat serum in PBS for 4 hours, cells were incubated with 
anti-LAMP2 Ab (Abcam) in a humidity chamber at 4°C overnight. The 
next day, cells were washed and incubated with secondary Alexa Fluor 350–
labeled anti-rat Ab. Colocalization of TRAF3 and LAMP2 in single cells was 
assessed using a FV1000 Olympus Laser Scanning Confocal Microscope.
In vivo PTH and CQ treatment and histological analysis. CQ (50 mg/kg/d) was 
administered i.p. for 10 days to female WT or L-cKO mice (10 to 12 weeks 
old; 4/group), as described (68). On day 7, mice were given supracalvarial 
injections of vehicle or hPTH(1–34 aa) (EMD Biosciences; 10 μg/injection) 
4×/d for 3 days, (using a protocol that induces hypercalcemia and bone 
resorption; ref. 34), and killed 16 hours after the last injection. Calvarial 
and tibial sections were prepared as described (9). OC numbers and mar-
row fibrosis were measured in TRAP- and H&E-stained sections using an 
eyepiece grid and an Olympus TH4-100 microscope.
Six-week-old female WT mice (7–8/group) were injected i.p. daily with 
50 mg/kg CQ and with hPTH (2 μg/mouse s.c.) 3×/d for 14 days to induce 
bone formation, as described (69). Tibiae were used for μCT scanning. Cal-
cein labeling was described previously (70). MAR and BFR in endocortical 
and trabecular bone were measured using standard procedures and Visio-
pharm Integrator System image analysis software.
OVX-induced bone loss. OVX or sham surgeries were performed in WT or 
C-cKO mice (8 to 9 weeks old; 5–9/group). CQ treatment (50 mg/kg i.p. daily 
injection for 28 days) was started 2 days after surgery. Controls received 
PBS. Calcein labeling was performed as described above. OVX was con-
firmed by uterine weight and histology. Tibiae were assessed by micro-CT 
and histomorphometry.
Electron microscopy. WT or RelB–/– OCPs were infected with Ctl-GFP, ATG5 
shRNA, BECN1 shRNA, or ATG7 shRNA (Santa Cruz Biotechnology Inc.) 
for 2 days, cultured on glass chamber slides for 4 days with RANKL, fixed 
in 0.1 M sodium cacodylate–buffered 2.5% glutaraldehyde for 24 hours, 
and post-fixed in 1% buffered osmium tetroxide for 30 minutes. Slides were 
transitioned through graded ethanols to 100% and infiltrated with Spurr’s 
epoxy resin overnight. The slides were dipped into liquid nitrogen, and the 
entrapped cells were popped off and thin sectioned, then placed onto nickel 
grids, stained with aqueous uranyl acetate and lead citrate and examined 
using a Hitachi 7650 Transmission EM.
Reporter assay. A pGL3 luciferase reporter containing 1.1 kbp of the 
human BECN1 promoter (CHET4) was from C. Schneider (Università 
degli Studi di Udine, Udine, Italy) (37). CHET4 and pcDNA3-RelA-cFlag 
(Addgene) or pcDNA3-RelB-cFlag plasmids (Addgene) was cotransfected 
into 293T cells together with a Renilla luciferase plasmid with or without 
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Tumor necrosis factor (TNF) plays an important role in the
pathogenesis of inflammatory bone loss through stimulation of
osteoclastic bone resorption and inhibitionof osteoblastic bone for-
mation. Compared with the well established role of TNF in oste-
oclastogenesis, mechanisms bywhich TNF inhibits osteoblast func-
tion have not been fully determined. Runx2 is an osteoblast-specific
transcription factor whose steady-state protein levels are regulated
by proteasomal degradation, mediated by the E3 ubiquitin ligases,
Smurf1 and Smurf2. We hypothesized that TNF inhibits osteoblast
function through Smurf-mediated Runx2 degradation. We treated
C2C12 and 2T3 osteoblast precursor cell lines and primary osteo-
blasts with TNF and found that TNF, but not interleukin-1, signifi-
cantly increased Smurf1 and Smurf2 expression. TNF increased the
degradation of endogenous or transfected Runx2 protein, which
was blocked by treating cells with a proteasomal inhibitor or by
infecting cells with small interfering (si)RNA against Smurf1 or
Smurf2. TNF inhibited the expression of bone morphogenetic pro-
tein and transforming growth factor- signaling reporter con-
structs, and the inhibition of each was blocked by Smurf1 siRNA
and Smurf2 siRNA, respectively. Overexpression of Smurf1 and/or
Smurf2 siRNAs prevented the inhibitory effect of TNF on Runx2
reporter. Consistent with these in vitro findings, bones from TNF
transgenic mice or TNF-injected wild type mice had increased
Smurf1 and decreasedRunx2 protein levels.We propose that one of
the mechanisms by which TNF inhibits bone formation in inflam-
matory bone disorders is by promoting Runx2 proteasomal degra-
dation through up-regulation of Smurf1 and Smurf2 expression.
Tumor necrosis factor (TNF)2 is a major contributor to pathologic
bone loss through stimulation of osteoclastic bone resorption and inhi-
bition of osteoblastic bone formation. In patients with rheumatoid
arthritis, TNF and other cytokines are overproduced in inflamed joints
by various cells infiltrating the synovial membrane. This leads to severe
local erosion of cartilage and bone, periarticular osteopenia, as well as
systemic osteoporosis (1, 2). Under these conditions, osteoblasts do not
catch up with the accelerated bone resorption, indicating impaired
osteoblast function (3). The inhibitory effects of TNF on bone forma-
tion in vitro were first described in 1987 in neonatal rat calvarial organ
cultures (4). Subsequent studies demonstrated that TNF inhibits
recruitment of osteoblast progenitors, reduces expression of genes pro-
duced by mature osteoblasts, and promotes osteoblast apoptosis
through nuclear factor-B signaling pathway (5–9). However, com-
pared with our understanding of the role of TNF in osteoclast biology,
little is known of the molecular mechanisms that mediate the effect of
TNF on osteoblast inhibition.
To date, the most important mechanistic finding of TNF-mediated
osteoblast inhibition was the demonstration that TNF decreases Runt-
related gene 2 (Runx2) expression and itsDNAbinding activity in osteo-
blasts (10). This is partially through suppression of Runx2 gene tran-
scription and destabilization of Runx2 mRNA through the TNF
receptor 1 signaling pathway (10–12). However, because TNF-induced
reduction in nuclear Runx2 protein (more than 90%) was greater than
expected, compared with the decrease in total Runx2 mRNA (50%), it
has been predicted that TNFmay also have post-transcriptional effects.
Furthermore, pharmacological inhibitors of the cell survival-promoting
kinases, Akt, phosphatidylinositol 3-kinase, and extracellular signal-
regulated kinases, fail to reverse the inhibitory effects of TNF on osteo-
blast differentiation in vitro (11), suggesting that other signal pathways
may be involved.
In the past several years, ubiquitin-mediated proteasomal degrada-
tion has been implicated in the regulation of bone morphogenetic pro-
tein (BMP)-2 and transforming growth factor- (TGF-) signaling
pathways in various cell types (13, 14). We and others have demon-
strated that the E3 ubiquitin ligase, Smad ubiquitin regulatory factor
(Smurf)1, regulates osteoblast differentiation by promoting proteaso-
mal degradation of the BMP signaling protein, Smad1 and Smad5, and
of the osteoblast transcription factor, Runx2 (15–18). Smurf2, a closely
related homolog of Smurf1, was shown to reduce the steady-state pro-
tein levels of Smad1 and 2, but not Smad3 and 4, in Smurf2-transfected
cells (19, 20). Ectopic expression of Smurf1 in 2T3 osteoblast precursors
and C2C12 myoblast/osteoblast precursors induces the proteasomal
degradation of Smad1 and Runx2 proteins, leading to inhibition of
osteoblast differentiation (17). Smurf1 blocks BMP-induced osteogenic
conversion of C2C12 cells and facilitates their myogenic differentiation
by inducing degradation of Smad5 (16). In vitro, Smurf1 also targets a
member of the Rho family of small GTPases, RhoA, for ubiquitination
and degradation (21, 22). In vivo, overexpression of Smurf1 in osteo-
blasts by the osteoblast-specific type I collagen (Col1a1) promoter leads
to reduction in osteoblast proliferation and activity. Col1a1-Smurf1
transgenic mice have decreased bone formation rates and decreased
Runx2 protein expression in osteoblasts (18). Smurf1 knock-out
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(Smurf1/) mice were generated recently. Although they survive to
adulthood, they exhibit an age-dependent increase in bone mass (23).
Interestingly, osteoblasts from Smurf1/mice have normal levels of
the BMP receptors, Smad1, 2, 3, and 5, and Runx2, all of which have
been defined previously as targets of Smurf1. Because Smurf1 and
Smurf2 possess overlapping functions, it is possible that Smurf2 com-
pensates for the loss of Smurf1 in these knock-out animals (19, 20, 24).
Currently, the role of Smurf2 in osteoblast function in vivo and the role
of Smurf E3 ligases in the pathogenesis of bone diseases remain poorly
understood. Additionally, there is little information on the regulation of
Smurfs expression under physiological and pathological conditions.
To explore the molecular mechanisms of TNF-mediated osteoblast
inhibition, we tested the hypothesis that TNF inhibits osteoblastic bone
formation by up-regulating Smurf E3 ligases that degrade Runx2 pro-
tein. We found that TNF increased Smurf1 and Smurf2 expression in
osteoblasts, leading to enhanced ubiquitination and degradation of
Runx2 protein. This TNF-induced Runx2 degradation was reversed by
proteasome inhibitors and by knocking down endogenous Smurf1 or
Smurf2 using small interfering RNA (siRNA) against Smurf1 or Smurf2.
Bones from TNF-overexpressing mice exhibited increased Smurf1 and
decreased Runx2 protein levels. Taken together, our findings point to a
novel molecular mechanism of TNF inhibition of osteoblasts, which
involves post-transcriptional regulation of protein function through
Smurf E3 ligase-mediated proteasomal degradation.
MATERIALS ANDMETHODS
Animals—TNF transgenic (Tg) mice in a CBA  C57BL/6 back-
ground (3647 TNF-Tg line) were obtained fromDr. G. Kollias. C57BL/6
mice were purchased from Jackson Laboratories (Bar Harbor,ME). The
Institutional Animal Care and Use Committee approved all animal
studies.
Antibodies—Monoclonal antibodies specific for FLAG and -actin
were purchased from Sigma. Anti-Runx2 monoclonal antibody was
from MBL (Woburn, MA). Anti-ubiquitin monoclonal antibody was
from Santa Cruz (Santa Cruz, CA). Anti-Smurf1 polyclonal antibody
was from Abgent (San Diego, CA).
Cell Culture and Transfection Conditions—C2C12 myoblast/osteo-
blast precursors were cultured in Dulbecco’s modified Eagle’s medium,
and 2T3 osteoblast precursors were cultured in -minimal essential
medium supplemented with 1% penicillin-streptomycin (all from
Invitrogen) and 10% fetal calf serum (JRH Biosciences, Lenexa, KS).
When cells were grown to 90% confluence, the cDNA expression plas-
mid, pCMV-FLAG-tagged Runx2 (F-Runx2) and/or a pCMV-Myc-
tagged Smurf1 (M-Smurf1) were transiently transfected into the cells
using Lipofectamine 2000 transfection reagent (Invitrogen) according
to the manufacturer’s instructions. Total amounts of transfected plas-
mids in each group were equalized by the addition of empty vector.
After transfection (24 h), the cells were cultured further in the presence
and absence of murine TNF (R&D Systems) and subjected to reverse
transcription (RT)-PCR or Western blot analysis.
Bone Nodule Formation—Bone marrow cells were flushed from the
tibiae and femur of wild type (wt) and TNF-Tg mice, and the cells were
seeded at a density of 2 106/ml. The cells were cultured in 37 °C with
a humidified 5% CO2 atmosphere. When the cells reached confluence
(day 0), the medium was changed to an osteoblast-inducing medium
(-minimal essential medium-supplemented 10% fetal calf serum with
100g/ml L-ascorbic acid and 5mM -glycerophosphate) with or with-
out 40 ng/ml BMP-2, and the medium was changed twice a week.
After an 18-day incubation, the cells were fixed with 10% formalin
and stained by the von-Kossa method. The area of mineralized bone
nodules was determined under light microscopy by point counting, as
described previously (25).
Quantitative Real Time RT-PCR—Cells were homogenized using 1
ml of TRIzol reagent (Invitrogen), and total RNAwas extracted accord-
ing to the manufacturer’s protocol. cDNA was synthesized using 20 l
of reverse transcription reaction solution containing 1 g of total RNA,
10 mM Tris-HCl buffer (pH 8.3), 50 mM KCl, 5 mM MgCl2, 1 mM
deoxynucleoside triphosphates, 2.5 M random hexamers, 20 units
RNase inhibitor, and 50 units ofMoloneymurine leukemia virus reverse
transcriptase (all from Roche Applied Science). Quantitative real time
PCR amplifications were performed in an iCycler real time PCR
machine using iQ SYBR Green supermix (both from Bio-Rad Labora-
tories) according to the manufacturer’s instruction. The sequences of
primer sets for Smurf1, Smurf2, alkaline phosphatase (ALP), osteocalcin
(OC), and -actinmRNAs, target sites on mRNAs and product sizes by
PCR are shown in Table 1. To minimize the background of products
amplified from genomic DNAs, these primers were designed to exist on
two different exons. The quantity of Smurf1, Smurf2, ALP, and OC
mRNA in each sample was normalized using the CT (threshold cycle)
value obtained for the -actinmRNA amplifications.
Western Blot Analysis—Cells werewashedwith cold phosphate-buff-
ered saline (PBS), andwhole cell lysateswere prepared by the addition of
M-PER mammalian protein extraction reagent (Pierce) containing a
protease inhibitor mixture (Roche Applied Science). Twenty g of pro-
tein was loaded per lane and separated on a 10% polyacrylamide gel,
followed by transfer to a nitrocellulose membrane (Bio-Rad) by electro-
blotting. Membrane was blocked for nonspecific binding in 3% nonfat
dry milk and followed by incubation with an antibody at 4 °C. After
membrane was washed, the blots were probed with a horseradish per-
oxidase-conjugated secondary antibody (Bio-Rad) and visualized by an
enhanced chemiluminescence system (AmershamBiosciences) accord-
ing to the manufacturer’s instructions.
TABLE 1
Sequences of primers used in the real time PCR
Genes GenBankTM accession number Sequences of primersa Target sites on genes Product sizes
bp
Smurf1 NM029438 F: 5-AGTTCGTGGCCAAATAGTGG-3 687–785 99
R: 5-GTTCCTTCGTTCTCCAGCAG-3
Smurf2 NM 025481 F: 5-GTGAAGAGCTCGGTCCTTTG-3 1041–1154 114
R: 5-AGAGCCGGGGATCTGTAAAT-3
ALP AF285233 F: 5-CGGGACTGGTACTCGGATAA-3 550–706 157
R: 5-ATTCCACGTCGGTTCTGTTC-3
OC AH004426 F: 5-CTTGGTGCACACCTAGCAGA-3 638–824 186
R: 5-CTCCCTCATGTGTTGTCCCT-3
-actin NM 001101 F: 5-AGATGTGGATCAGCAAGCAG-3 1134–1251 118
R: 5-GCGCAAGTTAGGTTTTGTCA-3
a F, forward primer; R, reverse primer.
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Ubiquitination of Runx2—2T3 cells were incubated in medium con-
taining 7.5 ng/ml TNF for 72 h in the presence of PBS or 0.1mMMG132
(Calbiochem) for the last 12 h of TNF treatment. For the immunopre-
cipitation, cell lysate was incubatedwith anti-Runx2 antibody overnight
at 4 °C followed by the addition of protein G-agarose (Roche Applied
Science) overnight at 4 °C. The immunoprecipitates were washed with
50 mM Tris-HCl buffer (pH 8.0), containing 150 mM NaCl, 1% Nonidet
P-40, 0.05% deoxycholate, and 0.1% SDS, resuspended in 1 reducing
sample buffer, and subjected to Western blot analysis with an anti-
ubiquitin antibody. The samemembrane was stripped and reprobed for
Runx2.
siRNA and Virus Infection—Platinum-E cells were transfected with a
retrovirus vector (pRetro-H1G) that encodes Smurf1 or Smurf2 siRNA,
or an empty vector using FuGENE 6 reagent (Roche Applied Science).
The sequences of Smurf1 and Smurf2 siRNAs are shown in Table 2.
After 2 days, viral supernatants were harvested and filtered using a
0.45-m membrane filter. 2T3 cells were infected with virus superna-
tant in the presence of Polybrene. After 4 h, 2 ml of -minimal essential
medium was added to the cells to dilute Polybrene. The cells were cul-
tured for an additional 48 h in -minimal essential medium containing
10% fetal bovine serum. The cells were then used for RNA extraction or
Western blot analysis.
Luciferase Assay—2T3 cells were transfected with the BMP,
12SBE-OC-Luc (17) or the TGF-, p3TP-Lux (18), signaling reporter
construct using Lipofectamine 2000 transfection reagent. After 6 h, cells
were treated with 10 ng/ml TNF for 48 h, followed by a 24-h incubation
in the presence or absence of 50 ng/ml BMP-2 or 2 ng/ml TGF- (both
from R&D Systems). For determination of the effect of TNF on Runx2
expression, 2T3 cells were cotransfected with a Runx2 expression vec-
tor, F-Runx2, and the Runx2 reporter construct, 6OSE2-OC-pGL3
(17) followed by a 48-h TNF treatment. Cell lysates were extracted, and
luciferase activity wasmeasured using a Dual Luciferase Reporter Assay
System (Promega) and normalized by Renilla luciferase activity.
Caspase-3 Assay—2T3 cells were treated with TNF (2.5, 5, and 7.5
ng/ml) for 24, 48, and 72 h and then lysed in a buffer containing 1%
Nonidet P-40, 200 mM NaCl, 20 mM Tris-HCl (pH 7.4), 10 g/ml leu-
peptin, and aprotinin (0.27mM trypsin inhibitor/ml). Caspase-3 activity
was determined by incubation of cell lysate (containing 25 g of total
protein) with 50 M fluorogenic substrate,N-acetyl-Asp-Glu-Val-Asp-
7-amino-4-methylcoumarin (Calbiochem) in 200 l of 10 mM HEPES
(pH 7.4), containing 220 mM mannitol, 68 mM sucrose, 2 mM NaCl, 2.5
mM KH2PO4, 0.5 mM EGTA, 2 mM MgCl2, 5 mM pyruvate, 0.1 mM
phenylmethylsulfonyl fluoride, and 1 mM dithiothreitol. The release of
fluorescent 7-amino-4-methylcoumarin was measured by spectroflu-
orometry (excitation/emission, 499/521 nm).
MTT Cell Viability Assay—Cell viability was determined by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT,
Sigma) dye reduction assay according to themethod of Green et al. (26).
Briefly, after cells in 96-well plates were treated with various concentra-
tions of TNF for 24, 48, or 96 h, 10l ofMTTwas added for 3 h, and the
absorbance was read at 540 nm. Cell viability was calculated as the ratio
of optical densities in wells with and without TNF.
Statistics Analysis—All data are represented as themean S.E. Com-
parisons of results were performed by paired Student’s t tests, accepting
p 0.05 as the criterion of significance. All experiments were repeated
at least twice with similar results.
RESULTS
TNF-Tg Mice Have Reduced Osteoblast Function—The TNF trans-
genic mouse is a well established animal model of rheumatoid arthritis,
which exhibits polyarthritis because of chronic exposure to low levels of
TNF (27). At 3–4 months of age, TNF-Tg mice develop a moderate to
severe form of rheumatoid arthritis-like joint inflammation and
destruction. This is characterized by chronic inflammation, local bone
and cartilage erosion, and increased circulating TNF levels (27, 28).
Apart from these well described features, animals develop general
osteoporosis as show in Fig. 1A. Trabecular bone ismarkedly reduced in
FIGURE1.Decreasedbonevolumeandosteoblast functions inTNF-Tgmice.A, femur
from a 4-month-old TNF-Tgmouse and a wt littermate were fixed and processed. Paraf-
fin-embedded sectionswere stainedwith hematoxylin and eosin. Lower bone volume in
themetaphysis of the femur (green stars) is present in the TNF-Tgmouse (magnification,
4). B, the distal femoral trabecular bone volumewasmeasured as described previously
(38). The values are the mean S.E. of eight or nine mice. *, p 0.05 versus wt mice. C,
bone marrow stromal cells were isolated from 4-month-old TNF-Tg mice and wt litter-
mates and cultured in osteoblast differentiationmedium containing 100g/ml L-ascor-
bic acid and 5mM-glycerophosphate in the presence or absence of 40 ng/ml BMP-2 for
2 weeks. The cells were fixed, and mineralized bone nodules were identified by von-
Kossa staining. The area of bone nodules was measured under light microscopy using
point counting. The values are the mean S.E. of three wells. *, p 0.05 versuswt cells.
The same results were obtained from three pairs of TNF-Tg mice and wt littermates. D,
mineralized bone nodules from one representative pair of TNF-Tg mice and wt litter-
mates (magnification,2).
TABLE 2
Sequences of siRNA used in the infection
Target genesa Sequences of siRNAb Target sites on mRNA
Smurf1 (NM 029438) 5-GATTCGAACCTTGCAAAGAAAGAC 372–390
ttcaagagaGTCTTTCTTTGCAAGGTTCTTTTTTC-3
Smurf2 (NM 025481) 5-GATTCGACCAACAGCAACAGCAAG 1199–1217
ttcaagagaCTTGCTGTTGCTGTTGGTCTTTTTTC-3
a Parentheses indicate GenBankTM accession numbers.
b siRNAs are designated to encode two complementary sequences of 19 nucleotides homologous to a segment of Smurf1 or Smurf2 mRNA (underlined) separated by a
nine-nucleotide space (small characters), and have a terminator signal (TTTTTTC) at a 3 terminus.
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themetaphysis of long bones of TNF-Tgmice, compared with wt litter-
mates (Fig. 1B). To examine whether osteoblast function is altered in
TNF-Tg mice, bone marrow stromal cells were isolated from 4-month-
old TNF-Tg mice and wt littermates. Cells were cultured in osteoblast
differentiation medium to form mineralized bone nodules. Compared
with wt mice, cells from TNF-Tg mice formed significantly fewer and
smaller nodules under basal conditions and in the presence of BMP-2
(Fig. 1, C and D), indicating reduced osteoblast function.
FIGURE 2. TNF increases Smurf1 expression and
induces Runx2 degradation. A, C2C12 or 2T3
cells were treated with PBS or TNF (2.5–7.5 ng/ml)
for 24, 48, and 72 h. Smurf1 and -actinmRNA lev-
els were measured by real time RT-PCR. The rela-
tive expression level of Smurf1 was normalized to
-actin in the same sample. The -fold increase was
calculated as follows: (relative Smurf1 level in TNF-
treated sample)/(relative Smurf1 level in PBS-
treated sample). The values are themean S.E. of
three dishes. *, p  0.05 versus the PBS-treated
group.B, cellswere treatedwith 2.5–7.5 ng/ml TNF
for 72 h. Smurf1 and -actin protein levels were
examined by Western blot analysis. C, cells were
treated with various doses of IL-1 and RANKL and
with 7.5 ng/ml TNF for 72 h. The relative expres-
sion levels of Smurf1 mRNA were determined by
real time RT-PCR, as described in A. The values are
the mean S.E. of three dishes. *, p 0.05 versus
the PBS-treated group. D, cells were treated with
2.5–7.5 ng/ml TNF for 24, 48, and 72 h. Cell lysates
were used formeasuring caspase-3 activity orMTT
assay. The values are the mean  S.E. of three
dishes. *, p 0.05 versus the PBS-treated group. E,
cells were transfected with M-Smurf1 and/or
F-Runx2 expression plasmids or empty vector for
24 h and cultured for 72 h in thepresence of PBS or
TNF (2.5–7.5 ng/ml). F-Runx2 expression was
detected by Western blot using anti-FLAG
antibody.
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TNF Increases Smurf1 Expression, Runx2 Degradation, and Ubiquiti-
nation of Runx2 Protein—Smurf1 is a negative regulator of the BMP
signaling pathway and inhibits osteoblast function by promoting Runx2
degradation (17). To determine whether TNF affects Smurf1 expres-
sion, C2C12 myoblast/osteoblast precursor cells, 2T3 osteoblast pre-
cursors, and primary wt calvarial preosteoblasts were treated with PBS
or 2.5–7.5 ng/ml TNF. Smurf1 expression was measured by real time
RT-PCR at 24, 48, and 72 h. The highest dose of TNF (7.5 ng/ml) sig-
nificantly increased Smurf1mRNA levels at 24 h in both cell lines, with
the highest indication being observed at 72 h. At this time, the lowest
dose of TNF (2.5 ng/ml) also had increased Smurf1 mRNA expression
(Fig. 2A). TNF-induced Smurf1 expression was similar in 2T3 and
C2C12 cells. No significant increase in Smurf1 level was observed when
the cells were treated with 7.5 ng/ml TNF for 2, 4, 8, and 12 h (data not
shown). Consistent with these mRNA results, TNF increased Smurf1
protein expression in a dose-dependent manner after 24 h (Fig. 2B).
Similarly, TNF also increased Smurf1 expression in primary preosteo-
blasts. TNF increased Smurf1 mRNA levels in these cells by 4–5-fold
over the PBS-treated cells at 48 h (the ratio of Smurf1/-actin in TNF-
treated group versus that from PBS group: 4.7  0.14, p  0.002). To
determine the specificity of TNF for Smurf1, C2C12 and 2T3 cells were
treated with IL-1 or receptor activator NF-B ligand (RANKL) that
activate intracellular signaling pathways similar to those activated by
TNF. They did not alter Smurf1 mRNA abundance (Fig. 2C). These
doses of IL-1 and RANKL (10 ng/ml) stimulate osteoclast formation
from osteoclast precursors (data not shown).
To examine whether TNF-induced apoptosis is associated with
increased Smurf1 expression, 2T3 cells were treated with various doses
of TNF for 24, 48, and 72 h. Apoptosis was determined by measuring
caspase-3 activity and cell viability by MTT assay. Smurf1 mRNA
expression was examined by real time PCR in the same samples. At the
doses (2.5–7.5 ng/ml) that TNF increased Smurf1 expression (data not
shown), osteoblasts were morphological normal with normal caspase-3
activity (Fig. 2D). In contrast, cells treated with 10 and 20 ng/ml TNF
induced cell apoptosis, and dead cells were detached from the culture
plates (data not shown).
To determine whether TNF induces Runx2 degradation, C2C12 or
2T3 cells were cotransfected with FLAG-tagged-Runx2 (F-Runx2)
and/or Myc-tagged-Smurf1 (M-Smurf1) expression vectors or an
empty vector in the presence of TNF. F-Runx2 expression was detected
by Western blot analysis using an anti-FLAG antibody. As a positive
control, Smurf1 overexpression decreased F-Runx2 protein levels. Sim-
ilar to Smurf1 overexpression, TNF significantly reduced F-Runx2 pro-
tein levels in a dose-dependent manner (Fig. 2E).
Smurf1 induces Runx2 degradation by increasing its ubiquitination
(17). If TNF-induced Runx2 degradation is mediated by Smurf1, we
should be able to detect increased ubiquitinated-Runx2 complexes in
TNF-treated cells. To test this hypothesis, 2T3 cells were treated with
TNF in the presence and absence of the proteasomal inhibitor MG132,
and endogenous Runx2 protein was immunoprecipitated with an anti-
Runx2 antibody and followed by Western blot analysis using an anti-
ubiquitin antibody. MG132 treatment revealed small amounts of ubiq-
uitinated Runx2 in vehicle-treated cells. These were greatly increased in
the presence of TNF (Fig. 3), indicating that TNF induces ubiquitination
of Runx2 protein, leading to its rapid breakdown through proteasomal
degradation.
TNF-induced Runx2 Degradation Is Dependent on Smurf1 and
Smurf2—To determine whether TNF-induced Runx2 degradation is
dependent on Smurf1, 2T3 cells were infected first with retroviral
supernatant containing double-stranded siRNA specific for Smurf1 to
knock down endogenous Smurf1. They were then transfected with
F-Runx2 in the presence of TNF. Smurf1 siRNA decreased TNF-in-
duced Smurf1 mRNA by 95% and reduced Smurf1 expression in PBS-
treated cells to almost undetectable levels (Fig. 4A). Without changing
the expression of Smurf2 mRNA (Fig. 4B), Smurf1 siRNA partially
blocked TNF-mediated inhibition of ALPmRNA expression compared
with the empty vector control (Fig. 4C) and reduced TNF-induced
Runx2 degradation by 30% (by a densitometric analysis, Fig. 4D). Inter-
estingly, Smurf1 siRNA alone increased ALPmRNA levels by 58%, sug-
gesting that Smurf1 may regulate osteoblast function under basal
conditions.
Smurf2 is another E3 ubiquitin ligase that affects osteoblast function
by interfering with TGF- signaling (20). To examine whether TNF
regulates Smurf2 expression, 2T3 cells were treated with PBS or TNF
(7.5 ng/ml) for 72 h, and Smurf2 mRNA levels were examined by real
time RT-PCR. Similar to, but to a lesser extent than Smurf1, TNF sig-
nificantly increased Smurf2mRNA by 9.5 0.88-fold (p 0.004 versus
PBS-treated cells). Because there is no Smurf2 antibody available to
detectmouse Smurf2, the effect of TNF on Smurf2 protein levels cannot
be assessed currently. To examine whether TNF-induced Runx2 degra-
dation is also mediated by Smurf2, we used Smurf2 siRNA. Similar to
Smurf1 siRNA, blocking endogenous Smurf2 led to reduced TNF-me-
diated inhibition of ALP expression and TNF-induced Runx2 degrada-
tion (Fig. 4,C andD) to a similar extent. Combining Smurf1 and Smurf2
siRNAs further prevented TNF-induced Runx2 degradation by 60%
(Fig. 4C).
TNF Inhibits BMP and TGF- Signaling through Individual Smurfs,
and Its Inhibition on Runx2 Is Mediated by Both Smurf1 and Smurf2—
Smurf1 recognizes and directs the ubiquitination and proteosomal deg-
radation of Smad1 and 5 (15), whereas Smurf2 acts on both Smad1 and
2, but not Smad3 (20). Therefore, Smurf1 is thought to target BMP-2
and Smurf2 to target TGF- signaling (14). Because TNF increases
Smurf1 and Smurf2, it should target the BMP-2 and/or TGF- signaling
pathways. To test this, 2T3 cells were transfected with the Runx2, BMP,
or TGF- reporter constructs and a Runx2 expression vector or treated
with BMP-2 or TGF-, in the presence or absence of TNF in a luciferase
reporter assay. Smurf1 and/or Smurf2, or control siRNA was used to
determine whether blockade of Smurfs affects the effect of TNF. TNF
significantly inhibited a Runx2-induced increase in Runx2 reporter by
86% (Fig. 5A). Smurf1 siRNAor Smurf2 siRNA alone reduced the inhib-
itory effect of TNF by 30–40%, and a combination of Smurf1 and
FIGURE 3. TNF induces ubiquitination of Runx2 protein. 2T3 cells were treated with
7.5ng/ml TNF for 72h in thepresenceor absenceof 0.1mMMG132 for the last 12hof TNF
treatment, and endogenous Runx2 was immunoprecipitated (IP) by anti-Runx2 anti-
body. Ubiquitinated Runx2 (Ub-Runx2) protein ladders were detected by anti-ubiquitin
antibody (upper panel). After stripping the antibody, total un-ubiquitinated Runx2 pro-
tein levels were determined by anti-Runx2 antibody (lower panel).MW, molecular mass.
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Smurf2 siRNA further inhibited TNF action by 60–80%, indicating an
additive effect (Fig. 5A). In contrast to the partial reduction of the effect
of TNF on Runx2 reporter, Smurf1 siRNA alone reduced TNF-medi-
ated inhibition of the BMP-2 signaling reporter by 90%, whereas Smurf2
siRNA had no effect (Fig. 5B). Smurf2 siRNA blocked TNF-mediated
TGF- signaling reporter inhibition by 60%, and Smurf1 siRNA had no
effect (Fig. 5C). A combination of Smurf1 and Smurf2 siRNA had no
additive effect on TNF inhibition on the BMP-2 or TGF- signaling
reporter. Thus, although TNF inhibits Runx2 activation through both
Smurf1 and Smurf2, its inhibition in the BMP-2 and TGF- signaling
pathways is through Smurf1 and Smurf2, respectively.
TNF-overexpressing Mice Have Increased Smurf1 and Decreased
Runx2 Expression—If Smurfs are responsible for reduced osteoblast
function in conditions inwhichTNF is overexpressed,we should be able
to detect elevated Smurf levels in TNF-Tg mice or mice receiving TNF
treatment. To examine this, total RNAwas extracted from the metaph-
ysis of 4-month-old TNF-Tg mice and wt littermates, and the expres-
sion of Smurf1, Smurf2,ALP, andOCmRNAwas examined by real time
RT-PCR. Compared with that of wt mice, the expression of Smurf1was
significantly increased, and ALP and OC expression was decreased in
TNF-Tg mice (Fig. 6A). No change of Smurf2 mRNA expression was
observed (data not shown). Western blot analysis revealed that Smurf1
protein was increased, and Runx2 protein was decreased (Fig. 6A). To
determine the acute effect of TNF on Smurf and osteoblast marker gene
expression, wt mice were injected with TNF (0.25 g/injection, three
times/day 3 days) or PBS over the calvarial bones. The expression of
Smurf1, Smurf2, ALP, and OC mRNA was assessed. Similar to the
results obtained from TNF-Tg mice, the expression of Smurf1 was
increased at bothmRNAand protein levels. Runx2 protein andALP and
OC mRNA levels were decreased in TNF-treated wt mice (Fig. 6B).
These results suggest that TNF may inhibit osteoblast function in vivo
FIGURE 4. Smurf1 or Smurf2 siRNA blocks TNF-induced Runx2 degradation. 2T3
cells were infectedwith retroviral supernatant containing Smurf1 and/or Smurf2 siRNAs
or empty vector, then cells were transfected with F-Runx2 expression plasmid (4
g/dish) and treated with 7.5 ng/ml TNF for 72 h. Smurf1 (A) and Smurf2 (B) mRNA levels
were measured by real time RT-PCR. The values are the mean S.E. of three dishes. The
-fold increase was calculated as described in Fig. 2A. *, p 0.05 versus the empty vector-
infected TNF group. C, the expression of F-Runx2 was determined byWestern blot anal-
ysis using anti-FLAG antibody as described in Fig. 2E. D, ALP mRNA expression was
assessed by real time RT-PCR. The values are the mean S.E. of three dishes. The -fold
increase was calculated as described in Fig. 2A. *, p 0.05 versus empty vector-infected
TNF group.
FIGURE 5. TNF targets both BMP and TGF- signaling pathways in osteoblasts. A,
2T3 cells were infected with retroviral supernatant containing Smurf1 and/or Smurf2
siRNAs or empty vector, then cells were cotransfected with the Runx2 expression vector
(Runx2), the empty expression vector (p3FAG-CMV), and the Runx2 reporter vector
(6OSE2-OC-Luc) for 8 h and then treatedwith 7.5 ng/ml TNF for 48 h. B and C, 2T3 cells
were infected with retroviral supernatant containing Smurf1 and/or Smurf2 siRNA or
empty vector, then the BMP-2 and TGF- signaling reporter constructs, 12SBE-OC-Luc
(B) or p3TP-Lux (C) were transfected into cells for 8 h. The cells were treated with 7.5
ng/ml TNF for 48 h and then stimulatedwith 50 ng/ml BMP-2 (B) or 2 ng/ml TGF- (C) for
24 h in the presence of PBS or 10 ng/ml TNF. The values are the mean  S.E. of three
dishes. *, p 0.05 versus empty vector-infected TNF group.
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by promoting Runx2 degradation through up-regulation of Smurf E3
ligases.
DISCUSSION
TNF is a central proinflammatory cytokine that contributes to local
and systemic bone loss in inflammatory bone diseases, such as rheuma-
toid arthritis. Under these conditions, osteoblast-mediated bone forma-
tion cannot compensate for accelerated osteoclastic bone resorption,
suggesting a direct inhibitory effect of TNF on osteoblasts. Here we
provide evidence for the regulation of osteoblast-specific transcription
factor Runx2 stability by TNF through the E3 ligases, Smurf1 and
Smurf2. Although overexpression of Smurfs has been known to pro-
mote Runx2 degradation in vitro, our findings provide the first report
that TNF inhibits osteoblast function by controlling the ubiquitination
status of Runx2 protein through Smurfs. We have several lines of evi-
dence implicating Smurfs in the regulation of TNF-induced Runx2
ubiquitination and degradation: (i) TNF promoted ubiquitination and
degradation of transfected and endogenous Runx2; (ii) it increased the
expression levels of Smurf1 and Smurf2; (iii) TNF-induced ubiquitina-
tion and degradation of Runx2 were attenuated in cells overexpressing
Smurf1 and Smurf2 siRNA; (iv) expression of Smurf1 and Smurf2
siRNA rescued the inhibitory effect of TNF on Runx2 reporter; (v)
bones of mice that have elevated TNF levels have increased Smurf1 and
decreasedRunx2 protein expression. In 2002,Gilbert et al. (10) reported
that TNF reduced nuclear Runx2 protein in osteoblasts by 90%, but it
inhibited Runx2 transcription only by 40–50%. They proposed that
there may be other mechanism(s) accounting for the 90% reduction in
Runx2 protein. Here, we found that overexpression of Smurf1 and
Smurf2 siRNA can reverse TNF-induced down-regulation of Runx2
protein by 50–60% (Fig. 4D). We suspect that there may also be tran-
scriptional inhibition of Runx2 to complement this TNF-induced
reduction in protein expression. Thus, our data complement Gilbert’s
results and demonstrate that TNF regulates Runx2 by two distinct
mechanisms: it inhibits Runx2 gene transcription and promotes Runx2
protein degradation through Smurf E3 ligases.
TNF has been implicated in mediating protein degradation through
several E3 ligases in other cell types. For example, TNF induces TNF
receptor-associated factor (TRAF)2 degradation in HeLa cells and
mouse embryonic fibroblasts through a RING-type ubiquitin ligase,
Siah2 (29). It stimulates expression of the gene for a F-box E3 ligase,
atrogin1/MAFbx (30), which is involved in muscle atrophy (31) and
sepsis (32). Interestingly, TNF-induced TRAF2 degradation or up-reg-
ulation of atrogin1/MAFbx occurs within 4 h, and this is within the
same time frame that treatment of bone marrow cells with RANKL and
interferon- resulted in degradation of TRAF6 (33). In contrast, TNF-
induced Smurf up-regulation and Runx2 degradation take 24–72 h (Fig.
2), suggesting an indirect effect. We have attempted to dissect the pos-
sible requirements of transcription or translation for TNF-increased
Smurf expression using pharmacological blockers. Unfortunately,
blocking of transcription or translation by cycloheximide or actinomy-
cin D in the presence of TNF causes massive apoptosis of cells, and thus
we could not determine whether newly synthesized proteins are
required for TNF-induced Smurf expression. Nevertheless, given that
TNF induces various E3 ligases at different times, it is possible that TNF
uses different types of E3 ligases to regulate the stability of specific
targeting proteins in response to various stimuli. For example, TNF
stimulates Siah2 and atrogin1/MAFbx E3 ligases in response to early
signaling events during acute stress conditions and increases Smurf
expression to regulate protein degradation in chronic conditions, such
as rheumatoid arthritis and cancer (34).
TNF binds to TNF receptors and transduces the signals through
TRAFs and various kinases to activate transcription factors, such as
NF-B and AP-1 family members. Activation of the IL-1 receptor via
IL-1 or RANK through RANKL results in the activation of similar sig-
naling pathways.Our finding that IL-1 andRANKLdonot affect Smurf1
expression is interesting. There are several possible explanations: (i)
osteoblasts do not express RANK, the receptor for RANKL, and thus
they cannot respond to RANKL treatment. Whether osteoblasts
express functional RANK is an issue of debate. It has been reported that
glutathione S-transferase-RANKL stimulates osteoblast bone forming
activity in vitro and in vivo (35). However, others argued that RANKL
has no effect on osteoblasts because they do not express RANK. We
have been unable to detect any effect of RANKL on osteoblast function
in various assays,3 suggesting that RANKL may not play an important
role in this cell type. (ii) IL-1 may affect Smurfs in experimental condi-
tions that differ fromours, given the fact that in some reports IL-1 has an
inhibitory effect on osteoblast function. (iii) TNF may use a unique
mechanism to regulate Smurf expression. Thus, characterization of the
Smurf1 and Smurf2 promoters should have a great impact on our
understanding of how Smurfs are regulated by TNF.
Unlike other cytokines, TNF is a strong apoptosis inducer (36, 37),
and thus increased Smurf expression could be associated with TNF-
3 H. Kaneki, R. Guo, D. Chen, Z. Yao, E. M. Schwarz, Y. E. Zhang, B. F. Boyce, and L. Xing,
unpublished findings.
FIGURE 6.TNF increases Smurf1 expression in vivo.A, RNA andproteinwere extracted
directly from the metaphyseal region of 4-month-old TNF-Tg mice and wt littermates.
The relative expression levels of Smurf1,ALP, andOCweremeasured by real time RT-PCR
(upper panels), as described in Fig. 2. The values are the mean  S.E. of four pairs of
TNF-Tg and wt mice. *, p 0.05 versus wt mice. Smurf1 and -actin protein levels were
determined byWestern blot analysis (lower panels). The data are representative of three
pairs of TNF-Tg or wtmice. B, TNF (0.25g/injection, three times/day 3 days, n 2) or
PBS was injected over the calvarial bones of wt mice. RNA and protein were extracted
directly from calvarial bones. Expression levels of Smurf1,ALP, andOCmRNAand Smurf1
and -actin protein were examined as described in A. The data show the values of indi-
vidual mice.
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induced cell death. Because Smurf1-overexpressing 2T3 cells and osteo-
blasts in Col1a1-Smurf1 transgenicmice have rates of cell survival com-
parable with those of empty vector-overexpressing or wt cells (17, 18),
elevated Smurf1 appears not to result in osteoblast apoptosis. Our find-
ing that at the doses that TNF induced Smurf 1 expression, osteoblasts
are normal suggests that increased Smurf1 is not associated with cell
apoptosis (Fig. 2).
It is of interest to note that even though only increased Smurf1
expression was detected in bones of TNF transgenic mice or TNF-
injected wt mice (Fig. 6), TNF increased both Smurf1 and Smurf2
expression in vitro (Figs. 2 and 4). One explanation is that Smurf1 and
Smurf2may have different response thresholds toTNF in vivo. Support-
ing this, our preliminary results showed that in joints of TNF-Tg mice
where TNF levels were extremely high (40-fold over wt mice), both
Smurf1 and Smurf2 levels were increased although the increase in
Smurf2 was half of that of Smurf1. This is important because cells from
Smurf1-null mice exhibit normal levels of Runx2 and BMP-Smads,
which is explained by elevated Smurf2 expression in the absence of
Smurf1 (23). By increasing both Smurf1 and Smurf2 in osteoblasts, TNF
can overcome this compensatory effect between Smurf1 and Smurf2 to
induce Runx2 degradation in vivo (Fig. 6). However, the real significance
of Smurf1-mediated protein degradation in TNF-induced osteoblast
inhibition needs to wait for in vivo data from TNF-Tg/Smurf1 knock-
out hybrid mice.
It is unlikely that increasing protein breakdown is the only mecha-
nism by which TNF executes its effect in bone cells.We have found that
TNF increased Smurf1 expression in several types of osteoblast precur-
sors, including MC3T3E1 (data not shown), 2T3, and primary calvarial
cells. Interestingly, TNF also increases Smurf1 expression in C2C12
cells (Fig. 2). Because untreated C2C12 cells have multiple potency to
differentiate to other cell types, we do not know whether TNF-induced
Smurf1/2 expression represents a generalized feature of connective tis-
sue cell signaling response to TNF. However, TNF had no effect on
Smurf1 expression in osteoclast precursors derived from bone marrow,
spleen, and peripheral blood, or in ST2 murine stromal cells under the
same experimental conditions (data not shown). Thus, TNF-induced
Smurf expression does not appear as a common phenomenon for all cell
types. Whether Smurfs have different target proteins in different cells
needs to be investigated further.
In summary, our findings reveal a novelmechanism for TNF-induced
osteoblast inhibition: through unregulation of Smurf1 and Smurf2 E3
ligases to promote the degradation of Runx2 protein. Better delineation
of the role of TNF and perhaps other inflammatory cytokines in protea-
somal regulation of protein function by Smurf E3 ligase in osteoblasts
will enhance our understanding of the molecular mechanisms respon-
sible for local or general bone loss in inflammatory bone diseases.
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Dimorphic effects of Notch signaling in bone homeostasis
Feyza Engin1, Zhenqiang Yao2,6, Tao Yang1,6, Guang Zhou1, Terry Bertin1, Ming Ming Jiang1,3, Yuqing Chen1,3,
Lisa Wang4, Hui Zheng1, Richard E Sutton5, Brendan F Boyce2 & Brendan Lee1,3
Notch signaling is a key mechanism in the control of embryogenesis. However, its in vivo function during mesenchymal cell
differentiation, and, specifically, in bone homeostasis, remains largely unknown. Here, we show that osteoblast-specific gain of
Notch function causes severe osteosclerosis owing to increased proliferation of immature osteoblasts. Under these pathological
conditions, Notch stimulates early osteoblastic proliferation by upregulating the genes encoding cyclin D, cyclin E and Sp7
(osterix). The intracellular domain of Notch1 also regulates terminal osteoblastic differentiation by directly binding Runx2 and
repressing its transactivation function. In contrast, loss of all Notch signaling in osteoblasts, generated by deletion of the genes
encoding presenilin-1 and presenilin-2 in bone, is associated with late-onset, age-related osteoporosis, which in turn results from
increased osteoblast-dependent osteoclastic activity due to decreased osteoprotegerin mRNA expression in these cells. Together,
these findings highlight the potential dimorphic effects of Notch signaling in bone homeostasis and may provide direction for
novel therapeutic applications.
Evolutionarily conserved Notch signaling has a crucial role in cell fate
determination and various developmental processes, as it translates
cell-cell interactions into specific transcriptional programs1,2. Tem-
poral and spatial modulation of this pathway can markedly affect
proliferation, differentiation and apoptotic events3. Moreover, the
timing of Notch signaling can lead to diverse effects within the same
cell lineage4,5. In mammals, activation of up to four Notch receptors
by membrane-bound ligands initiates a process leading to presenilin-
mediated cleavage and release from the membrane of the Notch
intracellular domain (NICD), which then traffics to the nucleus. The
NICD subsequently regulates the expression of genes, in cooperation
with the transcription factor RBP-Jk and Mastermind-like proteins.
The observation that mutations in the Notch ligand Delta-like–3
(Dll-3) and in the g-secretase presenilin-1 cause axial skeletal pheno-
types initially caused researchers to link Notch signaling with axial
skeletal development6,7. Recently, several in vitro studies yielded
conflicting results that implicated the Notch pathway in the regulation
of osteoblast differentiation; however, the in vivo role of Notch
signaling in bone homeostasis still remains unknown8–12.
In this study, we investigate the tissue, cellular and molecular
consequences of both gain and loss of function of Notch signaling
in committed osteoblasts.
RESULTS
Gain of Notch function results in severe osteosclerosis
To determine the pathological consequences of in vivo gain of Notch
function during bone formation and homeostasis, we generated
transgenic mice expressing the Notch1 intracellular domain
(N1ICD) under the control of the type I collagen (Col1a1) promoter
(Supplementary Fig. 1a,b online). Here, gain of Notch function
would occur in committed osteoblastic cells, as Col1a1 is both an
early and a late marker of the osteoblastic lineage. Notably, founder
mice expressing high levels of the transgene were small at birth and
showed progressive growth retardation. Analysis of three established
lines at 4 weeks of age showed increased bone mass on radiographs
and a thickened, osteosclerotic appearance after skeletal preparations
(Fig. 1a and Supplementary Fig. 1c). As determined by histology,
marrow spaces in 4-week-old transgenic mice were filled with trabe-
cular bone composed predominantly of immature woven, rather than
lamellar, bone and surrounded by fibrotic marrow containing cells
with morphologic features of early osteoblastic precursors, suggesting
the increased proliferation of these cells (Fig. 1b). The cortices of the
bones were also composed of woven bone, and this phenotype was
present in 11-week-old mice as well. Toluidine blue staining of
11-week-old transgenic mice indicated an increased number of osteo-
blasts in vertebrae (Fig. 1c). Quantitative histomorphometry of an
established mouse line confirmed the significant increase in trabecular
bone volume and osteoblast surface area, which would be consistent
with the high bone mass being due to increased osteoblastic activity
(Fig. 1d). This increased osteoblastic activity led to increased produc-
tion of osteoid (Fig. 1d) and bone formation (Supplementary Fig. 1d).
Because bone formation and resorption are coupled in vivo, we
analyzed the status of osteoclasts by staining for tartrate-resistant acid
phosphatase (TRAP) activity in osteoclasts from bone sections of
4-week-old mice. Although total TRAP staining was qualitatively
increased in the limb sections of transgenic mice (Supplementary
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Fig. 1e), consistent with increased bone mass and remodeling, the
osteoclastic parameters normalized to bone surface (that is, osteoclast
number per mm of bone surface and osteoclast surface) were
significantly decreased in trabecular bone of transgenic mice (Supple-
mentary Fig. 1e). Together, these data support the notion that gain of
Notch function in committed osteoblastic lineage cells stimulates the
proliferation of early osteoblastic precursors that differentiate into
immature osteoblasts producing increased amounts of immature
woven bone. Although osteoclastic activity was secondarily stimulated
by this massive osteoblastic proliferation, bone formation much greatly
outweighed bone resorption, leading to an osteosclerotic phenotype.
To determine the underlying cellular and molecular mechanism for
the increase in early osteoblastic precursors in transgenic bone, we
cultured postnatal day 6 (P6) calvarial osteoblasts and found signifi-
cantly increased numbers of BrdU-positive cells, consistent with
increased cellular proliferation (Fig. 1e). Quantitative real time RT-PCR
(qRT-PCR) of 1-month-old calvarial total RNA showed an increased
abundance of early osteoblastic differentiation markers, including
osterix (encoded by Sp7), alkaline phosphatase and bone sialoprotein.
In contrast, later markers of osteoblast differentiation, including
osteocalcin, were downregulated (Fig. 1f). To exclude the possibility
that the increased bone mass was due to decreased osteoclastic
activity, we assessed the expression of markers that regulate macrophage
differentiation along the osteoclastic lineage in the forelimbs of
4-week-old transgenic mice. RANK ligand (RANKL, encoded by
Tnfrsf11a), osteoprotegerin, TRAP and macrophage colony–stimulating
factor (M-CSF) were all highly expressed, suggesting that the hyper-
proliferation of the early osteoblastic pool was associated with increased
production of both pro- (RANKL and M-CSF) and anti- (osteoprote-
gerin) osteoclastic differentiation factors by osteoblasts (Fig. 1g).
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Figure 1 Gain of Notch function in transgenic mice cause osteosclerosis. (a) X-ray and skeletal preparations of 4-week-old transgenic mice show severe
osteosclerosis (white arrows) in the skull, ribs and long bones. WT, wild-type mice; Tg, transgenic mice. (b) H&E staining of 4-week-old WT (top) and Tg
(bottom) mouse hind limbs show immature woven bone formation with little distinction between cortex and marrow (black arrow). B, bone; BM, bone marrow.
Scale bars, 500 mm (left) and 50 mm (right). (c) Toluidine blue staining of lumbar sections of 11-week-old WT (top) and Tg (bottom) mice reveals an
increased number of osteoblasts (black arrow). Ob, osteoblasts lining bone. Scale bars, 500 mm (left) and 50mm (right). (d) Von Kossa staining of lumbar
sections of 11-week-old mice (top left) and trabecular bone volume density (BV/TV) analyses of 4-week- and 11-week-old mice (n ¼ 4; top right). Scale bar,
500 mm. Histomorphometric analyses of 4-week-old mice (bottom left) (n ¼ 5) and Goldner’s staining of spinal trabecular bone (bottom right). Boxed area
is enlarged in the right panel. Scale bars, 500 mm (left) and 50 mm (right). Ob.S/BS, osteoblast surface per bone surface; OS/BS, osteoid per bone surface.
(e) BrdU staining of osteoblastic cells from P6 calvaria (n ¼ 5). Scale bars, 200 mm (left) and 20 mm (right). (f) qRT-PCR of total RNA from 4-week-old
mouse calvaria (n ¼ 4). Osx, osterix; Alp, alkaline phosphatase; Bsp: bone sialoprotein; Oc, osteocalcin. (g) qRT-PCR of total RNA from 4-week-old mouse
calvaria and forelimbs (n ¼ 4). Opg, osteoprotegerin. *P o 0.05 between WT and Tg.
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Notch regulates osteoblastic transcription factors
How Notch signaling regulates these processes on a biochemical level
is unknown. Osteoblast differentiation from mesenchymal stem cells
and subsequent maturation steps require the function of the runt-
domain transcription factor Runx2 and the zinc-finger transcription
factor osterix. Runx2 is required for commitment of mesenchymal
osteochondroprogenitors to the osteoblastic lineage, differentiation
into mature osteoblasts and terminal differentiation into osteocytes. In
contrast, osterix is important in expansion of the early osteoblastic
pool13. Whereas bone sialoprotein and alkaline phosphatase are
markers of early osteoblasts, osteocalcin is a marker of later, mature
osteoblasts. To determine the mechanistic basis of Notch action in this
context, we tested the effects of Notch expression on these key
transcriptional regulators of osteoblast differentiation and maturation.
N1ICD alone was able to directly bind Runx2 and repress its
transactivation of a reporter osteocalcin enhancer in vitro (in Cos7
and rat osteosarcoma Ros17/2.8 cells; Fig. 2a–c and Supplementary
Fig. 1f). Electrophoretic mobility shift assays (EMSAs) showed that
N1ICD could inhibit Runx2 binding to a target cis element in the type
X collagen promoter (Supplementary Fig. 1g). Notably, there was
marked downregulation of Runx2 protein in P2 calvaria of transgenic
mice (Fig. 2d). Thus, the downregulation of osteocalcin and the delay
in late osteoblast differentiation in vivo is probably due, in part, to
direct repression of Runx2 by Notch at the protein level. At the same
time, we observed upregulation of osterix mRNA expression in the P2
calvaria of transgenic mice (Fig. 1f). Moreover, N1ICD activated the
Sp7 promoter in transient transfection studies in C2C12 cells that were
induced to differentiate into osteoblasts with bone morphogenic
protein-2 treatment (Fig. 2e). These data suggest that Notch can
induce proliferation of committed osteoblast precursors by directly
upregulating transcription of Sp7, while inhibiting their maturation by
repressing the function of Runx2.
To further understand the biochemical basis of the effects of
Notch on osteoblastic proliferation, we analyzed the expression of cell
cycle markers and detected increased mRNA expression of cyclin D
and cyclin A by qRT-PCR in osteoblasts overexpressing N1ICD
(Fig. 2f). This correlated with increased cyclin D and cyclin E
expression at the protein level (Fig. 2g). We did not, however,
observe significant differences in the abundance of two other
important cell cycle regulators implicated in bone homeostasis, p53
and Rb. Of note, it has been shown with in vitro and ex vivo studies
that Runx2 can suppress osteoblast proliferation and promote osteo-
blast maturation by supporting exit from the cell cycle14,15. Moreover,






























































































































































































Figure 2 Notch regulates key osteoblast transcription factors and cell cycle proteins. (a) Relative luciferase activity in Cos7 cells transfected with Runx2
and Runx2-dependent osteocalcin enhancer luciferase reporter with increasing dosage of N1ICD. Western blot analyses of cell lysates using the indicated
antibodies are shown. (b) Transfection of N1ICD inhibits endogenous Runx2 activity in ROS17/2.8 osteosarcoma cells as shown by relative luciferase activity
of the Runx2-responsive osteocalcin enhancer. Western blot analyses of cell lysates using the indicated antibodies are shown. (c) GST pull-down assay
with amino-terminal–truncated (GST-NICDRA) and carboxy-terminal–truncated (GST-NICDTAD) Notch fusion proteins and in vitro transcribed-translated,
35S-methionine–labeled Runx2 (IVT-Runx2). Strongest binding is noted with the carboxy-terminal portion of Notch. (d) Decreased Runx2 protein abundance
was detected by western blot analyses and quantified with densitometry on P2 calvarial protein extracts in Tg and WT mice. (e) Relative luciferase activity in
C2C12 cells transfected with Osterix promoter luciferase reporter gene and N1ICD. (f) qRT-PCR of cell cycle markers on RNA obtained from 4-week-old
mouse calvaria (n ¼ 4). (g) Western blot analyses of P2 calvarial protein extracts to detect cell cycle markers and quantification by densitometry. *P o 0.05
between WT and Tg.
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ubiquitination and degradation, and thus Runx2 activity can be
regulated by the cell cycle machinery16. Hence, gain of Notch function
can inhibit osteoblast maturation by direct repression of Runx2
activity, as well as by repression of Runx2’s antiproliferative effects via
cyclin D1 upregulation.
Loss of Notch signaling leads to age-related osteoporosis
To determine whether the pathological effects of gain of Notch
signaling reflect a physiological function during bone homeostasis,
we generated a tissue-specific model of loss of Notch signaling in

























































































Figure 3 Loss of Notch signaling via presenilin deletion causes osteoporosis. (a) Von Kossa staining of 6-month-old lumbar vertebrae of Psen1f/fPs2 –/–
(Control) and DKO mice showed osteoporosis. Scale bar, 500 mm. (b) Micro-CT reconstruction of distal femur from 6-month-old DKO mice showing
decreased trabecular bone. Scale bar, 1 mm. (c) Histomorphometry of 3-month-old and 6-month-old DKO L3–L4 spine showing age-related penetrance
of low bone mass phenotype. (d) TRAP staining (red) of 6-month-old lumbar vertebral sections from DKO and control mice indicated increased osteoclast
staining. Scale bar, 200 mm. (e) Histomorphometry of 6-month-old DKO and control (n ¼ 5 per group) mouse tibiae revealed decreased BV/TV (top left)
and increased osteoclast number per bone volume (N.Oc/BV; top right), osteoclast number per bone surface (N.Oc/BS), osteoclast surface per bone
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Figure 4 Loss of Notch signaling through presenilin deletion increases the osteoclastogenic pool. (a) Cocultures of WT or DKO
P7 (n ¼ 2, as indicated by ‘Pair 1’ and ‘Pair 2’) spleen cells (Spl) and osteoblasts (Ob) stained (images) and quantified
(graph) for TRAP+ osteoclasts. Scale bar, 250 mm. (b) Cocultures of P7 (n ¼ 2, as indicated by ‘Pair 1’ and ‘Pair 2’) N1ICD
lentivirus–transduced DKO osteoblasts with WT spleen cells quantified for TRAP+ osteoclasts. (c) Bone marrow cells obtained
from 3-month-old (n ¼ 3) WT and DKO mice were stained and subjected to FACS to detect the CD11b+Gr-1–/lo cells and the
c-Fms+ population specific for osteoclast precursors in both total gated and CD11b+Gr-1–/lo-gated populations. Representative
histograms show total c-Fms+ cells and c-Fms+ cells in the CD11b+Gr-1–/lo population. Percentages indicate the proportion of
total cells in a given gate (indicated by boxes). (d) qRT-PCR for osteoblast markers in total RNA obtained from P4 mouse
(DKO versus control calvaria (n ¼ 5 per group)). *P o 0.05.
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(data not shown), we abolished Notch signaling by generating null
mice for both presenilin-1 (Psen1) and presenilin-2 (Psen2). Because
Psen2-null mice are viable and fertile, we generated double homo-
zygotes for the Psen2-null allele and the Psen1 floxed allele, but
heterozygous for the type 1 collagen Cre recombinase transgene
(Psen1f/fPsen2 –/–Col1a1Cre/+, or DKO). DKO mice were compared to
their Psen1f/fPsen2 –/– littermates as controls, and efficient deletion of
the Psen1f/f allele (approximately 92%) was confirmed by RT-PCR for
presenilin mRNA expression and genomic PCR for DNA recombina-
tion in both calvarial osteoblasts and tail DNA, respectively (Supple-
mentary Fig. 2a,b online). Moreover, we confirmed that this led to
decreased NICD processing by western blot analysis (Supplementary
Fig. 2c). Histomorphometric analyses of DKO mice showed that
6-month-old, but not 3-month-old, mice were osteoporotic, a
decreased tissue bone mass phenotype that is the opposite of the
osteosclerotic tissue phenotype in gain-of-Notch-function transgenic
mice (Fig. 3a–c). Bone formation rates, osteoblast surfaces and
mineralized surfaces in vertebrae and long bones in the DKO mice
were similar to those in control mice (Supplementary Fig. 3 online).
However, osteoclast numbers, osteoclast surfaces and eroded surfaces
were increased in DKO vertebrae and long bones at 6 months of age,
but not at 3 months of age (Fig. 3d,e and Supplementary Fig. 3).
These findings suggest that loss of Psen1 and Psen2, and thus all Notch
signaling in osteoblasts, led to osteoporosis through activation of
osteoclastogenesis and the subsequent increased bone resorption over
bone formation with age-related penetrance.
Activated osteoblasts support osteoclast formation and differentia-
tion from osteoclast precursors by expressing M-CSF and RANKL, but
they also inhibit this process through osteoprotegerin, which binds to
and inactivates RANKL. To further examine the effects of loss of
Psen1 and Psen2 in osteoblasts on osteoclastogenesis, we performed
osteoblast-osteoclastic precursor (OCP) coculture studies. In this
ex vivo assay, P7 DKO calvarial osteoblasts stimulated the formation
of more osteoclasts from wild-type, spleen-derived OCPs than did
wild-type osteoblasts, suggesting that Psen1 and Psen2 deletions can
affect osteoclastogenesis in a non–cell-autonomous fashion (Fig. 4a).
To determine whether this effect was specific for Notch signaling, we
tested whether heterologous expression of N1ICD after lentiviral
transduction of DKO osteoblasts could suppress osteoclastogenesis
in coculture studies (Fig. 4b and Supplementary Fig. 4a online).
Compared to control vector expressing EGFP, lentiviral transduction
of N1ICD into Psen1-Psen2 mutant osteoblasts was able to suppress
osteoclastogenesis, suggesting that the DKO phenotype was primarily
due to presenilin effects on Notch signaling.
The in vivo relevance of this was confirmed by flow cytometric
analysis of markers on bone marrow cells from 3-month-old DKO
mice. This showed increased staining of early OCPs in total cells
(cFMS+) and in more differentiated OCPs (CD11b+Gr-1–/lo) com-
pared to controls, indicating an expansion of the OCP pool in DKO
mice (Fig. 4c). To determine whether this increase in osteoclast
differentiation was due to an imbalance of osteoblastic inductive
(RANKL and M-CSF) versus suppressive (osteoprotegerin) signals,
we analyzed their mRNA expression in DKO versus control bone at
P4. We found comparable expression of RANKL mRNA in DKO and
control mice, but expression of osteoprotegerin mRNA was markedly
decreased (Fig. 4d) in DKO mice. Similarly, we found decreased
osteoprotegerin production in cultured DKO calvarial osteoblasts as
compared to wild-type calvarial osteoblasts (Supplementary Fig. 4b).
Hence, under physiological conditions, Notch signaling enabled by
Psen1 and Psen2 function in osteoblasts represses osteoclast differ-
entiation by regulating osteoprotegerin expression.
Together, these in vivo gain-of-function and loss-of-function studies
lend support for a central role of Notch and presenilin signaling in
regulating both osteoclastogenesis and immature osteoblastic prolif-
eration during bone homeostasis (Fig. 5).
DISCUSSION
Until now, few primary signaling mechanisms regulating osteoblast
differentiation and function during bone homeostasis have been
identified in vivo by genetic and biochemical studies. Wnt signaling
via LRP5/6 coreceptors and canonical b-catenin activity are required
for osteoblast lineage commitment and function17–19. Activation of
this pathway leads to high bone mass20,21. Activating mutations in
transforming growth factor-b in humans is associated with increased
bone formation and inhibition of bone resorption22. However, and
not unexpectedly, apparently discrepant results in vivo have been
observed, depending on the timing of the gain versus the loss of
transforming growth factor-b function. Similarly, Notch signaling
probably has temporal and spatial dependence, as well.
In bone, our data suggest that Notch and presenilin signaling may
be important in the physiological regulation of osteoclastogenesis by
osteoblasts. Moreover, it raises the question of whether loss of Notch
signaling contributes to age-related osteoporosis, as this type of
osteoporosis is associated with increased resorption over bone forma-
tion23, as is seen in our DKO model. We discovered that one function
of Notch in committed osteoblasts is to regulate osteoclastogenesis via
regulation of osteoprotegerin production. The magnitude of osteo-
protegerin dysregulation and the age-related penetrance of the osteo-
porosis in the loss-of-function mouse phenotype correlate well with
epidemiological data in humans, in which age-related osteoporosis has
been associated with changes in osteoprotegerin production24–27.
Furthermore, the report that heterozygote osteoprotegerin-mutant
mice have an age-related osteoporotic phenotype suggests that this
mechanism is sufficient for disease pathogenesis28. What is unclear is
whether osteoprotegerin dysregulation is due to direct regulation by
N1ICD or by its target transcription factors, given the still poorly
characterized osteoprotegerin genetic regulatory region. Further
studies showing chromatin immunoprecipitation analysis of a well-
defined functional osteoprotegerin promoter with N1ICD or with its
target genes would help to address this issue. Likewise, our studies do
not address the potential role of Notch signaling before osteoblastic





















Figure 5 Model for Notch’s dimorphic effects in bone homeostasis. In
established osteoblastic lineages, pathological gain of Notch function
activates expansion of the immature osteoblastic pool by increasing
transcription of the genes encoding osterix, cyclin D and cyclin E and by
repressing the function of Runx2 by direct interaction and inhibition of its
binding. Physiologically, it inhibits osteoclastogenesis by increasing
osteoprotegerin production over RANKL production.
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the central role in osteoblastic commitment. Our data on the Notch-
Runx2 interaction suggest that early loss of function of Notch would
actually lead to increased commitment to the osteoblastic lineage and
perhaps depletion of the mesenchymal stem cell compartment.
In a pathological disease context, our findings show that activation
of Notch signaling in the committed osteoblastic lineage leads to
expansion of an immature osteoblast pool. The primary mode of
action is transcriptional upregulation of the early osteoblast transcrip-
tion factor osterix and increase of cyclin D and cyclin E proteins.
These data raise the question of the potential contribution of activa-
tion of Notch signaling in human diseases related to osteoblastic
proliferation, such as in bone pathologies including human osteo-
sarcomas. The substantial upregulation of cyclin D1 in the transgenic
mice correlates with the observation in humans that 10% of osteo-
sarcomas show amplification of the chromosomal region encoding
cyclin D1(ref. 29). Although our data suggest that Notch can directly
interact with Runx2 to inhibit its binding to target cis elements and its
prodifferentiation function, this is probably not the main determinant
of the gain-of-function phenotype in mice.
Finally, our data have key therapeutic implications. There are few
anabolic bone agents for the treatment of osteoporosis, with most
therapies targeted at inhibition of bone resorption. Upregulation of
Notch signaling may represent a potential approach for increasing
bone formation over bone resorption, as well as for inhibiting
osteoclastogenesis. However, it is clear that temporal effects of
Notch on other cellular compartments, such as the mesenchymal
stem cell pool, would have to be considered; that is, Notch inhibition
of Runx2 function could inhibit mesenchymal stem cell commitment
to the osteoblastic lineage. In opposing fashion, inhibition of Notch
signaling may be a therapeutic option to investigate for the treatment
of proliferative disorders of the osteoblast, such as osteosclerotic
diseases or bone cancers.
From a mechanistic perspective, the function of Notch signaling in
bone constitutes an example of a signaling pathway capable of
regulating both osteoblastic and osteoclastic lineages. Gain of Notch
function in osteoblasts affects osteoblastic differentiation in a cell-
autonomous fashion, whereas loss of Notch function in osteoblasts
affects osteoclastogenesis in a non–cell-autonomous manner. A
remaining question is how Notch-Notch ligand interactions with
neighboring cells, such as stromal and osteoclastic cells, may further
modify biological function in the respective lineages. For example,
ephrin B2 signaling in bone is bidirectional, with consequences for
both the cells expressing the ligand and the cells expressing the
receptor. In this case, reverse signaling through ephrin B2 ligand
expressed by osteoclasts suppresses osteoclast precursors, whereas
forward signaling through EphB4 receptor expressed by osteoblasts
enhances osteoblast formation30,31. Together, our data point to a
dimorphic role for Notch signaling in osteoblast biology; that is, the
stimulation of osteoblastic precursors in a pathological context and
the inhibition of osteoclastogenesis in the physiological regulation of
bone mass and homeostasis.
METHODS
Mice. We cloned Myc-His–tagged N1ICD, which includes amino acids 1760–
2556 of Notch (gift of T. Kadesch), under the control of the 2.3–kilobase (kb)
osteoblast-specific Col1a1 promoter in a coat-color vector containing the
tyrosinase minigene and the woodchuck posttranscriptional regulatory element
(WPRE) sequences32. We generated transgenic founders by pronuclear injec-
tions using standard techniques. We maintained all transgenic lines on a FVB/N
background. We identified the transgenic mice at birth by eye pigmentation
and confirmed by PCR using primers specific for the WPRE. We crossed
previously described Psen1f/f and Psen2–/– mice with Col1a1-Cre mice (gift of
G. Karsenty) to generate osteoblast-specific Psen1-Psen2 DKO mice. These
studies were approved by the Baylor College of Medicine Institutional Animal
Care and Use Committee.
Skeletal analyses, histology and bone histomorphometry. We cleared and
stained skeletons from 1-month-old mice with Alcian blue for cartilage and
Alizarin red for bone as described33. We killed the mice and fixed the whole
skeleton in 10% neutral-buffered formalin for 18 h. For radiographic analyses,
we analyzed the skeletons by contact radiography with a Faxitron X-ray cabinet
(Faxitron X-ray). We sectioned paraffin-embedded tissues to a 4–7–mm
thickness and stained the section with H&E. We performed toluidine blue,
Von Kossa and Goldner’s stains on 5–7–mm undecalcified lumbar vertebral
plastic sections by using standard protocols. We performed all static and
dynamic histomorphometry analyses according to standard protocols using
the OsteoMeasure histomorphometry system (Osteometrics). We performed
histomorphometric analyses on 4-week-old transgenic mice (n ¼ 3) and
6-month-old knockout mice (n ¼ 5–7).
We analyzed m–computed tomography (mCT) scanning of the trabecular
bone of the distal femur by the mCT system (mCT-40, Scanco Medical).
Plasmids. Osterix-luciferase was a gift of M.S. Nanes. For lentivirus vector
production, we constructed plasmid pHIV-N1-IRES-eYFP by inserting a
FLAG-tagged version of intracellular activated form of Notch1 (N1), just
upstream of the 1.4-kb IRES-eYFP cassette (an internal ribosomal entry site
fused to enhanced yellow fluorescence protein) of pHIV-IRES-eYFP34. For the
primary osteoblasts, the lentiviral vectors used were self-inactivating and had
the 0.5-kb mouse phosphoglycerate kinase promoter inserted upstream of
either N1-IRES-eYFP or IRES-eYFP35. We produced vesicular stomatitis virus
G protein–pseudotyped vector supernatants as previously described36. After
72 h, we harvested cell culture supernatants and clarified them. Typical titers
after concentration by ultracentrifugation were in excess of 1  108 interna-
tional units (IU)/ml for the two self-inactivating vectors as assessed on HOS
cells by epifluorescence microscopy. Titers of unconcentrated non-SIN vectors
were in excess of 1  107 IU/ml.
Coculture studies. We cocultured 5  103 calvarial osteoblasts from 1-week-
old mice (n ¼ 3) with 5  104 spleen cells per well in 96-well plates for 7 d in
the presence 108 M vitamin D3. We then stained the cells for TRAP activity
and counted as described previously37. For the lentiviral rescue experiment, we
cultured 5  103 osteoblasts isolated from calvaria of 10-d-old Psen1-Psen2
DKO mice in a 96-well plate for 2 d. We then infected the cells with either 5 ml
N1ICD lentivirus or the YFP lentiviral vector supernatant for 24 h in 100 ml
a-MEM containing 10% FBS and 8 mg polybrene/ml. We then cocultured the
infected cells with 5  104 spleen cells from 10-d-old WT mice for 7 d in the
presence of 108 M vitamin D3.
Fluorescence-activated cell sorting and cell sorting analyses. After lysis of
erythrocytes with ammonium chloride solution, we incubated 2  106 cells
from bone marrow or spleen for 5 min with antibody to murine CD16/32 to
block Fc receptor–mediated antibody binding, and then followed with triple
staining with allophycocyanin-conjugated antibody to mouse CD11b, FITC-
conjugated antibody to Gr-1 and phycoerythrin-conjugated antibody to c-Fms
for 30 min. We then subjected the cells to FACS to analyze the CD11b+Gr-1–/lo
cells that contain osteoclast precursors and c-Fms+ cells in both the total gated
and the CD11b+Gr-1–/lo populations.
Bromodeoxyuridine incorporation. We isolated osteoblasts from calvaria of
P6 transgenic mice and wild-type littermates (n ¼ 5 per group) as previously
described33. We replated cells 48 h after the initial culture and expanded them
for an additional day. We treated cells with BrdU labeling reagent (Zymed)
according to the manufacturer’s instructions for 6 h, washed them with PBS
and fixed them with 70% ethanol for 25 min at 4 1C. Three to five areas for
each genotype (n ¼ 3 slides) were counted by two independent observers
blinded to genotype. We scored BrdU-positive cells over total cells visually and
with Automeasure software (Zeiss Axiovision).
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Western blot analysis. We extracted proteins from P2 mice by homogenizing
the calvaria (n¼ 3 per group) in a buffer containing 5% SDS and 0.0625 M Tris
HCl. We performed western blot analyses with antibody to p53 (gift of
L. Donehower), polyclonal antibody to Runx2 (M70; Santa Cruz Biotechnol-
ogy), antibody to cyclin D1 (H-2953; Santa Cruz Biotechnology) and antibody
to cyclin E (ab-7959; Abcam). We normalized protein content using mouse
monoclonal antibody to-g-tubulin (Sigma).
Glutathione-S-transferase pulldown. We expressed GST, GST-NICDDTAD,
and GST-NICDDRA (gift of T. Kadesch) in the BL21 strain of Escherichia coli
(Stratagene). We induced production of the GST proteins were induced with
0.2 mM isopropyl b-D-thiogalactopyranoside (IPTG; Promega) and allowed the
to grow an additional 4–5 h. After induction, we lysed the cells by sonication.
We bound GST proteins to glutathione resin (Amersham Biosciences). We
generated 625-mM Met-labeled, FLAG-tagged Runx2 proteins by a T7 in vitro
transcription-translation kit (Novagen) and incubated them with GST or GST-
NICDTAD or GST-NICDRA immobilized on glutathione-Sepharose beads at
4 1C for 2 h. We then washed the beads five times with TNN buffer (1 M
TrisHCl, 5 M NaCl, 14.2 M 2-mercaptoethanol) containing 1% Nonidet P-40,
boiled the proteins in 2 SDS sample loading buffer and separated them by
SDS-PAGE. We performed western blotting to detect the FLAG-tagged Runx2
protein with M2 monoclonal antibody to FLAG (Sigma).
RNA extraction and quantitative reverse transcription PCR analysis. We
extracted total RNA from calvaria and forelimbs of P4 and 4-week-old mice
(n ¼ 5 and n ¼ 3, respectively) with TRIzol reagent (Invitrogen). We
synthesized cDNAs from extracted RNA with the Superscript III First Strand
RT-PCR kit (Invitrogen). We performed real-time quantitative PCR amplifica-
tions in a LightCycler (Roche) using a TaqMan assay (Applied Biosystems
probe HS00172878-M1). We used the genes encoding b-actin and b2-
microglobulin as internal controls for the quantity and quality of the cDNAs
in real-time PCR assays.
DNA transfection. We transfected Cos7 and Ros17/2.8 cells with the 6XOSE2-
luc reporter gene by using Lipofectamine Plus according to manufacturer’s
recommendations (Invitrogen). We assayed luciferase and b-galactosidase
activities 48 h after transfection. We transfected C2C12 cells with –1269/91
Osx-p-luc (gift of M.S. Nanes) by using Fugene6 according to the manufac-
turer’s instructions (Roche). We induced the cells 24 h after the transfection
with 300ng/ml recombinant human bone morphogenic protein-2 (R&D
Systems), and we harvested and assayed the cells the next day. We performed
all transfections in triplicate with pSV2bgal as an internal control for transfec-
tion efficiency.
Statistical analyses. Data are expressed as mean values ± s.d. We computed
statistical significance with Student’s paired t-test. A P value of o0.05 was
considered statistically significant.
Note: Supplementary information is available on the Nature Medicine website.
ACKNOWLEDGMENTS
We thank T. Kadesch (University of Pennsylvania) for Myc-His–tagged N1ICD,
GST-NICDDTAD and GST-NICDDRA, G. Karsenty (Columbia University) for
Col1a1-Cre mice, M.S. Nanes (Emory University) for osterix-luciferase and
–1269/91 Osx-p-luc, and L. Donehower (Baylor College of Medicine) for
antibody to p53. We thank M. Acar and O. Sirin for technical assistance. This
work was supported by US National Institutes of Health grants ES11253 (B.L.),
HD22657 (B.L.), DE016990 (B.L.) and AR43510 (B.F.B.).
Published online at http://www.nature.com/naturemedicine
Reprints and permissions information is available online at http://npg.nature.com/
reprintsandpermissions
1. Artavanis-Tsakonas, S., Rand, M.D. & Lake, R.J. Notch signaling: cell fate control and
signal integration in development. Science 284, 770–776 (1999).
2. Bray, S.J. Notch signalling: a simple pathway becomes complex. Nat. Rev. Mol. Cell
Biol. 7, 678–689 (2006).
3. Weinmaster, G. The ins and outs of Notch signaling. Mol. Cell. Neurosci. 9, 91–102
(1997).
4. Daudet, N. & Lewis, J. Two contrasting roles for Notch activity in chick inner ear
development: specification of prosensory patches and lateral inhibition of hair-cell
differentiation. Development 132, 541–551 (2005).
5. Brennan, C.A. & Moses, K. Determination of Drosophila photoreceptors: timing is
everything. Cell. Mol. Life Sci. 57, 195–214 (2000).
6. Bulman, M.P. et al. Mutations in the human delta homologue, DLL3, cause axial
skeletal defects in spondylocostal dysostosis. Nat. Genet. 24, 438–441 (2000).
7. Shen, J. et al. Skeletal and CNS defects in presenilin-1–deficient mice. Cell 89,
629–639 (1997).
8. Deregowski, V., Gazzerro, E., Priest, L., Rydziel, S. & Canalis, E. Notch 1 over-
expression inhibits osteoblastogenesis by suppressing Wnt/b-catenin but not bone
morphogenetic protein signaling. J. Biol. Chem. 281, 6203–6210 (2006).
9. Sakamoto, K., Chao, W.S., Katsube, K. & Yamaguchi, A. Distinct roles of EGF repeats
for the Notch signaling system. Exp. Cell Res. 302, 281–291 (2005).
10. Sciaudone, M., Gazzerro, E., Priest, L., Delany, A.M. & Canalis, E. Notch 1 impairs
osteoblastic cell differentiation. Endocrinology 144, 5631–5639 (2003).
11. Tezuka, K. et al. Stimulation of osteoblastic cell differentiation by Notch. J. Bone
Miner. Res. 17, 231–239 (2002).
12. Zamurovic, N., Cappellen, D., Rohner, D. & Susa, M. Coordinated activation of Notch,
Wnt, and transforming growth factor-b signaling pathways in bone morphogenic protein
2–induced osteogenesis. Notch target gene Hey1 inhibits mineralization and Runx2
transcriptional activity. J. Biol. Chem. 279, 37704–37715 (2004).
13. Nakashima, K. et al. The novel zinc finger–containing transcription factor osterix is
required for osteoblast differentiation and bone formation. Cell 108, 17–29 (2002).
14. Galindo, M. et al. The bone-specific expression of Runx2 oscillates during the cell
cycle to support a G1-related antiproliferative function in osteoblasts. J. Biol. Chem.
280, 20274–20285 (2005).
15. Pratap, J. et al. Cell growth regulatory role of Runx2 during proliferative expansion of
preosteoblasts. Cancer Res. 63, 5357–5362 (2003).
16. Shen, R. et al. Cyclin D1–cdk4 induce Runx2 ubiquitination and degradation. J. Biol.
Chem. 281, 16347–16353 (2006).
17. Hill, T.P., Spater, D., Taketo, M.M., Birchmeier, W. & Hartmann, C. Canonical Wnt/
b-catenin signaling prevents osteoblasts from differentiating into chondrocytes.
Dev. Cell 8, 727–738 (2005).
18. Day, T.F., Guo, X., Garrett-Beal, L. & Yang, Y. Wnt/b-catenin signaling in mesenchymal
progenitors controls osteoblast and chondrocyte differentiation during vertebrate
skeletogenesis. Dev. Cell 8, 739–750 (2005).
19. Glass, D.A., II et al. Canonical Wnt signaling in differentiated osteoblasts controls
osteoclast differentiation. Dev. Cell 8, 751–764 (2005).
20. Krishnan, V., Bryant, H.U. & Macdougald, O.A. Regulation of bone mass by Wnt
signaling. J. Clin. Invest. 116, 1202–1209 (2006).
21. Tu, X. et al. Noncanonical Wnt signaling through G protein–linked PKC-d activation
promotes bone formation. Dev. Cell 12, 113–127 (2007).
22. Janssens, K., ten Dijke, P., Janssens, S. & Van Hul, W. Transforming growth factor-b1
to the bone. Endocr. Rev. 26, 743–774 (2005).
23. Mezquita-Raya, P. et al. The contribution of serum osteoprotegerin to bone mass and
vertebral fractures in postmenopausal women. Osteoporos. Int. 16, 1368–1374
(2005).
24. Fahrleitner-Pammer, A. et al. Osteoprotegerin serum levels in women: correlation with
age, bone mass, bone turnover and fracture status. Wien. Klin. Wochenschr. 115,
291–297 (2003).
25. Arko, B., Prezelj, J., Kocijancic, A., Komel, R. & Marc, J. Association of the
osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal
women. Maturitas 51, 270–279 (2005).
26. Choi, J.Y. et al. Genetic polymorphisms of OPG, RANK, and ESR1 and bone mineral
density in Korean postmenopausal women. Calcif. Tissue Int. 77, 152–159 (2005).
27. Hofbauer, L.C. et al. Estrogen stimulates gene expression and protein production of
osteoprotegerin in human osteoblastic cells. Endocrinology 140, 4367–4370 (1999).
28. Bucay, N. et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and
arterial calcification. Genes Dev. 12, 1260–1268 (1998).
29. Wang, L.L. Biology of osteogenic sarcoma. Cancer J. 11, 294–305 (2005).
30. Boyce, B.F. & Xing, L. Osteoclasts, no longer osteoblast slaves. Nat. Med. 12,
1356–1358 (2006).
31. Zhao, C. et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell
Metab. 4, 111–121 (2006).
32. Zhou, G. et al. Dominance of SOX9 function over RUNX2 during skeletogenesis.
Proc. Natl. Acad. Sci. USA 103, 19004–19009 (2006).
33. Ducy, P. et al. A Cbfa1-dependent genetic pathway controls bone formation beyond
embryonic development. Genes Dev. 13, 1025–1036 (1999).
34. Segall, H.I., Yoo, E. & Sutton, R.E. Characterization and detection of artificial
replication-competent lentivirus of altered host range. Mol. Ther. 8, 118–129
(2003).
35. Dai, C., McAninch, R.E. & Sutton, R.E. Identification of synthetic endothelial cell–
specific promoters by use of a high-throughput screen. J. Virol. 78, 6209–6221
(2004).
36. Sutton, R.E., Wu, H.T., Rigg, R., Bohnlein, E. & Brown, P.O. Human immunodeficiency
virus type 1 vectors efficiently transduce human hematopoietic stem cells. J. Virol. 72,
5781–5788 (1998).
37. Xing, L. et al. NF-kB p50 and p52 expression is not required for RANK-expressing
osteoclast progenitor formation but is essential for RANK- and cytokine-mediated
osteoclastogenesis. J. Bone Miner. Res. 17, 1200–1210 (2002).
ART ICL ES









































NF‐kB RelB Negatively Regulates Osteoblast
Differentiation and Bone Formation
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ABSTRACT
RelA‐mediated NF‐kB canonical signaling promotes mesenchymal progenitor cell (MPC) proliferation, but inhibits differentiation of
mature osteoblasts (OBs) and thus negatively regulates bone formation. Previous studies suggest that NF‐kB RelBmay also negatively
regulate bone formation through noncanonical signaling, but they involved a complex knockout mouse model, and the molecular
mechanisms involved were not investigated. Here, we report that RelB/mice develop age‐related increased trabecular bone mass
associated with increased bone formation. RelB/ bone marrow stromal cells expanded faster in vitro and have enhanced OB
differentiation associated with increased expression of the osteoblastogenic transcription factor, Runt‐related transcription factor 2
(Runx2). In addition, RelB directly targeted the Runx2 promoter to inhibit its activation. Importantly, RelB/ bone‐derived MPCs
formed bone more rapidly than wild‐type cells after they were injected into a murine tibial bone defect model. Our ﬁndings indicate
that RelB negatively regulates bonemass asmice age and limits bone formation in healing bone defects, suggesting that inhibition of
RelB could reduce age‐related bone loss and enhance bone repair. © 2014 American Society for Bone and Mineral Research.
KEY WORDS: RELB; NF‐kB; MESENCHYMAL PROGENITOR CELLS; OSTEOBLASTS; BONE FORMATION
Introduction
Proinﬂammatory cytokines, such as receptor activator of NF‐kB ligand (RANKL) and tumor necrosis factor (TNF), mediate
bone destruction in common bone diseases, such as postmeno-
pausal osteoporosis, rheumatoid arthritis, and periodontitis.(1) In
these diseases, unlike in normal bone remodeling, bone
formation by osteoblasts (OBs) does not match the bone
lost,(1) resulting in localized and/or generalized bone loss. A role
in bone for the NF‐kB family of transcription factors, which
includes NF‐kB1 (p50 and its precursor p105), NF‐kB2 (p52 and its
precursor p100), RelA (p65), RelB, and c‐Rel,(2) was ﬁrst discovered
when expression of both NF‐kB1 and 2 was found unexpectedly
to be required for osteoclast precursor (OCP) differentiation into
osteoclasts (OCs).(3,4) Later it was discovered that they were
required for RANKL‐induced and TNF‐induced OC formation.(5)
RANKL and TNF induce proteasomal processing of p105 to
p50, which typically forms heterodimers with RelA to activate
canonical NF‐kB signaling.(2) RANKL, and to a much lesser extent
TNF, activate noncanonical signaling in OCPs, leading to NF‐kB–
inducing kinase (NIK)‐mediated processing of p100 to p52,(6)
which typically forms heterodimers with RelB to activate
noncanonical signaling and transcription of target genes. RelA
promotes OC differentiation by blocking a RANKL‐inducted
apoptotic pathway in OCPs, but it is not involved in terminal OC
differentiation.(7) RelB, in contrast, is not required for basal OC
formation, but appears to play a role in the enhanced
osteoclastogenesis observed in pathologic conditions such as
osteolysis induced by metastatic cancer cells and
inﬂammation.(8)
These previous studies have increased understanding of the
role for NF‐kB in OC formation and functions,(3–8) but the role of
NF‐kB signaling in bone formation is less well understood and
the published data are conﬂicting. For example, several groups
have shown that activation of canonical NF‐kB signaling inhibits
bone formation based on an inhibitory effect of TNF induction of
p65 on OB differentiation.(9–12) Recently it was reported that
inhibition of canonical signaling, speciﬁcally in mature OBs, by
genetic manipulation results in a transient increase in bonemass
in young mice.(13) Furthermore, the NF‐kB inhibitor S1627
promotes murine calvarial defect repair and increased bone
mineral density in ovariectomized mice,(14) providing additional
evidence that canonical NF‐kB signaling negatively regulates
bone formation. However, several other groups reported that
TNF‐induced activation of canonical NF‐kB signaling in mesen-
chymal progenitor cells (MPCs) promotes their differentiation
into OBs(15–17) through bone morphogenic protein 2 (BMP‐2)‐
mediated upregulation of Runt‐related transcription factor 2
(Runx2) and Osterix (Osx) expression.(16) These ﬁndings indicate
that there are complex interactions involving cytokines and
canonical NF‐kB signaling that can have positive or negative
regulatory effects on OBs to inﬂuence bone mass depending
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upon the form of stimulation and the state of osteoblastic cell
differentiation.
The role of noncanonical NF‐kB signaling in bone formation
has also been reported. For example, mice generated to have
accumulation of a nonprocessable form of NF‐kB2 p100 have
enhanced osteoblastic differentiation,(18) and mice with deletion
of p100, but retaining a functional p52, have osteopenia owing to
increased OC activity and impaired OB parameters.(19) Interest-
ingly, deletion of both RelB and p100 in the lattermice prevented
the osteopenia in the p100/mice and actually increased bone
mass accompanied by increased OB surfaces,(19) suggesting that
an important role of RelB is to inhibit OB differentiation. However,
these studies did not include reports of the OB phenotype
of single RelB/ mice and did not examine the molecular
mechanisms whereby RelB regulates OB differentiation or
function. We have found that bone mass increases in RelB/
mice as they age owing to increased OB precursor proliferation
associated with enhanced capacity of their MPCs to differentiate




RelBþ/ and RelB/ mice, including males and females for all
experiments, on an inbred C57BL/6 background, were obtained
from Dr. Mitchell Kronenberg and have been described.(20,21)
Severe combined immunodeﬁciency (SCID)mice were purchased
from Jackson Laboratory (Bar Harbor, ME, USA). The University of
Rochester Medical Center Institutional Animal Care and Use
Committee approved all animal studies. Labeled antibodies for
ﬂuorescence‐activated cell sorting (FACS) (APC‐CD45, PE‐CD105,
FITC‐Sca‐1) were purchased from eBioscience, San Diego, CA,
USA. Ascorbic acid and b‐glycerophosphate (b‐GP) were
purchased from Sigma, St. Louis, MO, USA. The 5‐bromo‐4‐
chloro‐3‐indolyl phosphate (BCIP)/4‐nitro blue tetrazolium (NBT)
alkaline phosphatase (ALP) substrate was purchased from ScyTek
Laboratories, Logan, UT, USA. RelB antibody was purchased from
Santa Cruz, Dallas, TX, USA.
OB differentiation
Bone marrow (BM) was ﬂushed from long bones of mice with a
modiﬁed essential medium (a‐MEM) containing 20% fetal bovine
serum (FBS) using a 25G needle. The cells were ﬁltered with a
40‐mm cell strainer, and 4 104 cells were cultured in 35‐mm
dishes at 37°C in 5% CO2 for 4 days. Unattached cells were
removed and replaced with 10% FBS in a‐MEM containing
25mg/mL L‐ascorbic acid and 5mM b‐GP to induce OB
differentiation. After 5 to 7 days in inducing medium, the cells
were stained for ALP activity using the ALP substrate, BCIP/NBT.
Mineralization typically occurs after 10 to 14 days in culture, and
the cells were stained with the von Kossa method for
measurement of mineralized nodule formation. Calvariae from
7‐day‐old wild‐type (WT) and RelB/ mice were cut into pieces
and digested six times with a mixture of 0.5% collagenase I and
0.125% trypsin (both from Sigma) for 20 minutes at 37°C. Cells
from the second to sixth digestions were collected for pre‐OB
cultures and OB differentiation experiments.
Generation of bone‐derived MPCs
We cut mouse tibiae and femora into small pieces after BM had
been ﬂushed out and the cavities had been washed extensively
with PBS using a modiﬁcation of a previously described
method.(22) The bone fragments were cultured for 4 days with
a‐MEM containing 20% FBS at 37°C. Bone pieces were
transferred into a new dish and cultured for an additional 4 to
5 days with a‐MEM containing 10% FBS. The cells grown on the
dish were passaged twice when they were 90% conﬂuent, each
time excluding cells tightly attached to the dishes. Third‐passage
cells contained over 99% MPCs, sufﬁcient for our experiments.
We named these cells “bone‐derived MPCs” (bMPCs) and they
were frozen for use later in OB differentiation and mineralization
experiments. mRNA expression levels of OB‐related genes were
tested using methods we described previously.(23)
FACS analysis
BM or cultured cells (2 106) were stained with APC‐anti‐CD45.2,
PE‐anti‐CD105 and FITC‐Sca‐1 antibodies. For cell‐cycle analysis,
the collected bMPCs were incubated with 1mM 4,6‐diamidino‐2‐
phenylindole (DAPI) with PBS containing 2% FBS for 20 minutes
at 37°C. Data were acquired using a FACScanto (BM Bioscience,
San Jose, CA, USA) ﬂow cytometer and analyzed using FlowJo
software (Ashland, OR, USA), as described.(24)
Micro–computed tomography and bone
histomorphometric analysis
Mice were given injections of calcein (10mg/kg) at 5 days and 1
day before euthanasia in a standard bone formation double‐
labeling protocol. Right tibiae were ﬁxed in 10% neutral buffered
formalin and micro–computed tomography (mCT) scanning
using a VivaCT 40mCT scanner (Scanco, Brüttisellen, Switzerland)
was performed following guidelines for assessment of bone
microstructure in rodents using mCT.(25) The bones were then
processed through graded alcohols and embedded in plastic,
and dynamic and static parameters of bone formation were
assessed, according to standard methods using OsteoMeasure
software (OsteoMetrics, Decatur, GA, USA). Left tibiae were ﬁxed
in 10% neutral buffered formalin for 2 days, decalciﬁed in 10%
EDTA for 3 weeks, and the bones were then processed and
embedded in parafﬁn. Sections (4‐mm‐thick) were stained with
hematoxylin and eosin (H&E) for analysis of bone volume, OB
surface, and tartrate‐resistant acid phosphatase–positive (TRAP
þ) OCs using OsteoMeasure software.
Tibial bone defects
A 2‐mm 5‐mm full‐thickness cortical defect was made on the
anterior surface of the left and right tibiae of SCID mice. Brieﬂy, a
hole was pierced through the cortex 1mm below the growth
plate using a 25G needle. Scissors were then inserted into the
hole and a 2‐mm 5‐mm defect was created by repeatedly
cutting distally through the cortex. The defects were then almost
completely ﬁlled with decalciﬁed trabecular bone matrix, which
had been extracted from bovine femoral necks using the
following serial processing: 20% H2O2 for 2 days, 5mmol Sodium
Azide (NaN3) overnight, 1mol NaOH containing 1% Triton X‐100
overnight, methanol/chloroform (1:1) for 24 hours, ether
overnight, and 10% EDTA for 2 weeks. bMPCs (5 105) in 5mL
of Hank’s solution were then injected into the bone matrix in the
defects. The muscle fascia and skin overlying the defects were
then sutured closed. Mice were euthanized 2, 4, and 8 weeks
postsurgery, and the tibiae were ﬁxed in 10% neutral buffered
formalin for 2 days. The volume of new bone formed in the
defects was measured using a VivaCT 40mCT scanner (Scanco,
Brüttisellen, Switzerland). The bones were then processed
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through alcohols, decalciﬁed, and embedded in parafﬁn. The
volume of newly formed bone and ﬁbrous tissue was quantiﬁed
in H&E‐stained sections using OsteoMeasure software.
Quantitative real‐time PCR
Total RNA was extracted from cultured cells using 1mL TRIzol
reagent, and 1mg was used for synthesis of cDNA using a
GeneAmp RNA PCR core kit. Quantitative PCR ampliﬁcation was
performed using an iCycler (Bio‐Rad, San Diego, CA, USA) real‐
time PCR machine and iQ SYBR (Bio‐Rad) Green. Relative mRNA
expression levels of target genes were analyzed using the
threshold cycle (CT) value of the gene, normalized to b‐actin.
Reporter constructs/luciferase assay
To clone the 50 upstream region of the mouse Runx2 gene, 1997‐
bp (2‐kb) fragments in the Runx2 promoter region were
ampliﬁed by PCR from C57Bl6 mouse DNA extracted from
bMPCs. The speciﬁc forward primer was: 50‐GTATTTCTGTGG‐
TTTTGTCATTAAAACT‐30, and the reverse primer was: 50‐
AGAAAGTTTGCACCGCACTT‐30 overlapping the putative tran-
scriptional start site (Fig. 5B). The 2‐kb promoter was found with
TFSEARCH software to contain two putative NF‐kB binding sites.
Overhangs containing the Kpn I restriction site were added to the
forward primer and an overhang containing the Xho I site was
added to the reverse primer at the 50 end. PCR products were
then subcloned into the pCRII TOPO vector (Invitrogen, Grand
Island, NY, USA) and sequenceswere veriﬁed before their transfer
into the Kpn I/Xho I backbone of pGL3‐basic (Promega, Madison,
WI, USA) driving the ﬁreﬂy Luciferase (Luc) gene. The Runx2 Luc
reporter plasmidwas cotransfectedwith either green ﬂuorescent
protein (GFP) control or RelB plasmid into C2C12 cells using a
FuGene6 reagent (Roche, Indianapolis, IN, USA). A 0.1‐mg aliquot
of the SV40‐Renilla Luc construct (Addgene, Cambridge, MA,
USA) was also cotransfected with the above ﬁreﬂy reporters to
standardize results for transfection efﬁciency. Cell lysates were
prepared using a reporter lysis buffer (Promega). Luciferase
activity was measured using a Microplate Luminometer
(PerkinElmer, Waltham, MA, USA).
To perform site‐directed mutagenesis of both kB binding sites
in Runx2 promoter, two pairs of primersmRunx2‐1fw 50‐AATATTT
GTAAAGGACCCAGGCTAACACTT, mRunx2‐1rv 50‐AAGTGTTAGCC
TGGGTCCTTTACAAATATT; and mRunx2‐2fw 50‐AGGAGAGAC‐
AGAGGACCCATAAGTAAAGAG, mRunx2‐2rv 50‐CTCTTTACTTATG
GGTCCTCTGTC‐TCTCCT were designed using an Invitrogen
software program and the GENEART Site‐Directed Mutagenesis
System (Invitrogen) was used to delete “ABC” and “ACA” in the
1 and 2 binding sites following the instruction manual. We
followed this procedure to test the role of RelB on the mutated
Runx2 promoter.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed using a
MAGnify ChIP kit (Invitrogen) following the instruction manual.
Brieﬂy, sheared chromatin fromWT and RelB/ bMPCs that had
been ﬁxed with 1% formaldehyde was immunoprecipitated with
5mg of antibody to RelB, negative control rabbit immunoglobu-
lin G (IgG) (Santa Cruz), or positive control H3 histone (Cell
Signaling, Danvers, MA, USA). Immunoprecipitated DNA was
then used as a template for quantitative PCR using primers
speciﬁc for the NF‐kB binding sites 1 (forward 50‐tcaactacacagc-
catgatt and reverse 50‐taagcttggggatctgtaac) or 2 (forward 50‐
cttctgaatgccaggaaggc and reverse 50‐tgggactgcctaccactgt) of
the Runx2 promoter as well as a pair of unrelated primers
(forward 50‐cactgctgactgaaacaagtc and reverse 50‐agtctgagt-
gagcttcctgat) designed in the region that is 3 kb apart from the
kB binding sites.
ELISA assay
Mouse serumosteocalcin (MyBioSource, SanDiego, CA, USA) levels
were assessed according to the manufacturer’s instructions.
Statistics
All results are given as mean SD. Comparisons between two
groups were analyzed using two‐tailed unpaired Student’s t test.
One‐way ANOVA and Dunnett’s post hoc multiple comparisons
were used for comparisons among three or more groups. Values
of p <0.05 were considered statistically signiﬁcant.
Results
RelB/ mice develop increased trabecular bone volume
as they age
To fully investigate the role of RelB in bone remodeling, we
analyzed the bone phenotype of RelB/ mice of various ages.
Consistent with a previous report that young RelB/ mice do
not appear to have a signiﬁcant bone phenotype,(8) we found
that 4‐week‐old RelB/ mice have normal trabecular bone
volume, as assessed by histomorphometric analysis (Fig. 1A).
However, mean diaphyseal trabecular bone volume values in 6‐
to 8‐week‐old RelB/mice were double those of WT littermates.
Importantly, their mean metaphyseal bone volumes remained
within the normal range, similar to those of littermates (Fig. 1A),
suggesting that OC function in the RelB/ mice is normal.
Furthermore, when the RelB/ mice were 10 to 14 weeks old,
their mean diaphyseal bone volumes had increased further to
fourfold higher than those in WT littermates, whereas their mean
metaphyseal bone volumes still remained within the normal
range (Fig. 1A). These histomorphometric ﬁndings were
conﬁrmed by mCT when the mice were 10 to 14 weeks old
(Fig. 1B), which showed that the increased bone mass was
associated with increased trabecular number (Fig. 1B, p< 0.01),
but not thickness. Ten‐ to 14‐week‐old RelB/ mice also had
increased vertebral trabecular bone volume associated with
increased trabecular number, but not thickness, as assessed by
mCT analysis (Fig. 1C), indicating that their increased bone mass
was not restricted to diaphyseal bone. Interestingly, however, the
RelB/ mice had normal cortical thickness, and periosteal and
endosteal surface areas of the cortical bone in the RelB/ mice
were also similar to that of the WT littermates (Fig. 1D).
RelB/ mice have a transient increase in bone formation
The increased diaphyseal and vertebral trabecular bone
observed in the RelB/ mice as they aged could be caused
by impaired OC and/or enhanced OB differentiation and
function. We conﬁrmed that metaphyseal OC numbers and
surfaces are normal in young RelB/ mice(8) (data not shown)
and they remained similar to those in WT control mice in the
metaphyseal bone as they aged to 8 weeks old (data not shown).
However, in the proximal diaphyses of RelB/mice OC surfaces
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were increased (15.6% 7.3% versus 7.8% 3.6% in WT
littermates, p< 0.05), whereas OC numbers were not, presum-
ably reﬂecting the increased bone mass in the RelB/ mice.
In fact, RelB regulation of OC differentiation is complicated.
We found that RelB/ mice have threefold to ﬁvefold
increase in monocyte‐macrophages in their blood, BM, and
spleen, and that sorted CD11bGr‐1 BM cells from RelB/mice
have signiﬁcantly enhanced OC differentiation, but their
Fig. 1. Trabecular bonemass increases in RelB/mice as they age. (A) H&E‐stained sections of tibiae fromWT and RelB/mice and histomorphometric
data showing trabecular BV/TV in the tibial metaphyses (area corresponding to the position of the white bar) and proximal diaphysis (vertical green bar) of
4‐ to 14‐week‐oldmice. n¼ 5–8mice/group. Metaphyseal bone (corresponding to ROI‐1 ofmCT) was deﬁned as a 0.3‐mm region along the long axis of the
tibia beginning at 0.15mm from the growth plate. Proximal diaphysis (corresponding to ROI‐2 of mCT) was deﬁned as a 0.6‐mm region under ROI‐1. (B)
RepresentativemCT scans and BV/TV, Tb.N, Tb.Th, and Tb.Sp in themetaphysis (ROI‐1) and in the proximal part of the diaphysis (ROI‐2) of tibiae from 10‐to
14‐week‐old mice. n¼ 5–8 mice/group. (C) mCT scans and data from fourth lumbar vertebrae from 10‐ to 14‐week‐old mice. n¼ 10 mice/group. (D) mCT
scans and data from cortical bone at the junction between ROI‐1 and ROI‐2 from mice in B. All groups contained male and female mice. p< 0.05;
p< 0.01 versus control. H&E¼hematoxylin and eosin; WT¼wild‐type; BV/TV¼bone volume/tissue volume; ROI¼ region of interest; mCT¼micro–
computed tomography; Tb.N¼ trabecular number; Tb.Th¼ trabecular thickness; Tb.Sp¼ trabecular separation.
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CD11bþGr‐1/loþ BM cells, the generally recognized OC
precursors,(24) did not form OCs in response to RANKL and
macrophage colony‐stimulating factor (M‐CSF) in in vitro culture
(data not shown). Because the increased trabecular bone volume
in RelB/ mice is not associated with unresorbed islands of
cartilage inside trabeculae, which is typically seen in osteopet-
rosis,(26,27) we concluded that the increased diaphyseal and
vertebral bone mass likely resulted from enhanced OB formation
or activity, as has been reported in RelB/p100 double knockout
mice.(19) Indeed, mean values for OB and mineralizing surfaces
and bone formation rates (BFR) in the trabecular bone in the
diaphyses of 4‐week‐old RelB/ mice are signiﬁcantly higher
than those in WT littermates (Fig. 2A, B). Surprisingly, however,
mean values for OB surface and BFRs were reduced signiﬁcantly
in the tibial diaphyseal bone in older (8‐ to 9‐week‐old) RelB/
mice (Fig. 2C), indicating that the increase in bone formation in
the RelB/ mice is transient. Consistent with this, serum
osteocalcin levels were signiﬁcantly increased in younger, but
not in older RelB/ mice (Fig. 2D), and mRNA levels of ALP,
Runx2, RANKL and osteoprotegerin (OPG) were similar in femoral
bone samples from 9‐week‐old RelB/ andWTmice, wheras the
osteocalcin mRNA levels were only slightly increased (Supple-
mental Fig. 1).
MurineMPCs have been deﬁned as CD45CD105þ cells,(28) and
we have reported that CD45cells can be used as mesenchymal
stem cell–enriched cells.(29) We found that RelB/ and WT mice
have similar numbers of CD45CD105þ cells in freshly isolated
BM from tibiae and femora (Fig. 3A, upper). However, these BM
cells from RelB/ mice generated twofold more CD45CD105þ
MPCs than WT cells 7 days after equal numbers of each were
placed in culture dishes (Fig. 3A, lower), indicating that RelB/
MPCs expanded faster in vitro. This was associatedwith formation
ofmore ALPþ colonies andmineralized nodules (Fig. 3B) from the
RelB/ BM cell cultures and a 3‐fold and 1.5‐fold increase in
osteocalcin and ALP mRNA expression levels (Fig. 3C) at day 10,
respectively, compared toWT cells, consistent with the enhanced
OB generation and function in the RelB/ mice. The enhanced
OB proliferation and differentiation persisted in BM cells cultured
from 3‐month‐old RelB/mice, despite the reduced BFR in vivo.
RelB/ BM stromal cells formed threefold more ALPþ cell
colonies than WT cells at day 7, but ALP mRNA expression levels
were similar at day 6. This may reﬂect the fact that the increased
numbers of ALPþ cells from RelB/ stromal cells were mainly
due to their faster expansion at an earlier stage of differentiation,
as shown in Fig. 3A.
To determine if the enhanced differentiation of RelB/ BM
stromal cells contributed to the increased ALPþ colony numbers
and mineralized nodule formation, we generated BM stromal
cells, reseeded them onto culture plates, and induced OB
differentiation when they were subconﬂuent to exclude the
inﬂuence of proliferation. These reseeded stromal cells still had
increased ALPþ cell formation (Fig. 3D), conﬁrming their
enhanced differentiation. Furthermore, we generated calvarial
pre‐OBs from 7‐day‐old WT and RelB/ pups and found that
RelB/ calvarial pre‐OBs also have enhanced ALPþ cell
differentiation at day 10, but not after 5 days of induction of
Fig. 2. RelB/ mice have a transient increase in bone formation. (A) Histology and histomorphometric analysis of OBs (arrows) and Ob.S/BS (%) in the
tibiae of 4‐week‐old RelB/ mice and WT littermates (n¼ 7/group). (B) Double calcein labeling (arrows) in trabeculae in proximal tibial diaphyses
corresponding to ROI‐2 in Fig. 1 and analysis of dynamic parameters of bone formation: sLS/BS, dLS/BS, MS/BS, MAR, and BFR in 4‐week‐old RelB/ andWT
mice (n¼ 8/group). (C) Analysis of dynamic parameters of bone formation listed in B andOb.S/BS in proximal tibial diaphyses of 7‐ to 8‐week‐old RelB/ and
WTmice (n¼ 5–6/group). (D) OCal levels from 4‐ to 5‐week‐old (n¼ 9) and 8‐ to 9‐week‐old (n¼ 8) male and female WT and RelB/mice tested by ELISA.
OB¼ osteoblast; Ob.S/BS¼ osteoblast surface; WT¼wild‐type; ROI¼ region of interest; sLS/BS¼ single‐labeled surface; dLS/BS¼double‐labeled surface;
MS/BS¼mineralization surface; MAR¼mineral apposition rate; BFR¼bone formation rate; OCal¼ osteocalcin.
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Fig. 3. RelB/mice have enhanced stromal cell proliferation and OB differentiation in vitro. (A) FACS analysis showing the % of CD45‐CD105þ MPCs in
freshly isolated BM cells from 2‐month‐old WT and RelB/mice and BM stromal cells from themice after being cultured for 7 days with growth‐inducing
medium. (B) Equal numbers of freshly isolated BM cells from 2 month‐old RelB/ and WT mice were cultured in OB differentiation medium containing
25mg/mL Vit C and 5mM b‐GP for 7 and 12 days. ALPþ cells colonies (upper panel) and mineralized nodules (lower panel) were evaluated after ALP and
von Kossa staining. (C) Expression of ALP and OCal was tested using real‐time PCR in BM stromal cells and in differentiating OBs induced by Vit C and b‐GP
after 6 and 10 days of culture. (D) BM stromal cells generated fromWT and RelB/micewere reseeded in 12‐well plates. After the cells were subconﬂuent,
they were induced for OB differentiation for 5 days and stained for ALP activity. (E) Calvarial pre‐OBs generated from 7‐day‐old pups were cultured in OB
differentiation medium for 5 and 10 days and stained for ALP activity. (F) Calvarial pre‐OBs were cultured in OB differentiation medium for the indicated
times, total RNA was extracted, and expression of ALP, OCal, and Runx2mRNA was tested by real‐time PCR. All mice in in vitro experiments were 1.5‐ to 2‐
month‐old males or females except for those used for calvarial pre‐OBss in E and F; 3 wells per group. p< 0.05 versus control. OB¼ osteoblast;
FACS¼ ﬂuorescence‐activated cell sorting; MPC¼mesenchymal progenitor cell; BM¼bone marrow; WT¼wild‐type; Vit C¼ L‐ascorbic acid; b‐GP¼b‐
glycerophosphate; ALP¼ alkaline phosphatase; OCal¼ osteocalcin; Runx2¼ Runt‐related transcription factor 2.
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differentiation (Fig. 3E). Consistent with the ﬁndings in BM
stromal cells, differentiating RelB/ OBs from calvariae had
signiﬁcantly increased ALP, osteocalcin, and Runx2 mRNA
expression, particularly at the later stage of differentiation (day
10; Fig. 3F).
RelB negatively regulates OB differentiation, associated
with reduced Runx2 activity
Primary BM stromal cell cultures contain variable numbers of
hematopoietic cells, including monocyte‐macrophages,(30) which
could inﬂuence stromal cell differentiation. To minimize this
possibility, we employed a recently describedmethod(22) inwhich
bMPCs are used to study MPC differentiation. We conﬁrmed that
almost 100% of these cells fromWT and RelB/ long bones were
of mesenchymal origin (ie, CD45–cells; Fig. 4A, left), and more
than 90% of these cells expressed the stem cell marker, Sca‐1 (Fig.
4A, right). These RelB/ bMPCs grew faster thanWT cells (Fig. 4B).
Consistent with this, cell‐cycle analysis using FACS (Fig. 4C)
showed that the percentage of MPCs undergoing basal
proliferation (S and G2/M phase cells) was higher in RelB/
than in WT cells (36.3% versus 29.5%, p< 0.05) and they formed
signiﬁcantly more ALPþ cells (Fig. 4D), similar to primary BM
stromal and calvarial cell cultures. Of note, the ratio of ALPþ cells
to total cells was threefold higher in RelB/ bMPCs cultures
than in WT cells (Fig. 4D), indicating that RelB/ bMPCs
have enhanced OB differentiation. Importantly and consistently,
RelB/ bMPCs have signiﬁcantly increased mineralized nodule
formation (Fig. 4E) and increased expression of ALP and
osteocalcin during their differentiation (Fig. 4F).
Runx2 and Osx are two critical transcription factors for OB
differentiation and maturation. Osx is a downstream target of
Runx2 and regulates expansion of an early osteoblastic pool
derived from MPCs.(31,32) Runx2 is required for commitment of
mesenchymal osteochondroprogenitors to the osteoblastic
lineage and OB differentiation during both endochondral and
intramembranous ossiﬁcation.(33) We found that differentiated
RelB/ stromal cells have threefold higher Runx2 (Fig. 5A, left)
and fourfold higher Osx (data not shown) mRNA expression
levels than WT cells. Although the endogenous Runx2 protein
level is low in osteoblastic cells,(23) we observed an increased
Runx2 protein in the differentiating RelB/ stromal cells
compared to the WT cells tested by Western blot (Fig. 5A, right).
Sequence analysis with TFSEARCH software showed that the
mouse Runx2 promoter contains two putative NF‐kB binding
sites, at –653/–644 and –1262/–1253 (Fig. 5B). We constructed a
2‐kb mouse Runx2 promoter Luc reporter, which contains two
putative NF‐kB binding sites (Fig. 5B). We then cotransfected the
Runx2 Luc reporter with RelB plasmids into C2C12 preosteo-
blastic cells, and found that RelB dose‐dependently inhibited
Runx2 Luc activity (Fig. 5C). We performed the site‐directed
mutagenesis of both kB binding sites in the promoter by deleting
“ATC” and “ACA” in binding sites 1 and 2, whichwas conﬁrmed by
sequencing. Then, using the mutated Runx2 reporter we found
that RelB did not affect the Luc activity of the mutated Runx2
promoter reporter (Fig. 5D), conﬁrming that RelB does indeed
regulate Runx2 activity via kB binding sites.
To further test if RelB directly binds to the putative kB binding
sites of the Runx2 promoter, we performed ChIP assays usingWT
and RelB/ MPCs. As shown in Fig. 5E, immunoprecipitation of
both binding sites with anti‐RelB antibody followed by qPCRwith
speciﬁc primers for each of the putative binding sites yielded
distinct enrichment in WT MPCs over the input chromatin
compared to that of an IgG negative control antibody (Fig. 5E).
No chromatin enrichment by the RelB antibody was observed in
RelB/ MPCs, indicating speciﬁc binding of RelB protein to the
Runx2 promoter. Importantly, a Runx2 short‐hairpin RNA (shRNA)
abolished the enhanced OB differentiation by RelB/MPCs (Fig.
5F).
RelB/ MPCs induce bone formation and repair in tibial
bone defects more rapidly than WT MPCs
To test if RelB/MPCs have enhanced bone forming potential in
vivo, we made 5‐mm 2‐mm cortical defects in the anterior
tibiae of SCID mice. We ﬁlled the defects with decalciﬁed bovine
bone matrix (DBM), which is used commonly to ﬁll bone defects
and stimulate bone formation. bMPCs from RelB/ and WT
littermates were then injected into the DBM in the left and right
tibiae, respectively. We found that the defects injected with
RelB/ bMPCs had signiﬁcantly more new bone formation than
those injected with WT cells, as assessed by mCT and histologic
analysis, at 4 weeks posttransplantation (Fig. 6A, B). The volume
of new bone formed from transplanted WT MPCs almost
matched that formed by the RelB/ cells at 8 weeks postsurgery.
However, at 8 weeks postsurgery almost all the area around the
new bone and surviving fragments of bone matrix implanted
before the injection of RelB/ MPCs had become ﬁlled with
hematopoietic marrow, whereas this space in the defects
injected with WT MPCs was still largely ﬁlled with immature
ﬁbrous tissue and unresorbed DBM (Fig. 6B), indicating that the
transplanted RelB/MPCs induced accelerated bone repair and
resorption of the DBM. In addition, by 8 weeks postsurgery, new
bone containing live osteocytes and partly covered with a
periosteum‐like membrane extended along70% of the surface
of the DBMparticles injectedwith RelB/MPCs. In contrast, only
20% of the surface of DBM injected with WTMPCs was covered
by viable new bone and the remainder of the surface was
covered by ﬁbrous tissue, indicating a marked delay in the
healing process (Fig. 6C).
Discussion
Here, we report that RelB/ mice have increased trabecular
bone volume in the diaphyses of their long bones and in their
vertebral bodies as they age. The mice have relatively normal OC
numbers and functions in vivo, but impaired RANKL‐induced OC
formation in vitro, similar to ﬁndings reported in RelB/mice by
other investigators.(8) Importantly, the metaphyseal bone in the
RelB/ mice does not have the typical histologic features of
osteopetrosis, such as increased trabecular bone volume with
unresorbed islands of cartilage inside trabeculae.(26,27) In
contrast, young RelB/ mice have signiﬁcantly increased OB
surfaces and BFRs in tibial and vertebral bone sections,
consistent with an enhanced OB phenotype being responsible
for the increased bone mass observed when the mice are older.
The RelB/ mice have normal numbers of BM MPCs, indicating
that RelB does not have a role in the maintenance of these
progenitor cells or in their differentiation from mesenchymal
stem cells, as it does along with p52 in the maintenance of
hematopoietic stem cells.(34) However, RelB/ MPCs derived
from either BM or bone have enhanced commitment of pre‐OBs
and their subsequent proliferation, OB differentiation, and
mineralization potential in vitro accompanied by increased
expression of Runx2, suggesting that RelB negatively regulates
their differentiation in part at least by limiting expression of
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this essential osteoblastogenic transcription factor. These
ﬁndings suggest that RelB plays an important role to limit
bone formation in the diaphysis, which could potentially reduce
the strength of bone near the distal ends of long bones as mice
and other mammals age, and increase the risk of fracture
through them.
The role of Runx2 in the regulation of bone formation is
complex. For example, it is required for commitment of
progenitors to the OB lineage and for OB differentiation, but it
also inhibits proliferation of MPCs and of mature OBs(33,35,36);
thus its presence reﬂects induction of differentiation of
osteoblastic cells. We found that MPCs and neonatal calvarial
Fig. 4. RelB/ bMPCs have enhanced proliferation and OB differentiation. (A) bMPCs generated from 8‐week‐old RelB/mice and WT littermates were
analyzed by FACS using CD45, CD105, and Sca‐1 antibodies. (B) A total of 2 104 bMPCs from WT and RelB/mice were seeded in 12‐well plates for the
indicated times. The cells were ﬁxed with 10% formalin followed by H&E staining to count cell numbers (4 wells/time point). (C) Cultured bMPCs at 60% to
70% conﬂuence were collected and incubated with DAPI (1mg/mL). The cell cycle was analyzed by FACS; the data presented are from 3 pairs of mice.
(D) bMPCs from RelB/ and WT littermates were cultured in OB differentiation medium for 5 days and stained for ALP activity followed by eosin
counterstaining. ALPþ and total cell numbers were counted and the ALPþ /total cell ratio was calculated. (E) A total of 1 104 bMPCs were cultured in 12‐
well plates for 5 days to subconﬂuence, thenOBdifferentiationmediumwas added for 21 days until nodules had formed. Von Kossa stainingwas performed
to quantify nodule area. (F) bMPCs cultured in a 60‐mmdish were induced for OB differentiation for the indicated times. Expression levels of ALP and OCal
were tested using real‐time PCR. All mice in in vitro experiments were 1.5‐ to 2‐month‐old males or females; 3 to 4 wells per group. p< 0.05; p< 0.01
versus control. bMPC¼bone‐derived mesenchymal progenitor cell; OB¼ osteoblast; WT¼wild‐type; FACS¼ ﬂuorescence‐activated cell sorting;
H&E¼hematoxylin and eosin; DAPI¼ 4,6‐diamidino‐2‐phenylindole; ALP¼ alkaline phosphatase; OCal¼ osteocalcin.
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Fig. 5. RelB directly targets the Runx2 promoter and inhibits Runx2 expression. (A) mRNA (left panel) and protein (right panel) expression of Runx2 were
tested by real‐time PCR and Western blot from RelB/ and WT BM stromal cells cultured with OB differentiation medium for 7 days. (B) Construction
scheme of mouse Runx2 promoter Luc reporter. The 2‐kb Runx2 promoter constructs contain two putative kB binding sites. (C) The 2‐kb Runx2 promoter
Luc reporter was cotransfectedwith RelB plasmid into C2C12 cells and the relative Luc activitywas tested. (D) Site‐directedmutagenesis of bothkB binding
sites 1 and 2 in the 2‐kb Runx2 promoter was performed by deleting “ATC” and “ACA.” A Luc activity assay was performed using C2C12 cells that were
cotransfected with a RelB plasmid and themutated Runx2 reporter. (E) ChIP assays were carried out using an anti‐RelB or control IgG antibody on sheared
chromatin fromWT and RelB/MPCs. Immunoprecipitated DNAwas analyzed by qPCR using primers covering either NF‐kB binding sites 1 (left panel) or
2 (middle panel) in the Runx2 promoter region or a pair of unrelated primers (right panel) designed in the region that is 3 kb apart from the kB binding sites.
Results are expressed as fold‐enrichment comparedwith IgG normalized to input. (F) bMPCs fromWT and RelB/micewere transfectedwith a scrambled
or Runx2 mouse shRNA sequence for 2 days followed by puromycin selection to kill the uninfected cells. The cells were treated with OB differentiation
medium for 5 days and stained for ALP activity to measure ALPþ cells (left and middle panel), and mRNA expression of Runx2 in these cells was tested by
real‐time PCR (right panel). All mice in in vitro experiments were 1.5‐ to 2‐months‐old. p< 0.05; p< 0.01 versus control. Runx2¼ Runt‐related
transcription factor 2; WT¼wild‐type; BM¼bone marrow; OB¼ osteoblast; Luc¼ luciferase; ChIP¼ chromatin immunoprecipitation; IgG¼ immuno-
globulin G; MPC¼mesenchymal progenitor cell; bMPC¼bone‐derived MPC; shRNA¼ short hairpin RNA; ALP¼ alkaline phosphatase.
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cells from RelB/ mice have increased OB differentiation
capacity and Runx2 mRNA expression levels (Figs. 3F, 5A) and
that RelB inhibits Runx2 expression in osteoblastic cells by
directly binding to kB binding sites in the Runx2 promoter. These
ﬁndings suggest that by inhibiting Runx2 expression in MPCs,
RelB plays an important contributory role to limit MPC
proliferation and subsequent OB differentiation. In this way,
RelB could limit trabecular bone formation in mice as they age.
However, there are other possible mechanisms, including RelB
regulation of expression of other genes that control proliferation,
such as cyclin D1, p53, etc., and these will require further study.
The increase in bone formation rate and diaphyseal OB
numbers in the RelB/ mice is transient, indicating that the
role of RelB in the regulation of OB differentiation and function
is complex. This could reﬂect the fact that diaphyseal bone
volume is not comparable between RelB/ and WT mice as
they age because very little trabecular bone remains in this
region in WT mice. However, another possibility is that because
RelB/ mice develop multiorgan inﬂammation(21) and in-
creased production of cytokines, such as TNF,(37) these could
inhibit bone formation as the mice age. Importantly, BM cells
from 3‐month‐old RelB/ mice (which have reduced bone
formation in vivo) have very signiﬁcantly enhanced capacity to
differentiate into ALPþ cells in vitro, suggesting that the
reduced bone formation in older RelB/ mice results from the
effects of secondary factors. Further studies using mice with
Fig. 6. RelB/ MPCs induce bone formation and repair in tibial bone defects more rapidly than WT MPCs. Bilateral 2‐mm 5‐mm cortical defects were
made in the anterior proximal tibiae of SCIDmice and ﬁlled with decalciﬁed bovine bonematrix. A total of 5 105 bMPCs from 7‐week‐old RelB/ andWT
mice were injected into the bone matrix in the left and right tibial defects, respectively. The mice were euthanized 4 and 8 weeks postsurgery and the
volume of new bone (BV/TV, expressed as a percentage of the total defect volume) formed in the defects was measured by mCT (A), followed by
histomorphometric analysis of the area of newly formed trabecular bone (Trab) and ﬁbrous tissue (Fib, black arrows) containing spindle‐shaped ﬁbroblast‐
like cells observed in decalciﬁed H&E‐stained sections of the bones (B). (C) Representative images of bone in the defect sites 8 weeks postsurgery, and the
extent of new bone (with viable osteocytes and covered with a periosteum‐likemembrane, green arrow) formed on the DBMwas quantiﬁed and expressed
as a percentage of the total length of implantedDBM. Theblack arrow shows ﬁbrous tissue covering the acellular DBM. n¼ 5/group. p< 0.05 versus control.
MPC¼mesenchymal progenitor cell; WT¼wild‐type; SCID¼ severe combined immunodeﬁciency; bMPC¼bone‐derived MPC; BV/TV¼bone volume/
tissue volume; mCT¼micro–computed tomography; Trab¼ trabecular bone; Fib¼ ﬁbrosis tissue; H&E¼hematoxylin and eosin; DBM¼decalciﬁed bone
matrix.
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tissue‐speciﬁc deletion of RelB will be necessary to deﬁnitively
address this issue.
Age‐related bone loss is a major health problem associated
with increased risk of fracture and morbidity and it will become
more prevalent as the aging population increases. Thus, it is
important to better understand the mechanisms that lead to loss
of trabecular and cortical bone with aging so that novel
therapeutic strategies can be developed to prevent it. Age‐
related osteoporosis is associated with so‐called low‐grade
molecular inﬂammation induced by increased production of
cytokines, including TNF, by immune cells and other cells as mice
and humans age.(38–40) RelB could also play a role in this cytokine‐
associated bone loss with aging because it negatively regulates
TNF expression.(37) Increased TNF production can lead to bone
loss by a variety of mechanisms, including increased OC
formation and activation, both directly(6) and indirectly,(41) and
inhibition of OB differentiation and function.(9–11) Thus, increas-
ing levels of cytokines, such as TNF, in blood and BM of RelB/
mice could secondarily mediate inhibition of bone formation in
the mice as they age and account for the decreased bone
formation rate we observed in older mice. The enhanced
differentiation of RelB/ MPCs occurred in vitro in the absence
of added TNF, and importantly, RelB/MPCs injected into tibial
cortical bone defects experienced the same cytokine microenvi-
ronment as WT MPCs in recipient SCID mice, but they induced
more bone formation in the defects, suggesting they have
intrinsically enhanced OB differentiation.
Transplanted DBM, similar to allograft bone, is osteoinduc-
tive,(42) and likely undergoes creeping substitution, with new
bone forming on it as bone defects are repaired. Once formed,
new bone and some of the DBM to which it attaches is
continually remodeled, but DBM typically is not fully resorbed
even at 42 weeks after surgery.(43) Thus, although it is hard to
predict when transplanted DBM will be resorbed completely to
allow restoration of normal cortical structure in tibial cortical
defects, the presence of new bone forming on and around DBM
would be indicative of healing. Our observation that by 8 weeks
after transplantation, 70% of the surface of DBM in defects
injected with RelB/MPCs was covered by newly‐formed viable
bone compared with only 20% of the surface of DBM injected
withWTMPCs further supports an important negative regulatory
role for RelB in bone defect repair. In addition to directly
differentiating into bone tissue, donor MPCs injected into bone
defects also produce cytokines and chemokines, which can
recruit host MPCs, promote angiogenesis and cellular migration,
and inhibit apoptosis,(44–46) to enhance tissue repair. Further
studies will be required to determine howmuch of the new bone
formed in the tibial bone defects in the SCID mice was derived
directly from RelB/ MSCs and if and how these injected MPCs
recruited host MPCs or promoted angiogenesis and callus
remodeling to enhance bone repair.
Interestingly, cortical thickness as well as the periosteal and
endosteal surface area did not increase in the RelB/ mice as
they aged. This may explain why vertebral bodies from 10‐ to 14‐
month‐old mice did not have increased biomechanical proper-
ties when we tested them ex vivo (data not shown). We do not
have an explanation for this differential role for RelB in trabecular
versus cortical bone, but we did not observe an increase in BFRs
on the endosteal bone surfaces of the RelB/ mice (data not
shown) as we did on their trabecular surfaces. That OBs on
trabecular and cortical bone surfaces may be regulated
differentially is supported by a recent study reporting the in
vivo effects of a peptide that inhibits OC formation by binding to
RANKL(47); it increased cortical, but not trabecular bone
formation and mass in mice by activating Smad1/5/8 and
working synergistically with BMP‐2 signaling in osteoblasts to
enhance OB differentiation and matrix mineralization.(47)
Another study reported that TRAF family‐member‐associated
NF‐kB activator (TANK)‐deﬁcient mice have increased cortical
bone mineral density and thickness, but trabecular osteope-
nia,(48) providing further support that signaling in trabecular and
cortical OBs can be regulated differentially.
In summary, our ﬁndings indicate that RelB inhibits OB
differentiation and bone formation directly, associated with
reduced Runx2 activation, and contributes to age‐related bone
loss in mice. The enhanced bone formation in RelB/mice and
from RelB/ MPCs transplanted into SCID mice suggests that
strategies to reduce or inhibit RelB functions in MPCs should
increase bone mass and enhance repair of bone defects and
possibly also of fractures.
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NOTCH inhibits osteoblast formation in 
inflammatory arthritis via noncanonical NF-κB
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NOTCH-dependent signaling pathways are critical for normal bone remodeling; however, it is unclear if dys-
functional NOTCH activation contributes to inflammation-mediated bone loss, as observed in rheumatoid 
arthritis (RA) patients. We performed RNA sequencing and pathway analyses in mesenchymal stem cells 
(MSCs) isolated from transgenic TNF-expressing mice, a model of RA, to identify pathways responsible for 
decreased osteoblast differentiation. 53 pathways were dysregulated in MSCs from RA mice, among which 
expression of genes encoding NOTCH pathway members and members of the noncanonical NF-κB pathway 
were markedly elevated. Administration of NOTCH inhibitors to RA mice prevented bone loss and osteo-
blast inhibition, and CFU-fibroblasts from RA mice treated with NOTCH inhibitors formed more new bone 
in recipient mice with tibial defects. Overexpression of the noncanonical NF-κB subunit p52 and RELB in a 
murine pluripotent stem cell line increased NOTCH intracellular domain–dependent (NICD-dependent) acti-
vation of an RBPjκ reporter and levels of the transcription factor HES1. TNF promoted p52/RELB binding to 
NICD, which enhanced binding at the RBPjκ site within the Hes1 promoter. Furthermore, MSC-enriched cells 
from RA patients exhibited elevated levels of HES1, p52, and RELB. Together, these data indicate that persis-
tent NOTCH activation in MSCs contributes to decreased osteoblast differentiation associated with RA and 
suggest that NOTCH inhibitors could prevent inflammation-mediated bone loss.
Introduction
Patients with chronic inflammatory diseases, such as rheumatoid 
arthritis (RA), often have severe systemic bone loss and increased 
risk of fracture due to increased bone resorption and decreased 
bone formation, partially mediated by elevated TNF levels (1). 
We (1–4) and others (5, 6) have reported that TNF inhibits bone 
formation by affecting major osteoblast regulatory pathways, 
including BMP/SMAD/RUNX2 and WNT–β-catenin, but the 
role of TNF in osteoblast differentiation from MSCs has not been 
fully defined. The TNF transgenic (TNF-Tg) mouse model we 
use, line 3647, represents a good model of RA to study the influ-
ence of chronically elevated, but relatively low, levels of TNF and 
TNF-induced inflammation on bone cell function and MSC dif-
ferentiation into osteoblasts (7). To attempt to identify molecules 
responsible for reduced differentiation of MSCs into osteoblasts 
in RA, we performed genome-wide screening and pathway analy-
ses using data from RNA sequencing (RNA-Seq) of MSCs purified 
from TNF-Tg mice and WT littermates. We found that genes in the 
NOTCH and noncanonical NF-κB signaling pathways were mark-
edly upregulated in TNF-Tg mouse MSCs, raising the possibility 
that NOTCH may interact with noncanonical NF-κB proteins in 
MSCs to inhibit their osteogenic differentiation.
NOTCH is a family of evolutionarily conserved receptors that 
regulate cell fate. NOTCH receptors are activated following direct 
contact with their ligands expressed on adjacent cells. In mammals, 
there are 4 NOTCH receptors (NOTCH1–NOTCH4) and 5 ligands 
(Jagged-1 [JAG1], JAG2, and Delta-like 1, 3, and 4). NOTCH recep-
tors have extracellular, transmembrane, and intracellular domains. 
Upon ligand binding, the NOTCH intracellular domain (NICD) of 
the receptor is cleaved by γ-secretase and translocates to the nucleus, 
where it associates with the recombination signal–binding protein jκ 
(RBPjκ). RBPjκ is a key transcription factor in canonical NOTCH 
signaling and acts downstream of all 4 NOTCH receptors. In the 
absence of a NOTCH signal, RBPjκ inhibits transcription of target 
genes by binding to transcriptional corepressors. Following NOTCH 
activation, NICD binds to RBPjκ and displaces corepressors, leading 
to transcriptional activation of target genes such as Hes1 and Hey1. 
Ligand binding also can lead to noncanonical NOTCH signaling, 
which is mediated through the interaction of NICD with factors 
other than RBPjκ to activate alternative signaling events.
Involvement of NOTCH in bone cells has been recognized since 
2008 (8), when in vivo studies of genetically modified mice demon-
strated that loss of NOTCH signaling in mesenchymal stem cells 
(MSCs) or osteoblast precursors resulted in increased bone mass 
(9, 10), whereas activation of NOTCH signaling decreased osteo-
blast numbers (11). NOTCH signaling maintains MSCs in a pro-
liferative phase and inhibits osteoblast differentiation. NOTCH 
also inhibits osteoclast formation via indirect and direct mecha-
nisms. Depletion of NOTCH (11) or γ-secretase (9) in osteoblasts 
decreased osteoprotegerin production, leading to increased osteo-
clast formation, whereas RBPjκ depletion specifically in myeloid 
cells increased osteoclast formation in response to inflammatory 
cytokines (12). Although a role for NOTCH signaling in MSC and 
osteoblast differentiation has been described in normal mice, lit-
tle is known about its role or the effects of NOTCH inhibitors in 
these cells in common bone diseases, such as RA.
NF-κB is a family of transcription factors that regulate many 
aspects of normal cellular functions as well as innate and adap-
tive immunity in response to pathogens and autoimmune 
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stimuli (13, 14). The family includes NF-κB1 (also known as 
p50, and its precursor p105), NF-κB2 (p52, and its precursor 
p100), RELA, RELB, and c-REL. Homo- and heterodimers of 
these proteins activate transcription of target genes, typically 
through canonical (p50/RELA) and noncanonical (p52/RELB) 
signaling. NF-κB signaling (which typically refers to canonical 
RELA-mediated transcription) regulates many aspects of cellu-
lar activity (15). Rela–/– mice die during embryonic development, 
making direct study of the role of RELA in bone difficult (16), 
although rescue studies indicate that RELA prevents osteoclast 
precursor apoptosis (17). Inhibition of RELA in mature osteo-
blasts by a dominant-negative IKK-γ mutant increases bone 
mass (18). Double-knockout Nfkb1–/– Nfkb2–/– mice are severely 
osteopetrotic because they have no osteoclasts (19). Double-
knockout Nfkb2–/– Relb–/– mice (referred to herein as p52/RELB 
dKO mice) have increased bone volume (20, 21), a phenotype 
also seen in Relb–/– mice due to enhanced RUNX2 activation and 
osteoblast precursor differentiation (22). Despite these advances 
in understanding of the role of NF-κB in bone, the relative roles 
of canonical versus noncanonical signaling in MSC functions 
in RA have not been defined. To date, the only reported interac-
tion between NOTCH and NF-κB was in cells in the hemato-
poietic lineage and cancer cells. Most of these studies suggested 
that NOTCH regulates the transcription of Nfkb (23, 24). They 
focused on canonical NF-κB signaling (25), and consequently, it 
is not known whether there is a relationship between NOTCH 
and noncanonical NF-κB signaling in bone cells.
In the present study, we found persistent activation of the 
NOTCH and noncanonical NF-κB pathways in MSCs and in MSC-
enriched cells from TNF-Tg mice. Enhanced NOTCH signaling 
in MSCs was associated with reduced osteoblast differentiation 
and bone formation, which was prevented by systemic adminis-
tration of the NOTCH inhibitors N-[N-(3,5-difluorophenacetyl)- 
l-alanyl]-S-phenylglycine t-butyl ester (DAPT) and thapsigargin. 
At the molecular level, we found that TNF increased expression 
of the noncanonical NF-κB proteins p52 and RELB, which poten-
tiated NOTCH activation by binding to and promoting nuclear 
translocation of NICD onto the Hes1 promoter. Thus, inhibition 
of NOTCH represents a potential new therapeutic approach for 
inflammatory bone loss when NOTCH is activated in MSCs.
Results
Increased expression of NOTCH target genes in MSCs from TNF-Tg 
mice and TNF-treated MSCs. BM MSCs from TNF-Tg mice with 
inflammatory arthritis have significantly decreased osteoblast 
differentiation potential (1). To identify the molecules and 
pathways responsible for TNF-induced inhibition of osteoblast 
differentiation, we purified MSCs (CD45–CD105+SCA1+) from 
6-month-old TNF-Tg mice (which typically have developed 
severe systemic bone loss by this age; ref. 1) and WT littermates 
by flow sorting, and performed RNA-Seq using a single-cell pro-
tocol. We identified 965 differentially expressed genes (>1.5-fold 
change; P < 0.05) between TNF-Tg and WT cells from a total of 
21,533 reference genes (Figure 1A; RNA-Seq results available at 
the NCBI Sequence Read Archive; accession no. SRX543086) 
and submitted them to 2 different pathway analyses: Ingenu-
ity Pathway Analysis (IPA) and David Bioinformatics Resources 
Program (David program), according to the Ingenuity Pathways 
Knowledge and KEGG databases, respectively. For all analyses, 
Fisher exact test was used to calculate a P value determining the 
probability that each pathway assigned to the data set was due 
to chance alone. IPA analysis revealed 53 dysregulated pathways 
between TNF-Tg and WT cells (Supplemental Figure 1A; supple-
mental material available online with this article; doi:10.1172/
JCI68901DS1). Among them, the NOTCH signaling pathway 
was in 14th place of 53 dysregulated pathways identified from 
the IPA analysis and in 7th place of 11 dysregulated pathways 
from the David program (Supplemental Figure 1B).
NOTCH signaling molecules contain 4 mammalian NOTCH 
receptors (NOTCH1–NOTCH4), 5 ligands (JAG1 and JAG2 and 
Delta-like 1, 3, and 4), 2 inhibitors (NUMB and NUMBL), and 
4 coactivators (DTX1–DTX4) (26). In MSCs, RNA-Seq detected 
various expression levels of these NOTCH-related genes (Sup-
plemental Figure 2). Interestingly, despite different levels of 
upstream NOTCH signaling molecules in cells from TNF-Tg 
mice, expression levels of the NOTCH target genes Hes1 and Hey1 
were increased, which was confirmed by quantitative real-time 
RT-PCR (qPCR) in purified CD45–CD105+SCA1+ MSCs (Figure 1B). 
Increased Hes1 and Hey1 expression was also demonstrated by 
qPCR in various TNF-treated MSC preparations, including: (a) 
3rd-passage bone-derived MSCs from WT mice (Figure 1C), which 
we characterized as cells expressing MSC surface markers (93% 
CD45–, 70% CD105+, 72% SCA1+, 90% CD44+) and able to differen-
tiate to osteoblasts, adipocytes, and chondrocytes in vitro (Supple-
mental Figure 3); (b) the murine MSC line C3H10T1/2 (Figure 1D); 
and (c) human MSCs purchased from Lonza and characterized 
as CD105+CD166+CD29+CD44+CD14–CD34–CD45– (Figure 1E). 
In a prior study, we demonstrated that mouse MSCs express Hes1 
among other NOTCH targets and that HES1 mediates much of 
the NOTCH effect on MSC-osteoblast differentiation (10), which 
indicates that Hes1 is an important NOTCH downstream gene in 
MSCs. Thus, in subsequent experiments, we used Hes1 as a readout 
measure for NOTCH activation.
TNF signals through TNF receptor 1 (TNFR1) and TNFR2 (27). 
To determine whether TNF receptors mediate Hes1 expression 
upregulated by TNF, we injected murine TNF (0.5 μg/injection/d 
i.p.) into double-knockout Tnfr1–/– Tnfr2–/– (TNFR1/2 dKO) mice 
and WT littermates for 5 days. We examined the expression level 
of Hes1 in CD45– MSC-enriched cells and in CD45+ non-MSCs 
by qPCR. TNF increased Hes1 expression in WT CD45– cells, but 
not CD45+ cells, and had no effect on CD45– or CD45+ cells in 
TNFR1/2 dKO mice (Figure 1F). Accordingly, TNF decreased alka-
line phosphatase–positive CFU-fibroblast (CFU-ALP+) numbers in 
WT cells, but had no effect in TNFR1/2 dKO cells (data not shown).
Short-term Notch inhibition by DAPT reverses decreased osteoblast dif-
ferentiation of MSCs from TNF-Tg mice. NOTCH controls the fate of 
MSCs, including their osteoblast differentiation potential (10). 
However, the role of NOTCH in common bone disorders, such 
as osteoporosis, has not been well investigated. NOTCH inhibi-
tors have not been tested in mouse osteoporotic models, perhaps 
reflecting concerns that sustained inhibition of NOTCH in the BM 
may have adverse effects, such as increased bone resorption (12). To 
investigate whether NOTCH inhibition can reverse the suppressed 
osteoblast differentiation in TNF-Tg mice, we administered the 
γ-secretase inhibitor DAPT to TNF-Tg mice and WT littermates 
by gavage for 4 days. The inhibitory effects of DAPT on NOTCH 
signaling was confirmed by decreased Hes1 mRNA levels in pop-
liteal lymph nodes (Figure 2A), an indicator of effective NOTCH 
inhibition in vivo, but not in spleen (Supplemental Figure 4), as 
described previously (28). Interestingly, CD45– MSC-enriched 
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cells from DAPT-treated WT mice had low levels of Hes1 expres-
sion, similar to cells from vehicle-treated WT mice. CD45– MSC-
enriched cells from vehicle-treated TNF-Tg mice had significantly 
increased Hes1 levels compared with WT cells, and this was reduced 
by 50% in cells from DAPT-treated TNF-Tg mice (Figure 2B). 
To investigate whether DAPT affects osteoblastic differentiation 
of MSCs in TNF-Tg mice, we examined CFU-ALP+ colony forma-
tion using BM stromal cells from DAPT- or vehicle-treated mice. 
As we previously reported (1), cells from TNF-Tg mice formed 
significantly decreased numbers of CFU-ALP+ colonies compared 
with WT cells, an effect that was largely reversed with DAPT treat-
ment. In contrast, CFU-ALP+ colony numbers were similar in cells 
of DAPT- and vehicle- treated WT mice (Figure 2C).
To determine whether MSCs from DAPT-treated mice can form 
more new bone, and whether increased new bone formation is 
independent of the BM environment of TNF-Tg mice, we per-
formed in vivo bone formation assays, as we described recently 
(22, 29), using cells from CFU mesenchymal colonies derived from 
Figure 1
Increased expression of NOTCH target genes in MSCs from TNF-Tg mice and TNF-treated MSCs. (A) BM cells were isolated from 6-month-old 
TNF-Tg mice and WT littermates (n = 3 per genotype). CD45–SCA1+CD105+ MSCs were subjected to RNA-Seq using a single-cell protocol. 
Differentially expressed genes between TNF-Tg and WT cells were subjected to pathway analysis. (B) RNA-Seq reads (top) and qPCR data (bot-
tom) from CD45–SCA1+CD105+ MSCs of TNF-Tg and WT mice. RPKM, reads per kilobase per million. (C and D) Expression of Hes1 and Hey1 
in TNF-treated (24 hours) 3rd passage of bone-derived WT MSCs (C) and in the C3H10T1/2 murine MSC line (D) by qPCR. (E) Expression of 
HES1 in TNF-treated (24 hours) human MSCs by qPCR. (F) 2-month-old TNFR1/2 dKO mice and WT littermates received TNF (0.5 μg/injection/d 
i.p.) or PBS for 5 days. BM cells were subjected to CD45– or CD45+ cell isolation for Hes1 expression by qPCR. *P < 0.05 vs. respective control.
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DAPT- or vehicle-treated TNF-Tg mice. We first demonstrated 
that a much higher percentage of CFU colony cells expressed MSC 
surface markers (50.4% CD45–, 89% SCA1+, 89% CD105+) com-
pared with primary BM stromal cells (16% CD45–, 13% SCA1+, 7% 
CD105+) or freshly isolated BM cells (6% CD45–, 8% SCA1+, 2% 
CD105+) (Supplemental Figure 5). We loaded CFU colony cells 
from DAPT- or vehicle-treated TNF-Tg mice on decalcified bovine 
bone scaffolds and implanted them in tibial defects in recipient 
mice for 6 weeks. We examined the volume of newly formed bone 
by μCT and histomorphometric analysis and found that cells from 
DAPT-treated mice formed more new bone than cells from vehicle-
treated mice (Figure 2, D and E).
To determine the fate of donor cells and their localization after 
they have been implanted in vivo for 6 weeks, we used CFU colo-
ny cells derived from Rosa26-LacZ mice in a separate experiment. 
LacZ+ cells were localized near the surfaces of newly formed 
bone, and they covered 37.3% of the total bone surface within 
the bone defect area (Figure 2F). To confirm that implanted 
MSCs were the major contributor to new bone formation, we 
compared mice that received only bone scaffolds with those that 
received bone scaffolds plus MSCs 6 weeks after implantation 
in WT mice (n = 5 per group). The implanting scaffold alone 
without MSCs could cause some degree of repair, perhaps via 
stimulation of MSCs from the host. However, the level of repair 
Figure 2
Short-term DAPT treatment revised decreased osteoblast differentiation of MSCs in TNF-Tg mice. (A–C) TNF-Tg mice and WT littermates were 
gavaged with DAPT (5 mg/kg each time) or vehicle daily for 4 days. The inhibitory effect of short-term DAPT treatment on NOTCH activation 
(Hes1 mRNA) was confirmed in the popliteal lymph nodes (A; positive control) and in CD45– MSC-enriched cells (B) by qPCR. (C) Representa-
tive images and number of CFU-ALP+ colonies in BM stromal cells. (D and E) CFU colony cells from vehicle- or DAPT-treated TNF-Tg mice were 
implanted to bone matrix in tibial cortical defects of SCID mice. Mice were sacrificed 6 weeks after surgery, and volume of new bone formed 
in the defects, relative to total defect volume (BV/TV), was measured by μCT (D), followed by histomorphometric analysis of the area of newly 
formed trabecular bone observed in decalcified H&E-stained bone sections (E). n = 8 per group. Scale bars: 1 mm (broken); 100 mm (solid). 
(F) CFU cells generated from BM stromal cells of Rosa26-LacZ mice were implanted to tibial cortical defects for 6 weeks as in D. Frozen sections 
were stained for LacZ enzymatic activity (blue) and counterstained with nuclear fast red (pink). Percent bone surface area covered by donor cells 
(LacZ+; red arrows) over total bone surface within the area of bone defect (green line) was assessed. n = 5 per group. Scale bars: 1 μm (broken); 
100 μm (solid). *P < 0.05 vs. WT; #P < 0.05 vs. vehicle.
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Figure 3
Long-term of DAPT treatment prevented bone loss in TNF-Tg mice. TNF-Tg mice were given with DAPT or vehicle as in Figure 2 for 3 months. 
(A) Representative μCT scans and morphometric data of BV/TV, trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular separa-
tion (Tb.Sp) in L1 vertebrae. (B) Histology and histomorphometric analysis of BV/TV and number of osteoblasts (Ob) and osteoclasts (Oc) per 
bone surface (BS) in L1 vertebrae. (C) Calcein double-labeling in L1 vertebrae and analysis of dynamic parameters of bone formation: double 
labeled surface per bone surface (dLS/BS), mineral apposition rate (MAR), and bone formation rate (BFR). Original magnification, ×40. (D) His-
tology and histomorphometric analysis in the tibial metaphysis. Values are mean ± SD of 7–8 mice per group. (E) BM cells were cultured in the 
basal or osteoblast-inducing medium for 21 days in CFU colony formation assays. The number of CFU-F and CFU-ALP+ colonies was evaluated. 
(F) Expression of Alp and Runx2 in CFU-ALP+ colonies, assessed by qPCR. (G) BM cells were cultured with RANKL and M-CSF for 5 days in 
osteoclastogenic assays. The number of TRAP+ osteoclasts was counted. Values are mean ± SD of 4 dishes. Scale bars: 1 mm. *P < 0.05 vs. vehicle.
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was much higher (5- to 6-fold) when MSCs were included along 
with scaffold (Supplemental Figure 6).
Long-term Notch inhibition by DAPT prevents bone loss in TNF-Tg mice. 
Patients and mice with inflammatory arthritis often have systemic 
bone loss due to increased bone resorption and decreased bone 
formation (1). Depletion of NOTCH in mice during embryonic 
development increased formation of both osteoblasts (10) and 
osteoclasts (12). We reasoned that NOTCH inhibition may have a 
different effect on bone mass of TNF-Tg mice compared with these 
genetically modified mice because MSCs from TNF-Tg mice have 
abnormally high NOTCH activation. Since persistent NOTCH 
inhibition (30) or activation (31) have detrimental effects on the 
skeleton, and high doses of NOTCH inhibitors have severe side 
effects in vivo, we decided to use low daily doses of DAPT. The 
half-life of DAPT in vivo is approximately 6 hours (32), and long-
term, low-dose DAPT appears to have no notable side effects (28).
To determine whether DAPT prevents inflammatory bone loss, 
we treated TNF-Tg mice with DAPT or vehicle by daily gavage for 
3 months. The efficacy of NOTCH inhibition was confirmed by 
demonstrating low expression of Hes1 in popliteal lymph nodes 
(data not shown). DAPT treatment had no effect on mouse surviv-
al or body weight (data not shown). μCT of vertebral bones showed 
that DAPT treatment significantly increased the bone volume and 
the trabecular number and thickness and decreased the trabecular 
spacing compared with vehicle-treated mice (Figure 3A). Increased 
bone volume in DAPT-treated mice was confirmed by histomor-
phometric analysis in H&E-stained sections (Figure 3B). Bones 
from DAPT-treated mice had significantly increased osteoblast 
and osteoclast numbers on trabecular surfaces (Figure 3B). Calcein 
double-labeling in undecalcified sections showed that mineraliza-
tion rate, bone formation rate, and mineral surface/bone surface 
were all increased in DAPT-treated mice compared with vehicle-
treated controls (Figure 3C). In addition, bone volume, osteoblast 
number, and osteoclast number were increased in long bones from 
the same DAPT-treated mice (Figure 3D). DAPT treatment did not 
affect the severity of inflammation or bone erosion in joints of 
TNF-Tg mice (data not shown).
To determine whether long-term DAPT treatment increased bone 
formation by increasing MSC osteoblastic differentiation, we cul-
tured BM stromal cells from DAPT- or vehicle-treated mice. Con-
sistent with increased osteoblast-mediated bone formation, cells 
from DAPT-treated mice formed more CFU-fibroblast (CFU-F) 
and CFU-ALP+ colonies compared with those from vehicle-treated 
mice (Figure 3E). mRNA expression of the osteoblast marker genes 
Alp and Runx2 from CFU-ALP+ colonies was increased in DAPT-
treated mice (Figure 3F). We also found a small, but significant, 
increase in osteoclast formation when BM cells were cultured from 
DAPT-treated mice (Figure 3G).
Long-term treatment with high doses of DAPT causes dam-
age to organs, including intestine and kidney, which could limit 
the potential clinical use of this class of reagents (33). Our DAPT 
regimen did not affect liver, lung, small intestine, or kidney at the 
microscopic level, nor did it affect body weight or survival (Supple-
mental Figure 7 and data not shown).
NOTCH inhibition by thapsigargin reverses decreased osteoblast differ-
entiation and prevents bone loss in TNF-Tg mice. To further demon-
strate that NOTCH inhibition reverses decreased osteoblast dif-
ferentiation of MSCs and prevents bone loss in TNF-Tg mice, we 
used thapsigargin, which has been identified recently as a NOTCH 
inhibitor via complementary genomic screening (34). Thapsigargin 
regulates intracellular Ca2+ via inhibition of the endoplasmic retic-
ulum in bone cells (35, 36) and interferes with processing of the 
NOTCH receptor in the endoplasmic reticulum, leading to accu-
mulation of misfolded receptor, which inhibits NOTCH signaling 
(34). Thapsigargin-derived drugs have been tested in phase I clini-
cal trails for breast, kidney, and prostate cancer (37). Thapsigargin 
is a much more potent inhibitor of NOTCH signaling than the 
γ-secretase activity inhibitor DAPT, requiring 0.4 mg/kg/injection 
(34) compared with 5 mg/kg/injection in vivo (28). However, the 
effects of thapsigargin on NOTCH signaling in osteoblasts have 
not previously been studied. We first demonstrated that admin-
istration of thapsigargin to TNF-Tg mice decreased Hes1 mRNA 
levels in popliteal lymph nodes and CD45– MSC-enriched cells and 
also increased CFU-ALP+ colony formation (Supplemental Figure 
8, A and B), which suggests that thapsigargin could be used as a 
new NOTCH inhibitor in our model.
To investigate whether thapsigargin has a bone-anabolic effect 
in TNF-Tg mice similar to that of DAPT, we treated mice with 
thapsigargin using both short- and long-term regimens as we did 
using DAPT (Figures 2 and 3). In vivo bone formation assays using 
CFU colony cells indicated that cells derived from TNF-Tg mice sub-
jected to short-term thapsigargin treatment (4 days) formed more 
new bone than cells derived from vehicle-treated mice (Figure 4A). 
Long-term treatment of TNF-Tg mice with thapsigargin (3 times 
per week for 2 months) rescued the decreased bone volume and 
trabecular number, as determined by μCT (Figure 4B).
Histomorphometric analyses confirmed the increased bone volume 
and osteoblast numbers in thapsigargin-treated mice (Figure 4C). 
We also tested whether long-term thapsigargin treatment increased 
bone formation by increasing MSC osteoblastic differentiation. 
Consistent with increased osteoblast-mediated bone formation, 
BM cells from thapsigargin-treated mice formed more CFU-F and 
CFU-ALP+ colonies, which expressed higher levels of osteoblast-
related genes and decreased NOTCH target gene levels compared 
with cells from vehicle-treated mice (Figure 4, D and E, and Sup-
plemental Figure 8C). In this set of experiments, we also treated 
WT littermates of TNF-Tg mice in parallel to determine whether 
thapsigargin affects osteoblast function in WT mice. Long-term 
thapsigargin treatment slightly increased bone volume and osteo-
blast numbers in WT mice, despite its strong stimulatory effects on 
osteoblast differentiation in vitro (Figure 4).
The noncanonical NF-κB proteins p52 and RELB mediate TNF-induced 
NOTCH activation. NF-κB is a major signaling pathway down-
stream from TNFRs, and it interacts with NOTCH in hematopoi-
etic cells (24). To investigate whether NF-κB proteins participate 
in TNF-induced NOTCH activation, we examined the expression 
pattern of Nfkb members in our RNA-Seq database. Expression of 
Nfkb2 and Relb, but not Nfkb1 or Rela, increased in MSCs from 
TNF-Tg mice (Figure 5A). To confirm this finding, we examined 
expression of p50, p52, RELA, and RELB proteins in CD45– MSC-
enriched cells from TNF-Tg mice and WT littermates by Western 
blot. Similar to mRNA levels, expression of RELA and p50 was not 
markedly changed, but levels of p52, p100, and RELB increased 
substantially (Figure 5B). DAPT treatment did not affect p52 or 
RELB levels in CD45– MSC-enriched cells in WT and TNF-Tg mice, 
but it rescued the decreased expression of osteoblast-related genes 
in TNF-Tg cells (Figure 5C), whereas Hes1 expression was signifi-
cantly decreased in the same samples (Figure 2B). These data indi-
cate that the change in p52 and RELB levels in MSCs from TNF-Tg 
mice is unlikely to be due to increased NOTCH activation.
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To examine whether p52 and RELB influence NOTCH activa-
tion, we overexpressed p52 and RELB in the presence or absence 
of low-dose NOTCH2-NICD in murine C3H10T1/2 cells with a 
RBPjκ-Luc reporter construct, which contains 6 RBPjκ response 
elements in front of the luciferase gene (10). Overexpression of p52 
or RELB alone had no effect on RBPjκ-Luc activity, and low-dose 
NOTCH2-NICD increased RBPjκ-Luc reporter activity 4-fold. 
Importantly, overexpression of p52 or RELB markedly increased 
Figure 4
Effects of thapsigargin on osteoblast differentiation and bone volume. (A) 2.5-month-old TNF-Tg mice and WT littermates were given thapsigargin 
(0.4 mg/kg/injection i.p.) or vehicle daily for 4 days. CFU colony cells were derived from the mice and implanted to bone matrix in tibial cortical 
defects of SCID mice as in Figure 2. Mice were sacrificed 6 weeks after surgery. Shown are histomorphometric analyses and the calculated area 
of newly formed trabecular bone in decalcified H&E-stained bone sections. n = 6 per group. (B–E) 2.5-month-old TNF-Tg mice and WT littermates 
were given thapsigargin (0.4 mg/kg/injection i.p.) or vehicle 3 times per week for 2 months. The lumbar vertebrae were subjected to μCT and histo-
logical analyses as in Figure 3, and BM cells from long bones were used for biological analyses. n = 6 per group. (B) Morphometric data from μCT. 
(C) Histology and histomorphometric analysis. (D) BM cells were cultured in basal or osteoblast-inducing medium for 21 days in CFU colony forma-
tion assays. The number of CFU-F and CFU-ALP+ colonies was evaluated. Values are mean ± SD of 4 dishes. (E) Expression of osteoblast-related 
and NOTCH target genes in CFU-F colony cells, determined by qPCR. Scale bars: 100 μm (A); 1 mm (C). *P < 0.05 vs. vehicle; #P < 0.05 vs. WT. 
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Figure 5
Noncanonical NF-κB proteins p52 and RELB mediate TNF-induced NOTCH activation. (A) Nfkb mRNA expression in CD45–SCA1+CD105+ 
MSCs from TNF-Tg mice and WT littermates by RNA-Seq. (B) NF-κB protein expression in CD45– MSC-enriched cells from TNF-Tg mice and 
WT littermates by Western blot. Fold change in protein level (below) was determined by measuring band intensity. (C) Nfkb2, Relb, Runx2, and 
Alp mRNA expression in CD45– MSC-enriched cells from DAPT- or vehicle-treated TNF-Tg mice by qPCR. (D) Reporter activity in C3H10T1/2 
cells cotransfected with RBPjκ-Luc and with NOTCH2-NICD–, p52-, and/or RELB-expressing vectors. Fold increase versus empty vector was 
calculated. (E) Expression of Hes1, Runx2, and Alp in cells as in D. (F) Expression of Hes1 and Hey1 in CD45–Ter119– MSCs from p52/RELB 
dKO mice, Relb–/– mice, and control littermates. Values are mean ± SD of 3 pairs of mice. (G and H) Bone-derived MSCs of p52/RELB dKO and 
control littermates were treated with TNF. (G) Expression of p52, RELB, and HES1 protein by Western blot. (H) Expression of Runx2 and Alp by 
qPCR. *P < 0.05, #P < 0.05 vs. control.
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NOTCH2-NICD–induced RBPjκ-Luc reporter activity, and p52 
and RELB combined had a synergistic effect, which was also 
observed in Hes1 expression levels when total RNA from transfect-
ed cells was used (Figure 5, D and E). Consistent with the notion 
that NOTCH activation limits osteoblast differentiation, overex-
pression of p52, RELB, and NICD significantly reduced Runx2 and 
Alp expression (Figure 5E). To investigate whether p52 and RELB 
regulate NOTCH signaling, we examined the gene expression lev-
Figure 6
p52 and RELB bind to NICD and are recruited to the Hes1 promoter. (A–E) C3H10T1/2 cells were treated with TNF for 24 hours in some experi-
ments. (A) Cells were cotransfected with Flag-tagged NOTCH2-NICD, p52, and RELB expression vectors. Whole-cell lysates were subjected to 
IP with anti-Flag or anti-p52 antibodies and blotted with anti-RELB or anti-Flag antibodies. Experiments were repeated independently 4 times. 
(B) Colocalization of p52 or RELB with NICD was determined by immunofluorescent staining using anti-p52, -RELB, and –NOTCH2-NICD 
antibodies under confocal microscopy. (C) Nuclear and cytoplasm proteins were isolated. Protein lysates were subjected to IP with anti-p52 or 
anti-RELB antibodies. Immunocomplexes were blotted with anti–NOTCH2-NICD. Expression of p52, RELB and NICD proteins were examined in 
cytoplasmic and nuclear fractions. Experiments were repeated independently 4 times. (D) The ChIP assay was performed on immunocomplex 
subjected to IP with anti–NOTCH2-NICD, anti-RELB or anti-p52 antibodies. Rat IgG was used as control. Precipitated DNA was measured by 
qPCR using sequence-specific primers. (E) Total protein lysates were subjected to IP with anti-p52 or anti-RELB antibodies. Immunocomplexes 
were washed with concentration gradient of NaCl, then blotted with anti–NOTCH2-NICD. Experiments were repeated independently 3 times. 
Lanes were run on the same gel but were noncontiguous. (F) Bone-derived MSCs from p52/RELB dKO and WT mice were treated with TNF or 
PBS and subjected to ChIP as in E. Values are mean ± SD of triplicate determinants. *P < 0.05 vs. respective control.
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els of Hes1 and Hey1 in purified CD45–Ter119– MSCs from p52/
RELB dKO mice and found that they were reduced (Figure 5F). 
To determine whether p52 and RELB mediate TNF-induced 
upregulation of Hes1, we treated 3rd-passage bone-derived MSCs 
from p52/RELB dKO mice and control littermates with TNF. 
Western blot analysis showed that TNF increased HES1 protein 
expression in cells from control mice, but not from p52/RELB 
dKO mice (Figure 5G). qPCR analysis showed that TNF decreased 
expression of osteoblast-related genes in WT cells, but not in p52/
RELB dKO cells (Figure 5H).
p52 and RELB bind to NICD and are recruited to the Hes1 promoter. 
To examine the molecular mechanism by which p52 and RELB 
activate NOTCH target gene transcription, we examined whether 
p52 and RELB bind to NICD, which associates with RBPjκ, the key 
transcription factor in canonical NOTCH signaling. We transfect-
ed C3H10T1/2 cells with Flag-tagged NOTCH2-NICD and with 
p52 and RELB expression plasmids, performed IP with anti-Flag 
antibody against NOTCH2-NICD or anti-p52 antibody against 
p52, and then blotted immunocomplexes with anti-RELB or anti-
Flag antibody. Both p52 and RELB bound to NICD (Figure 6A). We 
hypothesized that TNF enhances the interaction between RELB or 
p52 and the NICD in MSCs to activate NOTCH signaling. To test 
this, we cultured C3H10T1/2 cells to confluence; under this cul-
ture condition, expression of endogenous NICD was increased due 
to cell-cell contact–mediated NOTCH activation (Supplemental 
Figure 9). We treated cells with TNF for 24 hours and examined 
colocalization of p52, RELB, and NICD by immunofluorescence 
staining with anti-p52, -RELB, or –NOTCH2-NICD antibodies. As 
reported previously (38), under basal conditions, RELB and p52 
were expressed mainly in the cytoplasm and NICD mainly in the 
nucleus. After TNF treatment, colocalization of NICD with p52 
or RELB increased markedly in the nucleus (Figure 6B). To exam-
ine whether TNF increases the interaction of RELB or p52 with 
NICD and whether this occurs in the cytoplasm or the nucleus, 
we treated cells with TNF, isolated cytoplasmic or nuclear frac-
tions, performed IP with RELB or p52, and blotted the immuno-
complexes with anti–NOTCH2-NICD. TNF increased the total 
amount of RELB and p100/p52 proteins in both cytoplasmic and 
nuclear fractions. TNF increased the binding of NICD to RELB 
and p52 in both the cytoplasm and the nuclei, despite the fact that 
it decreased the total amount of NICD protein in these compart-
ments (Figure 6C). To determine whether TNF-induced NICD/
Figure 7
Increased NOTCH activation 
in CD45– MSC/osteogenic 
precursors from RA patients.  
(A) CD45– and CD45+ cells 
isolated from human BMMCs 
and PBMCs were stained with 
anti-CD45 antibody for FACS 
analysis. (B) CD45– cells iso-
lated from BMMCs and PBMCs 
were subjected to osteoblast 
(ALP) and adipocyte (Oil Red 
O) differentiation assays. Orig-
inal magnification, ×10. (C) 
Expression levels of NOTCH 
target genes, RUNX2, and 
noncanonical NF-κB mem-
bers were measured by qPCR 
in CD45– cells isolated from 
PBMCs from healthy control 
subjects (n = 14) and patients 
with RA (n = 11). Values were 
calculated as Ctgene of interest/ 
2 – Ctactin × 100.
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genes. MSCs from TNF-Tg mice, a model of chronic inflammatory 
arthritis, had significantly decreased osteoblast differentiation. 
The NOTCH inhibitors DAPT and thapsigargin increased bone 
volume and osteoblast number and activity in TNF-Tg mice. MSCs 
from DAPT-treated TNF-Tg mice had increased osteoblast dif-
ferentiation in in vitro cultures and formed more new bone after 
injection into recipient mice in vivo. At the molecular level, TNF 
increased the expression levels of noncanonical NF-κB proteins 
p52 and RELB, which interacted with NICD on the Hes1 promoter 
and upregulated NOTCH target gene expression. Thus, our find-
ings revealed a new role of NOTCH in inflammatory bone loss, 
such as occurs in RA, in which persistent NOTCH activation in 
MSCs inhibits their differentiation into osteoblasts.
We speculate that there are 2 fundamental differences between 
our TNF-Tg mice and genetically modified Notch mouse models 
with respect to NOTCH activation in MSCs. First, in TNF-Tg 
mice, NOTCH activation resulted from chronic low-level systemic 
inflammation, rather than being driven by a specific promoter 
(i.e., NOTCH manipulation occurs only when cells express the 
promoter). Second, in TNF-Tg mice, the degree of NOTCH activa-
tion was low to moderate, which we found to be preventable by 
NOTCH inhibitor treatment. In contrast, in most animal models, 
NOTCH activation is persistent because the mice carry a constitu-
tively activated NICD at very high levels that cannot be inhibited 
by NOTCH inhibitors unless very high doses are used.
NOTCH controls osteoclast function by negatively regulating 
osteoclastogenesis (40). Osteoclast-specific depletion of RBPjκ 
increases TNF-induced osteoclast formation (12) and local bone 
erosion in antibody-induced arthritis (41). The NOTCH/RBPjκ 
pathway promotes LPS-induced M1 inflammatory macrophage 
polarization (42), while osteoclasts are derived from M2 housekeep-
ing macrophages (43). These findings suggest that NOTCH/RBPjκ 
inhibition might favor osteoclastogenesis and bone loss in an 
inflammatory environment, which appears at odds with the ana-
bolic effect of NOTCH inhibition that we observed herein. In fact, 
we did observe a small increase in osteoclast numbers in DAPT-
treated TNF-Tg mice. However, the overall effect was a significant 
increase in bone volume in these animals (Figure 3D), which indi-
cates that the bone-anabolic effect of low-dose NOTCH inhibition 
in this study was greater than the bone-resorptive effects. NOTCH 
inhibition increases osteoclastogenesis (44), and myeloid-specific 
deletion of RBPjκ enhances TNF-induced osteoclast formation 
(41). However, NOTCH activation has been previously reported in 
synovial samples from RA patients and from mice in animal mod-
els of RA (45, 46). NOTCH mediates hypoxia-induced angiogen-
esis in RA by increasing the function of microvascular endothelial 
cells (47). Recent studies using DAPT (48) or an anti-mouse Delta-
like 1–blocking monoclonal antibody (49) reported that NOTCH 
inhibition in mice with inflammatory arthritis reduces the sever-
ity of inflammation and inhibits osteoclastogenesis. These reports 
highlight the complexity of NOTCH signaling under normal and 
pathological conditions. We did not observe reduced joint inflam-
mation in our present study. One potential reason why we did not 
find changes in inflammation or bone erosion in DAPT-treated 
mice is that the dose we used was low (5 mg/kg) compared with 
larger doses used previously (10–20 mg/kg; ref. 48).
Activation of NOTCH signaling is regulated at many levels. For 
example, TNF regulates NOTCH signaling in several cell types by 
different mechanisms: it regulates expression of NOTCH ligands 
(JAG2) and receptors (NOTCH1 and NOTCH4) in fibroblasts, 
RELB or NICD/p52 interaction occurs on the native Hes1 promot-
er, we performed ChIP assays using primers that flank the RBPjκ 
binding sites on the mouse Hes1 promoter. TNF treatment signifi-
cantly increased the amount of NICD, p52, and RELB that bound 
to the RBPjκ binding sites on the Hes1 promoter (Figure 6D).
To determine whether the increased binding of NICD to RELB 
and p52 resulted from altered affinity in response to TNF or was 
due only to increased p52 and RELB expression, we performed an 
affinity assay (39) by washing the IP complex with gradient NaCl 
solutions. A high NaCl concentration (500 mM) dissociated the 
binding of NICD with p52 and RELB in both TNF- and PBS-treat-
ed samples (Figure 6E), which suggests that TNF does not affect 
the binding affinity of NICD for NF-κB proteins. To determine 
whether TNF increases NICD ChIP without overexpression of p52 
or RELB, and whether knockdown of endogenous p52/RELB abol-
ishes this increase, we performed ChIP assays using bone-derived 
cells from p52/RELB dKO and WT mice. TNF increased the bind-
ing of NICD to native RBPjκ binding sites on the Hes1 promoter in 
WT cells, which was abolished in p52/RELB dKO cells (Figure 6F).
MSCs from patients with RA have elevated Notch activation. To deter-
mine the clinical relevance of our mouse findings, we next exam-
ined the expression levels of NOTCH, NF-κB, and osteoblast-relat-
ed genes in MSCs of RA patients. We first examined properties 
of CD45– MSCs isolated from healthy human BM mononuclear 
cells (BMMCs) and PBMCs. We isolated CD45– and CD45+ cells 
using magnetic beads as we did for mouse cells (Figure 1A) and 
stained them with FITC-conjugated anti-CD45 for fluorescence-
activated cell sorting (FACS; Figure 7A). CD45– cells were cultured 
in osteoblast- or adipocyte-inducing medium. CD45– cells from 
both BMMCs and PBMCs gave rise to osteoblasts and adipo-
cytes (Figure 7B), which indicates that CD45– cells from PBMCs 
contain MSC-enriched cells. Using CD45– MSC-enriched cells 
from PBMCs of 14 healthy controls and 11 RA patients (active 
disease, DAS28 score >5, not on bisphosphonates or biolog-
ics; see Methods), we measured gene expression levels by qPCR. 
Similar to our data from TNF-Tg RA mice, expression levels of 
NOTCH- and NF-κB–regulated genes were significantly increased 
in CD45– MSC-enriched cells from RA patients compared with 
those of healthy controls, whereas RUNX2 expression levels were 
markedly decreased (Figure 7C). In addition, CD45– cells from 
BMMCs or PBMCs of TNF-Tg mice had similarly increased Hes1 
and decreased Runx2 RNA expression levels (Supplemental Figure 
10). CD45– PBMCs from RA patients had increased mRNA levels 
of NOTCH- and NF-κB–regulated genes and decreased RUNX2 
compared with cells from healthy subjects (Figure 7C), which indi-
cates that elevated NOTCH in MSCs likely contributes to reduced 
osteoblast function in RA patients.
Discussion
Data from various genetically modified mice reveal a complicated 
role for NOTCH in MSC-osteoblast differentiation, which is tight-
ly regulated both temporally and spatially. For example, NOTCH 
blocks MSC commitment to the osteoblast lineage when activated 
in MSCs, although it does not appear to have an important role 
in committed osteoblasts. Consequently, therapeutic targeting of 
this pathway is considered to be challenging, and thus the role of 
NOTCH in common bone diseases has not been studied exten-
sively. Here, using unbiased pathway analysis of RNA-Seq data 
obtained from purified MSCs after chronic exposure to TNF in 
vivo, we found an increase in the expression of NOTCH signaling 
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ed NOTCH activation by binding to and promoting nuclear trans-
location of NICD. Thus, NOTCH inhibition represents a potential 
new therapy for inflammation-induced bone loss associated with 
NOTCH activation in MSCs.
Methods
Reagents and animals. DAPT was from Calbiochem and thapsigargin was 
purchased from ENZO life sciences. M-CSF, RANKL, and TNF for cell cul-
ture were purchased from R&D Systems. TNF-Tg mice (line 3647), origi-
nally obtained from G. Kollias (Biomedical Sciences Research Centre “Alex-
ander Fleming,” Vari, Greece), carry a 3′-modified human TNF transgene in 
which the 3′-region of the TNF gene was replaced with that of the human 
β-globin gene. These mice develop arthritis starting at 2 months of age, 
and arthritis and bone loss progress with age. TNF-Tg 3647 mice can sur-
vive to 1 year or older, unlike the commonly used TNF-Tg 197 mice, which 
develop more severe arthritis and die within a few months of birth. We con-
sider the chronic nature of the disease in TNF-Tg 3647 mice to be advanta-
geous because it is more closely mimics human RA. Nfkb2–/– mice, and mice 
with a mutation-disrupted Relb locus by random integration of transgene 
sequences, have been described previously (21, 55). Nfkb2+/– Relb+/– mice 
were crossed with Nfkb2–/– Relb+/– mice to generate Nfkb2–/– Relb–/– mice 
(p52/RELB dKO). The mice used were in a mixed 129 and C57BL/6J 
background. Tnfr1–/– Tnfr2–/– mice (TNFR1/2 dKO) in a C57BL/6J back-
ground were provided by G.S. Pryhuber (Department of Pediatrics, Univer-
sity of Rochester School of Medicine and Dentistry, Rochester, New York, 
USA; ref. 56). Transplant recipients were 2-month-old SCID mice (strain 
B6.CB17-Prkdcscid/SzJ; stock no. 001913; Jackson Laboratories). Rosa26-
LacZ mice (strain B6;129S-Gt[ROSA]26Sor/J; stock no. 002073; Jackson 
Laboratories) were used in in vivo tracking experiments.
MSC preparation. We used several types of cell preparations as MSCs and 
MSC-enriched cells based on individual experimental needs.
For FACS-sorted purified MSCs, we used the following antibodies (from 
eBioscience and BD Biosciences — Pharmingen): CD45, SCA1, CD105, 
Ter119. Whole BM cells were incubated with anti-CD45 antibody–conju-
gated microbeads (Miltenyi Biotec). The CD45– population was isolated by 
negative selection according to the manufacturer’s instructions. CD45– cells 
were stained with a combination of SCA1 and CD105. CD45–SCA1+CD105+ 
cells were isolated by FACS sorting and used in RNA-Seq and qPCR.
CD45– MSC-enriched cells were isolated by negative selection, as 
described above. We previously reported that CD45– cells express MSCs 
surface markers and can differentiate into multiple lineages (1). CD45– 
cells were used in qPCR and Western blot analysis.
Mesenchymal colony cells, generated by pooling cells from CFU colonies, 
were used for in vivo bone formation assays.
Bone-derived MSCs were isolated using a recently published protocol 
(57). Long bones were flushed several times with PBS, cut into small piec-
es, and cultured in a plastic dish for 3 days. The bone pieces were trans-
ferred into a clear dish as 1st-passage cells and continually cultured for 
another 7 days to allow the cells to become confluent. 3rd-passage cells 
were used for cell characterization and experiments. The MSC character-
istics of bone-derived MSCs were confirmed by FACS and multilineage 
differentiation assays (Supplemental Figure 1). Bone-derived MSCs were 
used for Western blot and IP.
The C3H10T1/2 mouse MSC cell line was used in experiments involving 
transient transfection, Western blot, and ChIP assays.
Human MSCs (catalog no. PT-2501; Lonza) were used in qPCR analyses.
RNA-Seq and IPA. CD45–SCA1+CD105+ MSCs were isolated from TNF-Tg 
mice and WT littermates. Cells (1 × 104) were subjected to mRNA isolation 
and RNA-Seq with SOLiD system (Applied Biosystems). Pathway analysis 
of statistically significant gene expression changes from mRNA sequenc-
endothelial cells, and skeletal muscle cells (45, 50, 51) and induces 
HES1 expression in mouse embryonic fibroblasts (50). Our pres-
ent results revealed a new molecular mechanism of TNF-induced 
NOTCH activation in MSCs: TNF activates NOTCH at a step after 
NICD release. Although TNF-treated cells had reduced NICD 
expression levels in both cytoplasm and nuclei, they had more NICD 
binding to the RBPjκ sequence on the Hes1 promoter (Figure 6, 
C and D). In this model, the noncanonical NF-κB proteins RELB 
and p52 potentiated the effect of TNF, and in their absence, TNF-
stimulated Hes1 expression was abolished.
Studies of NOTCH interaction with NF-κB have focused mainly 
on canonical NF-κB p65 and p50 proteins (25) and how NOTCH 
regulates Nfkb transcription (23–25). We found that NOTCH inhi-
bition did not affect Nfkb2 expression, but MSCs from p52/RELB 
dKO mice had significantly reduced expression levels of NOTCH 
target genes (Figure 5, C and H), which indicates that RELB and 
p52 work upstream of NOTCH signaling in MSCs. NF-κB consen-
sus sequences could interact with the RBPjκ binding site on target 
genes (52). However, our findings showed that overexpression of 
RELB and p52 did not affect RBPjκ-Luc reporter activity or Hes1 
expression, whereas RELB and p52 in combination with NICD 
significantly increased RBPjκ-Luc reporter activity as well as Hes1 
expression (Figure 5, D and E), which indicates that RELB and p52 
need the NICD to regulate NOTCH target gene expression.
We used DAPT, a γ-secretase inhibitor, and thapsigargin, a newly 
identified NOTCH inhibitor (34), to inhibit NOTCH activation. 
Several γ-secretase inhibitors have been used in phase II clinical 
trails in diseases such as Alzheimer’s disease (53) and cancer (31). 
It is unclear whether NOTCH inhibitors can be used to increase 
bone formation in RA patients; however, data from the genetically 
modified Notch mice demonstrated the complexity of the role of 
NOTCH in osteoblast differentiation: it functions early to block 
MSC commitment to the osteoblast lineage, and later promotes 
osteoblast maturation. Thus, therapeutic targeting of this path-
way could be challenging. However, our present data indicated 
that the NOTCH inhibitor has a clearly beneficial bone-anabolic 
effect in an experimental model of RA in which NOTCH signaling 
is already elevated. A recent study demonstrated that osteoblasts 
are short-lived, nonreplicative cells, requiring continual replenish-
ment from BM MSCs (54). Thus, if NOTCH signaling is elevated 
persistently in MSCs in RA patients, it will decrease the osteo-
blast pool by blocking the MSC-osteoblast transition and thereby 
inhibit bone formation. Under these conditions, NOTCH inhibi-
tion could lift this blockage to increase osteoblast numbers and 
thus bone volume. Our data showed that CD45– MSC-enriched 
cells from RA patients expressed increased levels of HES1 and 
HEY1 and decreased levels of RUNX2 compared with those from 
healthy subjects, which indicates that the elevated NOTCH sig-
naling in MSCs in RA mice likely occurs in human RA patients 
as well. Since patients with other types of chronic inflammatory 
diseases — such as systemic lupus erythematosus and Crohn’s dis-
ease — often have systemic bone loss, it is possible that they also 
have abnormal NOTCH activation in their MSCs that contributes 
to reduced osteoblast function.
In summary, using TNF-Tg mice as a model of RA, we demon-
strated that chronic inflammation caused persistent activation of 
the NOTCH pathway in MSCs, limiting their osteoblast differenti-
ation, which was prevented by administration of a NOTCH inhibi-
tor. At the molecular level, we found that inflammation increased 
the expression of noncanonical NF-κB proteins, which potentiat-
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trabecular bone was performed using Osteometrics image analysis software. 
The mineral apposition rate, bone formation rate, and double label surface/
bone surface ratio were calculated as we previously described (1).
Confocal microscopy. Cells were treated with TNF for 24 hours, fixed with 
4% paraformaldehyde, pretreated with 1% Triton X-100 and 0.5% BSA 
in PBST, and blocked in 10% BSA in PBST for 30 minutes at RT. Cells 
were immunostained with anti-NICD, anti-p52, or anti-RELB antibodies 
at 4°C overnight, incubated with secondary antibodies conjugated with 
Alexa Fluor 488 and Alexa Fluor 546 for 45 minutes at 37°C, and subjected 
to confocal microscopy. Confocal images were obtained with a MRC1024 
confocal microscope (Bio-Rad). Laser beams with 488- and 543-nm exci-
tation wavelengths were used for DAPI, FITC, and Cy5 imaging. Single 
confocal images were processed in Adobe Photoshop.
Transfection and luciferase reporter assay. Transient transfection was per-
formed with Lipofectamine (Roche). 1 × 104 C3H10T1/2 cells were seeded 
in 24-well plates and cotransfected with NOTCH2-NICD (0.05 μg), p52, 
and/or RELB expressing constructs or the corresponding empty vectors 
along with RBPjκ-Luc (0.5 μg) and pRL-renilla (0.01 μg; Promega). Cells 
were cultured for a further 48 hours followed by harvesting for dual lucif-
erase activity assays (Promega) according to the manufacturer’s instruc-
tion. RBPjκ-Luc reporter activity was defined as the ratio of Firefly/ 
Renilla luciferase activities.
IP and Western blot. For IP, C3H10T1/2 cells were seeded in 10-cm dishes 
and cotransfected with NICD, p52, or RELB expression vectors for 24 hours. 
Proteins from cell lysates were quantitated using a kit from Bio-Rad and 
subjected to IP as described in the technical bulletin from Sigma-Aldrich. 
Briefly, 300 μg of proteins in 1 ml cell lysis buffer were added with 1 μg 
antibody and incubated for 1 hour at 4°C, then incubated with prewashed 
EZview Red Protein A/G Affinity Gel beads (Sigma-Aldrich) for another 
hour at 4°C. To test whether TNF affected the binding affinity of NF-κB 
and NICD proteins, we performed an affinity assay according to a pub-
lished protocol (39). In brief, the IP complex was washed 3 times with gradi-
ent concentrations of NaCl wash buffer containing 0, 200, 350, or 500 mM 
NaCl for 15 minutes. Eluted samples were fractionated by SDS-PAGE and 
transferred to PVDF membranes. For Western blot analysis, whole-cell 
lysates (10 μg) were loaded in 10% SDS-PAGE gels and blotted with antibod-
ies against HES1, p52, RELB, p50, RELA (Santa Cruz Biotechnology Inc.) 
and NOTCH2-NICD (Developmental Studies Hybridoma Bank, University 
of Iowa) or mouse GAPDH (Santa Cruz Biotechnology Inc.).
ChIP. C3H10T1/2 cells and 3rd-passage bone-derived cells from WT 
and p52/RELB dKO mice were treated with TNF for 24 hours after 
reaching confluence. ChIP was performed with MAGnify Chromatin 
Immunoprecipitation System (Invitrogen) according to the manufacturer’s 
instructions. A total of 3 × 106 C3H10T1/2 cells was used for each experi-
ment. Cells were treated with 1% formaldehyde for 15 minutes and then 
sonicated on ice 16 times (30 seconds on, 30 seconds off) at high power using 
a Bioruptor UCD-200 sonicator. Antibodies against NOTCH2-NICD, RELB 
(Santa Cruz Biotechnology Inc.), or p52 (Cell Signaling Technology) and 
control rat IgG (Invitrogen) were used with 100 μg chromatin per ChIP pro-
cedure. The amounts of each specific DNA fragment in IPs were determined 
by qPCR. Primers used for this analysis were as follows: RBPjκ, –194 to +160, 
5′-CTCAGGCGCGCGCCATTGGCC-3′ (forward), 5′-GCTTACGTCCTTT-
TACTTGAC-3′ (reverse); negative control, 1.5 kb downstream from the 
RBPjκ binding sites of the Hes1 promoter, 5′-CCTAGGGAGAAGGAGCTG-
GCT-3′ (forward), 5′-TGGCCGTCAGGAGCCGGCACC-3′ (reverse).
Tibial bone defect model. 2 month-old SCID mice (n = 4) were anesthetized, 
and bilateral 2 × 5 mm cortical bone defects were made in the anterior proxi-
mal tibiae and filled with bovine bone matrix. 5 × 105 cells from mesenchymal 
colony cells were injected into the bone matrix in defects. The right tibiae 
received cells from vehicle-treated mice and the left tibiae received cells from 
ing was performed with IPA (Ingenuity System) and David Bioinformatics 
Resources program (Visualization and Integrated Discovery; http://david.
abcc.ncifcrf.gov/home.jsp; ref. 58). Genes from the mRNA sequencing data 
set that met the 1.5-fold (P < 0.05) change cutoff and were associated with 
biological functions in the Ingenuity Pathways Knowledge Base or KEGG 
database were considered for analysis. For all analyses, Fisher exact test was 
used to calculate a P value determining the probability that each signal 
pathway assigned to that data set was due to chance alone. RNA-Seq data 
were deposited in the NCBI Sequence Read Archive (http://www.ncbi.nlm.
nih.gov/sra; accession no. SRX543086).
Cell culture and analysis. For CFU-F and CFU-ALP assays, total BM cells were 
cultured in 10-cm dishes at 106 cells/dish in 10 ml α-MEM containing 10% FCS 
(Hyclone Laboratories) with or without 50 μg/ml ascorbic acid and 10 mM 
β-glycerophosphate for 28 days. At the end of the culture period, cells were 
stained for CFU-F or CFU-ALP activity. The stained CFU-F and CFU-AFP+ 
colonies were counted (>20 cells in a single colony). For osteoclastogenic 
assays, BM cells were cultured with conditioned medium (1:50 dilution) 
from a M-CSF–producing cell line for 3 days in α-MEM with 10% FCS to 
enrich for osteoclast precursors. Osteoclast precursors were cultured with 
M-CSF conditioned medium and RANKL (10 ng/ml, R&D) for 2–3 days. 
After multinucleated cells were observed under a microscope, the cells were 
fixed, stained for TRAP activity to identify osteoclasts (TRAP+ cells contain-
ing >3 nuclei), and counted, as described previously (55). For differentiation 
assay of human CD45– cells, PBMCs and BMMCs were cultured in 60-mm 
dishes at 2 × 106 cells/dish in 4 ml α-MEM culture medium containing 10% 
FCS with 50 μg/ml ascorbic acid and 10 mM β-glycerophosphate for osteo-
blast induction, or containing 10% FCS, 10 nM dexamethasone, 5 μg/ml 
insulin (Sigma-Aldrich), 100 nM indomethacin (Sigma-Aldrich), and 0.5 mM 
methylisobutylxanthine (Sigma-Aldrich) for adipocyte induction. Cells were 
stained for ALP activity for osteoblasts or with Oil Red for adipocytes.
qPCR. Total RNA was extracted from cell cultures using TRIzol reagent 
(Invitrogen). cDNAs were synthesized by iSCRIPT cDNA Synthesis Kit 
(Bio-Rad). qPCR amplifications were performed in an iCycler (Bio-Rad) 
real-time PCR machine using iQ SYBR Green supermix (Bio-Rad) accord-
ing to the manufacturer’s instructions. Gapdh was amplified on the same 
plates and used to normalize the data. Samples were prepared in triplicate, 
and each experiment was repeated at least 3 times. The relative abundance 
of each gene was calculated by subtracting the Ct value of each sample for 
an individual gene from the corresponding Ct value of Gapdh (ΔCt); ΔΔCt 
was obtained by subtracting the ΔCt of the reference point; and 2ΔΔCt was 
then calculated to yield fold expression relative to the reference point. Rep-
resentative data are presented as mean ± SD of the triplicates or of 4 wells 
of cell culture. See Supplemental Table 1 for sequence-specific primers.
μCT, histology, and histomorphometric analysis of bone sections. For μCT, lumbar 1 
(L1) vertebrae and femora were dissected free of soft tissue, fixed overnight in 
70% ethanol, and scanned at high resolution (10.5 μm) on a VivaCT40 μCT 
scanner (Scanco Medical) using 300 ms integration time, 55 kVp energy, and 
145 uA intensity. 3D images were generated using a constant threshold of 
275 for all samples. For histology and analysis, thoracic vertebrae and tibiae 
were removed from mice after sacrifice, fixed in 10% buffered formalin, decal-
cified in 10% EDTA, and embedded in paraffin. Sections (4 μm thick) were 
then stained with H&E and for TRAP activity. Histomorphometric analysis 
of osteoclast numbers and osteoblast numbers, expressed per millimeter 
bone surface in the vertebrae and tibiae, was carried out using an Osteomet-
rics image analysis software system. Calcein double-labeling was performed 
by i.p. injection of calcein (10 mg/g body weight; C-0875; Sigma-Aldrich) at 
6 and 1 days prior to sacrifice, as described previously (59). Bones were har-
vested and embedded in LR White acrylic resin. Serial sections were cut, and 
the freshly cut surface of each section was viewed and imaged using fluo-
rescence microscopy. The calcein double-labeled morphometric analysis in 
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conformed to the NIH Guide for the Care and Use of Laboratory Animals. For 
human studies, detailed written informed consent was obtained from all 
patients and healthy donors, in accordance with protocols approved by the 
Human Subjects IRB of the University of Rochester Medical Center (RSRB 
29181 and 24888).
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DAPT-treated mice. Mice were sacrificed 6 weeks after surgery, and the vol-
ume of new bone formed in the defects (expressed as a percentage of the total 
defect volume) was measured by μCT, followed by histomorphometric analy-
sis of the area of newly formed trabecular bone and associated spindle-shaped 
fibroblast-like cells observed in decalcified H&E-stained bone sections.
Patients and sampling. Patients (n = 11) met ACR criteria for RA, were seropos-
itive (CCP+), had a mean age of 56 years, mean disease duration of 3.25 years, 
and evidence of disease activity based on the presence of swollen and tender 
joints. Disease activity was measured by DAS28 scores (mean, 3.5; range, 2.19 
to 5.85). Patients on biologics were excluded. Healthy controls (n = 14) were 
age matched, and subjects on bisphosphonates were excluded. BMMCs and 
PBMCs were isolated from heparinized BM aspirate and heparinized PB by 
Ficoll-Hypaque density gradient centrifugation (Pharmacia Biotech) (60, 61). 
PBMCs and BMMCs were incubated with anti-human CD45 antibody–con-
jugated microbeads (Miltenyi Biotec). CD45– and CD45+ populations were 
collected according to the manufacturer’s instructions.
Statistics. All results are given as mean ± SD. Comparisons between 
2 groups were analyzed using 2-tailed unpaired Student’s t test. 1-way 
ANOVA and Dunnett’s post-hoc multiple comparisons were used for com-
parisons among 3 or more groups. P values less than 0.05 were considered 
statistically significant.
Study approval. All animal experiments were performed according to pro-
tocols approved by the University of Rochester Medical Center IACUC and 
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Abstract
Human Immunodeficiency Virus-1 (HIV-1)-associated neurocognitive disorder (HAND) is likely neuroinflammatory in origin,
believed to be triggered by inflammatory and oxidative stress responses to cytokines and HIV protein gene products such
as the HIV transactivator of transcription (Tat). Here we demonstrate increased messenger RNA for nuclear factor-kappa B
(NF-kB) family member, transcription factor RelB, in the brain of doxycycline-induced Tat transgenic mice, and increased
RelB synthesis in Tat-exposed microglial cells. Since genetic ablation of RelB in mice leads to multi-organ inflammation, we
hypothesized that Tat-induced, newly synthesized RelB inhibits cytokine production by microglial cells, possibly through the
formation of transcriptionally inactive RelB/RelA complexes. Indeed, tumor necrosis factor-alpha (TNFa) production in
monocytes isolated from RelB deficient mice was significantly higher than in monocytes isolated from RelB expressing
controls. Moreover, RelB overexpression in microglial cells inhibited Tat-induced TNFa synthesis in a manner that involved
transcriptional repression of the TNFa promoter, and increased phosphorylation of RelA at serine 276, a prerequisite for
increased RelB/RelA protein interactions. The Rel-homology-domain within RelB was necessary for this interaction.
Overexpression of RelA itself, in turn, significantly increased TNFa promoter activity, an effect that was completely blocked
by RelB overexpression. We conclude that RelB regulates TNFa cytokine synthesis by competitive interference binding with
RelA, which leads to downregulation of TNFa production. Moreover, because Tat activates both RelB and TNFa in microglia,
and because Tat induces inflammatory TNFa synthesis via NF-kB, we posit that RelB serves as a cryoprotective, anti-
inflammatory, counter-regulatory mechanism for pathogenic NF-kB activation. These findings identify a novel regulatory
pathway for controlling HIV-induced microglial activation and cytokine production that may have important therapeutic
implications for the management of HAND.
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Introduction
Human Immunodeficiency Virus-1 (HIV-1) enters the central
nervous system (CNS) early after infection, and in many cases may
ultimately result in HIV-1 associated neurologic disease (HAND)
[1]. HAND can include neurocognitive impairments, motor
deficits, or dementias [2], and continues to be a significant source
of morbidity despite efficacious reduction of viral load by
comprehensive anti-retroviral therapy (cART) [3–10]. Tradition-
ally, onset of HAND correlated with CNS viral load, and was
principally subcortical in origin, with neuropathology including
multinucleated giant cells, reactive astrocytosis, myelin pallor,
reduced dendritic complexity and synaptic density and neuronal
loss [11–16]. Recent neuropathologic reports of severe white
matter damage (i.e. leukoencephalopathy) in patients with HIV-1
infection and on cART [17–23], including significant frontostriatal
and prefrontal cortex involvement in HAND [24–27], suggest that
additional patterns of primary brain disease are emerging, either
due to alterations in host cell signaling, or as yet unexplained
interactions between virus, vulnerable populations of neural cells,
and cART [6,28].
The pathogenesis of HAND likely arises from a toxic milieu of
secretory neurotoxins released from HIV-1 infected, brain-resident
mononuclear phagocytes and glia, and oxidative stress, which
together adversely affect neuronal function. HIV productively
infects microglia and perivascular macrophages, the resident
phagocytes of the CNS, but does not infect neurons. This suggests
that the neuropathology caused by HIV is indirect. Accordingly,
neurologic deficits in HAND are more closely correlated with the
presence of activated macrophages and microglia than with the
amount of neuronal apoptosis or viral RNA [29–32]. Soluble viral
proteins such as Tat and the glycoprotein gp120 can be released
from infected microglia and macrophages [33]. Tat protein has
been detected in blood plasma, serum, and cerebral spinal fluid
(CSF) from HIV+ individuals, at levels ranging from 1–40 ng/ml
[34,35], thus local extracellular concentrations in the CNS may be
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11875
207
much higher, particularly proximal to HIV+ pervivascular cells
[36]. Tat also interacts with and activates neighboring, uninfected
cells including microglia, astrocytes and neurons. Both infected
and activated microglia and astrocytes produce the pro-inflam-
matory cytokines tumor necrosis factor-alpha (TNFa) and
interleukin-1 beta (IL-1b), which further activate neighboring
cells. Infected and activated cells also produce chemokines such
as monocyte chemotactic protein-1 (MCP-1), attracting more
inflammatory monocytes and macrophages [37–39]. Thus, circu-
lating Tat has a high propensity to trigger this vicious cycle,
leading to neurologic deficits [34].
HIV-1 Tat is necessary for viral replication and activates the
nuclear factor-kappa B (NF-kB) signal transduction pathway in
cells of the CNS [40,41]. Cytokine and chemokine gene expression
in microglia, in turn, is also NF-kB dependent [41]. The NF-kB
family of transcription factors is intricately involved in both innate
and adaptive immune responses as well as in inflammation. In
mammalian cells, there are five NF-kB family members including
RelA (p65), RelB, cRel, p52 (with its precursor p100), and p50
(with its precursor p105). Homo- and hetero-dimeric combinations
of the five NF-kB proteins activate transcription of NF-kB target
genes. In resting cells, NF-kB dimers are retained in the cytoplasm
through their inhibitory interaction with the inhibitor of kappa B
(IkB) molecules [42]. Signals leading to activation of the NF-kB
pathway include the pro-inflammatory cytokines TNFa and IL-1b
[43]. Initiation of the NF-kB pathway is characterized by signal-
induced activation of the inhibitory kB kinase (IKK) complex.
IKK then phosphorylates IkBa leading to its subsequent
ubiquitination and proteolytic degradation [44]. Degradation of
IkBa frees NF-kB dimers to move to the nucleus, where they can
then activate transcription. We, and others, have demonstrated
that Tat-induced production of cytokines (e.g. TNFa) by microglia
involves activation of the NF-kB pathway, as evidenced by the
rapid degradation of IkBa in Tat treated microglial cells [41,45].
Indeed, overexpression of IkBa S32/36A, which is resistant to
proteasomal degradation, blocks Tat-induced TNFa synthesis in
microglial cells, thereby suggesting that Tat-induced TNFa
synthesis is NF-kB dependent [45].
Here we show that Tat treatment of microglial cells induces de
novo synthesis of RelB. The NF-kB family member RelB has many
distinguishing features compared to the other NF-kB proteins,
such as its unique amino-terminal leucine zipper motif [46]. RelB
also preferentially interacts with p100 rather than the usual NF-kB
inhibitory molecules (e.g. IkBa) [47,48]. RelB has lower relative
DNA binding activity at prototypical response elements, and can
both activate and inhibit transcription of target genes [49,50].
Specific nuclear DNA kB binding sites are efficiently recognized
by RelB/p52 DNA heterodimers, allowing for transcription of
certain kB-regulated target genes [49,51]. RelB also forms inactive
complexes with RelA [52–55]. In addition, studies in RelB2/2
mice have demonstrated impaired cellular immunity and devel-
opment of multi-organ inflammation that involves activation of
myeloid cells [56,57]. RelB has also been shown to be inhibitory to
the TNFa promoter in fibroblasts [58,59]. Together these results
strongly suggest that RelB has anti-inflammatory and cytokine-
regulating properties. Herein we investigate these anti-inflamma-
tory properties of RelB in the context of HIV-induced neuro-
inflammation.
Initial experiments in transgenic mice expressing Tat under a
doxycycline (Dox)-inducible glial fibrillary acidic protein (GFAP)
promoter demonstrated increased RelB message in the brains of
Dox-induced mice, confirming that Tat increases RelB in vivo.
Furthermore, Tat also enhanced TNFa release from monocytes
isolated from RelB2/2 mice as compared to monocytes from wild-
type (WT) mice, which is in agreement with previous reports of
anti-inflammatory properties of RelB. Next, in vitro experiments
were conducted to determine the mechanisms of RelB inhibition
of TNFa release from microglial cells. These experiments
suggested that RelB binds RelA to inhibit RelA-dependent
activation of the TNFa promoter, and that this RelB/RelA
mechanism of interaction requires the entire RelB Rel Homology
Domain (RHD). Taken together, these results suggest that RelB
may regulate cytokine synthesis by counter-regulating NF-kB
activated pathways, a finding that has important therapeutic
implications for the management of HAND.
Methods
Reagents
Cycloheximide (CHX) and MG-132 were obtained from
BioMol International/Enzo Life Sciences (Plymouth Meeting,
PA, USA). CHX was used at concentrations of 10 and 25 mg/mL
and MG-132 was used at a concentration of 50mM. Viral protein
gp120 SF162 was obtained from Immunodiagnostics (Woburn,
MA, USA), and used at a concentration of 100nM. All other
chemicals and regents were purchased from Sigma-Aldrich (St.
Louis, MO, USA).
HIV-1 Tat 1–72 was expressed in Sf9 insect cells using a
baculovirus system and was purified using Ni-NTA agarose
according to the BD BaculoGold 66His expression and
purification protocol (BD Biosciences, San Jose, CA, USA).
Briefly, the Tat 1–72 sequence (from HIV-1, YU-2 isolate) was
PCR amplified and cloned into XhoI and NcoI sites in the
pAcHLT-B baculovirus transfer vector. The recombinant plasmid
was confirmed by sequencing. This transfer vector was then co-
transfected into Sf9 cells along with BD BaculoGold linearized
baculovirus backbone DNA. Resultant virus stock was propagated
in Sf9 cells. Tat protein was then purified from lysates of infected
Sf9 cells using Ni-NTA agarose beads.
Importantly, the Tat produced in this fashion and used for these
studies was functionally indistinguishable from E. coli prepared
Tat 1–72, and caused similar microglial activation of NF-kB
related pathways as previously seen for E. coli Tat 1–72 (Text S1,
Figure S1). Therefore this Sf9 Tat, hereafter referred to as ‘‘Tat,’’
was used for these studies, allowing us to take advantage of this
more efficient protocol for producing HIV-1 Tat in the high yields
required for these studies.
Tat 1–101 (Immunodiagnostics,Woburn, MA, USA), Tat 1–72
(Sf9-Tat), Tat 1–72 (E. coli Tat; kind gift of Dr. A. Nath, Johns
Hopkins University, Baltimore, MD, USA), Tat C31S (Diatheva,
Fano, Italy), Tat D31–61 (obtained from Philip Ray, University
of Kentucky, Lexington, KY, USA) and Tat peptides (Tat 48–
72: G-R-K-K-R-R-Q-R-R-R-P-P-Q-D-S-Q-T-H-Q-S-S-L-S-K-
Q; GenScript, Piscataway, NJ, USA; Tat 46–60: S-Y-G-R-K-K-
R-R-Q-R-R-R-P-P-Q; and Tat 65–80: H-Q-V-S-L-S-K-Q-P-T-
S-Q-P-R-G-D; Intracel Corp., Cambridge, MA, USA) were used
at 100nM (,800 ng/ml) concentration unless otherwise described.
It should be noted that soluble Tat levels in HIV patient sera have
been measured up to 40 ng/mL [34,35]. It has also been shown
that Tat can interact with endogenous glycosaminoglycans and
heparin sulfates, thereby potentially lowering its measurable
concentration in vivo [60]. Therefore, it is likely that Tat
concentrations surrounding HIV-infected cells are much higher
[36]. In addition, Tat’s exceedingly strong affinity for other
proteins and glass/plastic, and its temperature susceptibility, make
it impossible to determine exactly what fraction of the Tat
‘‘starting dose’’ actually reaches the experimental specimen, thus
likely leading to underestimation of Tat functions in vitro [61].
Anti-Inflammatory Role of RelB
PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11875
208
Finally, Tat’s effects in vivo are likely to occur over long-term
exposures. Chronic, low dose, in vivo effects of any reagent are
often appropriately modeled in vitro, by proportionately higher
doses of that same reagent, over more acute time frames. For these
reasons, and in order to be consistent with previous experiments
from our laboratories, and others, we use 100nM Tat for these
experiments, which is at the lower end of the Tat dose range seen
with many comparable studies, and which many studies have
found to be an appropriate Tat dose by which to model Tat’s in
vivo effects in vitro.
Cell Cultures
Primary cultures. Human peripheral monocytes were
isolated from commercially obtained soft-spun buffy coats (New
York Blood Center, Long Island City, NY, USA) derived from
HIV-1 and hepatitis B virus-seronegative donors, using immuno-
magnetic isolation methods as described [62,63]. Briefly,
peripheral blood mononuclear cells (PBMCs) were isolated from
buffy coats after centrifugation on a lymphoprep gradient (AXIS-
Shield, Oslo, Norway). Monocytes were then isolated by positive
selection with anti-CD14 MACS beads (Miltenyi Biotec, Bergisch
Gladbach, Germany; Auburn, CA, USA), and cultured in RPMI
1640 medium supplemented with 10% fetal bovine serum (FBS),
and antibiotics for 18–24h before use. The monocyte cultures
used in our experiments were .95% pure as determined by
morphologic criteria.
Mouse monocytes were isolated from bone marrow derived
from age-matched C57BL/6 (RelB+/+) or RelB2/2 mice by
positive selection with mouse/human anti-CD11b MACS beads
(Miltenyi Biotec, Bergisch Gladbach, Germany; Auburn, CA,
USA). These cells were cultured in RPMI 1640 medium
supplemented with 10% FBS and antibiotics for 16h before use.
Human astrocytes were kindly supplied by Dr. Anuja Ghorpade
(University of North Texas Health Science Center, Fort Worth,
Texas, USA). Briefly, brain tissue was mechanically dissociated,
centrifuged, and resuspended in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 10% FBS and 16 penicil-
lin-streptomycin-glutamine for 7 days. Non-adherent microglia and
oligodendrocytes were removed by extensive agitation (260 rpm)
on a rotating platform. Cultures of astrocytes were .98% pure
as determined by immunocytochemical (ICC) staining for GFAP
(rabbit polyclonal antibody, Chemicon/Millipore, Billerica, MA,
USA).
Cell-lines: The murine microglial cell-line (BV-2) and human
embryonic kidney cell line (HEK 293) were obtained from Dr. R.
Donato (University of Perugia, Perugia, Italy) and American Type
Culture Collection (ATCC, Manassas, VA, USA) respectively.
These cells were maintained in DMEM containing 10% FBS,
2mM glutamine, and antibiotics, by standard procedures.
ELISA
TNFa levels were measured in culture supernatants (pre-cleared
by brief centrifugation) by using a mouse TNFa ELISA kit
(eBioscience, San Diego, CA, USA) according to the manufactur-
er’s instructions. This kit has a minimum sensitivity threshold of
8 pg/ml. Briefly, 50 ml of cell culture supernatant was incubated in
a 96-well plate pre-coated with a TNFa-specific monoclonal
antibody for 1.5h. After extensive washing, binding of TNFa was
detected by incubation with biotinylated antibodies, followed by
streptavidin-peroxidase; colorimetric enzyme assays were per-
formed to detect bound TNFa. Other cytokine levels were
measured using Bio-Plex Multi-Plex analysis for detecting a panel
of multiple cytokines from a single sample (Bio-Rad, Hercules,
CA, USA). Briefly, this technology uses multiple spectrally
identifiable polystyrene beads, each coated with a different anti-
cytokine antibody, followed by target, then secondary antibody
binding, to detect multiple cytokines from a single sample in
typical sandwich-assay fashion. This assay was utilized to measure
levels of IL-1b, IL-6, and MCP-1 in supernatant samples, as
previously described [64–66]. TNFa ELISA results were also
confirmed by this assay.
Electrophoretic Mobility Shift Assays
Nuclear extracts were prepared from BV-2 cells as previously
described [67]. Electrophoretic mobility shift assays (EMSAs) were
performed by incubating nuclear extracts with 32P-radiolabeled
high affinity, double-stranded DNA probe suspended in EMSA
reaction buffer (12mM HEPES, pH 7.9, 100mM NaCl, 0.25mM
EDTA, 1mM dithiothreitol, and 1mM phenylmethanesulfonyl
fluoride) at room temperature for 10 min, followed by resolution
of the protein-DNA complexes on native 4% polyacrylamide gels,
then autoradiography. The double stranded oligonucleotide
probes used in EMSA were as follows: (1) NF-kB: 59-CAACGG-
CAGGGGAATTCCCCTCTCCTT-39 and (2) OCT-1: 59-TG-
TCGAATGCAAATCACTAGAA-39. For antibody supershift
assays, 1 mg of antiserum recognizing each of the NF-kB subunits
(Santa Cruz Biotechnologies Inc., Santa Cruz, CA, USA) was
added to the EMSA reaction 10 min prior to electrophoresis.
Specificity and reactivity of the antibodies was confirmed as
described previously [68,69].
Plasmids
The luciferase reporter construct driven by NF-kB as well as the
RelA and cRel plasmids were obtained from Dr. S. C. Sun (MD
Anderson Cancer Center, University of Texas, Houston, TX,
USA). The plasmids expressing mouse RelB (mRelB) and
influenza hemagglutinin (HA)-tagged derivative of RelA (HA-
RelA) were obtained from Dr. Bernd Baumann (Ulm University,
Ulm, Germany). We PCR amplified the mRelB sequence from
this plasmid and inserted it into the pcDNA3.1-Myc/His(-)B
vector (Invitrogen, Carlsbad, CA, USA). The luciferase reporter
construct driven by the mouse TNFa (mTNFa) promoter was
obtained from Dr. Dmitry Kuprash (Engelhardt Institute of
Molecular Biology, Moscow, Russia).
Transient Transfections
HEK 293 cells were transfected with plasmid DNA using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Cells were
seeded at 1.86105 cells/well in 24-well plates 18h prior to
transfection. Each transfection reaction contained a total of
0.85 mg plasmid DNA. After addition of the transfection mixture
to the cells, they were incubated at 37uC for 24h. BV-2 cells
were transfected with plasmid DNA using Lipofectamine LTX
(Invitrogen, Carlsbad, CA, USA) or Nucleofector (Amaxa/Lonza,
Basel, Switzerland; Walkersville, MD, USA). For Lipofectamine
transfections, cells were seeded at 16105 cells/well in 24-well
plates 18h prior to transfection, then transfected as for Lipofecta-
mine 2000 above. For nucleofection, 56106 cells were transfected
with 10 mg NF-kB luciferase plasmid DNA. Transfected cells were
plated at 56105 cells/well in a 24-well plate and incubated for 24h
prior to Tat treatment. Media was changed 4h after transfection
and again prior to treatment to reduce cell toxicity. To determine
nucleofection-based transfection efficiency, an aliquot of BV-2
cells was transfected with a GFP-expressing vector, pMax-GFP
(Amaxa/Lonza, Basel, Switzerland; Walkersville, MD, USA), and
24h after transfection, greater than 90% of BV-2 cells were GFP-
positive.
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Luciferase assays
A luciferase reporter plasmid containing NF-kB responsive
elements upstream of a firefly luciferase gene was transfected into
BV-2 cells using Nucleofector (Amaxa/Lonza, Basel, Switzerland;
Walkersville, MD, USA). 24h post-transfection, cells were either
left untreated or incubated for 8h with 100nM Tat. Cell lysates
were prepared using reporter lysis buffer (Promega Life Sciences,
Madison, WI, USA), and luciferase activity was measured. A
luciferase reporter plasmid with the mouse TNFa promoter region
upstream of a luciferase reporter was transfected into either HEK
293 cells using Lipofectamine (Invitrogen, Carlsbad, CA, USA) or
BV-2 cells using Nucleofector (Amaxa/Lonza, Basel, Switzerland;
Walkersville, MD, USA). 24h post-transfection, cell lysates were
prepared using reporter lysis buffer (Promega Life Sciences,
Madison, WI, USA), and luciferase activity was measured with a
Lumicount Microplate Luminometer (Packard Instrument Com-
pany, Meriden, CT; now PerkinElmer, Waltham, MA). In these
assays, total protein amount as determined by Bradford assay (Bio-
Rad, Hercules, CA, USA), was used to normalize the samples.
Immunoblotting assays
Following the indicated treatments, whole cell lysates were
prepared in ELB buffer (50mM HEPES (pH 7), 250mM NaCl,
0.1% Nonidet P-40, 5mM EDTA, 10mM NaF, 0.1mM Na3VO4,
50mM ZnCl2, supplemented with 0.1mM PMSF, 1mM DTT, and
a mixture of protease and phosphatase inhibitors). Cellular debris
was removed by high-speed centrifugation. Lysates were fraction-
ated on 7.5% SDS-PAGE gels and protein was electrophoretically
transferred to Hybond ECL nitrocellulose membrane (GE
Healthcare Bio-Sciences Corporation, Piscataway, NJ, USA).
The membranes were analyzed for immunoreactivity with
primary antibodies raised against RelB (1:1000), RelA (1:1000),
IkBa (1:1000), or a-Tubulin (1:1000; all from Santa Cruz
Biotechnologies Inc., Santa Cruz, CA, USA), RelA P-S276
(1:1000), p100/p52 (1:1000, Cell Signaling Technology, Danvers,
MA, USA), Actin (1:1000, Calbiochem/EMD Chemicals, Gibbs-
town, NJ, USA), or antiserum to HIV-1 Tat (1:3000; NIH AIDS
Research & Reference Reagent Program, Germantown, MD,
USA). Bound antibodies were detected by species-specific,
horseradish peroxidase (HRP)-conjugated secondary antibodies
(1:3000, GE Healthcare Bio-Sciences Corporation, Piscataway,
NJ, USA), followed by addition of ECL reagent (Pierce
Biotechnology/Thermo Fisher Scientific, Rockford, IL, USA)
and subsequent exposure to x-ray film. Equal loading and
uniformity of protein transfer to the nitrocellulose membrane
were verified by stripping and reprobing the membranes with
primary antibodies specific to a-Tubulin or Actin.
Tat transgenic mice and Real-Time RT-PCR analyses
Tat transgenic mice were kindly provided by Dr. Johnny He
(Indiana University School of Medicine, Indianapolis, IN, USA)
[70]. Briefly, 6-week old Tat transgenic mice were treated with
80 mg/kg of doxycycline in saline, injected intraperitoneally (IP)
once daily for 0, 3, or 14 days. There were 4 mice per group for
the 0 and 14 day groups, and 5 mice in the 3 day group. Mice
were euthanized via cervical dislocation and brain tissue was
immediately dissected at 4uC, flash frozen in isopentene, and
stored at 280uC. RNA was isolated from half of each brain using
the PureLinkTM Total RNA Purification System (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s protocol.
Complementary DNA (cDNA) synthesis was performed using 2 mg
total RNA, oligo-dT primers, and the Superscript III first-strand
synthesis system (Invitrogen, Carlsbad, CA, USA). Gene-specific
primer sequences were as follows: 1) Tat primers: forward
59-GCATCCAGGGGATCAGCCTA-39, reverse 59-CTGATG-
AGCTCTTCGTCGCT-39; 2) RelB primers: forward 59-CC-
CCTACAATGCTGGCTCCCTGAA-39, reverse 59-CACGGC-
CCGCTCTCCTTGTTGATT-39; 3) TNFa primers: forward 59-
ACTCCAGAACATCTTGGAAATAGC-39, reverse 59-GCGG-
ATCATGCTTTCTGTGC-39; 4) RelA primers: forward 59-
TCAAGATCAATGGCTACACAGG-39, reverse 59-GCATTC-
AAGTCATAGTCCCCG-39; 5) GAPDH primers: forward 59-
TGATGACATCAAGAAGGTGGTGAA-39, reverse 59-TCCT-
TGGAGGCCATGTAGGCCAT-39. Real-time RT-PCR was
performed using iQTM SYBRH Green PCR Supermix (Bio-Rad,
Hercules, CA, USA) and 100nM gene-specific forward and reverse
primers in 20 mL total volume. After denaturation for 3 min. at
95uC, the PCR was run for 40 cycles of 95uC for 30 sec., primer-
specific melting temperature (Tm uC) for 1 min., and 72uC for
30 sec. using an iCycler instrument (Bio-Rad, Hercules, CA,
USA). GAPDH served as an internal control in these experiments.
All animal experiments were carried out in accordance with the
Animal Welfare Act and the National Institute of Health
guidelines. The animal protocol was approved by the University
Committee on Animal Resources of the University of Rochester
Medical Center. The facilities and programs of the Vivarium and
Division of Laboratory Animal Medicine of the School of
Medicine and Dentistry are fully accredited by the Association
for the Assessment and Accreditation of Laboratory Animal Care
International (AAALAC) and are in compliance with state law,
federal statute and NIH policy.
Immunoprecipitation
Samples containing equal amounts of protein were pre-cleared
by incubation with 2 mg of normal rabbit serum and 20 mL of a
50/50 protein A/G+ agarose beads solution (both from Santa
Cruz Biotechnologies Inc., Santa Cruz, CA, USA) at 4uC on a
rotator for 1h. After the pre-clear step, the beads were removed by
centrifugation and samples were transferred to tubes with specific
antibodies (2 mg per sample). Samples were incubated with the
antibodies at 4uC for 18h on a rotator. 30 mL of 50/50 protein A/
G+ agarose beads were added to the samples, then they were
incubated with rotation for an additional 2h at 4uC. The beads
were then washed extensively with ELB lysis buffer supplemented
with 0.1mM PMSF, 1mM DTT, and a mixture of protease and
phosphatase inhibitors, and then boiled for 5 minutes in 20 mL of
Laemmli buffer. Immunocomplexes were separated using SDS-
PAGE (7.5%), transferred to a nitrocellulose membrane and
probed with the indicated antibodies.
Statistical analysis
Mean data values and the standard error of the mean (SEM)
were calculated for each variable. Data involving the analysis of
multiple sample groups were analyzed by one-way ANOVA
followed by Bonferroni’s test for multiple comparisons. A value of
p,0.05 was designated as statistically significant.
Results
Transgenic expression of Tat induces RelB synthesis in
mouse brain
Tat transgenic (Tat-Tg) mice are used as a model of HIV-
induced neurocognitive disorders, as they develop Tat-induced
behavioral changes and neurological abnormalities including
hunched posture, tremor, ataxia, slow motor movement, and
seizures [70]. In addition, these mice exhibit neuropathologies
including astrocytosis, degeneration of neuronal dendrites, neuro-
nal apoptosis, and increased infiltration of activated monocytes
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[70], all of which replicate features of HIV-associated neurologic
disease (HAND). These mice express a Dox-inducible Tat gene
driven by the GFAP promoter, which drives Tat protein
production by astrocytes in the CNS [70].
RelB was originally identified as a protein that controls
inflammation [56,57,59], leading us to hypothesize that RelB
may mediate Tat’s effects in models of HAND. Thus, we first used
quantitative real-time PCR (qRT-PCR) to determine whether Tat
altered RelB or RelA expression levels in the brains of the Tat-Tg
mice. Total RNA isolated from brain tissue of mice induced with
doxycycline for 0, 3, or 14 days was used to measure the abundance
of Tat, RelB, and RelA transcripts. As compared to non-induced
Tat-Tg mice (Day 0, Dox–), there was an approximately 20-fold
increase in Tat mRNA levels in 14 day Dox-treated animals
(Figure 1). Since Tat is known to activate TNFa production, in
order to confirm the activity of Tat, we also measured TNFa
synthesis in Dox-exposed mice. Our results revealed an increase in
TNFa mRNA in the brains of Dox-induced mice, validating the
functional activity of Tat in these animals (data not shown).
Consistent with these effects, we also observed a nearly 5-fold
increase in RelB mRNA levels by day 14 Dox treatment,
confirming that Tat also increased RelB expression (Figure 1).
Interestingly, under these conditions, RelA mRNA levels remained
unchanged, suggesting that the Tat-mediated increase in RelB was
not a generalized effect of Tat on NF-kB subunits (Figure 1). Since
total RNA was isolated from whole brain tissue, we could not
determine which cell type most contributed to this Tat-induced
increase in RelB message in this in vivomodel. However, our further
experiments in BV-2 microglial cells, primary human monocytes,
and primary human astrocytes suggest that both microglia and
astrocytes contribute to this increase.
RelB inhibits TNFa and cytokine production triggered by
Tat treatment
Microglia are believed to be principal mediators of HAND-
associated neuropathology. Therefore, to explore the functional
role of Tat-RelB induction in microglia, we examined Tat’s ability
to stimulate TNFa synthesis in magnetically sorted CD11b+
monocytic cells derived from the bone marrow of RelB deficient
(RelB2/2) mice. We chose these cells to model microglia for three
reasons: (1) microglia originate from myeloid lineage precursors in
the bone marrow [71], (2) CD11b+ bone marrow cells are sensitive
to Tat [72], and (3) highly homogeneous monocyte cultures can be
obtained from the bone marrow of genetically modified mice [73].
The vast majority of CD11b-positive cells (nearly 95% of the total
isolated population) were monocytes, as determined by morpho-
logic criteria. Using immunoblot analyses, we first verified that 8h
100 nM Tat treatment stimulated RelB synthesis in these murine
monocytes, and that RelB is indeed absent in RelB2/2 derived
cells (Figure 2A). Again, following 8h 100 nM Tat treatment of
these cells, we also collected culture supernatants and measured
TNFa levels by ELISA. The results shown in Figure 2B reveal
enhanced production of TNFa in Tat-treated RelB2/2 monocytes
as compared to their RelB+/+ counterparts, strongly suggesting an
anti-inflammatory role for RelB. The Bio-Plex Multi-Plex cytokine
array assay was also used to measure additional inflammatory
cytokine and chemokine levels in these same culture supernatants.
Likewise, these results (Figure 2C) indicated enhanced production
of IL-1b, IL-6, and MCP-1 in Tat-treated RelB2/2 monocytes
compared to Tat-treated RelB+/+ cells, further supporting an anti-
inflammatory role for RelB in the context of HIV. TNFa levels, as
determined by ELISA above, were also validated using the Bio-
Plex cytokine array, with similar results (data not shown).
We performed additional complementary experiments to test
whether RelB overexpression in the microglial BV-2 cell line could
reverse Tat’s effects on TNFa synthesis. In contrast to cRel
overexpression, which had no effect on Tat-induced TNFa pro-
duction, RelB overexpression reduced Tat-induced TNFa release
from BV-2 cells as we anticipated (Figure 3), further confirming
the inhibitory properties of RelB.
Because RelB was over-expressed in these BV-2 cells, there is
the possibility that over-expressing high levels of exogenous RelB
could interfere with cells’ ability to respond to Tat. This is not
likely for two reasons: 1. cRel overexpression did not affect Tat’s
ability to induce TNFa production, and 2. Immunoblot analysis of
transfected RelB levels, compared to RelB levels stimulated by 8h
100nM Tat treatment, showed no significant differences, thus
suggesting that exogenous RelB levels resulting from transfection
were similar to inducible RelB levels (data not shown). Together
these data indicate that RelB’s ability to reduce TNFa production
in Tat-exposed cells results from a functional effect of RelB, and is
not due to overexpression of RelB interfering with cells’ ability to
respond to Tat.
Tat induces de novo synthesis of RelB
Next we examined the mechanisms by which RelB regulates
TNFa production through Tat. To do this we employed the easily
genetically manipulatable microglial BV-2 cell line. First, we
needed to confirm that the Tat-induced increases in RelB that we
observed in our in vivo models, also translated to this in vitro model.
Although activation of NF-kB involves cytosolic-nuclear redistri-
bution of RelA (a major component of NF-kB) rather than de novo
synthesis of this protein, NF-kB activation also positively regulates
expression of other NF-kB family members, including RelB
Figure 1. Transgenic expression of Tat induces RelB synthesis in mouse brain. 6-week old Tat-transgenic mice were induced with
doxycycline for the indicated periods of time. Total RNA was extracted from brain tissue, reverse transcribed using oligo-dT primers, and subjected to
Real-Time SYBR Green RT-PCR amplification. Fold induction of Tat, RelB and RelA mRNA species was normalized to GAPDH and presented as a
function of the expression level in D0 samples. Data represent mean 6 SEM of four replicates for D0 and D14 samples, and five replicates for D3
samples. Statistical significance (***, p,0.001 or *, p,0.05) is denoted as compared to D0 samples.
doi:10.1371/journal.pone.0011875.g001
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[74,75]. Therefore, we speculated that Tat might be inducing de
novo synthesis of RelB in our model systems. As shown in Figure 4A,
relatively low levels of RelB were detected in untreated BV-2 cells.
Within 4h, these levels were profoundly elevated by 100nM Tat
and remained higher for up to 24h of Tat exposure. Under these
conditions, Tubulin levels (protein loading control) were not
altered. Further immunoblot analyses revealed that the Tat-
induced increase in RelB expression resulted from enhanced RelB
synthesis, as this effect was blocked by pre-treatment with the
protein translation inhibitor Cycloheximide (CHX) (Figure 4B).
Consistently, the Tat-induced increase in RelB expression was also
blocked by pre-treatment of BV-2 cells with a proteasomal
inhibitor, MG-132, or an inhibitor of chymotrypsin-like serine
proteases, N-alpha-tosylphenylalanyl chloromethyl ketone (TPCK),
suggesting that activation of the NF-kB signaling pathway might be
crucial for this effect (Figure 4C). Furthermore, the increase in RelB
levels was found to be a specific effect of Tat, as RelB was not
increased by treatment with another HIV viral protein, gp120
(Figure 4D). However, gp120’s failure to induce RelB synthesis was
not due to failure of cellular activation by gp120, because, as
expected [76], gp120 was able to induce TNFa release from BV-2
cells (data not shown).
Since microglia are a monocyte-derived cell type, we also
examined RelB protein levels in primary human monocytes, to
further translational relevance to primary human disease models.
Analogous to the responses seen in BV-2 cells, treatment of primary
human monocytes with Tat also resulted in increased RelB
expression, albeit with delayed kinetics (Figure 4E), suggesting that
Tat-mediated synthesis of RelB occurs in non-dividing cells as well.
Active RelB is associated with NF-kB family member p52, which is
proteolytically cleaved from the inhibitor p100 [48]. As such,
further immunoblot analysis revealed increased p100 expression,
and its processing into p52 molecules, in Tat-exposed primary
human monocytes (Figure 4F), as well as in BV-2 cells (Figure 4G).
Furthermore, we observed that this newly synthesized RelB rapidly
relocates to the nucleus, and thus is functionally active (Figure 4H).
Astrocytes are the most abundant cell type in the brain, are non-
productively infected with HIV-1 and, similar to microglia, can be
activated by viral proteins such as Tat, thereby contributing to
HIV-induced neuroinflammation [77]. For these reasons, we also
measured RelB protein levels following Tat treatment of primary
human astrocytes. As shown in Figure 4I, by 8h of Tat treatment
there is increased RelB synthesis in astrocytes, while Tubulin levels
remain unchanged.
Figure 2. RelB inhibits Tat-induced TNFa and cytokine production in monocytes. A, Monocytes from RelB+/+ or RelB2/2 mice (36105)
treated with Tat (100nM) for 8h and subjected to immunoblot analysis with either RelB-specific (upper panel) or Actin-specific (lower panel)
antibodies, confirmed that Tat induced RelB in these cells. Data are representative of results from two separate experiments. B, Levels of TNFa in
culture supernatants from these cells were analyzed by ELISA, and C, Levels of IL-1b, IL-6, and MCP-1 were anlayzed by Multi-Plex cytokine array as
described in Results. Data is shown as mean 6 SEM of values derived from three replicates each from two combined experiments. Statistical
significance (p,0.001) is indicated (***), as compared with Tat treated RelB+/+ cells.
doi:10.1371/journal.pone.0011875.g002
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RelB inhibits TNFa synthesis at the transcriptional level,
but RelA increases TNFa synthesis
To better understand how RelB inhibits Tat-induced TNFa
production, we used a reporter gene assay. To do this, BV-2 cells
were transiently transfected with a TNFa-promoter luciferase
reporter plasmid, either alone or together with increasing amounts
of WT RelB plasmid. The total amount of DNA in each
transfection was kept constant by addition of an appropriate
amount of pcDNA3.1 empty vector plasmid. These results
revealed that basal TNFa promoter activity was blocked by
overexpression of RelB (Figure 5A). To compare the effects of
RelA overexpression on TNFa promoter activity, we performed
similar additional luciferase assays in which HEK 293 cells were
transfected with the TNFa-promoter luciferase reporter, together
with increasing amounts of either RelA or RelB. As shown in
Figure 5B, in contrast to RelB, overexpression of increasing
amounts of RelA led to dose-dependent activation of the TNFa
promoter. These latter studies utilized HEK 293 cells for their
high transfection yields, and their robust (and thus readily
detectable) increases in TNFa promotor activity with RelA
expression, thus allowing us to determine the effects of RelB
expression on RelA transcriptional activity.
RelB interaction with RelA inhibits upregulation of the
TNFa promoter by RelA
Previous reports have shown that RelB and RelA interact, and
that this interaction can lead to inhibition of either RelA-
dependent or RelB-dependent gene expression in multiple cell
types [52–55]. Based on these reports, first we examined the effect
of RelB overexpression on RelA-induced activation of the TNFa
promoter. Overexpression of RelA alone resulted in an approx-
imately 10-fold increase in TNFa promoter activation, an effect
that was completely blocked by expressing increasing amounts of
RelB (Figure 5C). Interestingly, consistent with Figure 3, overex-
pressing increasing amounts of cRel (relevant control), or b-
galactosidase (irrelevant control), did not significantly inhibit
RelA-dependent activation of the TNFa promoter (Figure 5D),
suggesting that RelB exerts a selective inhibitory effect on RelA
transcriptional activity.
Next, to determine whether RelB interacts with RelA to achieve
these effects, we tested whether Tat stimulates protein-protein
interactions between endogenous RelA and RelB in BV-2 cells.
After addition of Tat for either 4h or 8h, whole cell lysates of BV-2
cells were collected, and RelA protein complexes were captured
with a RelA-specific antibody using Protein A/G+ agarose beads.
The bound proteins were then visualized by immunobloting with a
RelB-specific antibody. By 4h of Tat treatment there was a
significant increase in RelB protein that was pulled down with the
RelA antibody, thus demonstrating that Tat treatment was
stimulating interactions between RelA and RelB in BV-2 cells
(Figure 6A, top panel). The blot was stripped and re-probed with a
RelA-specific antibody to confirm that approximately equivalent
amounts of RelA protein were pulled down in each sample
(Figure 6A, bottom panel). Comparative densitometric analysis of
these bands, normalized to the RelA IP/RelA IB bands (bottom
panel), informed us that Tat increased RelB/RelA interactions by
4-fold at both 4h and 8h (Figure 6A, bar graph).
It was previously reported that RelA phosphorylation at serine
276 is required for the interaction between RelB and RelA to
occur [53]. Accordingly, using an antibody that specifically
recognizes serine 276 phosphorylated RelA, we were able to
confirm that RelA is indeed phosphorylated at serine 276 in Tat-
treated BV-2 cells (Figure 6B, blots). Quantification of these blots
found a 20–40 fold increase in the phosphorylated form of RelA in
Tat treated BV-2 cells versus controls (Figure 6B, graphs).
Thus, we predicted that this Tat-induced interaction between
RelB and RelA would therefore inhibit Tat-induced, RelA-
mediated transcriptional activation of NF-kB pathways. Indeed,
using an NF-kB luciferase reporter plasmid in BV-2 cells, our
results confirmed that overexpression of RelB inhibits activation of
endogenous NF-kB induced by 8h 100 nM Tat treatment
(Figure 6C). Likewise, analogous to the results shown in
Figure 5C, we observed a dose-dependent inhibition of RelA-
mediated NF-kB luciferase transcription following overexpression
of RelB in BV-2 cells (Figure 6D).
The entire Rel Homology Domain of RelB is necessary for
the interaction with RelA
To clarify how RelB might interact with RelA to inhibit
activation of the TNFa promoter, sequential deletion mutants
within RelB were made. These RelB deletion mutants were
overexpressed in HEK 293 cells together with HA-tagged RelA.
Co-immunoprecipitation (co-IP) was then used to test for
interactions between these proteins. Parallel cultures were also
co-transfected with the TNFa-promoter luciferase reporter, to
determine which of these deletion mutated RelB derivatives failed
to block transcriptional activity of RelA, which would suggest an
inhibitory domain interaction with RelA. We first focused on the
amino terminal leucine zipper domain of RelB, because this
domain is unique to RelB among the NF-kB family members.
Leucine zipper domains are also known to be involved with
protein-protein interactions [46]. However, amino terminal
truncation mutants of RelB, including deletion of the entire
leucine zipper domain, still interacted with HA-RelA as shown by
co-IP, and these mutants also inhibited RelA activity equally well
(Figure 7A), suggesting that this region was not responsible for the
transcription-inhibiting interactions of RelB on RelA.
We then introduced sequential deletions within the Rel
Homology Domain (RHD) of RelB (Figure 7B). The RHD
of NF-kB proteins is known to be responsible for homo- and
Figure 3. RelB inhibits Tat-induced TNFa production in BV-2
microglia. BV-2 cells (56106) were transiently transfected with either
empty vector (pcDNA3.1-Myc/His-B), cRel, or RelB (10 mg), using
Nucleofector (Amaxa/Lonza), and treated with Tat (100nM) for the
indicated periods of time. TNFa release was measured by ELISA and
normalized to total cellular protein content in the culture wells. Results
are shown as mean 6 SEM of values derived from two replicates from
one representative experiment; two total experiments were performed.
Statistical significance (p,0.05) is indicated, as compared to empty
vector transfected cells (*).
doi:10.1371/journal.pone.0011875.g003
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Figure 4. Tat induces de novo synthesis of RelB. A, BV-2 cells (1.26105) were treated with Tat (100nM) for the indicated periods of time and
whole cell lysates were subjected to immunoblot analysis using either RelB-specific (upper panel) or a-Tubulin-specific (lower panel) antibodies. B, BV-
2 cells (1.26105) were treated with Tat alone or together with CHX as indicated for 4h. Whole cell lysates were subjected to immunoblot analysis
using either RelB-specific (upper panel) or a-Tubulin-specific (lower panel) antibodies. C, BV-2 cells (1.26105) were treated with Tat (100nM) alone or
together with MG-132 or TPCK both at a concentration of 50mM for the indicated periods of time. Whole cell lysates were subjected to immunoblot
analysis using a RelB-specific (upper panel) antibody. Levels of a nonspecific (n.s.) band (lower panel) are shown to indicate equal protein loading. D,
BV-2 cells (1.26105) were treated with gp120 (SF162, 100nM) for the indicated periods of time and whole cell lysates were subjected to immunoblot
analysis using either RelB-specific (upper panel) or a-Tubulin-specific (lower panel) antibodies. E, Primary human monocytes (26105) were treated with
Tat for the indicated periods of time and whole cell lysates were subjected to immunoblot analysis using either RelB-specific (upper panel) or Actin-
specific (lower panel) antibodies. F, Primary human monocytes (26105) were treated with Tat for the indicated periods of time and whole cell lysates
were subjected to immunoblot analysis using either p100/p52-specific (upper panel) or Actin-specific (lower panel) antibodies. G, BV-2 cells (1.26105)
were treated with Tat for the indicated periods of time and whole cell lysates were subjected to immunoblot analysis using either p100/p52-specific
(upper panel) or a-Tubulin-specific (lower panel) antibodies. H, BV-2 cells (1.26105) were treated with Tat as indicated and cytosolic (labeled ‘‘C’’) and
nuclear (labeled ‘‘N’’) extracts were subjected to immunoblot analysis with either RelB-specific (upper panel) or a-Tubulin-specific (lower panel)
antibodies. I, Primary human astrocytes (46104) were plated 72h prior to treatment. These cells were treated with Tat as indicated and whole cell
lysates were subjected to immunoblot analysis using either RelB-specific (upper panel) or a-Tubulin-specific (lower panel) antibodies.
doi:10.1371/journal.pone.0011875.g004
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hetero-dimer formation with other NF-kB proteins [78]. All of
these sequential RelB RHD deletion mutants, as well as deletion of
the proximal nuclear localization signal located between residues
388–392 within RelB, still formed complexes with RelA and
inhibited its activity (Figure 7B). However, the ability of RelB to
interact with RelA, and to inhibit RelA-dependent activation of the
TNFa promoter, was lost following deletion of the entire RHD
(D52–402, Figure 7B; akaDRHDRelB, Figures 7C and 7D). This is
reported in tabular format in Figure 7B (bottom line), with
Figures 7C and 7D illustrating the failure of DRHD RelB to
interact with RelA (7C), and to inhibit RelA activation of TNFa
transcriptional activity (7D), respectively. These results indicate that
the entire RHD of RelB is necessary for its interaction with RelA.
Amino terminal region of Tat is necessary for RelB
induction in microglia
The HIV-1 protein Tat is a multi-functional protein. Residues
1–72 are encoded by the first exon and residues 73–101 are
encoded by a second exon [79]. It is released from infected
microglia, macrophage and astrocytes in the CNS [80]. Despite its
small size, Tat has multiple domains conferring different
functional effects. For example, amino acids 1–48 contain
protine-rich as well as cysteine-rich regions that represent a
minimal activation domain of HIV-1 Tat required for activation of
the HIV-1 promoter region, known as the long terminal repeat
(LTR). The basic domain 49–72 contains an RKKRRQRRR
motif, which confers the RNA binding activity of Tat and is also
important for cellular uptake and nuclear distribution of this
protein [81], while amino acids 65–80 of Tat include the RGD
motif that is involved in binding to cellular integrins [81,82].
Sequences from 22–37, a cysteine-rich domain, bind with divalent
cations like zinc and cadmium, thereby inducing the dimerization
and subsequent inactivation of Tat [83]. Mutations in the region
1–21 are tolerant to changes without the loss of biologic activity; in
contrast, changes in amino acids 25–40 are generally deleterious
for transactivation. Moreover, substitution at cysteine residues 22,
25, 27 and 37 alters transactivation of the HIV LTR [81]. The
cysteine residue at position 31 is critical for binding to the NMDA
receptor on neurons and mediating neurotoxicity [84]. Chemo-
tactic properties have also been attributed to this residue [85].
Here we have tested various length Tat proteins to determine
which domains are necessary for induction of RelB synthesis in
microglial cells. A diagram depicting the Tat peptides we used to
treat BV-2 cells is shown in Figure 8A.
Figure 5. Opposing effects of RelA and RelB on TNFa promoter activity. A, BV-2 cells (1.26105) were transiently transfected with 0.25 mg of
plasmid DNA containing a luciferase reporter gene under transcriptional control of the mouse TNFa promoter region in the absence or presence of
increasing amounts of a RelB-encoding plasmid. 24h later cells were lysed and luciferase activity was determined. Total protein amount, as
determined by Bradford assay was used to normalize the samples. Data are presented as fold change compared to cells transfected with the
luciferase reporter alone. ***, p,0.001, and **, p,0.01 as compared to cells transfected with the luciferase reporter alone. B, HEK 293 cells (1.86105)
were transiently transfected with the mouse TNFa promoter-luciferase reporter plasmid along with increasing amounts of a plasmid for RelA or RelB.
The luciferase (i.e. TNFa promoter) activity in whole cell lysates was determined 24h post-transfection. Samples were subjected to immunoblot
analysis using either RelA or RelB-specific antibodies to determine the expressed level of RelA and RelB protein. ***, p,0.001 as compared to cells
transfected with the luciferase reporter alone. C, HEK 293 cells (1.86105) were transiently transfected with the mouse TNFa promoter-luciferase
reporter plasmid along with a plasmid for RelA in the absence or presence of increasing amounts of RelB-encoding plasmid. The luciferase activity in
whole cell lysates was determined 24h post-transfection. Samples were subjected to immunoblot analysis using either RelA or RelB-specific
antibodies to determine the expressed level of RelA and RelB protein. ***, p,0.001 as compared to cells transfected with the luciferase reporter
alone. D, HEK 293 cells (1.86105) were transiently transfected with the mouse TNFa promoter-luciferase reporter along with a plasmid for RelA in the
absence or presence of increasing amounts of cRel or b-galactosidase-encoding plasmid. Luciferase activity in whole cell lysates was determined 24h
post-transfection.
doi:10.1371/journal.pone.0011875.g005
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As shown in Figure 8, full-length Tat (Tat 1–101) and Tat 1–
72 both induced an approximately 10–12-fold increase in RelB
levels by 8h of treatment in BV-2 cells, suggesting that the first
exon of Tat is required for RelB induction in microglia.
Similarly, Tat C31S and Tat D31–61 treatments led to a 10–
12-fold increase in RelB synthesis, suggesting that the altered
residues in these variants are dispensible. In contrast, Tat 48–
72, 46–60 and 65–80 did not induce RelB synthesis in BV-2
cells, indicating that the basic motif within Tat is not sufficient
to stimulate RelB production. Our results suggest that the
amino terminal region, consisting of amino acids 1–30 of
Tat, is critical for Tat-dependent RelB activation in microglia.
It may also be that multiple domains within the first exon of
Tat are necessary for the Tat-induced increase in RelB
synthesis. This possibility is currently under investigation in
our laboratory.
Discussion
Neuroinflammatory responses and monocyte/macrophage
CNS infiltration appear critical to the development of HAND
even with cART, and are not significantly reduced by cART
[86,87], thus, this remains a critical area of investigation in the
pursuit of adjunctive therapies for reducing the impact of HIV on
the nervous system. We, and colleagues, have previously shown
that TNFa released from HIV infected or activated monocytes/
microglia is a major contributor to HIV-induced neuroinflamma-
tion that leads to neuron damage and cognitive impairment
[45,88–94]. Moreover, many key aspects of TNFa signaling occur
via NF-kB [95,96], and NF-kB signaling is likely to be a key
mediator of TNFa’s neurotoxic actions in HAND, particularly in
regards to activation and HIV infection of brain macrophages and
microglia [97,98]. Accordingly, TNFa and NF-kB signal trans-
Figure 6. RelB inhibits NF-kB activation via physical interaction with RelA. A, BV-2 cells (86105) were treated with Tat (100nM) for the
indicated periods of time. Whole cell lysates were subjected to immunoprecipitation using a RelA-specific antibody and Protein A/G+ agarose beads.
Immunocomplexes were separated by 7.5% SDS-PAGE and blotted onto nitrocellulose membrane and subjected to immunoblot analysis with
antibodies specific for RelB or RelA. The plot below the bands represents densitometry values for each band, normalized as a ratio of RelA(IP)/RelB(IB)
(i.e. top bands): RelA(IP)/RelA(IB) (i.e. bottom bands), to indicate the increase in RelB/RelA interactions at each time point. B, BV-2 cells (1.26105) were
treated with Tat (100nM) for the indicated periods of time and whole cell lysates were subjected to immunoblot analysis using either RelA-specific
(upper panel), RelA phospho-serine 276-specific (center panel) or a-Tubulin-specific (lower panel) antibodies. Protein levels were quantified using
ImageJ software (bottom graphs). The results of a single representative experiment are shown. C, BV-2 cells (56106) were transiently transfected
using Nucleofector (Amaxa/Lonza) with an NF-kB-dependent luciferase reporter plasmid either alone or together with a RelB-encoding plasmid. 16h
post-transfection cells were either left untreated or were treated with Tat (100nM) for 8h. Luciferase activity in whole cell lysates was determined.
Results are shown as mean 6 SEM of values derived from three replicates from one representative experiment; two total experiments were
performed. Statistical significance (p,0.001) is indicated (***). D, BV-2 cells (1.56105) were transiently transfected using Lipofectamine (Invitrogen)
with the NF-kB-luciferase reporter plasmid together with a plasmid for RelA in the absence or presence of increasing amounts of RelB-encoding
plasmid. The luciferase activity in whole cell lysates was determined 18h post-transfection. Results are shown as mean 6 SEM of values derived from
two replicates from one representative experiment; two total experiments were performed.
doi:10.1371/journal.pone.0011875.g006
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duction are principal mechanistic pathways by which Tat and
other viral proteins or mediators are thought to perpetuate HIV-
induced nervous system damage [99–108]. RelB, in turn, is an NF-
kB family molecule with known anti-inflammatory properties and
modulatory roles in NF-kB signal transduction. While Rel family
members have previously been implicated as possible mediators of
HIV- and Tat-dependent transcription [100], the precise mech-
anisms of this regulation remain unclear. Furthermore, RelB
modulation of cytokine and TNFa activation in microglial cells is
an area that may have significant importance for understanding
HAND pathology, yet until now has remained unexplored.
Herein we describe a novel inhibitory regulatory feedback loop
for reducing inflammatory responses in microglial cells, whereby
RelB protein-protein interactions with RelA inhibit RelA’s
transcriptional activity, to regulate NF-kB mediated cytokine
synthesis. Early reports indicated that RelB exclusively formed
heterodimers with p50 and p52. It was not until 2003 that
Marienfeld et. al reported an interaction between RelB and RelA
in multiple cell types [52]. RelB/RelA interactions may not have
been reported earlier because this complex might not bind well to
typical kB DNA binding elements, or the level of this complex
might be low compared to levels of other RelB complexes.
Figure 7. RelB Rel homology domain required for interaction with RelA and blockade of TNFa promoter activity. A, B, Diagrams show
representation of full length and deletion mutants of RelB used to determine the domains of RelB necessary for interaction with RelA. HEK 293 cells
(1.86105) were transiently transfected with either HA-tagged RelA or Myc-tagged RelB deletion mutants alone or in combination. Interaction was
determined by immunoprecipitation with Myc-specific antibody and Protein A/G+ agarose beads followed by immunoblot analysis with HA-specific
or Myc-specific antibodies. Interacting (+) and non-interacting (2) mutants are indicated. These RelB deletion mutants were also analyzed using the
TNFa promoter-luciferase reporter plasmid co-transfected into HEK 293 cells together with a plasmid for RelA in the absence or presence of
increasing amounts of RelB-encoding plasmid (WT or deletion mutants). Inhibition of RelA activation of the TNFa promoter is indicated (+/2). C, HEK
293 cells (1.86105) were transiently transfected with either HA-tagged RelA or Myc-tagged RelB D52–402 alone or in combination. Interaction was
determined by immunoprecipitation with Myc-specific antibody and Protein A/G+ agarose beads followed by immunoblot analysis with HA-specific
or Myc-specific antibodies. D, RelB D52–402 was also analyzed using the TNFa promoter-luciferase reporter plasmid co-transfected into HEK 293 cells
along with a plasmid for RelA in the absence or presence of increasing amounts of RelB D52–402-encoding plasmid. Statistical significance (p,0.001)
as compared to cells transfected with 0.1 mg WT RelB+RelA is indicated (***).
doi:10.1371/journal.pone.0011875.g007
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Additional reports of an inhibitory RelB/RelA interaction have
since been described in fibroblasts, dendritic cells, and THP-1
human monocyte cells [53–55].
Here we describe for the first time, direct inhibition of RelA-
dependent TNFa transcription by RelB in microglia, as a result of
RelB/RelA protein interactions. These findings are supported by
other work showing that LPS stimulation of RelB2/2 fibroblasts
resulted in enhanced production of cytokines IL-1a, IL-1b, and
TNFa [58], and chemokines RANTES, MIP-1a, MIP-1b, MIP-2,
IP-10, JE/MCP-1, and KC/CINC [59]. In addition, another
study demonstrated that RelB expression correlated with IL-1b
repression in human monocyte THP-1 cells [55]. All these findings
likely have parallels with our findings herein, that RelB deficiency
leads to enhanced Tat-induced TNFa transcriptional activity, and
that RelB expression reduces this activity. On the other hand, and
in stark contrast, macrophages isolated from RelB2/2 deficient
mice demonstrated impaired TNFa production in response to LPS
[57]. This study emphasizes that the exact consequences of
RelB regulation of TNFa may be specifically dependent upon
both the nature of the inflammatory insult, and upon the cell type
affected – as is commonly the case with immunomodulatory signal
transduction – thus highlighting the need for further studies of
these effects in other cell types relevant to HIV neurologic disease,
as we seek to further validate RelB as a potential therapeutic target
in HAND.
Finally, since TNFa can be a downstream modulator of Tat’s
effects [104], it is possible that TNFa, rather than Tat directly, is
the molecule responsible for inducing the RelA serine 276
phosphorylation that we observed in Tat-treated microglia. In
addition, it is likely that either Tat- or TNFa-induced activation of
NF-kB could also explain the increase in RelB, as RelB is known
to be induced by NF-kB, and blockade of NF-kB signaling
mechanisms with inhibitors MG-132 or TPCK inhibited the
increase in microglial RelB. While additional studies are needed to
further clarify these mechanisms, these possibilities do not conflict
with our supposition that the RelB/RelA interactions shown here
in Tat-treated microglial cells, represent a novel negative
regulatory feedback loop for the resolution of inflammation in
microglial cells, specifically by inhibiting RelA activation of pro-
inflammatory cytokines such as TNFa. This mechanism may
explain why more severe cognitive impairment is not present until
late in the course of HIV infection, with HIV-induced inflamma-
tory mediators provoking a constant ‘‘yin and yang’’ between
inflammation and resolution of inflammation in the CNS.
Uncovering new mechanisms involved in resolving CNS
inflammation has many potential benefits both in terms of
reducing inflammation-induced neuronal damage, and also
possibly limiting viral spread by reducing inflammation-induced
influx of monocytes into the CNS. Moreover, TNFa and related
cytokines have pleiotropic neuromodulatory, neurotoxic, and even
neuroprotective functions [109], and are implicated in a wide
range of CNS and peripheral disease states. Thus, identifying this
novel negative regulatory feedback loop involving RelB could be
particularly useful as an adjunctive therapeutic approach for
HAND, peripheral HIV infection, or even other neurologic or
immune diseases, since overexpression of RelB in microglial cells
does not completely block Tat-induced release of TNFa, which
would negatively impact TNFa’s other endogenous functions. In
total, these results described herein represent an important first-
step toward furthering our understanding of RelB as a potentially
important mediator of wide-ranging disease states.
Supporting Information
Text S1 Recombinant Tat produced in eukaryotic cells activates
microglia.
Found at: doi:10.1371/journal.pone.0011875.s001 (0.04 MB
DOC)
Figure S1 Recombinant Tat produced in eukaryotic cells
activates microglia. A, HIV-1 Tat 1–72 protein was purified from
recombinant baculovirus infected Sf9 insect cell cultures. Increas-
ing volumes of the eluted protein were subjected to immunoblot
analysis using antiserum to HIV-1 Tat. The Tat-specific band is
indicated. B, BV-2 cells (1.26105) were treated with Sf9-Tat (1–72,
100nM), or E.Coli-Tat (1–72, 100nM, from Dr. A. Nath) for 8h
and levels of TNFa in the culture supernatant quantified by
ELISA. Data correspond to mean6 SEM of three replicates, from
a single representative experiment; the experiment was performed
twice. C, BV-2 cells (1.26105) were treated with Sf9-Tat (100nM)
for the indicated periods of time and whole cell lysates were
subjected to immunoblot analysis using either IkBa-specific (upper
panel) or a-Tubulin-specific (lower panel) antibodies. Data are
representative of results from two separate experiments. D, For the
EMSA, 4 mL of nuclear protein extract from BV-2 cells treated
Figure 8. Amino terminal region of Tat is necessary for RelB
induction in microglia. A, Diagram shows a representation of full
length, mutated and truncated Tat proteins and peptides used in these
experiments. B, BV-2 cells (1.26105) were treated with Tat (100nM) for
8h and whole cell lysates were subjected to immunoblot analysis using
either RelB-specific (upper panel) or a-Tubulin-specific (lower panel)
antibodies. These results indicate that standard Tat 1–101, Tat 1–72, Tat
C31S, and Tat D31–61 all activated RelB, whereas Tat peptides 48–72,
46–60 and 65–80 did not. C, Densitometry quantification of immuno-
blots shown in B. RelB levels were normalized to Tubulin levels and fold
change compared to non-treated (NT) was calculated.
doi:10.1371/journal.pone.0011875.g008
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with Sf9-Tat (100nM) for the indicated times was incubated
together with a 32P-labeled palindromic NF-kB oligonucleotide.
The samples were separated on a native polyacrylamide gel that
was then fixed, dried, and exposed to x-ray film. The two major
DNA binding complexes consisting of NF-kB family members, as
labeled, were identified by antibody supershift analysis.
Found at: doi:10.1371/journal.pone.0011875.s002 (0.67 MB TIF)
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Abstract
Angiogenesis is involved in the pathogenesis of inflammatory
arthritis, but little is known about the role of lymphangiogenesis
in this setting. Here, we examined whether tumor necrosis factor
(TNF) stimulates osteoclast precursors (OCPs) to produce the
lymphatic growth factor, vascular endothelial growth factor-C
(VEGF-C), and induce lymphangiogenesis. We used TNF-
transgenic (Tg) mice and mice with serum-induced arthritis.
OCPs were purified by fluorescence-activated cell sorting of
CD11b+/Gr-1-/lo blood or bone marrow cells and subjected to
microarray analysis or were generated from spleen or joint cells
and treated with TNF. Expression of VEGFs was analyzed and
examined by real-time reverse transcription-polymerase chain
reaction and Western blotting. Immunostaining and magnetic
resonance imaging were used to quantify lymphatic vessels and
volumes of synovium and draining lymph nodes. TNF stimulated
VEGF-C expression by OCPs and increased nuclear factor-
kappa B (NF-κB) binding to an NF-κB sequence in the VEGF-C
promoter. OCPs from joints of TNF-Tg mice express high levels
of VEGF-C. Lymphatic vessel numbers and size were markedly
increased in joint sections of TNF-Tg mice and mice with serum-
induced arthritis. The severity of synovitis correlated with
draining lymph node size. In summary, TNF induces OCPs to
produce VEGF-C through NF-κB, leading to significantly
increased lymphangiogenesis in joints of arthritic mice. The
lymphatic system may play an important role in the pathogenesis
of inflammatory arthritis.
Introduction
Joint disease in rheumatoid arthritis (RA) is characterized by
inflamed hyperplastic synovial tissue or 'pannus' formation [1].
Pannus is composed of various cell types that produce a vast
array of inflammatory mediators, including cytokines and
chemokines that destroy the extracellular matrix in the joint by
direct and indirect mechanisms. Pannus is extremely vascular,
providing portals of entry for effector cells to enter the joint
from the circulation and mediate joint destruction via autocrine
and paracrine mechanisms. As a result of neovascularization,
inflammatory cell infiltration, and concomitant synovial cell
hyperplasia, the volumes of the synovium and synovial fluid
increase, resulting in joint swelling and pain [2]. Thus, inhibi-
tion of new blood vessel formation has been proposed as an
important therapeutic approach for patients with inflammatory-
erosive arthritis [3].
The lymphatic circulation has been known for many years to be
an important secondary vascular system to remove fluid, mac-
romolecules, and cells from the interstitial spaces, and it func-
tions as a 'compensatory' system for blood circulation.
However, studies of the lymphatic system have been ham-
pered until recently by the lack of markers that definitively dis-
tinguish blood from lymphatic vessels and a paucity of
knowledge about growth factors specific to lymphatic
endothelial cells. Gene array analysis comparing lymphatic
endothelial cells and blood vascular endothelial cells has
recently identified numerous previously unknown lineage-spe-
3D = three-dimensional; CT = threshold cycle; EMSA = electrophoretic mobility shift assay; FACS = fluorescence-activated cell sorting; FITC = flu-
orescein isothiocyanate; IgG = immunoglobulin G; IL-1 = interleukin 1; LYVE-1 = lymphatic endothelial hyaluronan receptor 1; M-CSF = macrophage 
colony-stimulating factor; MRI = magnetic resonance imaging; NF-κB = nuclear factor-kappa B; OCP = osteoclast precursor; PBS = phosphate-
buffered saline; PCR = polymerase chain reaction; PDGF = platelet-derived growth factor; RA = rheumatoid arthritis; SIA = serum-induced arthritis; 
Tg = transgenic; TNF = tumor necrosis factor; VEGF = vascular endothelial growth factor; VEGFR-3 = vascular endothelial growth factor receptor 
3; WT = wild-type.
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cific markers for blood and lymphatic vascular endothelium.
Newly identified lymphatic endothelium-specific markers
include [4] lymphatic endothelial hyaluronan receptor 1
(LYVE-1), prospero-related homeobox 1, vascular endothelial
growth factor receptor 3 (VEGFR-3), and the mucin-type
transmembrane glycoprotein, podoplanin [5-8].
In studies using these lymphatic markers, several factors, such
as VEGF-A, platelet-derived growth factor (PDGF)-BB, and
fibroblast growth factor, have been shown to affect lymphang-
iogenesis [9]. However, the most specific and potent lym-
phatic growth factors reported to date are VEGF-C and
VEGF-D [10,11], members of the VEGF family. These differ
from VEGF-A (also named VEGF) in that they promote prolif-
eration, migration, and survival of lymphatic vascular endothe-
lial cells through the VEGFR-3 signaling pathway [12]. This
appears to be a non-redundant function because VEGF-C-/-
mice are embryonic lethal due to the lack of lymphatic vessels
[12]. Under physiologic conditions, VEGF-C is expressed
most prominently in the heart, lymph nodes, placenta, and gut
[13] but is also expressed by many cancer cells, which can
induce lymphatics in metastases. Recent studies reported that
VEGF-C is also expressed by CD11b+ myeloid cells that have
migrated to inflammatory sites in several animal models of
inflammation [14-17], such as corneal transplantation and
bacterial lung infection. It was speculated that inflammatory
cytokines, such as tumor necrosis factor (TNF) or interleukin 1
(IL-1), stimulate these CD11b+ cells to produce VEGF-C
because TNF and IL-1 increase VEGF-C expression in human
lung fibroblasts and human umbilical vein endothelial cells in
vitro [18,19]. However, it has not been formally proven that
these cytokines promote VEGF-C expression by CD11b+
cells, and the mechanisms involved are not known.
CD11b antigen is a pan marker for myeloid lineage cells,
which also give rise to osteoclasts. We used a combination of
fluorescence-activated cell sorting (FACS) and osteoclas-
togenesis and colony-forming assays to demonstrate that, in
peripheral tissues, only CD11b+/Gr-1-/lo cells have osteoclas-
togenic potential [20]. Thus, we termed CD11b+/Gr-1-/lo cells
osteoclast precursors (OCPs), although this population in
bone marrow and spleen also contains macrophage and den-
dritic cell precursors. Over the last 2 to 3 years, immune cells
and molecules that primarily function in immune responses
have been demonstrated to affect the functions of cells
involved in bone remodeling, particularly osteoclasts [21],
which has led to development of the new field of osteoimmu-
nology. We have pursued this line of investigation with OCPs
because they belong to a subset of macrophages that can be
activated to produce autocrine and paracrine factors that con-
tribute to inflammation and autoimmunity [22]. In our micro-
array analysis of RNA from OCPs from TNF-transgenic (Tg)
and wild-type (WT) mice, we found that VEGF-C expression is
significantly increased in cells from TNF-Tg mice, suggesting
that VEGF-C-mediated biologic events (for example, lym-
phangiogenesis) may be involved in the pathogenesis of arthri-
tis. In this study, we used recently developed anti-lymphatic
marker antibodies and contrast-enhanced magnetic reso-
nance imaging (MRI) to demonstrate that TNF-Tg mice have a
significant increase in the number and size of synovial lym-
phatic vessels compared with their WT littermates. Further-
more, the severity of erosive synovitis correlates with the
lymphatic drainage capacity to local lymph nodes. Together,
these findings demonstrate significant changes in lymphatic
architecture and draining potential around inflamed joints of
arthritic mice and suggest the possible involvement of the lym-




TNF-Tg mice (Tg 3647 line) in a CBA × C57BL/6 background
were originally obtained from George Kollias (The Biomedical
Sciences Research Center, Greece). We backcrossed them
with C57BL6 mice for seven generations [20]. All TNF-Tg
mice used in this study were 4 to 8 months old with severe
joint synovitis and bone and cartilage destruction. WT litterma-
tes were used as controls. TNF-Tg mice were identified by tail
polymerase chain reaction (PCR) genotyping and paw defor-
mation. KRN-TCR-Tg mice were obtained from Drs. Diane
Mathis and Christophe Benoist (Harvard University, Cam-
bridge, MA, USA) [23]. K/B × N mice were generated by
breeding male KRN-TCR-Tg mice with female non-obese dia-
betic mice (The Jackson Laboratory, Bar Harbor, ME, USA).
Serum was collected from 6- to 12-week-old K/B × N arthritic
mice, pooled, and stored at -80°C. To generate mice with
serum-induced arthritis (SIA), 4- to 5-week-old BALB/c mice
were injected with K/B × N serum intraperitoneally (10 μL/
gram body weight) on day 1 and day 3. Paw swelling and red-
ness usually occurred the day after the first injection, peaked
at 7 to 14 days, and declined thereafter. The Institutional Ani-
mal Care and Use Committee of the University of Rochester
(Rochester, NY, USA) approved all studies.
Reagents
Recombinant murine TNF-α was purchased from R&D Sys-
tems, Inc. (Minneapolis, MN, USA). Allophycocyanin-, fluores-
cein isothiocyanate (FITC)-, and phycoerythrin-anti-mouse
CD11b (M1/70) were purchased from eBiosciences (San
Diego, CA, USA); FITC-anti-mouse Gr-1 (RB6-8C5) from BD
Pharmingen (San Diego, CA, USA); rabbit polyclonal antibody
to VEGF-C (H-190) from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA); rabbit polyclonal antibody to LYVE-1
from Abcam (Cambridge, MA, USA); mouse monoclonal anti-
body to CD31 (Mec13.3) from Biocare Medical LLC (Con-
cord, CA, USA); Alexa Fluor 488 goat anti-hamster
immunoglobulin G (IgG) from Molecular Probes Inc. (now part
of Invitrogen Corporation, Carlsbad, CA, USA); and Alexa
Fluor 546 F(ab')2 fragment of goat anti-rabbit IgG (H+L) and
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To-Pro-3 iodid (642/661) were purchased from Invitrogen
Corporation.
Generation of osteoclast precursors
OCPs were generated from two sources:
(a) Spleen. Splenocytes were extracted from spleens of 8- to
12-week-old C57/B6 WT mice through a fine wire mesh, and
red blood cells were lyzed with NH4Cl (StemCell Technolo-
gies, Vancouver, BC, Canada) on ice for 10 minutes. The cells
were then washed twice with medium and cultured with con-
ditioned medium from a macrophage colony-stimulating factor
(M-CSF)-producing cell line [24] (1:20 dilution) for 3 days to
enrich for OCPs, as we described previously [25].
(b) Joints. Ankle and wrist joints were isolated from TNF-Tg
mice and WT littermates according to published protocols
[26,27] with minor modifications. In brief, mice were sacrificed
and skin and muscle were removed from their limbs. Long
bones together with a front or rear paw were cut from the
limbs. Forceps were used to loosen the joints. The joints were
then cut open and digested with 1 mg/mL of collagenase
(Sigma-Aldrich, St. Louis, MO, USA) at 37°C for 3 hours with
rotation. Cells were then filtered and used for cultures or
FACS analysis.
Affymetrix gene chip analysis
CD11b+/Gr-1-/lo OCPs were purified by flow sorting from
peripheral blood and bone marrow of TNF-Tg mice and age-
matched WT mice by a FACSVantage SE Turbo sorter (Bec-
ton, Dickinson and Company, Franklin Lakes, NJ, USA), as we
described previously [20,28]. To obtain enough RNA from
samples, bone marrow OCPs were pooled from 7 TNF-Tg
mice or 11 WT mice and peripheral blood OCPs were from
pooled from 7 TNF-Tg mice or 23 WT mice. Two completely
independent experiments were performed. Total RNA was
prepared using TRIzol (Invitrogen Corporation), processed,
and hybridized to MG-U74Av2 gene chips according to
Affymetrix protocols (Affymetrix, Santa Clara, CA, USA). Chips
were scanned and analyzed using the GeneTraffic (version
3.2) microarray data analysis software (Lobion Informatics, La
Jolla, CA, USA). In each group, WT samples were set as the
baseline. Data were presented as the fold increase of samples
from TNF-Tg mice over WT samples (baseline sample).
Real-time quantitative reverse transcription-polymerase 
chain reaction
Total RNA was extracted using TRIzol reagent, and cDNA was
synthesized by an RNA PCR Core Kit (Applied Biosystems,
Foster City, CA, USA). Quantitative PCR amplification was
performed with gene-specific primers using an iCycler iQ Mul-
tiple-Color Real-Time PCR Detection System (Bio-Rad Labo-
ratories, Inc., Hercules, CA, USA), as we described previously
[25,28]. The primer sequences are listed in Table 1. Expres-
sion levels were normalized relative to β-actin in the same sam-
ple. For each sample, we first obtained the ΔCT (difference in
threshold cycle values), which is equal to CT (target gene) – CT
(β-actin). We then used control (for example, phosphate-buff-
ered saline [PBS]-treated) values as baseline to obtain the
ΔΔCT, which is equal to the ΔCT of the sample minus the ΔCT
of the baseline. Finally, we set the baseline as '1', and thus the
fold change of each sample is equal to 2-ΔΔCT.
Table 1
Sequences of primers used in the real-time reverse transcription-polymerase chain reaction
Genes Sequences of primers Accession number Target sites Size (base pairs)
VEGF-A F: 5'-TTTACTGCTGTACCTCCACCA-3' M95200 125–423 298
R: 5'-ATCTCTCCTATGTGCTGGCTTT-3'
VEGF-B F: 5'-CCTGGAAGAACACAGCCAAT-3' NM_011697 537–701 165
R: 5'-GGAGTGGGATGGATGATGTC-3'
VEGF-C F: 5'-GGGAAGAAGTTCCACCATCA-3' NM_009506 1258–1392 135
R: 5'-ATGTGGCCTTTTCCAATACG-3'
VEGF-D F: 5'-GCTGTCACTGTTGCCCACTA-3' NM_010216 1423–1611 207
R: 5'-CCCTTCCTTTCTGAGTGCTG-3'
PLGF F: 5'-GGGAAGAAGCAAGACATGGA-3' NM_008827 1055–1261 189
R: 5'-ATGTCCTGTCCCATCTCCAG-3'
β-actin F: 5'-ACCCAGATCATGTTTGAGAC-3' X03765 280–503 224
R: 5'-GTCAGGATCTTCATGAGGTAGT-3'
F, forward primer; PLGF, placental growth factor; R, reverse primer; VEGF, vascular endothelial growth factor.
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Immunofluorescence staining and imaging cytometry
Cells were cytospun on glass slides and fixed by cold metha-
nol at -20°C for 10 minutes. After washing with PBS, cells
were incubated in 0.1% Triton and blocked with 1% bovine
serum albumin/PBS for 30 minutes at room temperature. The
fixed cells were stained with a mixture of FITC-anti-CD11b and
anti-VEGF-C antibody followed by Alexa Fluor 546 F(ab')2
fragment of goat anti-rabbit IgG (H+L) and by To-Pro-3 iodid.
Immunohistomorphometry of lymphatic vessels
Joint sections from TNF-Tg and WT mice were fixed in 4.5%
phosphate-buffered formalin, decalcified in 14% ethylenedi-
aminetetraacetic acid, and embedded in paraffin wax. Depar-
affinized sections were quenched with 3% hydrogen peroxide
and treated for antigen retrieval for 30 minutes. Adjacent serial
sections were then stained with anti-LYVE-1 or anti-CD31
antibodies. Lymphatic vessels were quantified by a point-
counting method, as we described previously [29]. For each
mouse, two sections were cut at 250 μm apart and the area
and size of LYVE-1+ lymphatic vessels were measured within
the synovial tissue. The size and area of lymphatic vessels
were expressed per square millimeter of synovium.
Electrophoretic mobility shift assay
Raw 264.7 osteoclast/macrophage precursor cells were
serum-starved overnight and then treated with 10 ng/mL of
TNF for 30 and 60 minutes. Nuclear extract preparation and
electrophoretic mobility shift assay (EMSA) were performed
as described previously [30]. The following double-stranded
oligonucleotides were used in this study according to the pub-
lished mouse VEGF-C promoter sequence [18] (only the top
strands are shown): VEGF-C nuclear factor-kappa B (NF-κB)-
like sequence (WT), 5'-GCCCAGGGGGGTCCCCG-
GGAGG-3'; mutated VEGF-C NF-κB-like sequence (mutation
underlined), 5'-GCCCAGGGGATTCTCCGGGAGG-3'; and
SP-1-binding sequence (control; Invitrogen Corporation), 5'-
CGAGCCGGCCCCGCCCATC-3'. For competition assays,
binding reactions were pre-incubated with unlabeled oligonu-
cleotides for 15 minutes at room temperature.
In vivo contrast-enhanced magnetic resonance imaging
A detailed methodology of this new technique in mice will be
published in a separate manuscript [31]. Briefly, mice were
positioned with the right leg in a custom-designed murine knee
coil and scanned in a Siemens 3 Tesla clinical magnet (Sie-
mens AG, Munich, Germany). A high-resolution fat-sup-
pressed T1-weighted sequence (Sagittal T1-weighted FLASH
[fast low-angle shot], repetition time = 45 ms, echo time =
9.03 ms, 192 × 192 pixels, 20 mm × 20 mm field of view, 32
slices of 0.16-mm slice thickness, flip angle = 25°, 1 signal
average, time: 8:28) was then initiated. An intravenous injec-
tion of Gd-DTPA contrast agent (Omniscan; Amersham
Health, now part of GE Healthcare, Little Chalfont, Bucking-
hamshire, UK) was given, and a post-contrast high-resolution
scan (same parameters) was collected. Analysis was per-
formed with Amira 3.1 (TGS; Mercury Computer Systems,
Inc., Chelmsford, MA, USA). An image registration and sub-
traction algorithm on the pre- and post-contrast images in
Amira generated an image of the voxels of contrast enhance-
ment. From this image, a three-dimensional (3D) region of
interest of muscle tissue was used as a measure of delivered
contrast agent, and a threshold of enhancing synovial tissue
was generated from this value. Lymph nodes were traced man-
ually and thresholded to define the margin between the node
and surrounding fat. Tissue volumes (3D) were reconstructed
using a surface generation module in Amira.
Statistics
Data are presented as mean ± standard deviation of three cul-
ture dishes, and all experiments were performed at least twice.
Statistical analyses were performed with Statview statistical
software (SAS Institute Inc., Cary, NC, USA). Differences
among more than two groups were compared using one-way
analysis of variance followed by the Mann-Whitney U test. P
values of less than 0.05 were considered statistically signifi-
cant. Each experiment was repeated at least twice with similar
results.
Results
VEGF-C expression is upregulated in CD11b+/Gr-1-/lo 
osteoclast precursors from tumor necrosis factor-
transgenic mice
Previous studies demonstrated an increase in circulating
OCPs in patients [32] and animals [20] with arthritis and that
OCP frequency is reduced in response to anti-TNF therapy,
suggesting that OCPs may play important roles in the patho-
genesis of arthritis [33]. To screen for novel genes that are dif-
ferentially expressed by OCPs between arthritic and normal
mice, we performed microarrays on RNA isolated from
CD11b+/Gr-1-/lo OCPs from peripheral blood mononuclear
cells and bone marrow pooled from TNF-Tg and WT mice. The
purity of CD11b+/Gr-1-/lo cells was confirmed by FACS. In our
initial bioinformatic screen, we focused on genes encoding
angiogenic factors because they are critical for development
of inflammation and bone erosion in arthritic joints. Among
more than 50 known angiogenic factors (including matrix met-
alloproteinases, adhesion molecules, enzymes, and growth
factors), we found that expression levels of PDGF-B, PDGF
receptor β, and VEGF-C were significantly increased in circu-
lating OCPs of TNF-Tg mice (approximately six-fold in TNF-Tg
over WT OCPs) (Figure 1). Expression levels of these genes
were also increased in bone marrow OCPs but to a lesser
extent. Since TNF is known to induce PDGF signaling [34], we
decided to explore the possibility that VEGF-C has a novel role
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Tumor necrosis factor stimulates osteoclast precursors 
to produce VEGF-C
To determine whether TNF directly upregulates expression of
VEGF-C by OCPs, we cultured WT spleen cells with M-CSF
for 3 days to generate OCPs, as we described previously [25].
The rationale for using spleen cells rather than bone marrow
cells is that spleen-derived OCPs are closer to circulating
OCPs than bone marrow OCPs in terms of their osteoclast-
forming potency [37] and the increased VEGF-C expression
level in circulating OCPs is more than three times higher than
in bone marrow OCPs (Figure 1). TNF treatment increased
VEGF-C mRNA levels by three- to four-fold in a time- and
dose-dependent manner, beginning at between 4 and 8 hours,
suggesting transcriptional regulation (left panel in Figure 2a).
It also increased VEGF-C protein expression at 24 hours (right
panels in Figure 2a). TNF did not significantly affect expression
of other VEGF members (Figure 2b). Dose-response experi-
ments demonstrated that a low dose of TNF (0.5 ng/mL) is suf-
ficient to stimulate VEGF-C protein expression, supporting an
in vivo role for TNF to induce VEGF-C expression (Figure 2c).
We also examined whether IL-1, another cytokine whose lev-
els are increased significantly in joints of TNF-Tg mice, affects
VEGF-C levels in OCPs. Similar to TNF, IL-1 treatment (by 24
hours) also increased VEGF-C mRNA by two- to three-fold,
but IL-1 + TNF did not have an additive effect (Figure 2d). This
suggests that TNF and IL-1 may use a similar signaling path-
way to regulate VEGF-C expression.
Figure 1
Differential expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) family genes in CD11b+/Gr-1-/lo oste-oclast precursors (OCPs) from tumor necrosis factor-transgenic (TNF-Tg) and wild-type (WT) mice
oclast precursors (OCPs) from tumor necrosis factor-transgenic (TNF-Tg) and wild-type (WT) mice. CD11b+/Gr-1-/lo cells from peripheral blood and 
bone marrow from TNF-Tg (7 mice per array) and WT (23 mice per array) mice were pooled and purified by flow sorting. The RNA samples were 
subjected to microarray analysis using the GeneChip mouse genome 430A 2.0 array from Affymetrix. The array data on angiogenic gene expression 
were analyzed using GeneTraffic software. The expression ratio was calculated by dividing the mean value of the intensity of RNA signals from two 
separate arrays of TNF-Tg OCPs by that from WT cells.
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Nuclear factor-kappa B mediates tumor necrosis factor-
induced VEGF-C expression
NF-κB is a transcription factor that mediates induction of
genes by TNF in many cell types, including OCPs [38]. NF-κB
also mediates heregulin-beta-1-induced VEGF-C expression
in human breast cancer cells [39]. We found that there is a
putative NF-κB-binding element, GGGGTCCC, at the -108/-
99 region of the mouse VEGF-C promoter, which is at a loca-
tion similar to that in the human promoter [18]. Thus, to deter-
mine whether TNF stimulates binding of NF-κB proteins to this
element in OCPs, we treated Raw 264.7 cells with TNF for 30
and 60 minutes and performed Western blot analysis and
EMSA on nuclear extracts from the cells. TNF treatment for 30
minutes increased nuclear translocation of NF-κB p65 and
p50 proteins (Figure 3a) and specific binding of NF-κB to the
VEGF-C DNA probe (Figure 3b). To further confirm the
involvement of NF-κB in TNF-induced VEGF-C expression, we
treated WT OCPs with an NF-κB inhibitor (Calbiochem, now
Figure 2
Tumor necrosis factor (TNF) increases expression of vascular endothelial growth factor-C (VEGF-C) by osteoclast precursors (OCPs). Wild-type 
(WT) spleen cells were cultured with macrophage colony-stimulating factor (M-CSF) for 3 days to enrich for OCPs. OCPs were cultured in 10% 
serum with M-CSF and treated with phosphate-buffered saline (PBS) or TNF (10 ng/mL). (a) Expression of VEGF-C and β-actin mRNA was meas-
ured by real-time reverse transcription-polymerase chain reaction (RT-PCR) at various times (left panel), and protein levels were measured by West-
ern blot analysis (right panels). (b) Expression of VEGF-A, -B, -C, -D, and placental growth factor (PLGF) mRNA was examined in samples treated 
for 24 hours. The fold increases in TNF-treated over PBS-treated cells at a given time were calculated. Values are the means of triplicate loadings 
plus standard deviation. The effect of different doses of TNF (c) or a combination with interleukin 1 (IL-1) (TNF and IL-1 10 ng/mL) (d) on VEGF-C 
expression at 24 hours was examined by RT-PCR. Experiments were repeated twice with similar results.
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part of EMD Biosciences, Inc., San Diego, CA, USA) and
found that it inhibited TNF-induced VEGF-C expression in a
dose-dependent manner (Figure 3c). These data support TNF
induction of VEGF-C expression by activation of NF-κB.
CD11b+/Gr-1-/lo cells isolated from joints of tumor 
necrosis factor-transgenic mice express high levels of 
VEGF-C
To examine whether OCPs at the site of inflammation express
VEGF-C, we isolated cells from joints of TNF-Tg mice and WT
littermates using a sequence enzyme digestion method
[26,27]. We obtained, on average, a total of 1.5 × 106 cells
from the four paws of a TNF-Tg mouse. FACS analysis
revealed that approximately 60% of joint cells from TNF-Tg
mice are CD11b+ and almost all of them are Gr-1- (Figure 4a).
Thus, in subsequent experiments, we used only CD11b as a
single marker for OCPs. To determine whether CD11b+ cells
express VEGF-C, we performed double immunofluorescence
staining using anti-CD11b and VEGF-C antibodies in a cyt-
ospin preparation of these cells. There were much more
CD11b and VEGF-C double-stained cells in the joints of TNF-
Tg mice than in WT mice (Figure 4b). We also found that most
of the VEGF-C+ cells are CD11b+, whereas no CD11b- cells
are VEGF-C-, suggesting that VEGF-C is produced in arthritic
joints by OCPs. To examine whether these joint CD11b+ cells
specifically produce more VEGF-C than other VEGFs, we cul-
tured them with M-CSF for 3 days, harvested adherent cells,
and performed real-time reverse transcription-PCR to assess
the expression level of VEGF-A, VEGF-C, and VEGF-D. The
rationale for using these M-CSF-dependent adherent cells is
that they are composed mainly of OCPs and monocytes, as
we described previously [25]. We found that M-CSF-depend-
ent cells that were derived from joints of TNF-Tg mice
expressed much higher levels of VEGF-C compared with
those of WT mice (Figure 4c) whereas VEGF-A and VEGF-D
levels were similar, suggesting that OCPs/monocytes are the
major source of VEGF-C in arthritic joints of TNF-Tg mice. To
confirm that there is elevated TNF or IL-1 expression in the
joints of TNF-Tg mice, we measured the expression levels of
TNF and IL-1 mRNA and demonstrated that they were remark-
ably increased compared with levels in WT joints (Figure 4d),
which supports the hypothesis that local increased cytokines
stimulate VEGF-C production.
Increased lymphangiogenesis in joints of tumor necrosis 
factor-transgenic mice
Since VEGF-C is a specific lymphatic growth factor [40] and
VEGF-C expression is increased in OCPs, we sought to
determine whether there was increased lymphangiogenesis in
joint sections from TNF-Tg mice compared with WT mice
using immunohistochemistry and an antibody to the lymphatic
endothelial cell marker, LYVE-1. We also assessed, as a pos-
itive control, blood vessels lined by endothelial cells using a
CD31 antibody because these are known to be increased in
TNF-Tg versus WT joints [41]. These results clearly demon-
strated large LYVE-1+ lymphatic vessels compared with
smaller CD31+ vessels in the pannus of TNF-Tg mice (Figure
5a). Histomorphometric quantitation of the area and number of
these lymphatic vessels confirmed a significant increase in
TNF-Tg versus WT joints (Figure 5b). To assess the functional
significance of this increased lymphangiogenesis, we used a
new in vivo MRI technology that we have developed [31] to
see whether the draining popliteal lymph nodes from the knee
and ankle joints of TNF-Tg mice with synovitis are increased
versus WT littermates. Figure 6a demonstrates the remarkable
differences in 2D MRI and 3D reconstructed images of the
synovium and popliteal lymph nodes of TNF-Tg versus WT
mice. Volumetric analyses confirmed that TNF-Tg mice have
significantly larger synovial and popliteal lymph node volumes
compared with WT mice (Figure 6b) and these were con-
firmed with histology (Figure 6c).
To demonstrate that increased lymphangiogenesis is not lim-
ited to the arthritis in TNF-Tg mice and to determine the asso-
ciation between joint inflammation and lymphatic vessel
formation during the course of arthritis induction, we used
mice with K/B × N SIA. This SIA model has clearly distinguish-
able phases of disease progression and uniform severity of
joint lesions among animals compared with TNF-Tg mice. The
SIA mice were sacrificed at 0, 14, and 35 days after K/B × N
serum injection, and joint samples were subjected to histology
and LYVE-1 immunostaining. At day 14 after serum injection,
mice developed severe joint inflammation with pannus forma-
tion and inflammatory cell infiltration, which is accompanied
with increased lymphatic vessel area and number (Figure 7).
By day 35, the inflammation declined, but the lymphatic vessel
formation had increased further (Figure 7) to a degree similar
to that seen in TNF-Tg mice (Figure 5). These data suggest
that increased lymphangiogenesis is a common phenotype of
inflammatory-erosive arthritis.
Discussion
Patients with RA often accompany with enlarged draining
lymph nodes [42] and increased lymph flow rates [43] in
affected limbs, which are correlated with inflamed synovial vol-
ume. However, a cellular and molecular mechanism to explain
these changes has yet to be postulated. In the present study,
we demonstrated that CD11b+/Gr-1-/lo OCPs from joints of
TNF-Tg mice produce high levels of the lymphatic growth fac-
tor, VEGF-C, and that joints from mice in two models of RA
have increased numbers of lymphatic vessels and enlarge-
ment of draining popliteal lymph nodes. Thus, lymphangiogen-
esis is also significantly increased in joints of mice with
inflammatory arthritis. To date, most studies of inflammation-
induced lymphangiogenesis have been performed in animal
models in which the examined tissues have included cornea,
lung, and skin [15,17,44], because frozen sections from these
tissues can be prepared readily for immunostaining to identify
lymphatic vessels and because dye injection can be used to
examine the lymphatic drainage. However, it is difficult to apply
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Figure 3
Tumor necrosis factor (TNF) promotes the binding of nuclear proteins to the nuclear factor-kappa B (NF-κB) binding sequences of the vascular endothelial growth factor-C (VEGF-C) promoter
endothelial growth factor-C (VEGF-C) promoter. Raw264.7 osteoclast/macrophage precursors were cultured in 0.5% bovine serum albumin over-
night. Cells were treated with TNF for 30 to 60 minutes. Nuclear extracts were isolated and subjected to Western blot analysis using anti-NF-κB p65 
and p50 antibodies (a) or to electrophoretic mobility shift assay using a 32P-labeled probe consisting of the putative NF-κB binding sequence of the 
mouse VEGF-C promoter (b). The specificity of binding was confirmed by using 50-fold more unlabeled wild-type (WT) or mutated probe in which 
the putative NF-κB binding sequence was mutated and could not be bound by NF-κB in a competition reaction. An SP-1 probe was used as a load-
ing control. WT osteoclast precursors were treated with TNF ± an NF-κB inhibitor for 24 hours, and expression of VEGF-C was determined by real-
time reverse transcription-polymerase chain reaction. Values are the means of three mice plus standard deviation. (c) The fold decrease in expres-
sion in the NF-κB inhibitor-treated over vehicle-treated cells was calculated. Experiments were repeated two times with similar results.
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Figure 4
Cells from joints of tumor necrosis factor-transgenic (TNF-Tg) mice express high levels of vascular endothelial growth factor-C (VEGF-C)i  f t r-tr i  ( - ) i  ex ress high levels of vascular endothelial growth factor-C (VEGF-C). Ankle and 
wrist joints of TNF-Tg mice and wild-type (WT) littermates were subjected to collagenase digestion to isolate cells, which then were stained with flu-
orescein isothiocyanate (FITC)-anti-CD11b and phycoerythrin-anti-Gr-1 and subjected to fluorescence-activated cell sorting analysis. (a) The per-
centage of CD11b+/Gr-1-/lo cells is shown in a representative histogram from one pair of TNF-Tg and WT mice. Cells (3 × 105) were cytospun onto 
glass slides and double-stained with FITC-anti-CD11b and rabbit anti-VEGF-C followed by anti-rabbit Alexa 546. TO-PRO-3 iodide was used as a 
DNA dye for nuclear staining. (b) Co-localization of CD11b and VEGF-C proteins was observed, and pictures were taken under a confocal micro-
scope at a power of × 20. Cells were cultured with M-CSF for 3 days, and adherent cells were harvested. (c) Expressions of VEGF-A, -C, and -D 
mRNA were measured by real-time reverse transcription-polymerase chain reaction (RT-PCR). The fold increases in expression in TNF-Tg over WT 
cells were calculated. Values are the means of triplicate loadings plus standard deviation (SD). (d) The expression levels of TNF and IL-1 mRNA in 
joint extracts from TNF-Tg mice and WT littermates were determined by real-time RT-PCR. Values are the means of three mice plus SD. Experiments 
were repeated using four additional pairs of TNF-Tg and WT mice with similar results.
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these methods to joints. Here, we used a combination of
microarrays, FACS, immunohistochemistry, and a novel in vivo
contrast-enhanced-MRI technique to demonstrate that the
lymphatic vasculature in inflamed joints and draining lymph
nodes are significantly increased in mice with TNF and SIA.
Our findings are consistent with those in clinical studies dem-
onstrating increased VEGF-C expression in RA joints [45,46]
and increased size of lymph nodes [43]. Furthermore, based
on increased volume of collected lymph [42] and our
demonstration of increased VEGF-C production by joint
OCPs, we propose that the development of large lymphatic
vessels in the pannus results from proliferation of lymphatic
endothelial cells and their distention by increased amounts of
lymph.
While the origin of lymphatic endothelia cells remains an area
of active research, several studies on inflamed corneas, skin,
and lung have reported the presence of CD11b+ myeloid cells
expressing VEGF-C in these tissues [15,47]. These studies
speculated that inflammatory cytokines stimulate VEGF-C pro-
duction by these CD11b+ cells based on previous work in
human lung fibroblasts and human umbilical vein endothelial
cells [18,19]. Here, we demonstrated that TNF and IL-1 upreg-
ulate VEGF-C expression in CD11b+ OCPs. To validate our
microarray findings and provide insight into the mechanism of
TNF-induced VEGF-C expression in OCPs, we provide prelim-
inary evidence indicating that this response is mediated by NF-
κB-dependent transcription. Since other signal transduction
pathways could also be involved and TNF could be acting indi-
Figure 5
Enlargement of lymphatic vessels in the joints of tumor necrosis factor-transgenic (TNF-Tg) micei  j i t  f t r cr sis factor-transgenic (T F-Tg) ice. Joint sections from TNF-Tg mice or wild-type (WT) 
littermates were immunostained with anti-LYVE-1 or CD31 antibody. (a) Micrographs (× 20) show increased numbers and diameters of LYVE-1+ 
lymphatic vessels in the synovium of TNF-Tg mice. (b) The area and number of lymphatic vessels within the synovium were counted. Values are the 
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rectly through prostaglandins [48], which also mediate VEGF-
C transcription in cancer cells [49], future studies are needed
to elucidate the mechanisms of inflammation-induced VEGF-C
expression in OCPs.
Considering the cellular heterogeneity of joint pannus, it is
important to determine the primary source of VEGF-C in
arthritic joints. While our studies focused on OCPs, others
have shown that TNF and/or IL-1 stimulates VEGF-C expres-
sion by human lung fibroblasts, blood vascular endothelial
cells, and synovial cells [19,46]. We found that TNF also stim-
ulates VEGF-C expression in NIH3T3 and C2C12 fibroblast
cell lines (data not shown), suggesting that fibroblast-like cells
in synovium could perhaps be another source of VEGF-C in
arthritic pannus. However, these results were obtained from in
vitro treatment of cells with cytokines and may not precisely
reflect the in vivo situation, particularly in the joint local micro-
environment. Our immunocytochemistry studies using cells
freshly isolated from joints demonstrated that most of the
VEGF-C-expressing cells are CD11b+ (Figure 4b). One
potential concern with this approach is that primary joint cells
are composed of a mixture of cell types. To address this limi-
tation, we cultured these cells with M-CSF and used only
adherent cells for further study. Under these culture condi-
tions, more than 90% of adherent cells are CD11b+/Gr-1-/lo
OCPs (Q. Zhang, Y. Lu, S. Proulx, R. Guo, Z. Yao, E.M.
Schwarz, B.F. Boyce, L. Xing, unpublished data). We found
that these M-CSF-dependent joint cells express much higher
levels of VEGF-C than cells treated in vitro (20- to 30-fold
increase in joint cells in Figure 3c versus 3- to 5-fold increase
in TNF-treated cells in Figure 2a). Thus, although other cell
types may also be VEGF-C-producing cells, CD11b+/Gr-1-/lo
OCPs likely are one of the major sources of VEGF-C in joint
pannus.
Our findings demonstrated that increased lymphangiogenesis
is associated with the progression of joint inflammation, which
occurs not only in dysregulated TNF-induced arthritis (Figure
5) but also in mice with SIA (Figure 7). A recent study reported
that, in joint sections of collagen-induced arthritis, the number
of LYVE-1+ lymphatic vessels is increased [50]. Thus, elevated
lymphangiogenesis likely is a common feature of inflammatory
arthritis. Inflammation-induced lymphangiogenesis in joints
appears to be a slow process, taking 2 to 3 weeks (Figure 7).
Our explanation is that OCPs or other VEGF-C-producing
cells may need to migrate to the inflamed joints first and then
respond to elevated cytokine levels to produce VEGF-C,
which then stimulates formation of lymphatic endothelial cells.
Interestingly, increased lymphatic vasculature persists even
after serum-induced inflammation has resolved (Figure 7). This
is consistent with our observation of no change in lymphatic
vessel area or number in TNF-Tg mice with a significant
reduction in their joint inflammation after anti-TNF therapy
treatment (see Additional File 1). Persistent lymphangiogen-
esis was also reported in a mouse model of chronic respiratory
tract infection in which inflammation has been cured by antibi-
otics [17]. Currently, there is no explanation why these lym-
phatic vessels do not disappear along with the reduction in
inflammation. One speculation is that lymphatic enlargement
makes affected tissues more susceptible to later inflammation
by facilitating the accumulation of immune cells at the site of
injury or infection [51]. However, it is also possible that an
increased lymphatic network will prime tissues to respond to
acute inflammation.
Figure 6
Increased volume of popliteal lymph nodes in tumor necrosis factor-transgenic (TNF-Tg) mice
transgenic (TNF-Tg) mice. (a) A representative post-contrast magnetic 
resonance imaging slice from a TNF-Tg and wild-type (WT) mouse (5 
months old). (b) Using a semi-automated segmentation procedure in 
Amira software, the synovial (yellow) and lymph node (red) volumes 
were quantified and visualized in TNF-Tg and WT mice. *p < 0.05 ver-
sus WT samples (n = 5). (c) Representative hematoxylin-and-eosin 
sections (× 4) demonstrate differences in lymph node size between 
TNF-Tg and WT animals.
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A central question that arises from our study and other recent
studies regarding inflammation-induced lymphangiogenesis is
whether lymphangiogenesis in arthritis is beneficial or harmful
to affected joints. Early clinical studies proposed that inflam-
mation-driven lymphangiogenesis induces the expansion of
the lymphatic network in an exacerbated manner such that the
lymphatic vessels may be dysfunctional, as reported in
psoriasis and Crohn disease [52-54]. Recently, VEGF-C or
VEGFR-3 antagonists have been used to directly stimulate or
block VEGF-C/VEGFR-3-mediated lymphangiogenesis in sev-
eral models of inflammation. In general, the effects of
manipulating lymphangiogenesis in inflammatory conditions
are not clear and appear to be largely dependent on the type
of model used. For example, in the corneal transplantation
model, lymphangiogenesis and angiogenesis are increased by
grafting, and blockade of either form of new vessel formation
has a similar beneficial effect and prevents graft rejection [55].
In contrast, UVB-induced skin inflammation is exacerbated by
VEGF-C antagonism [56], suggesting that stimulation of the
lymphatic system might reduce disease severity. Thus, the
functional importance of lymphangiogenesis in the pathogen-
esis of RA remains to be determined.
Conclusion
Our findings demonstrate that lymphangiogenesis is signifi-
cantly increased in joints of mice with inflammatory arthritis.
TNF and OCPs appear to play a critical role in initiating this
process through stimulation of VEGF-C production.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
LX participated in study design; acquisition, analysis, and
interpretation of data; and manuscript preparation and had full
access to all of the data in the study and takes responsibility
for the integrity of the data and the accuracy of the data anal-
ysis. QZ and STP participated in study design; acquisition,
analysis, and interpretation of data; manuscript preparation;
and statistical analysis. YL participated in study design; acqui-
sition, analysis, and interpretation of data; and statistical anal-
ysis. EMS and BFB participated in study design, analysis and
interpretation of data, and manuscript preparation. RG and ZY
participated in acquisition, analysis, and interpretation of data.
All authors read and approved the final manuscript.
Figure 7
Increased lymphangiogenesis in joints of mice with serum-induced arthritisj i  f i  ith seru -induced arthritis. Wild-type mice received serum from K/B × N mice to induce arthritis and 
were sacrificed at 0, 14, and 35 days after serum injection (n = 3 or 4 mice at each time point). Ankle joint sections were immunostained with anti-
LYVE-1 antibody. (a) Representative pictures show inflamed pannus and large numbers of LYVE-1+ lymphatic vessels in an adjacent section (pink 
arrows) at day 35. (b) The area and number of lymphatic vessels within the pannus were determined by histomorphometric analysis. Values are the 
means plus standard deviation of 3 or 4 mice at each time point. H&E, hematoxylin and eosin; LYVE-1, lymphatic endothelial hyaluronan receptor 1.
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